WO2022228302A1 - Heteroaromatic carboxamide compounds and its use - Google Patents
Heteroaromatic carboxamide compounds and its use Download PDFInfo
- Publication number
- WO2022228302A1 WO2022228302A1 PCT/CN2022/088440 CN2022088440W WO2022228302A1 WO 2022228302 A1 WO2022228302 A1 WO 2022228302A1 CN 2022088440 W CN2022088440 W CN 2022088440W WO 2022228302 A1 WO2022228302 A1 WO 2022228302A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- mmol
- leukemia
- group
- lymphoma
- Prior art date
Links
- -1 Heteroaromatic carboxamide compounds Chemical class 0.000 title claims description 133
- 150000001875 compounds Chemical class 0.000 claims abstract description 187
- 238000000034 method Methods 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 107
- 150000003839 salts Chemical class 0.000 claims description 92
- 239000012453 solvate Substances 0.000 claims description 72
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims description 67
- 125000001424 substituent group Chemical group 0.000 claims description 65
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 201000010099 disease Diseases 0.000 claims description 59
- 229910052799 carbon Inorganic materials 0.000 claims description 51
- 208000035475 disorder Diseases 0.000 claims description 48
- 125000000623 heterocyclic group Chemical group 0.000 claims description 37
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 32
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 29
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 24
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 24
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 24
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 24
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 24
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 24
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 24
- 208000032839 leukemia Diseases 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 23
- 208000027866 inflammatory disease Diseases 0.000 claims description 21
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 20
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 19
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 18
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 18
- 208000037244 polycythemia vera Diseases 0.000 claims description 18
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 17
- 201000003791 MALT lymphoma Diseases 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 17
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 16
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 16
- 208000034578 Multiple myelomas Diseases 0.000 claims description 16
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 16
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 claims description 16
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 16
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims description 16
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 16
- 208000036676 acute undifferentiated leukemia Diseases 0.000 claims description 16
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 16
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 15
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 15
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 15
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 14
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 14
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 14
- 208000024908 graft versus host disease Diseases 0.000 claims description 14
- 206010028537 myelofibrosis Diseases 0.000 claims description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 208000017604 Hodgkin disease Diseases 0.000 claims description 12
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 12
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 12
- 230000036210 malignancy Effects 0.000 claims description 12
- 201000006417 multiple sclerosis Diseases 0.000 claims description 12
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 10
- 208000006673 asthma Diseases 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 231100000419 toxicity Toxicity 0.000 claims description 10
- 230000001988 toxicity Effects 0.000 claims description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 9
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 9
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 9
- 201000010105 allergic rhinitis Diseases 0.000 claims description 9
- 201000003444 follicular lymphoma Diseases 0.000 claims description 9
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 9
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 9
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 9
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 9
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 9
- 230000002685 pulmonary effect Effects 0.000 claims description 9
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims description 8
- 201000005569 Gout Diseases 0.000 claims description 8
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 8
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 8
- 208000007452 Plasmacytoma Diseases 0.000 claims description 8
- 201000002661 Spondylitis Diseases 0.000 claims description 8
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 8
- GJWAPAVRQYYSTK-UHFFFAOYSA-N [(dimethyl-$l^{3}-silanyl)amino]-dimethylsilicon Chemical compound C[Si](C)N[Si](C)C GJWAPAVRQYYSTK-UHFFFAOYSA-N 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 8
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 8
- 230000000366 juvenile effect Effects 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 206010028417 myasthenia gravis Diseases 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 206010043554 thrombocytopenia Diseases 0.000 claims description 8
- 206010001889 Alveolitis Diseases 0.000 claims description 7
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 7
- 206010014561 Emphysema Diseases 0.000 claims description 7
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 7
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 208000025966 Neurological disease Diseases 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 7
- 201000010001 Silicosis Diseases 0.000 claims description 7
- 206010047115 Vasculitis Diseases 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 201000009267 bronchiectasis Diseases 0.000 claims description 7
- 206010006451 bronchitis Diseases 0.000 claims description 7
- 208000007451 chronic bronchitis Diseases 0.000 claims description 7
- 229910052805 deuterium Inorganic materials 0.000 claims description 7
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 7
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 208000008423 pleurisy Diseases 0.000 claims description 7
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 229940034982 antineoplastic agent Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 4
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 230000003439 radiotherapeutic effect Effects 0.000 claims description 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 398
- 239000011541 reaction mixture Substances 0.000 description 205
- 235000019439 ethyl acetate Nutrition 0.000 description 199
- 239000000243 solution Substances 0.000 description 192
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 186
- 239000000203 mixture Substances 0.000 description 177
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 173
- 239000012043 crude product Substances 0.000 description 170
- 239000007787 solid Substances 0.000 description 153
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 141
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 125
- 239000000741 silica gel Substances 0.000 description 125
- 229910002027 silica gel Inorganic materials 0.000 description 125
- 239000011734 sodium Substances 0.000 description 124
- 238000004440 column chromatography Methods 0.000 description 120
- 239000012074 organic phase Substances 0.000 description 117
- 239000012267 brine Substances 0.000 description 108
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 108
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 103
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 94
- 239000000047 product Substances 0.000 description 90
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 70
- 125000005843 halogen group Chemical group 0.000 description 66
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 61
- 238000005160 1H NMR spectroscopy Methods 0.000 description 57
- 239000012299 nitrogen atmosphere Substances 0.000 description 54
- 239000000460 chlorine Substances 0.000 description 51
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 47
- 239000000543 intermediate Substances 0.000 description 41
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 32
- 238000000746 purification Methods 0.000 description 31
- 125000004432 carbon atom Chemical group C* 0.000 description 28
- 125000006413 ring segment Chemical group 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 13
- 229940124291 BTK inhibitor Drugs 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000013543 active substance Substances 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000012298 atmosphere Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- FFXSWFXNUPKQHQ-UHFFFAOYSA-N COC1=CC=C(CN(C=C2C(Cl)=N3)N=C2C(C(N)=O)=C3Cl)C=C1 Chemical compound COC1=CC=C(CN(C=C2C(Cl)=N3)N=C2C(C(N)=O)=C3Cl)C=C1 FFXSWFXNUPKQHQ-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 7
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 229960001507 ibrutinib Drugs 0.000 description 7
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000004808 supercritical fluid chromatography Methods 0.000 description 6
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 5
- VOERFQASIJHIAB-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C(CC2)CCC2=O)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C(CC2)CCC2=O)=N1)=O VOERFQASIJHIAB-UHFFFAOYSA-N 0.000 description 5
- JITGMKNHDOWPDK-UHFFFAOYSA-N COC1=CC=C(CN(C=C2C(Br)=C3)N=C2C(C#N)=C3O)C=C1 Chemical compound COC1=CC=C(CN(C=C2C(Br)=C3)N=C2C(C#N)=C3O)C=C1 JITGMKNHDOWPDK-UHFFFAOYSA-N 0.000 description 5
- OEHZLIBONSLOBF-UHFFFAOYSA-N COCOC1=CC(Br)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N Chemical compound COCOC1=CC(Br)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N OEHZLIBONSLOBF-UHFFFAOYSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- JFTZVYKESKQING-UHFFFAOYSA-N 2-(cyclopenten-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCCC1 JFTZVYKESKQING-UHFFFAOYSA-N 0.000 description 4
- NLGJFPBLHAEFQI-UHFFFAOYSA-N COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CCC2)C2O)=C(C=NN2)C2=C1C#N)=O Chemical compound COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CCC2)C2O)=C(C=NN2)C2=C1C#N)=O NLGJFPBLHAEFQI-UHFFFAOYSA-N 0.000 description 4
- REVSIFKVFUEHEQ-UHFFFAOYSA-N COC1=CC=C(CN2N=CC(C(Cl)=N3)=C2C(Br)=C3Cl)C=C1 Chemical compound COC1=CC=C(CN2N=CC(C(Cl)=N3)=C2C(Br)=C3Cl)C=C1 REVSIFKVFUEHEQ-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 4
- UNWSFYJZXCWYEL-UHFFFAOYSA-N ClC1=C(C2OCCCO2)C(Cl)=NC(Cl)=C1 Chemical compound ClC1=C(C2OCCCO2)C(Cl)=NC(Cl)=C1 UNWSFYJZXCWYEL-UHFFFAOYSA-N 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 3
- QLRRJMOBVVGXEJ-XHSDSOJGSA-N (3r,4s)-1-(6-amino-5-fluoropyrimidin-4-yl)-3-[(3r)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxopiperidin-1-yl]piperidine-4-carboxamide Chemical compound N([C@@H]1CCCN(C1=O)[C@H]1CN(CC[C@@H]1C(=O)N)C=1C(=C(N)N=CN=1)F)C1=CC(Cl)=CC(C(F)(F)F)=C1 QLRRJMOBVVGXEJ-XHSDSOJGSA-N 0.000 description 3
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- JCHWHOHZZYWUMP-UHFFFAOYSA-N 2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C(CC1)=CCC21OCCO2 JCHWHOHZZYWUMP-UHFFFAOYSA-N 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 229940125814 BTK kinase inhibitor Drugs 0.000 description 3
- UQZFBMAYCJFROO-UHFFFAOYSA-N COC(C(C(Cl)=NC(C1CCCC1)=C1Br)=C1N)=O Chemical compound COC(C(C(Cl)=NC(C1CCCC1)=C1Br)=C1N)=O UQZFBMAYCJFROO-UHFFFAOYSA-N 0.000 description 3
- ZXPJJDQZEGKRRU-UHFFFAOYSA-N COC(C1=CC(C2=CCCC2)=C(C=NN2)C2=C1OC)=O Chemical compound COC(C1=CC(C2=CCCC2)=C(C=NN2)C2=C1OC)=O ZXPJJDQZEGKRRU-UHFFFAOYSA-N 0.000 description 3
- HRFMYLJABYZXQM-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C(CC2)CCC2O)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C(CC2)CCC2O)=N1)=O HRFMYLJABYZXQM-UHFFFAOYSA-N 0.000 description 3
- JHKYPVDBSKWBFV-UHFFFAOYSA-N COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NC=C2)=C2C(C2CCCC2)=N1)=O Chemical compound COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NC=C2)=C2C(C2CCCC2)=N1)=O JHKYPVDBSKWBFV-UHFFFAOYSA-N 0.000 description 3
- FVGYXQQHOMAEJJ-UHFFFAOYSA-N COC1=CC=C(CN(C2=C(C(O)=C3)C#N)N=CC2=C3C2=CCCC2)C=C1 Chemical compound COC1=CC=C(CN(C2=C(C(O)=C3)C#N)N=CC2=C3C2=CCCC2)C=C1 FVGYXQQHOMAEJJ-UHFFFAOYSA-N 0.000 description 3
- VKKUKWJCRKQKPD-UHFFFAOYSA-N COC1=CC=C(CN(C=C2C(C(CC3)=CCC33OCCO3)=C3)N=C2C(C#N)=C3OS(C(F)(F)F)(=O)=O)C=C1 Chemical compound COC1=CC=C(CN(C=C2C(C(CC3)=CCC33OCCO3)=C3)N=C2C(C#N)=C3OS(C(F)(F)F)(=O)=O)C=C1 VKKUKWJCRKQKPD-UHFFFAOYSA-N 0.000 description 3
- NZAMVTFRYOYXTC-UHFFFAOYSA-N ClC(C1=C2NN=C1)=NC(Cl)=C2Br Chemical compound ClC(C1=C2NN=C1)=NC(Cl)=C2Br NZAMVTFRYOYXTC-UHFFFAOYSA-N 0.000 description 3
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 3
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 3
- TWDNCKOLGHSAQR-UHFFFAOYSA-N FC(F)(F)c1ccnc(NC(=O)c2ccc(Br)cc2)c1 Chemical compound FC(F)(F)c1ccnc(NC(=O)c2ccc(Br)cc2)c1 TWDNCKOLGHSAQR-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- JSJPZIVQGBCRJC-UHFFFAOYSA-N N#CC1=C2NN=CC2=C(C2CCCC2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 Chemical compound N#CC1=C2NN=CC2=C(C2CCCC2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1 JSJPZIVQGBCRJC-UHFFFAOYSA-N 0.000 description 3
- OCLQHDNRNODZNO-UHFFFAOYSA-N NC(C(C(NN=C1)=C1C(Cl)=N1)=C1Cl)=O Chemical compound NC(C(C(NN=C1)=C1C(Cl)=N1)=C1Cl)=O OCLQHDNRNODZNO-UHFFFAOYSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- ZRJAJMZWPJTFHU-UHFFFAOYSA-N O=CC(C(Cl)=C(C(Cl)=N1)Br)=C1Cl Chemical compound O=CC(C(Cl)=C(C(Cl)=N1)Br)=C1Cl ZRJAJMZWPJTFHU-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 101150012828 UPC2 gene Proteins 0.000 description 3
- NOTRZTPOXARWOQ-ZWGNLJFGSA-N [2H]C([2H])([2H])OC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C2C(N(CC2)C[C@@H]2O)=N1)=O Chemical compound [2H]C([2H])([2H])OC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C2C(N(CC2)C[C@@H]2O)=N1)=O NOTRZTPOXARWOQ-ZWGNLJFGSA-N 0.000 description 3
- 229950009821 acalabrutinib Drugs 0.000 description 3
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001952 enzyme assay Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- CKWCWMGUTHMWPC-UHFFFAOYSA-N methyl 5-bromo-2-methoxy-4-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C([N+]([O-])=O)=C1OC CKWCWMGUTHMWPC-UHFFFAOYSA-N 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 102200162764 rs1057519825 Human genes 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 3
- AGDWTMCGSFANIG-UHFFFAOYSA-N tert-butyl-diphenyl-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-3-en-1-yl]oxysilane Chemical compound C(C)(C)(C)[Si](OC1CC(=CC1)B1OC(C(O1)(C)C)(C)C)(C1=CC=CC=C1)C1=CC=CC=C1 AGDWTMCGSFANIG-UHFFFAOYSA-N 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 229950009104 tirabrutinib Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229950007160 vecabrutinib Drugs 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 229950007153 zanubrutinib Drugs 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- JSFCZQSJQXFJDS-QAPCUYQASA-N (2-chloro-4-phenoxyphenyl)-[4-[[(3R,6S)-6-(hydroxymethyl)oxan-3-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]methanone Chemical compound ClC1=C(C=CC(=C1)OC1=CC=CC=C1)C(=O)C1=CNC=2N=CN=C(C=21)N[C@H]1CO[C@@H](CC1)CO JSFCZQSJQXFJDS-QAPCUYQASA-N 0.000 description 2
- ABNUYUHNVPIZKK-UHFFFAOYSA-N (2-methyl-3-oxocyclopenten-1-yl) trifluoromethanesulfonate Chemical compound CC1=C(OS(=O)(=O)C(F)(F)F)CCC1=O ABNUYUHNVPIZKK-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- ICWZWXAOAUJEHX-UHFFFAOYSA-N (3-bromocyclopent-3-en-1-yl)oxy-tert-butyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OC1CC=C(Br)C1 ICWZWXAOAUJEHX-UHFFFAOYSA-N 0.000 description 2
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 2
- OGHQURIMSDKAGH-UHFFFAOYSA-N (4,6-dimethylpyrimidin-5-yl)boronic acid Chemical compound CC1=NC=NC(C)=C1B(O)O OGHQURIMSDKAGH-UHFFFAOYSA-N 0.000 description 2
- KANQVPGFNZKJMR-UHFFFAOYSA-N (4-bromo-3-chlorophenyl)methanamine hydrochloride Chemical compound Cl.NCc1ccc(Br)c(Cl)c1 KANQVPGFNZKJMR-UHFFFAOYSA-N 0.000 description 2
- RGHPCLZJAFCTIK-RXMQYKEDSA-N (R)-2-methylpyrrolidine Chemical compound C[C@@H]1CCCN1 RGHPCLZJAFCTIK-RXMQYKEDSA-N 0.000 description 2
- KZMQPYCXSAGLTB-ZWUNQBBJSA-N (e)-2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile Chemical compound C1N(C(=O)C(/C#N)=C/C(C)(C)C)CCC[C@H]1N1C2=NC=NC(N)=C2C(C=2C(=CC(OC=3C=CC=CC=3)=CC=2)F)=N1 KZMQPYCXSAGLTB-ZWUNQBBJSA-N 0.000 description 2
- LCFFREMLXLZNHE-GBOLQPHISA-N (e)-2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Chemical compound C12=C(N)N=CN=C2N([C@@H]2CCCN(C2)C(=O)C(/C#N)=C/C(C)(C)N2CCN(CC2)C2COC2)N=C1C(C(=C1)F)=CC=C1OC1=CC=CC=C1 LCFFREMLXLZNHE-GBOLQPHISA-N 0.000 description 2
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 description 2
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 2
- GFYQPYYDIRRMSX-UHFFFAOYSA-N 1H-pyrazolo[4,3-c]pyridine-7-carboxamide Chemical class N1N=CC=2C=NC=C(C=21)C(=O)N GFYQPYYDIRRMSX-UHFFFAOYSA-N 0.000 description 2
- FJNNGKMAGDPVIU-UHFFFAOYSA-N 2,4,6-trichloropyridine Chemical compound ClC1=CC(Cl)=NC(Cl)=C1 FJNNGKMAGDPVIU-UHFFFAOYSA-N 0.000 description 2
- RESMQRUOHBZJCA-UHFFFAOYSA-N 2,4,6-trichloropyridine-3-carbaldehyde Chemical compound ClC1=CC(Cl)=C(C=O)C(Cl)=N1 RESMQRUOHBZJCA-UHFFFAOYSA-N 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WUSDXDFGVZYLEV-UHFFFAOYSA-N 2-fluoro-6-(methoxymethoxy)benzonitrile Chemical compound COCOC1=CC=CC(F)=C1C#N WUSDXDFGVZYLEV-UHFFFAOYSA-N 0.000 description 2
- XMYCQNIQHWDRTP-UHFFFAOYSA-N 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-one Chemical compound CC1=C(CCC1=O)B1OC(C)(C)C(C)(C)O1 XMYCQNIQHWDRTP-UHFFFAOYSA-N 0.000 description 2
- ONCZHVKFNHOSKZ-UHFFFAOYSA-N 2-methylpyrrolidin-3-one Chemical compound CC1NCCC1=O ONCZHVKFNHOSKZ-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- ADFSHCQBXFFYBM-UHFFFAOYSA-N 3,5-dibromo-2-(trifluoromethyl)pyridin-4-amine Chemical compound BrC=1C(=NC=C(C=1N)Br)C(F)(F)F ADFSHCQBXFFYBM-UHFFFAOYSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- QFOHOAKSKFYSFE-UHFFFAOYSA-N 3-methyl-2-(trifluoromethyl)pyridin-4-amine Chemical compound NC1=C(C(=NC=C1)C(F)(F)F)C QFOHOAKSKFYSFE-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- JUQCLKZAHDRORK-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(5-methyl-2,3-dihydrofuran-4-yl)-1,3,2-dioxaborolane Chemical compound CC1=C(CCO1)B1OC(C)(C)C(C)(C)O1 JUQCLKZAHDRORK-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- TZHQWUAOIWRFSW-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzonitrile Chemical compound FC1=CC(Br)=CC(F)=C1C#N TZHQWUAOIWRFSW-UHFFFAOYSA-N 0.000 description 2
- ARDAEBQYIBXEMA-UHFFFAOYSA-N 4-bromo-2-fluoro-6-hydroxybenzonitrile Chemical compound OC1=CC(Br)=CC(F)=C1C#N ARDAEBQYIBXEMA-UHFFFAOYSA-N 0.000 description 2
- ODOOXPNYBHBBBF-UHFFFAOYSA-N 4-bromo-2-fluoro-6-phenylmethoxybenzonitrile Chemical compound FC1=CC(Br)=CC(OCC=2C=CC=CC=2)=C1C#N ODOOXPNYBHBBBF-UHFFFAOYSA-N 0.000 description 2
- WVBQVGPTDCDFGW-UHFFFAOYSA-N 4-bromo-3-methyl-2-(trifluoromethyl)pyridine Chemical compound CC1=C(Br)C=CN=C1C(F)(F)F WVBQVGPTDCDFGW-UHFFFAOYSA-N 0.000 description 2
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 2
- ZTUJNJAKTLHBEX-UHFFFAOYSA-N 6-cyclopropyl-8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-6-oxopyridin-3-yl]phenyl]isoquinolin-1-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C(=C(C=CC=2)N2C(C3=C(F)C=C(C=C3C=C2)C2CC2)=O)CO)=CN(C)C1=O ZTUJNJAKTLHBEX-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- 208000027496 Behcet disease Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- KTSBWBOHWWSTOL-UHFFFAOYSA-N CC(C(Br)=CC(C(OC)=O)=C1OC)=C1N Chemical compound CC(C(Br)=CC(C(OC)=O)=C1OC)=C1N KTSBWBOHWWSTOL-UHFFFAOYSA-N 0.000 description 2
- PVBWOGSXBCGUIG-UHFFFAOYSA-N CC(C(F)(F)F)OC1=NC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 Chemical compound CC(C(F)(F)F)OC1=NC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 PVBWOGSXBCGUIG-UHFFFAOYSA-N 0.000 description 2
- BTZMTNSEPPDZAB-UHFFFAOYSA-N CC(C(F)(F)F)OC1=NC(Cl)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 Chemical compound CC(C(F)(F)F)OC1=NC(Cl)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 BTZMTNSEPPDZAB-UHFFFAOYSA-N 0.000 description 2
- LMNNHYVDBGNATN-UHFFFAOYSA-N CC(C)(C)OC(C(C(NC(OC(C)(C)C)=O)=CC(C1=CCCC1)=N1)=C1Cl)=O Chemical compound CC(C)(C)OC(C(C(NC(OC(C)(C)C)=O)=CC(C1=CCCC1)=N1)=C1Cl)=O LMNNHYVDBGNATN-UHFFFAOYSA-N 0.000 description 2
- OZBUMAJNQMARAP-UHFFFAOYSA-N CC(C)(C)OC(C(C(NC(OC(C)(C)C)=O)=CC(C1CCCC1)=N1)=C1Cl)=O Chemical compound CC(C)(C)OC(C(C(NC(OC(C)(C)C)=O)=CC(C1CCCC1)=N1)=C1Cl)=O OZBUMAJNQMARAP-UHFFFAOYSA-N 0.000 description 2
- PNGVSCRROYLFGA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)C(C)(C(OC)=O)C1=O)=O Chemical compound CC(C)(C)OC(N(CC1)C(C)(C(OC)=O)C1=O)=O PNGVSCRROYLFGA-UHFFFAOYSA-N 0.000 description 2
- DVOSENIOUYGHNY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)C(C)=C1OS(C(F)(F)F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)C(C)=C1OS(C(F)(F)F)(=O)=O)=O DVOSENIOUYGHNY-UHFFFAOYSA-N 0.000 description 2
- LRDUIJOHLKYAPN-UHFFFAOYSA-N CC(C)(C)OC(N1C(C)=C(B2OC(C)(C)C(C)(C)O2)CC1)=O Chemical compound CC(C)(C)OC(N1C(C)=C(B2OC(C)(C)C(C)(C)O2)CC1)=O LRDUIJOHLKYAPN-UHFFFAOYSA-N 0.000 description 2
- LRHNLIBHYIRHNS-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC(CC1)CC1C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)=CC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1C#N Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC(CC1)CC1C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)=CC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1C#N LRHNLIBHYIRHNS-UHFFFAOYSA-N 0.000 description 2
- PHYSCRPRBJIAHW-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC(CC1)CC1C1=NC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC(CC1)CC1C1=NC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 PHYSCRPRBJIAHW-UHFFFAOYSA-N 0.000 description 2
- QGQBEWSVLCMMIC-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC1CC(C(C2=CN(CC(C=C3)=CC=C3OC)N=C22)=CC(C3=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C3)=C2C#N)=CC1 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC1CC(C(C2=CN(CC(C=C3)=CC=C3OC)N=C22)=CC(C3=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C3)=C2C#N)=CC1 QGQBEWSVLCMMIC-UHFFFAOYSA-N 0.000 description 2
- CSGCXKLVGVACRH-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC1CC(C(C2=CN(CC(C=C3)=CC=C3OC)N=C22)=CC(OS(C(F)(F)F)(=O)=O)=C2C#N)=CC1 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC1CC(C(C2=CN(CC(C=C3)=CC=C3OC)N=C22)=CC(OS(C(F)(F)F)(=O)=O)=C2C#N)=CC1 CSGCXKLVGVACRH-UHFFFAOYSA-N 0.000 description 2
- PORRJEVUMQVEJY-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC1CC(C2=NC(Cl)=C(C(N)=O)C3=NN(CC(C=C4)=CC=C4OC)C=C23)=CC1 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC1CC(C2=NC(Cl)=C(C(N)=O)C3=NN(CC(C=C4)=CC=C4OC)C=C23)=CC1 PORRJEVUMQVEJY-UHFFFAOYSA-N 0.000 description 2
- AABFELGNJIMOKC-UHFFFAOYSA-N CC(C=NC=C1)=C1C1=NC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 Chemical compound CC(C=NC=C1)=C1C1=NC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 AABFELGNJIMOKC-UHFFFAOYSA-N 0.000 description 2
- CLOZVQURVXDBGM-UHFFFAOYSA-N CC(C=NC=C1)=C1C1=NC(Cl)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 Chemical compound CC(C=NC=C1)=C1C1=NC(Cl)=C(C(N)=O)C2=NN(CC(C=C3)=CC=C3OC)C=C12 CLOZVQURVXDBGM-UHFFFAOYSA-N 0.000 description 2
- IQYIIRAKBOMCNL-UHFFFAOYSA-N CC(OCC1)=C1OS(C(F)(F)F)(=O)=O Chemical compound CC(OCC1)=C1OS(C(F)(F)F)(=O)=O IQYIIRAKBOMCNL-UHFFFAOYSA-N 0.000 description 2
- PCLNGMKWPINXDN-UHFFFAOYSA-N CC1(C)OB(C(C=CC(CNC(C(C=C(C=C2)F)=C2OC)=O)=C2)=C2Cl)OC1(C)C Chemical compound CC1(C)OB(C(C=CC(CNC(C(C=C(C=C2)F)=C2OC)=O)=C2)=C2Cl)OC1(C)C PCLNGMKWPINXDN-UHFFFAOYSA-N 0.000 description 2
- OEIPOLCAFPMAQI-UHFFFAOYSA-N CCOC(=O)C1CN(C(C)C1=O)C(=O)OC(C)(C)C Chemical compound CCOC(=O)C1CN(C(C)C1=O)C(=O)OC(C)(C)C OEIPOLCAFPMAQI-UHFFFAOYSA-N 0.000 description 2
- RSTGHTNLHYCVHR-UHFFFAOYSA-N COC(C(C(Cl)=NC(C1CCCC1)=C1)=C1N)=O Chemical compound COC(C(C(Cl)=NC(C1CCCC1)=C1)=C1N)=O RSTGHTNLHYCVHR-UHFFFAOYSA-N 0.000 description 2
- NATAAIWTKHHEDT-UHFFFAOYSA-N COC(C(C(N(CC(C=C1)=CC=C1OC)N=C1)=C1C(C(CC1)=CCC11OCCO1)=N1)=C1Cl)=O Chemical compound COC(C(C(N(CC(C=C1)=CC=C1OC)N=C1)=C1C(C(CC1)=CCC11OCCO1)=N1)=C1Cl)=O NATAAIWTKHHEDT-UHFFFAOYSA-N 0.000 description 2
- AFNBXLWQYTXOTP-UHFFFAOYSA-N COC(C1=C(C2=CC=C(CNC(C(C=CC=C3)=C3OC)=O)C=C2)N=C(C2=CCCC2)C2=C1N(CC(C=C1)=CC=C1OC)N=C2)=O Chemical compound COC(C1=C(C2=CC=C(CNC(C(C=CC=C3)=C3OC)=O)C=C2)N=C(C2=CCCC2)C2=C1N(CC(C=C1)=CC=C1OC)N=C2)=O AFNBXLWQYTXOTP-UHFFFAOYSA-N 0.000 description 2
- CROPOMNABMFVNK-UHFFFAOYSA-N COC(C1=C(C2=CC=C(CNC(C(C=CC=C3)=C3OC)=O)C=C2)N=C(C2CCCC2)C2=C1N(CC(C=C1)=CC=C1OC)N=C2)=O Chemical compound COC(C1=C(C2=CC=C(CNC(C(C=CC=C3)=C3OC)=O)C=C2)N=C(C2CCCC2)C2=C1N(CC(C=C1)=CC=C1OC)N=C2)=O CROPOMNABMFVNK-UHFFFAOYSA-N 0.000 description 2
- DUEXCVXLOHKLIW-UHFFFAOYSA-N COC(C1=C(C2=CC=C(CNC(C(C=CC=C3)=C3OC)=O)C=C2)N=C(C2CCCC2)C2=C1NC=C2)=O Chemical compound COC(C1=C(C2=CC=C(CNC(C(C=CC=C3)=C3OC)=O)C=C2)N=C(C2CCCC2)C2=C1NC=C2)=O DUEXCVXLOHKLIW-UHFFFAOYSA-N 0.000 description 2
- ZLDHJNIFRUKLGV-UHFFFAOYSA-N COC(C1=C(C2=CC=C(CNC(C(C=CC=C3)=C3OC)=O)C=C2)N=C(C2CCCC2)C2=C1NN=C2)=O Chemical compound COC(C1=C(C2=CC=C(CNC(C(C=CC=C3)=C3OC)=O)C=C2)N=C(C2CCCC2)C2=C1NN=C2)=O ZLDHJNIFRUKLGV-UHFFFAOYSA-N 0.000 description 2
- USOREJZWBSGSRB-UHFFFAOYSA-N COC(C1=CC(Br)=C(C=NN2)C2=C1OC)=O Chemical compound COC(C1=CC(Br)=C(C=NN2)C2=C1OC)=O USOREJZWBSGSRB-UHFFFAOYSA-N 0.000 description 2
- YDOAUTLHRNOKJZ-UHFFFAOYSA-N COC(C1=CC(C2CCCC2)=C(C=NN2)C2=C1C#N)=O Chemical compound COC(C1=CC(C2CCCC2)=C(C=NN2)C2=C1C#N)=O YDOAUTLHRNOKJZ-UHFFFAOYSA-N 0.000 description 2
- WBBYETMFLNZVOO-UHFFFAOYSA-N COC(C1=CC(C2CCCC2)=C(C=NN2)C2=C1O)=O Chemical compound COC(C1=CC(C2CCCC2)=C(C=NN2)C2=C1O)=O WBBYETMFLNZVOO-UHFFFAOYSA-N 0.000 description 2
- SMDVAYYDZUHKRF-UHFFFAOYSA-N COC(C1=CC(C2CCCC2)=C(C=NN2)C2=C1OC)=O Chemical compound COC(C1=CC(C2CCCC2)=C(C=NN2)C2=C1OC)=O SMDVAYYDZUHKRF-UHFFFAOYSA-N 0.000 description 2
- YDMIVDQNHZBCCT-UHFFFAOYSA-N COC(C1=CC(C2CCCC2)=C(C=NN2)C2=C1OS(C(F)(F)F)(=O)=O)=O Chemical compound COC(C1=CC(C2CCCC2)=C(C=NN2)C2=C1OS(C(F)(F)F)(=O)=O)=O YDMIVDQNHZBCCT-UHFFFAOYSA-N 0.000 description 2
- TWDYNNRSRXMYOH-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC(Cl)=C1Br)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC(Cl)=C1Br)=O TWDYNNRSRXMYOH-UHFFFAOYSA-N 0.000 description 2
- IXVBBNGOQZOSJQ-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NC=C2)=C2C(C2CCCC2)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NC=C2)=C2C(C2CCCC2)=N1)=O IXVBBNGOQZOSJQ-UHFFFAOYSA-N 0.000 description 2
- FSZZGILIXLXZIR-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C2=NC=NC=C2)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C2=NC=NC=C2)=N1)=O FSZZGILIXLXZIR-UHFFFAOYSA-N 0.000 description 2
- YCKARNYAWNCQHD-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(O)=O)C(NC=C2)=C2C(C2CCCC2)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(O)=O)C(NC=C2)=C2C(C2CCCC2)=N1)=O YCKARNYAWNCQHD-UHFFFAOYSA-N 0.000 description 2
- JQAAEOGREOIUSK-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CC2)CC2O)=C(C=NN2)C2=C1C(N)=O)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CC2)CC2O)=C(C=NN2)C2=C1C(N)=O)=O JQAAEOGREOIUSK-UHFFFAOYSA-N 0.000 description 2
- GNSILCBNIWTUHV-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CC2)CCC2=O)=C(C=NN2)C2=C1C#N)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CC2)CCC2=O)=C(C=NN2)C2=C1C#N)=O GNSILCBNIWTUHV-UHFFFAOYSA-N 0.000 description 2
- GYOFABFXHMENFW-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CC2)CCC2O)=C(C=NN2)C2=C1C#N)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CC2)CCC2O)=C(C=NN2)C2=C1C#N)=O GYOFABFXHMENFW-UHFFFAOYSA-N 0.000 description 2
- PIAUDZXBFVRVNO-LJQANCHMSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(N(CC2)C[C@@H]2O)=C(C=NN2)C2=C1C#N)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(N(CC2)C[C@@H]2O)=C(C=NN2)C2=C1C#N)=O PIAUDZXBFVRVNO-LJQANCHMSA-N 0.000 description 2
- QJPCGCDESKYEMX-GOSISDBHSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(N(CC2)C[C@@H]2O)=C(C=NN2)C2=C1C(N)=O)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(N(CC2)C[C@@H]2O)=C(C=NN2)C2=C1C(N)=O)=O QJPCGCDESKYEMX-GOSISDBHSA-N 0.000 description 2
- FZGDECNALJZYSA-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(N2CCCC2)=C(C=NN2)C2=C1C#N)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(N2CCCC2)=C(C=NN2)C2=C1C#N)=O FZGDECNALJZYSA-UHFFFAOYSA-N 0.000 description 2
- MNAJOTUUCQSTOP-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(N2CCCC2)=C(C=NN2)C2=C1C(N)=O)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(N2CCCC2)=C(C=NN2)C2=C1C(N)=O)=O MNAJOTUUCQSTOP-UHFFFAOYSA-N 0.000 description 2
- PECCYNFPBXXBCS-UHFFFAOYSA-N COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CCC2)C2O)=C(C=NN2)C2=C1C(N)=O)=O Chemical compound COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CCC2)C2O)=C(C=NN2)C2=C1C(N)=O)=O PECCYNFPBXXBCS-UHFFFAOYSA-N 0.000 description 2
- BDUUUYBZENHAKV-UHFFFAOYSA-N COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=CC=C(C=NN2)C2=C1C#N)=O Chemical compound COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=CC=C(C=NN2)C2=C1C#N)=O BDUUUYBZENHAKV-UHFFFAOYSA-N 0.000 description 2
- SIAPCVRGFUFQOE-UHFFFAOYSA-N COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=CC=C(C=NN2)C2=C1C(N)=O)=O Chemical compound COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=CC=C(C=NN2)C2=C1C(N)=O)=O SIAPCVRGFUFQOE-UHFFFAOYSA-N 0.000 description 2
- VOELJYUTGPPGLK-AREMUKBSSA-N COC1=CC=C(CN(C2=C(C(C3=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C3)=C3)C#N)N=CC2=C3N(CC2)C[C@@H]2O)C=C1 Chemical compound COC1=CC=C(CN(C2=C(C(C3=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C3)=C3)C#N)N=CC2=C3N(CC2)C[C@@H]2O)C=C1 VOELJYUTGPPGLK-AREMUKBSSA-N 0.000 description 2
- FWTSUXFZVZQDFS-CQSZACIVSA-N COC1=CC=C(CN(C2=C(C(O)=C3)C#N)N=CC2=C3N(CC2)C[C@@H]2O)C=C1 Chemical compound COC1=CC=C(CN(C2=C(C(O)=C3)C#N)N=CC2=C3N(CC2)C[C@@H]2O)C=C1 FWTSUXFZVZQDFS-CQSZACIVSA-N 0.000 description 2
- HDHIGDHKOZUSES-UHFFFAOYSA-N COC1=CC=C(CN(C2=C(C(O)=C3)C#N)N=CC2=C3N2CCCC2)C=C1 Chemical compound COC1=CC=C(CN(C2=C(C(O)=C3)C#N)N=CC2=C3N2CCCC2)C=C1 HDHIGDHKOZUSES-UHFFFAOYSA-N 0.000 description 2
- WVKGPDZXDIWOJP-UHFFFAOYSA-N COC1=CC=C(CN(C2=C(C(OS(C(F)(F)F)(=O)=O)=C3)C#N)N=CC2=C3C2=CCCC2)C=C1 Chemical compound COC1=CC=C(CN(C2=C(C(OS(C(F)(F)F)(=O)=O)=C3)C#N)N=CC2=C3C2=CCCC2)C=C1 WVKGPDZXDIWOJP-UHFFFAOYSA-N 0.000 description 2
- GUNOYFQLFJVMNY-CQSZACIVSA-N COC1=CC=C(CN(C2=C(C(OS(C(F)(F)F)(=O)=O)=C3)C#N)N=CC2=C3N(CC2)C[C@@H]2O)C=C1 Chemical compound COC1=CC=C(CN(C2=C(C(OS(C(F)(F)F)(=O)=O)=C3)C#N)N=CC2=C3N(CC2)C[C@@H]2O)C=C1 GUNOYFQLFJVMNY-CQSZACIVSA-N 0.000 description 2
- MXRCKVZPLXWMPB-UHFFFAOYSA-N COC1=CC=C(CN(C=C23)N=C2C(C(N)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3N2CCCC2)C=C1 Chemical compound COC1=CC=C(CN(C=C23)N=C2C(C(N)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3N2CCCC2)C=C1 MXRCKVZPLXWMPB-UHFFFAOYSA-N 0.000 description 2
- AWCMWNKRIKYUIZ-UHFFFAOYSA-N COC1=CC=C(CN(C=C2C(C(CC3)=CCC33OCCO3)=C3)N=C2C(C#N)=C3C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)C=C1 Chemical compound COC1=CC=C(CN(C=C2C(C(CC3)=CCC33OCCO3)=C3)N=C2C(C#N)=C3C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)C=C1 AWCMWNKRIKYUIZ-UHFFFAOYSA-N 0.000 description 2
- DCYJUEGNEDPTLW-UHFFFAOYSA-N COC1=CC=C(CN(C=C2C(C(CC3)CCC33OCCO3)=C3)N=C2C(C#N)=C3C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)C=C1 Chemical compound COC1=CC=C(CN(C=C2C(C(CC3)CCC33OCCO3)=C3)N=C2C(C#N)=C3C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)C=C1 DCYJUEGNEDPTLW-UHFFFAOYSA-N 0.000 description 2
- JHQPGPRAUYSBRW-UHFFFAOYSA-N COC1=CC=C(CN(C=C2C(C3=NC=NC=C3)=N3)N=C2C(C(N)=O)=C3Cl)C=C1 Chemical compound COC1=CC=C(CN(C=C2C(C3=NC=NC=C3)=N3)N=C2C(C(N)=O)=C3Cl)C=C1 JHQPGPRAUYSBRW-UHFFFAOYSA-N 0.000 description 2
- PJEDLJCSPAYXAV-UHFFFAOYSA-N COC1=CC=C(CN(C=C2C(N3CCCC3)=N3)N=C2C(C(N)=O)=C3Cl)C=C1 Chemical compound COC1=CC=C(CN(C=C2C(N3CCCC3)=N3)N=C2C(C(N)=O)=C3Cl)C=C1 PJEDLJCSPAYXAV-UHFFFAOYSA-N 0.000 description 2
- IFOKFCDKAGLTKH-UHFFFAOYSA-N COC1=CC=C(CN2N=C3C(C(N)=O)=C(C4=CC=C(CNC(C(C=C(C=C5)F)=C5OC)=O)C=C4)N=C(C(CC4)CCC44OCCO4)C3=C2)C=C1 Chemical compound COC1=CC=C(CN2N=C3C(C(N)=O)=C(C4=CC=C(CNC(C(C=C(C=C5)F)=C5OC)=O)C=C4)N=C(C(CC4)CCC44OCCO4)C3=C2)C=C1 IFOKFCDKAGLTKH-UHFFFAOYSA-N 0.000 description 2
- RXVAWQCWPGTJIA-UHFFFAOYSA-N COC1=CC=C(CN2N=CC(C(C3=CCCC3)=N3)=C2C(Br)=C3Cl)C=C1 Chemical compound COC1=CC=C(CN2N=CC(C(C3=CCCC3)=N3)=C2C(Br)=C3Cl)C=C1 RXVAWQCWPGTJIA-UHFFFAOYSA-N 0.000 description 2
- JSLBTZWGBNXHFQ-UHFFFAOYSA-N COC1=CC=C(CN2N=CC(C(Cl)=N3)=C2C(C(N)=O)=C3Cl)C=C1 Chemical compound COC1=CC=C(CN2N=CC(C(Cl)=N3)=C2C(C(N)=O)=C3Cl)C=C1 JSLBTZWGBNXHFQ-UHFFFAOYSA-N 0.000 description 2
- COVANXJHCYOBON-UHFFFAOYSA-N COC1=CC=C(CN2N=CC3=C(C(CCC4)C4O)C=C(C4=CC=C(CNC(C(C=CC=C5)=C5OC)=O)C=C4)C(C#N)=C23)C=C1 Chemical compound COC1=CC=C(CN2N=CC3=C(C(CCC4)C4O)C=C(C4=CC=C(CNC(C(C=CC=C5)=C5OC)=O)C=C4)C(C#N)=C23)C=C1 COVANXJHCYOBON-UHFFFAOYSA-N 0.000 description 2
- QAXKCOIKKWTKQI-UHFFFAOYSA-N COC1=CC=C(CN2N=CC3=CC=C(C4=CC=C(CNC(C(C=CC=C5)=C5OC)=O)C=C4)C(C#N)=C23)C=C1 Chemical compound COC1=CC=C(CN2N=CC3=CC=C(C4=CC=C(CNC(C(C=CC=C5)=C5OC)=O)C=C4)C(C#N)=C23)C=C1 QAXKCOIKKWTKQI-UHFFFAOYSA-N 0.000 description 2
- XTYURBOUYDXUBY-UHFFFAOYSA-N COCOC(C=C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)Br)=C1C#N Chemical compound COCOC(C=C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)Br)=C1C#N XTYURBOUYDXUBY-UHFFFAOYSA-N 0.000 description 2
- MLDBHHIGVYCPCP-UHFFFAOYSA-N COCOC1=CC(Br)=C(C=NN2)C2=C1C#N Chemical compound COCOC1=CC(Br)=C(C=NN2)C2=C1C#N MLDBHHIGVYCPCP-UHFFFAOYSA-N 0.000 description 2
- MEHRCHOQPBVEHP-UHFFFAOYSA-N COCOC1=CC(Br)=C(C=O)C(F)=C1C#N Chemical compound COCOC1=CC(Br)=C(C=O)C(F)=C1C#N MEHRCHOQPBVEHP-UHFFFAOYSA-N 0.000 description 2
- JKTGPIACPXHZGI-UHFFFAOYSA-N COCOC1=CC(Br)=CC(F)=C1C#N Chemical compound COCOC1=CC(Br)=CC(F)=C1C#N JKTGPIACPXHZGI-UHFFFAOYSA-N 0.000 description 2
- HMLFXGMGXWEJSH-MRXNPFEDSA-N COCOC1=CC(N(CC2)C[C@@H]2O)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N Chemical compound COCOC1=CC(N(CC2)C[C@@H]2O)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N HMLFXGMGXWEJSH-MRXNPFEDSA-N 0.000 description 2
- YCMGXVZXFKTKEM-UHFFFAOYSA-N COCOC1=CC(N2CCCC2)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N Chemical compound COCOC1=CC(N2CCCC2)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N YCMGXVZXFKTKEM-UHFFFAOYSA-N 0.000 description 2
- BMQPGYBFFUVLAR-UHFFFAOYSA-N COCOC1=CC=C(C=NN2)C2=C1C#N Chemical compound COCOC1=CC=C(C=NN2)C2=C1C#N BMQPGYBFFUVLAR-UHFFFAOYSA-N 0.000 description 2
- OSWIZLQLFXMJJQ-UHFFFAOYSA-N COCOC1=CC=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N Chemical compound COCOC1=CC=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N OSWIZLQLFXMJJQ-UHFFFAOYSA-N 0.000 description 2
- CLQQAXYYYVBWFM-UHFFFAOYSA-N COCOC1=CC=C(C=O)C(F)=C1C#N Chemical compound COCOC1=CC=C(C=O)C(F)=C1C#N CLQQAXYYYVBWFM-UHFFFAOYSA-N 0.000 description 2
- GHRJMAWSCNPYSL-HSZRJFAPSA-N C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)=CC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1C#N Chemical compound C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)=CC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1C#N GHRJMAWSCNPYSL-HSZRJFAPSA-N 0.000 description 2
- BQUNQJLWUUCZLW-CQSZACIVSA-N C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)=CC(O)=C1C#N Chemical compound C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)=CC(O)=C1C#N BQUNQJLWUUCZLW-CQSZACIVSA-N 0.000 description 2
- HDGWNRZYMGACTH-CQSZACIVSA-N C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)=CC(OS(C(F)(F)F)(=O)=O)=C1C#N Chemical compound C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C11)=CC(OS(C(F)(F)F)(=O)=O)=C1C#N HDGWNRZYMGACTH-CQSZACIVSA-N 0.000 description 2
- UOZHBFXVRWTODL-JOCHJYFZSA-N C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C1C(C#N)=C1C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1Cl Chemical compound C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C1C(C#N)=C1C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1Cl UOZHBFXVRWTODL-JOCHJYFZSA-N 0.000 description 2
- KQIIXCDAUNVOJU-CYBMUJFWSA-N C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C1C(C#N)=C1O)=C1Cl Chemical compound C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C1C(C#N)=C1O)=C1Cl KQIIXCDAUNVOJU-CYBMUJFWSA-N 0.000 description 2
- NYADXLQNBNEEGY-CYBMUJFWSA-N C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C1C(C#N)=C1OS(C(F)(F)F)(=O)=O)=C1Cl Chemical compound C[C@H](CCC1)N1C(C1=CN(CC(C=C2)=CC=C2OC)N=C1C(C#N)=C1OS(C(F)(F)F)(=O)=O)=C1Cl NYADXLQNBNEEGY-CYBMUJFWSA-N 0.000 description 2
- GFUUTXZCOLZVLM-QGZVFWFLSA-N C[C@H](CCC1)N1C(C=C1C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C=NN2)C2=C1C#N Chemical compound C[C@H](CCC1)N1C(C=C1C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C=NN2)C2=C1C#N GFUUTXZCOLZVLM-QGZVFWFLSA-N 0.000 description 2
- YJBASUGMFHWRDP-CQSZACIVSA-N C[C@H](CCC1)N1C(C=C1O)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N Chemical compound C[C@H](CCC1)N1C(C=C1O)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N YJBASUGMFHWRDP-CQSZACIVSA-N 0.000 description 2
- CEPLSORQNJFSGX-OAHLLOKOSA-N C[C@H](CCC1)N1C1=C(C=NN2)C2=C(C(N)=O)C(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1Cl Chemical compound C[C@H](CCC1)N1C1=C(C=NN2)C2=C(C(N)=O)C(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1Cl CEPLSORQNJFSGX-OAHLLOKOSA-N 0.000 description 2
- BMOPINCEHARHAR-UHFFFAOYSA-N ClC(C(C1OCCCO1)=C(N=C1Cl)Cl)=C1Br Chemical compound ClC(C(C1OCCCO1)=C(N=C1Cl)Cl)=C1Br BMOPINCEHARHAR-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- MWHHJYUHCZWSLS-UHFFFAOYSA-N FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F Chemical compound FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F MWHHJYUHCZWSLS-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- SBURXEAWLPGPDG-UHFFFAOYSA-N N-[(4-bromophenyl)methyl]-5-fluoro-2-hydroxybenzamide Chemical compound Oc1ccc(F)cc1C(=O)NCc1ccc(Br)cc1 SBURXEAWLPGPDG-UHFFFAOYSA-N 0.000 description 2
- BMWMKGNVAMXXCH-UHFFFAOYSA-N N-[[2-methyl-4-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]phenyl]methyl]-3-propan-2-yloxyazetidine-1-carboxamide Chemical compound C(C)(C)OC1CN(C1)C(=O)NCC1=C(C=C(C=C1)C1=NC(=NC=C1)NC=1C=NN(C1)C)C BMWMKGNVAMXXCH-UHFFFAOYSA-N 0.000 description 2
- UNHZLHSLZZWMNP-LLVKDONJSA-N NC(=O)c1ccc([C@@H]2CCCN(C2)C(=O)C=C)c2cc[nH]c12 Chemical compound NC(=O)c1ccc([C@@H]2CCCN(C2)C(=O)C=C)c2cc[nH]c12 UNHZLHSLZZWMNP-LLVKDONJSA-N 0.000 description 2
- QIXLORFNOGEKHV-UHFFFAOYSA-N NC(C(C(Cl)=C(C=O)C(Cl)=N1)=C1Cl)=O Chemical compound NC(C(C(Cl)=C(C=O)C(Cl)=N1)=C1Cl)=O QIXLORFNOGEKHV-UHFFFAOYSA-N 0.000 description 2
- LCWJCAJOYQAACH-UHFFFAOYSA-N NC(C1=C2NN=CC2=C(C2CCCC2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O Chemical compound NC(C1=C2NN=CC2=C(C2CCCC2)C=C1C(C=C1)=CC=C1OC1=CC=CC=C1)=O LCWJCAJOYQAACH-UHFFFAOYSA-N 0.000 description 2
- RIJUMSQRJSTJIR-UHFFFAOYSA-N NC1=C(C(O)=O)C(Cl)=NC(C2CCCC2)=C1 Chemical compound NC1=C(C(O)=O)C(Cl)=NC(C2CCCC2)=C1 RIJUMSQRJSTJIR-UHFFFAOYSA-N 0.000 description 2
- PLLRTFORXLRVHF-UHFFFAOYSA-N NC1=CC(C2CCCC2)=C(C=NN2)C2=C1C#N Chemical compound NC1=CC(C2CCCC2)=C(C=NN2)C2=C1C#N PLLRTFORXLRVHF-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- AONLLLWXAWNGRE-UHFFFAOYSA-N Nc1ccnc(c1Br)C(F)(F)F Chemical compound Nc1ccnc(c1Br)C(F)(F)F AONLLLWXAWNGRE-UHFFFAOYSA-N 0.000 description 2
- PDOKGEJFWOPUID-UHFFFAOYSA-N OC(C(C(Cl)=C(C1OCCCO1)C(Cl)=N1)=C1Cl)=O Chemical compound OC(C(C(Cl)=C(C1OCCCO1)C(Cl)=N1)=C1Cl)=O PDOKGEJFWOPUID-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 2
- MFGOMUWEODSEPT-JCNGFBMWSA-N [2H]C([2H])([2H])OC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(N(CC2)C[C@@H]2O)=N1)=O Chemical compound [2H]C([2H])([2H])OC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(N(CC2)C[C@@H]2O)=N1)=O MFGOMUWEODSEPT-JCNGFBMWSA-N 0.000 description 2
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229940125808 covalent inhibitor Drugs 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 229950003411 evobrutinib Drugs 0.000 description 2
- QUIWHXQETADMGN-UHFFFAOYSA-N evobrutinib Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C=1C(N)=NC=NC=1NCC1CCN(C(=O)C=C)CC1 QUIWHXQETADMGN-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000003674 kinase activity assay Methods 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DEMKAVJRIYGNEQ-UHFFFAOYSA-N methyl 5-bromo-2-hydroxy-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C=C1O DEMKAVJRIYGNEQ-UHFFFAOYSA-N 0.000 description 2
- DIQFMWHELJHNFZ-UHFFFAOYSA-N methyl 5-bromo-2-methoxy-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C=C1OC DIQFMWHELJHNFZ-UHFFFAOYSA-N 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229950007968 poseltinib Drugs 0.000 description 2
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 2
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 2
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- CUABMPOJOBCXJI-UHFFFAOYSA-N remibrutinib Chemical compound CN(CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C)C(=O)C=C CUABMPOJOBCXJI-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940018008 rilzabrutinib Drugs 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229950002089 spebrutinib Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RCXMPEQNIFMEKQ-UHFFFAOYSA-N tert-butyl 2,6-dichloro-4-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)NC1=CC(Cl)=NC(Cl)=C1C(=O)OC(C)(C)C RCXMPEQNIFMEKQ-UHFFFAOYSA-N 0.000 description 2
- FQBIJMMPYGOFFR-UHFFFAOYSA-N tert-butyl 2-methyl-3-oxopyrrolidine-1-carboxylate Chemical compound CC1N(C(=O)OC(C)(C)C)CCC1=O FQBIJMMPYGOFFR-UHFFFAOYSA-N 0.000 description 2
- GOEVSCZPRWWIEO-UHFFFAOYSA-N tert-butyl-(3,4-dibromocyclopentyl)oxy-diphenylsilane Chemical compound C(C)(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC1CC(C(C1)Br)Br GOEVSCZPRWWIEO-UHFFFAOYSA-N 0.000 description 2
- GCODZQWZNXYLIA-UHFFFAOYSA-N tert-butyl-cyclopent-3-en-1-yloxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OC1CC=CC1 GCODZQWZNXYLIA-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 239000001612 (2R)-2-methyloxolan-3-one Substances 0.000 description 1
- KSERCJHSQPNSJM-UHFFFAOYSA-N (3-methylpyridin-4-yl)boronic acid Chemical compound CC1=CN=CC=C1B(O)O KSERCJHSQPNSJM-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 1
- KZEDPVFJLQLDIZ-UHFFFAOYSA-N (5-diphenylphosphanyl-9,9-dimethylxanthen-4-yl)-diphenylphosphane Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1.C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZEDPVFJLQLDIZ-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- GILIYJDBJZWGBG-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-ol Chemical compound CC(O)C(F)(F)F GILIYJDBJZWGBG-UHFFFAOYSA-N 0.000 description 1
- XCJXYTFYKPVYMK-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC(CBr)=CC=C1Br XCJXYTFYKPVYMK-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- WAEZOSSWRXDWAX-UHFFFAOYSA-N 2,6-dichloropyridin-4-amine Chemical compound NC1=CC(Cl)=NC(Cl)=C1 WAEZOSSWRXDWAX-UHFFFAOYSA-N 0.000 description 1
- HYQOZAWBANMOTL-UHFFFAOYSA-N 2-(2-ethoxyethenyl)-4,4,5,5-tetramethyl-1,3-dioxolane Chemical compound CCOC=CC1OC(C)(C)C(C)(C)O1 HYQOZAWBANMOTL-UHFFFAOYSA-N 0.000 description 1
- LYNBZRJTRHTSKI-UHFFFAOYSA-N 2-(trifluoromethyl)pyridin-4-amine Chemical compound NC1=CC=NC(C(F)(F)F)=C1 LYNBZRJTRHTSKI-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- MRAYNLYCQPAZJN-BQYQJAHWSA-N 2-[(e)-2-ethoxyethenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CCO\C=C\B1OC(C)(C)C(C)(C)O1 MRAYNLYCQPAZJN-BQYQJAHWSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- YEBHNFDMNFHZFF-UHFFFAOYSA-N 2-fluoro-6-hydroxybenzonitrile Chemical compound OC1=CC=CC(F)=C1C#N YEBHNFDMNFHZFF-UHFFFAOYSA-N 0.000 description 1
- IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- HXZILEQYFQYQCE-UHFFFAOYSA-N 2-methylcyclopentane-1,3-dione Chemical compound CC1C(=O)CCC1=O HXZILEQYFQYQCE-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QGMYWOHXZMRAHQ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-n-[4-(trifluoromethyl)pyridin-2-yl]benzamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C(=O)NC=2N=CC=C(C=2)C(F)(F)F)C=C1 QGMYWOHXZMRAHQ-UHFFFAOYSA-N 0.000 description 1
- RWGBXAQMUBGGKQ-UHFFFAOYSA-N 4-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=CC(C(F)(F)F)=CC=N1 RWGBXAQMUBGGKQ-UHFFFAOYSA-N 0.000 description 1
- VVLHQJDAUIPZFH-UHFFFAOYSA-N 4-[4-[[5-fluoro-4-[3-(prop-2-enoylamino)anilino]pyrimidin-2-yl]amino]phenoxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC=3N=C(NC=4C=C(NC(=O)C=C)C=CC=4)C(F)=CN=3)=CC=2)=C1 VVLHQJDAUIPZFH-UHFFFAOYSA-N 0.000 description 1
- TUXYZHVUPGXXQG-UHFFFAOYSA-N 4-bromobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- JIFCFQDXHMUPGP-UHFFFAOYSA-N 4-tert-butyl-n-[2-methyl-3-[4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxopyrazin-2-yl]phenyl]benzamide Chemical compound C1=CC=C(C=2N=C(NC=3C=CC(=CC=3)C(=O)N3CCOCC3)C(=O)N(C)C=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 JIFCFQDXHMUPGP-UHFFFAOYSA-N 0.000 description 1
- FWZAWAUZXYCBKZ-NSHDSACASA-N 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide Chemical compound COc1ccc(F)cc1C(=O)NCc1ccc(cc1)-c1nn([C@@H](C)C(F)(F)F)c(N)c1C(N)=O FWZAWAUZXYCBKZ-NSHDSACASA-N 0.000 description 1
- WDMWXYZJJVYMHE-UHFFFAOYSA-N 5-bromo-4,6-dimethylpyrimidine Chemical compound CC1=NC=NC(C)=C1Br WDMWXYZJJVYMHE-UHFFFAOYSA-N 0.000 description 1
- WPXFJBPJUGMYOD-UHFFFAOYSA-N 5-fluoro-2-methoxybenzoic acid Chemical compound COC1=CC=C(F)C=C1C(O)=O WPXFJBPJUGMYOD-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- HJKUAGNVSQIKCR-UHFFFAOYSA-N CC(C(F)(F)F)OC1=NC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C(N)=O)C2=C1C=NN2 Chemical compound CC(C(F)(F)F)OC1=NC(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C(N)=O)C2=C1C=NN2 HJKUAGNVSQIKCR-UHFFFAOYSA-N 0.000 description 1
- ZGCBNFNGYKKKJN-UHFFFAOYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC1CC(C(C2=CN(CC(C=C3)=CC=C3OC)N=C22)=CC(O)=C2C#N)=CC1 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC1CC(C(C2=CN(CC(C=C3)=CC=C3OC)N=C22)=CC(O)=C2C#N)=CC1 ZGCBNFNGYKKKJN-UHFFFAOYSA-N 0.000 description 1
- JXWBVVZHDVDRQK-UHFFFAOYSA-N CC1=C(B(O)O)C=CN=C1C(F)(F)F Chemical compound CC1=C(B(O)O)C=CN=C1C(F)(F)F JXWBVVZHDVDRQK-UHFFFAOYSA-N 0.000 description 1
- PODBNKSWBGPQLS-UHFFFAOYSA-N COC(C(C(N(CC(C=C1)=CC=C1OC)N=C1)=C1C(C1=CCCC1)=N1)=C1Cl)=O Chemical compound COC(C(C(N(CC(C=C1)=CC=C1OC)N=C1)=C1C(C1=CCCC1)=N1)=C1Cl)=O PODBNKSWBGPQLS-UHFFFAOYSA-N 0.000 description 1
- VQFMEUZVNHRSDE-UHFFFAOYSA-N COC(C(C1=C2C=NN1CC(C=C1)=CC=C1OC)=C(C1=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C1)N=C2C(CC1)=CCC11OCCO1)=O Chemical compound COC(C(C1=C2C=NN1CC(C=C1)=CC=C1OC)=C(C1=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C1)N=C2C(CC1)=CCC11OCCO1)=O VQFMEUZVNHRSDE-UHFFFAOYSA-N 0.000 description 1
- RFZJQARZIZCRLI-UHFFFAOYSA-N COC(C1=C(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)N=C(C(CC2)CCC22OCCO2)C2=C1N(CC(C=C1)=CC=C1OC)N=C2)=O Chemical compound COC(C1=C(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)N=C(C(CC2)CCC22OCCO2)C2=C1N(CC(C=C1)=CC=C1OC)N=C2)=O RFZJQARZIZCRLI-UHFFFAOYSA-N 0.000 description 1
- SPAKBEQNTSBTPY-UHFFFAOYSA-N COC(C1=C(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)N=C(C2CCCC2)C2=C1NC=C2)=O Chemical compound COC(C1=C(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)N=C(C2CCCC2)C2=C1NC=C2)=O SPAKBEQNTSBTPY-UHFFFAOYSA-N 0.000 description 1
- FVOWTIXXXGMVNA-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NC(C2)=O)=C2C(C2CCCC2)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NC(C2)=O)=C2C(C2CCCC2)=N1)=O FVOWTIXXXGMVNA-UHFFFAOYSA-N 0.000 description 1
- MQSFXAYFVOVBFD-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C(CC2)CC2O)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C(CC2)CC2O)=N1)=O MQSFXAYFVOVBFD-UHFFFAOYSA-N 0.000 description 1
- NNKBDHDQKFOGCZ-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(N(CCC2)C2=O)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(N(CCC2)C2=O)=N1)=O NNKBDHDQKFOGCZ-UHFFFAOYSA-N 0.000 description 1
- BBOXRTJBEBCVDP-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(N2CCCC2)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(N2CCCC2)=N1)=O BBOXRTJBEBCVDP-UHFFFAOYSA-N 0.000 description 1
- PCVKQWFYIHEWNI-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(NCCCC(O)=O)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(NCCCC(O)=O)=N1)=O PCVKQWFYIHEWNI-UHFFFAOYSA-N 0.000 description 1
- XBXDUKSTTCPCKD-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CC2)CCC2O)=C(C=NN2)C2=C1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(C(CC2)CCC2O)=C(C=NN2)C2=C1)=O XBXDUKSTTCPCKD-UHFFFAOYSA-N 0.000 description 1
- APTDDLXHJBOYPY-UHFFFAOYSA-N COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(NN=C2)=C2C(N2CCCC2)=N1)=O Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1C1=CC(NN=C2)=C2C(N2CCCC2)=N1)=O APTDDLXHJBOYPY-UHFFFAOYSA-N 0.000 description 1
- YTOWDACPUWNNPM-UHFFFAOYSA-N COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C2CCCC2)=N1)=O Chemical compound COC(C=CC=C1)=C1C(NCC(C=C1)=CC=C1C1=C(C(N)=O)C(NN=C2)=C2C(C2CCCC2)=N1)=O YTOWDACPUWNNPM-UHFFFAOYSA-N 0.000 description 1
- OQHJIBIQAVRLAN-UHFFFAOYSA-N COC1=CC=C(CN(C2=C(C(C3=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C3)=C3)C#N)N=CC2=C3N2CCCC2)C=C1 Chemical compound COC1=CC=C(CN(C2=C(C(C3=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C3)=C3)C#N)N=CC2=C3N2CCCC2)C=C1 OQHJIBIQAVRLAN-UHFFFAOYSA-N 0.000 description 1
- OVYKHDXTRYKRML-UHFFFAOYSA-N COC1=CC=C(CN(C2=C(C(C3=CC=C(CNC(C(C=CC=C4)=C4OC)=O)C=C3)=C3)C#N)N=CC2=C3C2=CCCC2)C=C1 Chemical compound COC1=CC=C(CN(C2=C(C(C3=CC=C(CNC(C(C=CC=C4)=C4OC)=O)C=C3)=C3)C#N)N=CC2=C3C2=CCCC2)C=C1 OVYKHDXTRYKRML-UHFFFAOYSA-N 0.000 description 1
- XJADMVXJJDOPCU-UHFFFAOYSA-N COC1=CC=C(CN(C2=C(C(OS(C(F)(F)F)(=O)=O)=C3)C#N)N=CC2=C3N2CCCC2)C=C1 Chemical compound COC1=CC=C(CN(C2=C(C(OS(C(F)(F)F)(=O)=O)=C3)C#N)N=CC2=C3N2CCCC2)C=C1 XJADMVXJJDOPCU-UHFFFAOYSA-N 0.000 description 1
- ANJHPOMOIZCNQU-UHFFFAOYSA-N COC1=CC=C(CN(C2=C3C#N)N=CC2=CC=C3O)C=C1 Chemical compound COC1=CC=C(CN(C2=C3C#N)N=CC2=CC=C3O)C=C1 ANJHPOMOIZCNQU-UHFFFAOYSA-N 0.000 description 1
- ZNNVRJXJMTWWFT-UHFFFAOYSA-N COC1=CC=C(CN(C2=C3C#N)N=CC2=CC=C3OS(C(F)(F)F)(=O)=O)C=C1 Chemical compound COC1=CC=C(CN(C2=C3C#N)N=CC2=CC=C3OS(C(F)(F)F)(=O)=O)C=C1 ZNNVRJXJMTWWFT-UHFFFAOYSA-N 0.000 description 1
- AIWFBLDDWWZXGI-UHFFFAOYSA-N COC1=CC=C(CN(C=C23)N=C2C(C(N)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3C(CC2)=CCC22OCCO2)C=C1 Chemical compound COC1=CC=C(CN(C=C23)N=C2C(C(N)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3C(CC2)=CCC22OCCO2)C=C1 AIWFBLDDWWZXGI-UHFFFAOYSA-N 0.000 description 1
- RYKATAITDNMPOR-UHFFFAOYSA-N COC1=CC=C(CN(C=C23)N=C2C(C(N)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3C2=NC=NC=C2)C=C1 Chemical compound COC1=CC=C(CN(C=C23)N=C2C(C(N)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3C2=NC=NC=C2)C=C1 RYKATAITDNMPOR-UHFFFAOYSA-N 0.000 description 1
- CWBRUVYHFNWOFR-UHFFFAOYSA-N COC1=CC=C(CN(C=C2C(C(CC3)=CCC33OCCO3)=C3)N=C2C(C#N)=C3O)C=C1 Chemical compound COC1=CC=C(CN(C=C2C(C(CC3)=CCC33OCCO3)=C3)N=C2C(C#N)=C3O)C=C1 CWBRUVYHFNWOFR-UHFFFAOYSA-N 0.000 description 1
- UERHCULTMVFEMG-UHFFFAOYSA-N COC1=CC=C(CN(C=C2C(Cl)=N3)N=C2C(Br)=C3Cl)C=C1 Chemical compound COC1=CC=C(CN(C=C2C(Cl)=N3)N=C2C(Br)=C3Cl)C=C1 UERHCULTMVFEMG-UHFFFAOYSA-N 0.000 description 1
- FBDPUCIUPSGPTL-UHFFFAOYSA-N COC1=CC=C(CN2N=CC(C(C(CC3)=CCC33OCCO3)=N3)=C2C(Br)=C3Cl)C=C1 Chemical compound COC1=CC=C(CN2N=CC(C(C(CC3)=CCC33OCCO3)=N3)=C2C(Br)=C3Cl)C=C1 FBDPUCIUPSGPTL-UHFFFAOYSA-N 0.000 description 1
- DTAALCXKXLZNOY-UHFFFAOYSA-N COC1=CC=C(CN2N=CC3=C2C(C(N)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3C(CC2)CCC22OCCO2)C=C1 Chemical compound COC1=CC=C(CN2N=CC3=C2C(C(N)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3C(CC2)CCC22OCCO2)C=C1 DTAALCXKXLZNOY-UHFFFAOYSA-N 0.000 description 1
- PHSOCUPEKVWSAU-UHFFFAOYSA-N COC1=CC=C(CN2N=CC3=C2C(C(O)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3C(CC2)CCC22OCCO2)C=C1 Chemical compound COC1=CC=C(CN2N=CC3=C2C(C(O)=O)=C(C2=CC=C(CNC(C(C=C(C=C4)F)=C4OC)=O)C=C2)N=C3C(CC2)CCC22OCCO2)C=C1 PHSOCUPEKVWSAU-UHFFFAOYSA-N 0.000 description 1
- XBNXUXMWEWNZJH-UHFFFAOYSA-N COCOC1=CC(C2=CCCC2)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N Chemical compound COCOC1=CC(C2=CCCC2)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N XBNXUXMWEWNZJH-UHFFFAOYSA-N 0.000 description 1
- VAPRJMHAFNOBEP-MRXNPFEDSA-N C[C@H](CCC1)N1C(C(Cl)=C1C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C=NN2)C2=C1C#N Chemical compound C[C@H](CCC1)N1C(C(Cl)=C1C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C(C=NN2)C2=C1C#N VAPRJMHAFNOBEP-MRXNPFEDSA-N 0.000 description 1
- UJLGDTHEHGJYPP-MRXNPFEDSA-N C[C@H](CCC1)N1C(C=C1OCOC)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N Chemical compound C[C@H](CCC1)N1C(C=C1OCOC)=C(C=NN2CC(C=C3)=CC=C3OC)C2=C1C#N UJLGDTHEHGJYPP-MRXNPFEDSA-N 0.000 description 1
- FCQQGWRJDQUGHT-MRXNPFEDSA-N C[C@H](CCC1)N1C1=C(C=NN2)C2=C(C(N)=O)C(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1 Chemical compound C[C@H](CCC1)N1C1=C(C=NN2)C2=C(C(N)=O)C(C2=CC=C(CNC(C(C=C(C=C3)F)=C3OC)=O)C=C2)=C1 FCQQGWRJDQUGHT-MRXNPFEDSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FZCDIXBSXHQPFJ-UHFFFAOYSA-N Cc1c(ccnc1C(F)(F)F)B1OC(C)(C)C(C)(C)O1 Chemical compound Cc1c(ccnc1C(F)(F)F)B1OC(C)(C)C(C)(C)O1 FZCDIXBSXHQPFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- FCWYQRVIQDNGBI-UHFFFAOYSA-N Dihydro-2-methyl-3(2H)-furanone Chemical compound CC1OCCC1=O FCWYQRVIQDNGBI-UHFFFAOYSA-N 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 238000003043 HTRF KinEASE-TK Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- TWNOORLXHZTPNX-UHFFFAOYSA-N N#CC1=C2NN=CC2=C(C2CCCC2)C=C1C(O)=O Chemical compound N#CC1=C2NN=CC2=C(C2CCCC2)C=C1C(O)=O TWNOORLXHZTPNX-UHFFFAOYSA-N 0.000 description 1
- DOATVMHTANWYBK-UHFFFAOYSA-N N#CC1=C2NN=CC2=C(C2CCCC2)C=C1I Chemical compound N#CC1=C2NN=CC2=C(C2CCCC2)C=C1I DOATVMHTANWYBK-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- DDLXIPOLLUSEIV-UHFFFAOYSA-N N-[(4-bromophenyl)methyl]-5-fluoro-2-methoxybenzamide Chemical compound COC(C=CC(F)=C1)=C1C(NCC(C=C1)=CC=C1Br)=O DDLXIPOLLUSEIV-UHFFFAOYSA-N 0.000 description 1
- GWOXVNOLEPNQGX-UHFFFAOYSA-N N-[(4-fluorophenyl)methyl]-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=C2OCCCN2N=C1 GWOXVNOLEPNQGX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000025316 Richter syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- WEIMJSIRDZDHAH-UHFFFAOYSA-N cyclopent-3-en-1-ol Chemical compound OC1CC=CC1 WEIMJSIRDZDHAH-UHFFFAOYSA-N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- QCONYJQZFUESJD-UHFFFAOYSA-N cyclopentyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OC1CCCC1 QCONYJQZFUESJD-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- KVBKAPANDHPRDG-UHFFFAOYSA-N dibromotetrafluoroethane Chemical compound FC(F)(Br)C(F)(F)Br KVBKAPANDHPRDG-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- JJTJZFLRKYYGGS-UHFFFAOYSA-N ethoxyethane;methylsulfinylmethane Chemical compound CS(C)=O.CCOCC JJTJZFLRKYYGGS-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000006974 gastroesophageal cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- UHNSRFWQBVXBSK-UHFFFAOYSA-N methanol;2,2,2-trifluoroacetic acid Chemical class OC.OC(=O)C(F)(F)F UHNSRFWQBVXBSK-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- FGNGTWFJQFTFGN-UHFFFAOYSA-N n,n,n',n'-tetramethylethane-1,2-diamine Chemical compound CN(C)CCN(C)C.CN(C)CCN(C)C FGNGTWFJQFTFGN-UHFFFAOYSA-N 0.000 description 1
- IJMHHZDBRUGXNO-UHFFFAOYSA-N n-[3-(8-anilinoimidazo[1,2-a]pyrazin-6-yl)phenyl]-4-tert-butylbenzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NC1=CC=CC(C=2N=C(NC=3C=CC=CC=3)C3=NC=CN3C=2)=C1 IJMHHZDBRUGXNO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- XVJCTIVCSIUXOC-UHFFFAOYSA-N pyrrolidin-3-yl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OC1CCNC1 XVJCTIVCSIUXOC-UHFFFAOYSA-N 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- LZCVVMQABORALM-UHFFFAOYSA-N spiro[2.5]octyl Chemical group [CH]1CC11CCCCC1 LZCVVMQABORALM-UHFFFAOYSA-N 0.000 description 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- XFZZZOMHBHBURH-UHFFFAOYSA-N tert-butyl 4-aminobutanoate Chemical compound CC(C)(C)OC(=O)CCCN XFZZZOMHBHBURH-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000005039 triarylmethyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- HQMLIWXIPSYXMY-UHFFFAOYSA-N tributyl(pyrimidin-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=NC=N1 HQMLIWXIPSYXMY-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present disclosure provides heteroaromatic carboxamide compounds that inhibit Bruton’s Tyrosine kinase, BTK.
- the disclosure also provides processes for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of using these compounds to treat BTK-associated disease or disorder.
- BTK tyrosine kinase
- BCR B-cell antigen receptor
- Fc ⁇ R Fc ⁇ receptor
- first generation BTK inhibitor ibrutinib (PCI-32765, Imbruvica) has been successful in treating B-cell malignancies and is approved for chronic lymphocytic leukemia (CLL) , relapsed or refractory mantle-cell lymphoma (MCL) and macroglobulinemia (WM) .
- CLL chronic lymphocytic leukemia
- MCL mantle-cell lymphoma
- WM macroglobulinemia
- therapy-discontinuation occurred in up to 30%of patients with ibrutinib, which leads to a poor clinical outcome.
- BTK inibhitors such as acalabrutinib, zanubrutinib, and tirabrutinib which offer greater BTK selectivity may limit off-target toxicity
- all of them are irreversible BTK inhibitors.
- the compounds react covalent and irreversibly with cysteine-481 in the ATP binding site of BTK, and therefore do not overcome common mechanisms of ibrutinib resistance that occurred in 30%of patient after treatment last more than 12 month.
- reversible BTK inhibitors including vecabrutinib, ARQ-531and LOXO-305, that do not rely on cysteine-481 for interactions with BTK, inhibit BTK activities in the presence of C481S mutation, and clinical evidence is starting to emerge to show that they can overcome resistance toward irreversible BTK inhibitors.
- BTK-targeted therapy for chronic autoimmune indications. This slow progress in the autoimmune/inflammatory arena may, at least in part, be due to the stringent safety requirements these indications indication such as RA and SLE demand. Therefore, the efforts continue in the search of reversible BTK inhibitors with better efficacy and less toxicities.
- X 1 , X 2 and X 3 are each independently CR’ or N; R’ is selected from a group consisting of H, C 1-6 alkyl, halo and oxo;
- R 1 is selected from a group consisting of H, deuterium, 3-10 membered heterocyclyl, 5-12 membered heteroaryl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-O-, C 3-10 cycloalkenyl, 3-10 membered heterocyclyl-O-, C 6-10 aryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, -C 1-6 alkyl-O-C 1-6 alkyl, -NH 2 , -NH (C 1-6 alkyl) and N (C 1-6 alkyl) 2 , wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of deuterium, halo, -OH, -CN, -NH 2 , -NH (C 1-6 alkyl) and -NH (C 1-6 alkyl) 2 ; and wherein each hetero
- Ar is -C 6-10 aryl-Y-R 2 , or -5-6 membered heteroaryl-Y-R 2 , wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from a group consisting of halo, C 1-6 alkoxyl and C 1-6 alkyl;
- Y is selected from a group consisting of O, S, - (CH 2 ) m -NH-C (O) -, - (CH 2 ) m -NH-S (O) n -, - (CH 2 ) m -N (C 1-6 alkyl) -C (O) -, - (CH 2 ) m -N (C 1-6 alkyl) -S (O) n -, - (CH 2 ) m -C (O) -NH-, - (CH 2 ) m -S (O) n -NH-, - (CH 2 ) m -C (O) -N (C 1-6 alkyl) -and - (CH 2 ) m -S (O) n -N (C 1-6 alkyl) -;
- R 2 is C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with one or more substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl, -OH, -SH, -CN, -NH 2 , -NH (C 1-6 alkyl) , -NH (C 1-6 alkyl) 2 , C 1-6 alkyl-S-, -C 1-6 alkyl-O-C 1-6 alkyl, -C (O) C 1-6 alkyl, -C (O) OH, -C (O) OC 1-6 alkyl, -C (O) NH 2 , -C (O) NH (C 1-6 alkyl) , -C (O) N (C 1-6 alkyl) 2 , and -NHC (O) C 1-6 alkyl;
- n 0 or 1
- n 1 or 2.
- the compounds or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof above as well as the active compounds disclosed in the context of the present invention and covered by the scope of the compounds above are collectively called “the compound of the present invention” or “a compound of the present invention” .
- the present disclosure also provides the compound of the present invention for use as a medicament.
- the present disclosure also provides the compound of the present invention for use in the treatment or prevention of a BTK-associated disease or disorder.
- the present disclosure also provides a pharmaceutical composition, comprising the compound of the present invention, and optionally a pharmaceutically acceptable carrier.
- the present disclosure also provides a kit for treating or preventing a BTK-associated disease or disorder, comprising a pharmaceutical composition of the present disclosure and an instruction for use.
- the present disclosure also provides the use of the compound of the present invention for treatment or prevention of a BTK-associated disease or disorder.
- the present disclosure also provides the use of the compound of the present invention in the manufacture of a medicament for treatment or prevention of a BTK-associated disease or disorder.
- the present disclosure also provides a method of in vivo or in vitro inhibiting the activity of BTK, comprising contacting an effective amount of the compound of the present invention with BTK.
- the present disclosure also provides a method of treating or preventing a BTK-associated disease or disorder, comprising administering to the subject in need thereof an effective amount of the compound of the present invention.
- the present disclosure also provides a combination, comprising the compound of the present invention and at least one additional therapeutic agent.
- the present disclosure also provides a process for the preparation of the compound of the present invention, and itermediates for preparing the compound of the present invention.
- Embodiment 1 A compound of formula I:
- X 1 , X 2 and X 3 are each independently CR’ or N; R’ is selected from a group consisting of H, C 1-6 alkyl, halo and oxo;
- R 1 is selected from a group consisting of H, deuterium, 3-10 membered heterocyclyl, 5-12 membered heteroaryl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-O-, C 3-10 cycloalkenyl, 3-10 membered heterocyclyl-O-, C 6-10 aryl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, -C 1-6 alkyl-O-C 1-6 alkyl, -NH 2 , -NH (C 1-6 alkyl) and N (C 1-6 alkyl) 2 , wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of deuterium, halo, -OH, -CN, -NH 2 , -NH (C 1-6 alkyl) and -NH (C 1-6 alkyl) 2 ; and wherein each hetero
- Ar is -C 6-10 aryl-Y-R 2 , or -5-6 membered heteroaryl-Y-R 2 , wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from a group consisting of halo, C 1-6 alkoxyl and C 1-6 alkyl;
- Y is selected from a group consisting of O, S, - (CH 2 ) m -NH-C (O) -, - (CH 2 ) m -NH-S (O) n -, - (CH 2 ) m -N (C 1-6 alkyl) -C (O) -, - (CH 2 ) m -N (C 1-6 alkyl) -S (O) n -, - (CH 2 ) m -C (O) -NH-, - (CH 2 ) m -S (O) n -NH-, - (CH 2 ) m -C (O) -N (C 1-6 alkyl) -and - (CH 2 ) m -S (O) n -N (C 1-6 alkyl) -;
- R 2 is C 6-10 aryl or 5-10 membered heteroaryl, optionally substituted with one or more substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl, -OH, -SH, -CN, -NH 2 , -NH (C 1-6 alkyl) , -NH (C 1-6 alkyl) 2 , C 1-6 alkyl-S-, -C 1-6 alkyl-O-C 1-6 alkyl, -C (O) C 1-6 alkyl, -C (O) OH, -C (O) OC 1-6 alkyl, -C (O) NH 2 , -C (O) NH (C 1-6 alkyl) , -C (O) N (C 1-6 alkyl) 2 , and -NHC (O) C 1-6 alkyl;
- n 0 or 1
- n 1 or 2.
- Embodiment 2 The compound of embodiment 1 or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X 1 and X 3 are each independently CR’ or N; R’ is selected from a group consisting of H, C 1-6 alkyl, halo and oxo.
- Embodiment 3 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X 2 is CH.
- Embodiment 4 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Y is selected from a group consisting of O, S, - (CH 2 ) m -NH-C (O) -or - (CH 2 ) m -C (O) -NH-.
- Embodiment 5 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 2 is C 6-10 aryl or 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl, -OH, -CN and -NH 2 .
- Embodiment 6 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
- X 1 and X 3 are each independently CR’ or N; R’ is selected from a group consisting of H, C 1-6 alkyl, halo and oxo;
- X 2 is CH
- R 1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C 6-10 aryl, C 1-6 alkyl, C 1-6 alkoxyl, -NH 2 , -NH (C 1-6 alkyl) and N (C 1-6 alkyl) 2 , wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo, -OH, -CN and -NH 2 ; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -NH 2 , oxo, halo, -CN, C 1-6 alkyl, C 1-6 haloalkyl, C
- Ar is -C 6-10 aryl-Y-R 2 or -5-6 membered heteroaryl-Y-R 2 , wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from a group consisting of halo, C 1-6 alkoxyl and C 1-6 alkyl;
- Y is selected from a group consisting of O, S, - (CH 2 ) m -NH-C (O) -and - (CH 2 ) m -C (O) -NH-;
- R 2 is C 6-10 aryl or 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl, -OH, -CN and -NH 2 ;
- m 0 or 1.
- Embodiment 7 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X 1 is CR’ or N; R’ is H or halo.
- Embodiment 9 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
- X 1 is CR’ or N; R’ is H or halo;
- X 2 is CH
- R 1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C 6-10 aryl, C 1-6 alkyl, C 1-6 alkoxyl -NH 2 , -NH (C 1-6 alkyl) and N (C 1-6 alkyl) 2 , wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo, -OH, -CN and -NH 2 ; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -NH 2 , oxo, halo, -CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6
- Ar is -C 6-10 aryl-Y-R 2 , or -5-6 membered heteroaryl-Y-R 2 , wherein each aryl or heteroaryl is optionally substituted with one or more halo;
- Y is selected from a group consisting of O, S, - (CH 2 ) m -NH-C (O) -and - (CH 2 ) m -C (O) -NH-;
- R 2 is C 6-10 aryl or 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl, -OH, -CN and -NH 2 ; and
- m 0 or 1.
- Embodiment 10 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C 6-10 aryl, C 1-6 alkyl, C 1-6 alkoxyl and N (C 1-6 alkyl) 2 , wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo, -OH and -CN; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -NH 2 , oxo
- R 1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-10 membered heteroaryl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C 6-10 aryl, C 1-6 alkyl, C 1-6 alkoxyl and N (C 1-6 alkyl) 2 , wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, oxo, halo, -CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxyl, C 1-6 haloalkoxyl and -C 1-6 alkyl-OH.
- Embodiment 11 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is -C 6-10 aryl-Y-R 2 , wherein said aryl is optionally substituted with one or more halo.
- Embodiment 12 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is -5-6 membered heteroaryl-Y-R 2 , wherein said heteroaryl is optionally substituted with one or more halo.
- Embodiment 13 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 2 is C 6-10 aryl or 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl and -OH.
- Embodiment 14 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 2 is 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl and -OH.
- Embodiment 15 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 2 is phenyl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl and -OH.
- Embodiment 16 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 2 is phenyl or 6-membered heteroaryl, optionally substituted with 1 or 2 substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl and -OH.
- Embodiment 17 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 2 is phenyl, optionally substituted with 1 or 2 substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl, halo, C 1-6 haloalkyl and -OH.
- Embodiment 18 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 2 is phenyl, optionally substituted with 1 or 2 substituents selected from a group consisting of C 1-6 alkoxyl and halo.
- Embodiment 19 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Y is selected from a group consisting of O, -CH 2 -NH-C (O) -, -CH 2 -C (O) -NH-and -C (O) -NH-.
- Embodiment 20 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Y is O.
- Embodiment 21 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Y is -CH 2 -NH-C (O) -.
- Embodiment 22 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X 3 is N.
- Embodiment 23 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
- X 1 is CR’ or N; R’ is H or halo;
- X 2 is CH
- X 3 is N
- R 1 is selected from a group consisting of 3-8 membered heterocyclyl, 5-10 membered heteroaryl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-O-, C 6-10 aryl and N (C 1-6 alkyl) 2 , wherein alkyl is optionally substituted with one or more halo, -OH and -CN; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxyl;
- Ar is -C 6-10 aryl-Y-R 2 , wherein each said C 6-10 aryl is optionally substituted with one halo;
- Y is -CH 2 -NH-C (O) -
- R 2 is C 6-10 aryl substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6 alkoxyl, deuterated C 1-6 alkoxyl and halo.
- Embodiment 24 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X 1 is CH.
- Embodiment 25 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X 3 is N.
- Embodiment 26 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is phenyl-Y-R 2 , wherein said phenyl is optionally substituted with one halo.
- Embodiment 27 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein: Ar is wherein R 3 is H or halo.
- Embodiment 28 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is wherein R 3 is H or halo.
- Embodiment 29 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is phenyl-Y-R 2 .
- Embodiment 30 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 2 is 2-methoxyl-phenyl or 2-methoxyl-5-fluoro-phenyl.
- Embodiment 31 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is selected from a group consisting of 4-6 membered heterocyclyl, 5-10 membered heteroaryl, C 5-6 cycloalkyl, C 3-6 cycloalkyl-O-and phenyl, which are each optionally substituted with one or more with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxyl.
- Embodiment 32 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is selected from a group consisting of 5-10 membered heteroaryl optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxyl.
- Embodiment 33 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is N (C 1-6 alkyl) 2 optionally substituted with one or more halo; preferably, R 1 is N (C 1-6 alkyl) 2 substituted with one or more halo; more preferably, R 1 is
- Embodiment 34 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is selected from a group consisting of 5-6 membered heteroaryl optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxyl.
- Embodiment 35 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is selected from a group consisting of 5 membered heteroaryl optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxyl.
- Embodiment 36 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is selected from a group consisting of 6 membered heteroaryl optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxyl.
- Embodiment 37 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is pyridyl, optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxyl.
- Embodiment 38 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein halo is F or Cl, preferably is F.
- Embodiment 39 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein C 1-6 haloalkyl is CF 3 .
- Embodiment 40 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is pyridyl optionally substituted with one or two substituents selected from a group consisting of -OH, methyl, F, OMe, and CF 3 .
- Embodiment 41 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is pyridin-4-yl substituted with C 1-6 alkyl at 2-position and optionally further substituted at 3-position with a substituent selected from a group consisting of -OH, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxyl.
- Embodiment 42 The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
- R 1 is selected from a group consisting of:
- R 1 is selected from a group consisting of:
- Embodiment 43 The compound of embodiment 1 which is selected from a group consisting of:
- Embodiment 44 The compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, for use as a medicament.
- Embodiment 45 The compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a BTK-associated disease or disorder;
- the disease or disorder is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders, preferably hematological malignancies, more preferably B-cell malignancies, further more preferably, leukemias, lymphomas, Hodgkin's disease and myeloma;
- the disease or disorder is selected from acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., poly
- Embodiment 46 A pharmaceutical composition, comprising the compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.
- Embodiment 47 Use of the compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment or prevention of a BTK-associated disease or disorder;
- the disease or disorder is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders, preferably hematological malignancies, more preferably B-cell malignancies, further more preferably, leukemias, lymphomas, Hodgkin's disease and myeloma;
- the disease or disorder is selected from acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., poly
- Embodiment 48 A method of in vivo or in vitro inhibiting the activity of BTK, comprising contacting an effective amount of the compound of any one of embodiments 1-43 or a pharmaceutically acceptable salt thereof with BTK.
- Embodiment 49 A method of treating or preventing a BTK-associated disease or disorder, comprising administering to the subject in need thereof an effective amount of the compound of any one of embodiments 1-43 or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof;
- the disease or disorder is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders, preferably hematological malignancies, more preferably B-cell malignancies, further more preferably, leukemias, lymphomas, Hodgkin's disease and myeloma;
- the disease or disorder is selected from acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., poly
- Embodiment 50 A combination, comprising the compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent, wherein said additional therapeutic agent preferably is an anti-neoplastic agent, e.g., a radiotherapeutic agent, a chemotherapeutic agent, an immunotherapeutic agent, or a targeted therapeutic agent.
- an anti-neoplastic agent e.g., a radiotherapeutic agent, a chemotherapeutic agent, an immunotherapeutic agent, or a targeted therapeutic agent.
- Embodiment 51 A compound selected from:
- P 1 is an amino-protecting group, preferably p-methoxybenzyl
- P 2 is a hydroxy-protecting group, preferably methoxymethyl
- Embodiment 52 A compound selected from:
- a dash ( “-” ) that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
- C 3-8 cycloalkyl-O- is attached to the rest of the molecule through the oxygen.
- alkyl refers to a straight or branched saturated hydrocarbon radical having 1-18 carbon atoms (C 1-18 ) , preferably 1-10 carbon atoms (C 1-10 ) , preferably 1-6 carbon atoms (C 1-6 ) , and more preferably 1-4 carbon atoms (C 1-4 ) or 1-3 carbon atoms (C 1-3 ) .
- C 1-6 alkyl refers to the alkyl having 1-6 (1, 2, 3, 4, 5 or 6) carbon atoms.
- alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl.
- C 2-6 alkenyl refers to the alkenyl having 2-6 (2, 3, 4, 5 or 6) carbon atoms, which preferably contains 1 or 2 carbon-carbon double bonds
- C 2-4 alkenyl refers to the alkenyl having 2-4 carbon atoms, which preferably contains 1 carbon-carbon double bond.
- Examples of the alkenyl include, but are not limited to, vinyl, 2-propenyl, and 2-butenyl. The point of attachment for the alkenyl may or may not be on the double bond.
- alkynyl refers to a straight or branched unsaturated hydrocarbon radical containing one or more, for example 1, 2, or 3, carbon-carbon triple bonds (C ⁇ C) and having 2-10 carbon atoms (C 2-10 ) , preferably 2-6 carbon atoms (C 2-6 ) , more preferably 2-4 carbon atoms (C 2-4 ) .
- C 2-6 alkynyl refers to the alkynyl having 2-6 (2, 3, 4, 5 or 6) carbon atoms, which preferably contains 1 or 2 carbon-carbon triple bonds
- C 2-4 alkynyl refers to the alkynyl having 2-4 carbon atoms, which preferably contains 1 carbon-carbon triple bond.
- Examples of the alkynyl include, but are not limited to, ethynyl, 2-propynyl, and 2-butynyl. The point of attachment for the alkynyl may or may not be on the triple bond.
- halogen refers to fluoro, chloro, bromo, and iodo, preferably fluoro, chloro and bromo, more preferably fluoro and chloro, most preferably fluoro.
- haloalkyl or alkyl substituted with halo as used interchangeably herein refers to the alkyl as defined herein, in which one or more, for example 1, 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atom, and when more than one hydrogen atoms are replaced with halogen atoms, the halogen atoms may be the same or different from each other.
- the term “haloalkyl” as used herein refers to the alkyl as defined herein, in which two or more, such as 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atoms, wherein the halogen atoms are the same as each other.
- haloalkyl refers to the alkyl as defined herein, in which two or more, for example 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atoms, wherein the halogen atoms may be different from each other.
- the haloalkyl include, but are not limited to, -CF 3 , -CHF 2 , -CH 2 F, -CH 2 CF 3 , -CF 2 CF 3 , -CF 2 CH 3 , and the like.
- haloalkyl is C 1-6 trifluoroalkyl, more preferably-CF 3 .
- alkoxyl refers to the group -O-alkyl, wherein the alkyl is as defined above.
- alkoxyl include, but are not limited to, C 1-6 alkoxyl, such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, t-butoxy, pentoxy, and hexyloxy, including their isomers.
- alkoxyl is methoxy.
- haloalkoxyl or alkoxyl substituted with halo as used interchangeably herein refers to the alkoxyl as defined herein, in which one or more, for example 1, 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atom, and when more than one hydrogen atoms are replaced with halogen atoms, the halogen atoms may be the same or different from each other.
- the haloalkoxyl include, but are not limited to, trifluoroalkoxyl, preferably C 1-6 trifluoroalkoxyl, more preferably
- cycloalkyl refers to saturated cyclic hydrocarbon radical having 3-10 ring carbon atoms (C 3-10 ) , such as 3-8 ring carbon atoms (C 3-8 ) , 3-7 ring carbon atoms (C 3-7 ) , 3-6 ring carbon atoms (C 3-6 ) or 5-6 ring carbon atoms (C 5-6 ) , which may have one or more rings, e.g., 1 or 2 rings.
- Cycloalkyl may include a fused ring, a bridged ring, or a spirocyclic ring.
- said cycloalkyl is monocyclic cycloalkyl, preferably monocyclic C 3-8 cycloalkyl, preferably monocyclic C 3-6 cycloalkyl, and more preferably monocyclic C 5-6 cycloalkyl.
- the monocyclic cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl.
- said cycloalkyl is bicyclic cycloalkyl, preferably bicyclic C 5 -C 10 cycloalkyl.
- bicyclic cycloalkyl examples include, but are not limited to, bicyclo [4.1.0] heptyl, bicyclo [3.1.1] heptyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, bicyclo [3.2.2] nonyl, spiro [3.3] heptyl, spiro [2.2] pentyl, spiro [2.3] hexyl, spiro [2.4] heptyl, spiro [2.5] octyl, and spiro [4.5] decyl.
- the cycloalkyl is monocyclic C 3-6 cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
- cycloalkenyl refers to non-aromatic, unsaturated cyclic hydrocarbon radical with at least one carbon-carbon double bond, having 3-10 ring carbon atoms (C 3-10 ) , such as 3-8 ring carbon atoms (C 3-8 ) , 3-7 ring carbon atoms (C 3-7 ) , 3-6 ring carbon atoms (C 3-6 ) or 5-6 ring carbon atoms (C 5-6 ) , which may have one or more rings, e.g., 1 or 2 rings.
- said cycloalkenyl is monocyclic cycloalkenyl.
- Examples of the monocyclic cycloalkenyl include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl.
- heterocyclyl refers to a saturated or partially unsaturated ring having 3-10 ring atoms (3-10 membered) , such as 3-8 ring atoms (3-8 membered) , 5-7 ring atoms (5-7 membered) , 3-6 ring atoms (3-6 membered) , 4-6 ring atoms (4-6 membered) or 5-6 ring atoms (5-6 membered) , with one or more of, such as 1, 2 or 3, preferably 1 or 2 of the ring atoms being heteroatoms independently selected from N, O and S, and the remaining ring atoms being carbon, and having one or more, for example 1, 2 or 3, preferably 1 or 2 rings, wherein the N or S heteroatom is optionally oxidized to various oxidation states.
- the point of attachment of heterocyclyl may be on N heteroatom or carbon atom.
- the ring (s) of the heterocyclyl also include (s) a fused ring, a bridged ring, or a spirocyclic ring.
- the ring (s) of the heterocyclyl may be saturated or contain (s) one or more, for example, one or two double bonds (i.e. partially unsaturated) , but is (are) not fully conjugated, and not the heteroaryl as defined herein.
- heterocyclyl refers to the heterocyclyl having 3-8 ring atoms and containing 1, 2 or 3, preferably 1 or 2 ring heteroatoms independently selected from N, O and S preferably is saturated monocyclic 3-8 membered heterocyclyl.
- 4-6 membered heterocyclyl refers to the heterocyclyl having 4-6 ring atoms and containing 1 or 2 ring heteroatoms independently selected from N, O and S, preferably is saturated monocyclic 4-6 membered heterocyclyl, such as saturated monocyclic 4, 5, or 6 membered heterocyclyl.
- heterocyclyl examples include, but are not limited to, oxiranyl, aziridinyl, thiiranyl, oxetanyl, azetidinyl (e.g., azetidin-1-yl, azetidin-2-yl, azetidin-3-yl) , thietanyl, pyrrolidinyl (e.g., pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl) , oxopyrrolidinyl (e.g., 2-oxopyrrolidin-1-yl) , tetrahydrofuryl (e.g., tetrahydrofuran-2-yl, tetrahydrofuran-3-yl) , dioxolaneyl, imidazolidinyl, morpholinyl (e.g., morpholino (i.e., morpholin
- the heterocyclyl is azetidinyl, pyrrolidinyl, tetrahydrofuryl, piperidyl, piperazinyl, morpholino or tetrahydropyranyl, such as azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, piperid-1-yl, piperazin-1-yl or morpholino.
- aryl refers to carbocyclic hydrocarbon radical having 6-14 carbon atoms (C 6-14 ) , preferably 6-10 carbon atoms (C 6-10 ) and consisting of one ring or more fused rings, wherein at least one ring is aromatic.
- examples of the aryl include, but are not limited to, phenyl, naphthalenyl, 1, 2, 3, 4-tetrahydronaphthalenyl, phenanthryl, indenyl, indanyl, azulenyl, preferably phenyl and naphthalenyl, more preferably phenyl.
- heteroaryl refers to a monocyclic, bicyclic or tricyclic ring system having 5-12 ring atoms (5-12 membered) , such as 5-10 ring atoms (5-10 membered) , 8-12 ring atoms (8-12 membered) , 5-8 ring atoms (5-8 membered) , 5-7 ring atoms (5-7 membered) , 5-6 ring atoms (5-6 membered) , 5 ring atoms (5 membered) or 6 ring atoms (6 membered) , wherein at least one ring is an 5 or 6 membered aromatic ring with one or more of, such as 1, 2 or 3, preferably 1 or 2 of the ring atoms being heteroatoms independently selected from N, O and S, and the remaining ring atoms being carbon, and wherein the N or S heteroatom is optionally oxidized to various oxidation states.
- the heteroaryl is:
- monocyclic heteroaryl i.e. monocyclic aromatic hydrocarbon radical having 5 or 6 ring atoms (5 or 6 membered) , with one or more of, for example 1, 2 or 3, preferably 1 or 2 of the ring atoms being ring heteroatoms independently selected from N, O, and S (preferably N) , and the remaining ring atoms being carbon; preferably, monocyclic aromatic hydrocarbon radical having 6 ring atoms (6 membered) , with 1, 2 or 3, preferably 1 or 2 of the ring atoms being heteroatoms independently selected from N, O, and S, preferably N;
- bicyclic heteroaryl i.e. bicyclic aromatic hydrocarbon radical having 8, 9, 10, 11 or 12 ring atoms (8, 9, 10, 11 or 12 membered) , with one or more, for example, 1, 2, 3 or 4, preferably 1, 2 or 3 of the ring atoms are ring heteroatoms independently selected from N, O, and S (preferably N) , and the remaining ring atoms being carbon, wherein at least one of the rings is aromatic.
- heteroaryl examples include, but are not limited to, pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridin-5-yl, pyridin-6-yl) , pyridyl N-oxide, pyrazinyl (e.g., pyrazin-2-yl, pyrazin-3-yl) , pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl) , pyridazinyl (e.g., pyridazin-3-yl, pyridazin-4-yl) , pyrazolyl (e.g., pyrazol-1-yl, pyrazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-1
- the heteroaryl is pyrazolyl, pyridyl, pyridazinyl or pyrazinyl, more preferably pyrazol-1-yl, pyrazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl or pyrazin-3-yl.
- the compounds of the present disclosure have an enantiomeric purity of at least 60%ee (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%ee (enantiomeric excess) , or any values between those enumerated values) , or have a diastereomeric purity of at least 60%de (diastereomeric excess) (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%de, or any values between those enumerated values) .
- 60%ee e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
- cis or trans When a structure of a compound herein is marked by “cis or trans” , it means that the compound is an individual stereoisomer, but the configuration of the compound are assigned arbitrarily as cis or trans.
- the wavy line indicates the point of attachment of the group to the rest of the molecule.
- substituted or “substituted with ...” as used herein, means that one or more hydrogens on the designated atom or group are replaced with one or more substituents independently selected from the indicated group of substituents, provided that the designated atom's normal valence is not exceeded.
- substituted with one or more ...” means that one or more (e.g. 1, 2, 3 or 4, preferably 1 or 2) hydrogens on the designated atom or group are replaced with one or more (e.g. 1, 2, 3 or 4, preferably 1 or 2) substituents independently selected from the indicated group of substituents, provided that the designated atom's normal valence is not exceeded.
- the compounds disclosed herein may contain one or more chiral centers or ring and therefore exist in two or more stereoisomers.
- the racemates of these isomers, the individual isomers and mixtures enriched in one enantiomer, as well as diastereomers and mixtures partially enriched with specific diastereomers when there are two chiral centers are within the scope of the present disclosure.
- the present disclosure includes all the individual stereoisomers (e.g. enantiomers, diastereoisomers, or cis-or trans-isomers) , racemic mixtures or partially resolved mixtures of the compounds disclosed herein and, where appropriate, the individual tautomeric forms thereof.
- racemate or other mixtures of isomers can be used as such or can be resolved into their individual isomers.
- the resolution can afford stereochemically pure compounds or mixtures enriched in one or more isomers.
- Methods for separation of isomers are well known (e.g., cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry” , Vol. 6, Wiley Interscience, 1971) .
- pharmaceutically acceptable salt includes, but is not limited to, acid addition salts formed by the compounds disclosed herein with an inorganic acid, such as hydrochloride, hydrobromide, carbonate, bicarbonate, phosphate, sulfate, sulfite, nitrate and the like; as well as with an organic acid, such as formate, acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and salts with alkane-dicarboxylic acid of formula HOOC- (CH 2 ) n -COOH wherein n is 0-4, and the like.
- pharmaceutically acceptable salt includes base addition salts formed by the compound of the present invention carrying an acidic moiety with pharmaceutically acceptable cations, for example, sodium, potassium, calcium,
- the free base can be obtained by basifying a solution of the acid addition salt.
- an acid addition salt particularly a pharmaceutically acceptable acid addition salt
- a person skilled in the art will recognize various synthetic methodologies that may be used without undue experimentation to prepare non-toxic pharmaceutically acceptable acid addition salts or base addition salts.
- solvate means a solvent addition form that contains either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the solid state, thus forming a solvate. If the solvent is water, the solvate formed is a hydrate, when the solvent is ethanol, the solvate formed is an alcoholate.
- deuterated group means a group, in which one or more, for example 1, 2 or 3 hydrogen atoms are replaced with its isotope deuterium (D) .
- protecting group refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound.
- an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound.
- Suitable amino-protecting groups include p-methoxybenzyl (PMB) , benzyl (Bn) , trityl (Trt) , acetyl, trifluoroacetyl, phthalimido, t-butoxycarbonyl (BOC) , benzyloxycarbonyl (CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc) .
- a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable hydroxy-protecting groups include methoxymethyl, benzyl, benzyloxymethyl, methyl, triarylmethyl, acetyl, trialkylsilyl, dialkylphenylsilyl, benzoyl, and tetrahydropyranyl.
- Suitable hydroxy-protecting groups include methoxymethyl, benzyl, benzyloxymethyl, methyl, triarylmethyl, acetyl, trialkylsilyl, dialkylphenylsilyl, benzoyl, and tetrahydropyranyl.
- pharmaceutical combination means a product that results from the mixing or combining of more than one active agent and includes both fixed and non-fixed combinations of the active agents, e.g., kit or pharmaceutical composition.
- fixed combination means that the active agents, e.g. disclosure and an additional active agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
- non-fixed combination means that the active agents, e.g. disclosure and an additional active agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the compounds in the body of the patient.
- treating refers to administering one or more pharmaceutical substances, especially the compound of the present invention or a pharmaceutically acceptable salt thereof described herein to a subject that has the disease or disorder, or has a symptom of a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disease or disorder, the symptoms of the disease or disorder.
- the disease is BTK-associated disease or disorder, such as a disease or disorder responsive to inhibition of BTK, preferably cancer.
- prevent or “preventing” in connection with a disease refer to administering one or more pharmaceutical substances, especially the compound of the present invention or a pharmaceutically acceptable salt thereof described herein to a subject that has a predisposition toward a disease or disorder, or has a risk of suffering from a disease or disorder, with the purpose to prevent or slow down the occurrence of the disease or disorder in the subject.
- the disease is BTK-associated disease or disorder, such as a disease or disorder responsive to inhibition of BTK, preferably cancer.
- effective amount refers to an amount of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein effective to “treat” or “prevent” , as defined above, BTK-associated disease or disorder, such as a disease or disorder responsive to inhibition of BTK in a subject.
- the effective amount may cause any changes observable or measurable in a subject as described in the definition of “treating” , “treat” , “treatment” , “preventing” , or “prevent” above.
- the effective amount can reduce the number of cancer or tumor cells; reduce the tumor size; inhibit or stop tumor cell infiltration into peripheral organs including, for example, the spread of tumor into soft tissue and bone; inhibit and stop tumor metastasis; inhibit and stop tumor growth; relieve to some extent one or more of the symptoms associated with the cancer; reduce morbidity and mortality; improve quality of life; or a combination of such effects.
- An effective amount may be an amount sufficient to reduce the symptoms of a BTK-associated disease or disorder.
- the term “effective amount” may also refer to an amount of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein effective to inhibit the activity of BTK in a subject.
- inhibitortion indicates a decrease in the baseline activity of a biological activity or process.
- “Inhibition of BTK” refers to a decrease in the activity of BTK as a direct or indirect response to the presence of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein, relative to the activity of BTK in the absence of the compound of the present invention or a pharmaceutically acceptable salt thereof.
- the decrease in activity may be due to the direct interaction of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein with BTK, or due to the interaction of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein with one or more other factors that in turn affect the BTK activity.
- the presence of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein may decrease the BTK activity by directly binding to the BTK, by directly or indirectly causing another factor to decrease the BTK activity, or by directly or indirectly decreasing the amount of BTK present in the cell or organism.
- subject means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like.
- the term “subject” does not denote a particular age or sex. In some embodiments, the subject is a human. In some embodiments of any of the methods or uses described herein, the subject is BTK-inhibitor naive. In other embodiments of any of the methods or uses described herein, the subject is not BTK-inhibitor naive.
- pharmaceutically acceptable means that the substance following this term is useful in preparing a pharmaceutical composition and is generally safe, non-toxic, and neither biologically nor otherwise undesirable, especially for human pharmaceutical use.
- tumors herein refers to a cellular disorder characterized by uncontrolled or disregulated cell proliferation, decreased cellular differentiation, inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at other sites.
- the term “tumor” includes, but is not limited to, hematological malignancies and solid tumors, preferably is B-cell malignancies.
- the term “tumor” includes, but is not limited to, leukemias, lymphomas (non-Hodgkin's lymphoma) , Hodgkin's disease (also called Hodgkin's lymphoma) and myeloma.
- Non-limiting examples of tumor are acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., polycyth
- autoimmune diseases refers to a disease or condition arising from damage to an individual's own tissues or organs caused by the body's immune response to self-antigens.
- autoimmune diseases include, but are not limited to, chronic obstructive pulmonary disease (COPD) , allergic rhinitis, systemic lupus erythematosus, myasthenia gravis, multiple sclerosis (MS) , rheumatoid arthritis (RA) , psoriasis, inflammatory bowel disease (IBD) , asthma, idiopathic thrombocytopenic purpura, and myeloproliferative disease, such as myelofibrosis, post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET myelofibrosis) .
- COPD chronic obstructive pulmonary disease
- MS multiple sclerosis
- RA rheumatoid arthritis
- inflammatory diseases refers to a pathological state that leads to inflammation, especially due to chemotaxis of neutrophils.
- Non-limiting examples of inflammatory diseases include chronic inflammation, autoimmune diabetes, rheumatoid arthritis (RA) , spondylitis, gouty arthritis and other joint disorders, multiple sclerosis (MS) , asthma, systemic lupus erythematosus, adult respiratory distress syndrome, Behcet disease, psoriasis, chronic lung inflammatory disease, allograft rejection, Crohn's disease, ulcerative colitis, inflammatory bowel disease (IBD) .
- RA rheumatoid arthritis
- MS multiple sclerosis
- asthma systemic lupus erythematosus
- adult respiratory distress syndrome Behcet disease
- psoriasis chronic lung inflammatory disease
- IBD ulcerative colitis
- the compounds of the present invention can be formulated into a pharmaceutical composition.
- the pharmaceutical composition includes: (a) an effective amount of invention; (b) a pharmaceutically acceptable excipient (for example, one or more pharmaceutically acceptable carriers) ; and optionally (c) at least one additional active agent.
- a pharmaceutically acceptable excipient refers to an excipient that is compatible with the active ingredient (s) in the composition (in some embodiments, can stabilize the active ingredient) and is not harmful to the subject being treated.
- Suitable pharmaceutically acceptable excipients are disclosed in standard reference books in the art (e.g., Remington's Pharmaceutical Sciences, Remington: The Science and Practice of Pharmacy.
- ) including one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., the compounds of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament) .
- buffers including one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., the compounds of the present invention or pharmaceutical composition thereof) or
- the compound of the invention can be administered in various known manners, such as orally, parenterally, by inhalation, or by implantation.
- parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion.
- the compound of the present invention may be administered in any convenient formulation, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc.
- Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and an addtional active agent.
- the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01 to 100 mg/kg, alternatively about 0.1 to 20 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day.
- oral unit dosage forms such as tablets and capsules, contain from about 0.1 to about 1000 mg of the compound of the invention.
- the disclosure relates to a method of treating or preventing a BTK-associated disease or disorder, comprising administering to the subject in need thereof an effective amount of the compound of the present invention.
- the compound of the present invention is used for the treatment or prevention of a BTK-associated disease or disorder.
- the BTK-associated disease or disorder as used herein is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders.
- the tumors are hematological malignancies or solid tumors. More preferably the tumors are B-cell malignancies.
- Non-limiting examples of BTK-associated disease or disorder include:
- Tumor hematological malignancies, solid tumors, preferably B-cell malignancies
- Hematological malignancies e.g., hematological malignancies that are BTK-associated tumors
- the tumors used herein also include transformation in hematological malignancies.
- transformation in hematological malignancies include Richter's transformation, prolymphocytic transformation (e.g., prolymphocytic transformation of CLL) , transformed non-Hodgkins lymphoma, and blastoid lymphoma (e.g., blastoid variant mantle cell lymphoma) .
- Solid tumors e.g., solid tumors that are BTK-associated tumors
- solid tumors include, for example, bone cancer, bone metastasis, breast cancer, gastro-esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer, prostate cancer, lung cancer, colon cancer, uterine cancer, hepatocellular cancer, head and neck cancer, gastric cancer, esophageal cancer, bladder cancer, colorectal cancer, renal cancer, skin cancer, brain tumors, thyroid cancer, and glioma.
- solid tumors include, for example, bone cancer, bone metastasis, breast cancer, gastro-esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer, prostate cancer, lung cancer, colon cancer, uterine cancer, hepatocellular cancer, head and neck cancer, gastric cancer, esophageal cancer, bladder cancer, colorectal cancer, renal cancer, skin cancer, brain tumors, thyroid cancer, and glioma.
- B-cell malignancies include a B-cell non-Hodgkin lymphoma, Hodgkin lymphoma, or B-cell leukemia.
- Examples of the B-cell malignancies also include a Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia (ALL) , B-cell prolymphocytic leukemia,
- BTK-associated diseases including inflammatory diseases and autoimmune diseases
- Arthritic diseases such as rheumatoid arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis;
- Pulmonary or respiratory disorders such as asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) , chronic pulmonary inflammatory disease (e.g., chronic obstructive pulmonary disease) , silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia, bronchiectasis, pulmonary oxygen toxicity, and chronic lung inflammatory disease;
- ARDS adult respiratory distress syndrome
- chronic pulmonary inflammatory disease e.g., chronic obstructive pulmonary disease
- silicosis e.g., chronic obstructive pulmonary disease
- silicosis e.g., chronic obstructive pulmonary disease
- silicosis e.g., chronic obstructive pulmonary disease
- silicosis e.g., chronic obstructive pulmonary disease
- silicosis e.g.
- Fibrosis such as cystic fibrosis; keloid formation or scar tissue formation; atherosclerosis;
- Autoimmune diseases including, but are not limited to, systemic lupus erythematosus (SLE) , autoimmune thyroiditis, multiple sclerosis, chronic obstructive pulmonary disease (COPD) , allergic rhinitis, lupus erythematosus, myasthenia gravis, rheumatoid arthritis (RA) , psoriasis, inflammatory bowel disease (IBD) , asthma, idiopathic thrombocytopenic purpura, and myeloproliferative disease, such as myelofibrosis, post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET myelofibrosis) ;
- SLE systemic lupus erythematosus
- COPD chronic obstructive pulmonary disease
- RA rheumatoid arthritis
- IBD inflammatory bowel disease
- asthma
- Inflammatory dermatoses such as contact dermatitis, atopic dermatitis, psoriasis, or urticaria; fever and myalgias due to infection;
- BTK inhibitor resistance mutations e.g., that result in an increased resistance to a first BTK inhibitor, e.g., a substitution at amino acid position 481, e.g., C481S, C481T, C481R, C481G, and/or one or more BTK inhibitor resistance mutations.
- the compound of the present invention is used for treating or preventing a disease of resistance to other BTK related treatment by either dosing in combination or as a subsequent or additional (e.g., follow-up) therapy to existing drug treatments (e.g., said other BTK kinase inhibitors; e.g., first and/or second BTK kinase inhibitors) .
- a first or second BTK kinase inhibitor can be selected from the group consisting of: ibrutinib, PRN1008, PRN473, ABBV-105, AC0058, acalabrutinib, zanubrutinib, spebrutinib, poseltinib, evobrutinib, M7583, tirabrutinib, CG'806, ARQ 531, BIIB068, vecabrutinib, AS871, CB 1763, CB988, GDC-0853, RN486, dasatinib, GNE-504, GNE-309, BCB-311, BTK Max, CT-1530, CGI-1746, CGI-560, LFM Al3, TP-0158, dtrmwxhs-12, CNX-774, and LOU064.
- the first or second BTK kinase inhibitor is a covalent inhibitor.
- covalent inhibitors of a BTK kinase include, but are not limited to, ibrutinib, PRN1008, PRN473, ABBV-105, AC0058, acalabrutinib, zanubrutinib, spebrutinib, poseltinib, evobrutinib, M7583, and tirabrutinib.
- the first or second BTK kinase inhibitor is a non-covalent inhibitor.
- Exemplary non-covalent inhibitors of a BTK kinase include, but are not limited to, CG'806, ARQ 531, BIIB068, vecabrutinib, AS871, CB 1763, CB988, GDC-0853, RN486, and dasatinib.
- the compound of the present invention may be used in combination with an additional active agent in the treatment of a BTK-associated disease or disorder.
- the additional active agent may be administered separately with the compound of the present invention or may be included with the compound of the present invention in a pharmaceutical composition according to the disclosure, such as a fixed combination product.
- the additional active agent are those that are known or discovered to be effective in the treatment of BTK-associated disease or disorder, such as another BTK inhibitor or a compound that antagonizes another target associated with said particular disease.
- the combination may serve to increase efficacy, decrease one or more side effects, or decrease the required dose of the compound of the present invention.
- the compound of the present invention is administered in combination with an anti-neoplastic agent.
- the anti-neoplastic agents include, but are not limited to: radiotherapeutic agents, chemotherapeutic agents, immunotherapeutic agents, targeted therapeutic agents.
- A-1-1 was synthesized from commercially available starting material 2, 4, 6-trichloropyridine based on literature synthesis of similar compounds (WO 2017042100) , and subsequent bromination followed deprotection afforded intermediate A-1-2.
- compound A-1-1 can be turned into intermediate A-2-2 following carboxylation, amide formation and deprotection.
- A-2-2 was then turned into key intermediate A-2-4a after ring closure and protection.
- 4-Nitrogen analogs with the general structure represented by A-2 can be obtained after treating A-2-4a with corresponding amines followed by Suzuki reactions.
- Ra is R 1 which is attached to the ring by C
- Rb is R 1 which is attached to the ring by N or O
- P 1 or P 2 is protecting group
- R 1 and Ar are as defined for formula I herein.
- Ra is R 1 which is attached to the ring by C
- Rb is R 1 which is attached to the ring by N or O
- P 1 or P 2 is protecting group
- R 1 and Ar are as defined for formula I herein.
- intermediate B-1-1 can be obtained from commercially available 4-bromo-2, 6-difluorobenzonitrile following a two-steps procedure disclosed in WO2010059658 with modifications. Protection followed by formylation afforded compound B-1-2, which then was transformed to compound B-1-3a after separation from its regioisomer B-1-3b. B-1-3a and its deprotected version, B-1-3c, as key intermediates, can be used as starting points to prepare target compounds represented as B-1 or B-2 following multiple-step sequences, respectively.
- Route 2 was also used in some cases.
- commercially available methyl 5-bromo-2-hydroxy-4-methylbenzoate was transformed to methyl 5-bromo-2-methoxy-4-methyl-3-nitrobenzoate, which was subsequently turn into compound methyl 3-amino-5-bromo-2-methoxy-4-methylbenzoate following a reduction step.
- the subsequent ring closure afforded key intermediate B-1-6, which was transformed into key intermediate B-1-9 after a number of bond-forming and functional-group-transformation steps.
- key intermediate B-1-9 target compounds represented by B-1 were prepared.
- the empty valence is the hydrogen atom which is omitted for convenience.
- Step 1 To a stirred suspension of 2, 4, 6-trichloropyridine (9.1 g, 49.8 mmol) in THF (100 mL) was added LDA (27.4 mL, 54.8 mmol) at -65°C, and the resulting mixture was stirred for 1 h under N 2 before piperidine-1-carbaldehyde (5.6 mL, 49.8 mmol) was added at this temperature. The mixture was stirred at -65°C for 3h. Then the reaction mixture was quenched with sat.
- Step 2 To a stirred suspension of 2, 4, 6-trichloropyridine-3-carbaldehyde (4.1 g, 19.5 mmol) and propane-1, 3-diol (2.1 mL, 29.2 mmol) in toluene (40 mL) was added p-TSA (0.7 g, 3.9 mmol) at 120°C and the resulting mixture was stirred for 3h under N 2 . After cooled down to rt, the reaction mixture was diluted with water (20 mL) , extracted with EtOAc (30 mL x 3) . The combined organic phase was washed by brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated.
- Step 1 To a stirred suspension of 2, 4, 6-trichloro-3- (1, 3-dioxan-2-yl) pyridine (A-1-1) (4.2 g, 15.6 mmol) and TMEDA (5.5 mL, 54.7 mmol) in THF (40 mL) was added n-BuLi (31.4 mL, 78.5 mmol) at -65°C, and the resulting mixture was stirred for 1h under N 2 before 1, 2-dibromotetrafluoroethane (4.1 mL, 31.3 mmol) was added. The mixture was stirred at the same temperature for 3h. After warmed to rt, the reaction mixture was quenched with sat.
- Step 2 To a stirred suspension of 3-bromo-2, 4, 6-trichloro-5- (1, 3-dioxan-2-yl) pyridine (4.0 g, 11.5 mmol) in THF (10 mL) was added 3N HCl (20 mL, 60 mmol) , the mixture was stirred at 80 °C overnight. After cooled down to rt, the reaction mixture was diluted with water (20 mL) , extracted with EtOAc (50 mL x 3) .
- Step 1 To a solution of 2, 4, 6-trichloro-3- (1, 3-dioxan-2-yl) pyridine (A-1-1) (79 g, 294 mmol) in THF (1 L) was added LDA (220 mL, 440 mmol) dropwise at -80°C and stirred for 1 h, then the solution was bubbled with CO 2 for 1 h (maintain the inner temperature below -70°C) .
- A-1-1 2, 4, 6-trichloro-3- (1, 3-dioxan-2-yl) pyridine
- Step 2 To a solution of 2, 4, 6-trichloro-5- (1, 3-dioxan-2-yl) nicotinic acid (A-2-1) (39 g, 124.78 mmol) and DMF (0.5 mL, 6.24 mmol) in THF (400 mL) was added oxalic dichloride (13 mL, 149.8 mmol) dropwise at -5°C and the resulting mixture was stirred for 1 h, then bubbled with NH 3 for 1 h (maintain the inner temperature ⁇ 0°C) .
- Step 3 To a solution of 2, 4, 6-trichloro-5- (1, 3-dioxan-2-yl) nicotinamide (30 g, 96.3 mmol) in AcOH (400 mL) was added HCl (200 mL, 2.4 mol) at 5°C, the reaction mixture was heated to 50°C for 2 h. the reaction mixture was cooled down to room temperature, the mixture was extracted with EtOAc (400 mL x 3) , the combined the organic phase was washed with sat.
- Step 4 To a solution of NaHCO 3 (13.3 g, 157.81mmol) and 2, 4, 6-trichloro-5-formylnicotinamide (A-2-2, 20 g, 78.91 mmol, 80%) in THF (600 mL) was added hydrazine hydrate (7.2 mL, 118.39 mmol) dropwised at 10°C, the reaction mixture was stirred for another 4 h at the same temperature. Then the mixture was quenched with sat.
- Step 5 To a solution of 4, 6-dichloro-1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (6.0 g, 25.97 mmol) and Na 2 CO 3 (8.3 g, 77.91 mmol) in DMF (50 mL) was added PMBCl (5.3 mL, 38.95 mmol) dropwised at room temperature, the reaction mixture was heated to 50°C for 2 h.
- Step 1 To a solution of phenyl methanol (99.7 g, 922 mmol) in THF (1 L) was added NaH (44.3 g, 1.1 mol) at 0°C, the reaction mixture was stirred at 0 °C for 30 min under a nitrogen atmosphere, then 4-bromo-2, 6-difluorobenzonitrile (200 g, 922 mmol) in THF (1 L) was added dropwised to the solution and stirred for another 2 h. The reaction mixture was quenched by aq.
- Step 3 To a solution of 4-bromo-2-fluoro-6-hydroxybenzonitrile (B-1-1, 145 g, 674.41 mmol) in DCM (1.5 L) was added DIPEA (232 mL, 1.35 mmol) , then MOMCl (59.1 g, 741.85 mmol) was added dropwiseat 0°C. The reaction mixture was stirred at 0 °C for 2 h under a nitrogen atmosphere.
- DIPEA 232 mL, 1.35 mmol
- MOMCl 59.1 g, 741.85 mmol
- reaction mixture was extracted with DCM (500 mL x 2) , the combined organic phase was washed by H 2 O and brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuum to obtain 4-bromo-2-fluoro-6- (methoxymethoxy) benzonitrile (160 g, yield: 91.6%) as a yellow solid which was used to next step without further purified.
- Step 4 To a solution of 4-bromo-2-fluoro-6- (methoxymethoxy) benzonitrile (160 g, 617.76 mmol) in THF (1.6 L) was added LDA (401.5 mL, 803.09 mmol, 2M in THF) dropwise at -78°C, the mixture was stirred at -78 °C for 2 h under a nitrogen atmosphere, then DMF (117.3 g, 1606.18 mmol) was added to the mixture and keep the inner temperature under -70 °C, the reaction mixture was stirred for another 1h at -78 °C. The reaction mixture was quenched by aq.
- LDA 401.5 mL, 803.09 mmol, 2M in THF
- Step 5 To a solution of 4-bromo-2-fluoro-3-formyl-6- (methoxymethoxy) benzonitrile (115 g, 400.70 mmol) in MeCN (1.5 L) was added N 2 H 4 . H 2 O (26 g, 400.70 mmol, 80%in H 2 O) dropwised at 0°C,the mixture was stirred at 0°C for 1h, then the reaction mixture heated to 90°C for 12 h.
- Step 6 To a solution of 4-bromo-6- (methoxymethoxy) -1H-indazole-7-carbonitrile (27 g, 96.09 mmol) in DMF (300 mL) was added K 2 CO 3 (26.5 g, 192.17 mmol) , and PMBCl (17.9 g, 115.3 mmol) , the mixture was stirred at 60°C for 2 h.
- Step 1 To a stirred solution of methyl 5-bromo-2-hydroxy-4-methylbenzoate (5.0 g, 20.4 mmol) and K2CO3 (4.0 g, 28.9 mmol) in DMF (30 mL) was added MeI (3.6 g, 25.352 mmol) at room temperature slowly, the reaction mixture was stirred at 60°C for 18h. The reaction mixture was diluted with water (200 mL) and extracted with EtOAc (100 mL x 3) . The combined organic phases were washed with water and brine.
- Step 2 To a stirred H 2 SO 4 (30 mL) at 0°C was added methyl 5-bromo-2-methoxy-4-methylbenzoate (5.0 g, 19.2 mmol) in portions. After the solution was clear, HNO 3 (1.25 mL, 19.2 mmol) was added dropwised over 30min, the mixture was stirred at 0°C for extra 1h. The reaction mixture was diluted with sat. NaHCO 3 (200 mL) , extracted with EtOAc (100 mL x 3) .
- Step 3 To a stirred solution of methyl 5-bromo-2-methoxy-4-methyl-3-nitrobenzoate (2g, 6.5 mmol) and Fe powder (2g, 35.7 mmol) in EtOH (20mL) at 25 °C was added HCl (0.2 mL, 2.400 mmol) and then heated to 80°C stirred for 18 h. The reaction mixture was cooled down to r.t.
- Step 4 To a stirred solution of methyl 3-amino-5-bromo-2-methoxy-4-methylbenzoate (300 mg, 1.0 mmol) in HBF 4 (2 mL, 31.4 mmol) was added NaNO 2 (75 mg, 1.0 mmol, in 1mLwater) dropwised. The reaction mixture was stirred at 10°C for 30 min and precipitate formed. The cooled reaction mixture was filtered and the solid product washed with small amounts of H 2 O, MeOH and Et 2 O subsequently and dried under high vacuum to obtain yellow solid 400mg of diazonium salt.
- 18-crowm-6 (289 mg, 1.0 mmol) and AcOK (200 mg, 2.0 mmol) were pre-dried under high vacuum for 1 h and CHCl 3 (50mL) was added. The suspension was stirred at room temperature for 10 min. Then the diazonium salt was added to the mixture in small portions under N 2 atmosphere. The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with water (20 mL) , extracted with EtOAc (15 mL x 3) .
- Step 1 To a solution of Sodium hydride (417 mg, 10.44mmol) in dry DMF (10 mL) was added tert-butyl N- [ (tert-butoxy) carbonyl] carbamate (756 mg, 3.48 mmol) portion wise at 0°C, the resulting mixture was stirred for 1 h at 0°C followed by the addition of 1-bromo-4- (bromomethyl) -2-chlorobenzene (900 mg, 3.17 mmol) , the reaction mixture was stirred for another 2 h at the same temperature. Then the mixture was quenched with cold sat.
- 1-bromo-4- (bromomethyl) -2-chlorobenzene 900 mg, 3.17 mmol
- Step 2 To a solution of tert-butyl N- [ (4-bromo-3-chlorophenyl) methyl] -N- [ (tert-butoxy) carbonyl] carbamate (1.6 g, 3.8 mmol) in EtOAc (10 mL) was added HCl (10 mL, 4 mol/L in 1, 4-dioxane) at 0°C, the reaction mixture was stirred for 2 h at room temperature. Then concentrated under reduced pressure to obtain crude product (4-bromo-3-chlorophenyl) methanamine hydrochloride (0.7 g, yield: 83.3%) as a yellow solid, which was used to next step directly without further purification. LC/MS (ESI) m/z: 220/222 (M+H) + .
- Step 3 To a solution of (4-bromo-3-chlorophenyl) methanamine hydrochloride (0.7 g, 3.18 mmol) , 5-fluoro-2-methoxybenzoic acid (0.65g, 3.81 mmol) and HATU (1.69 g, 4.44 mmol) in DMF (5 mL) was added TEA (1.32 mL, 9.52 mmol) , the mixture was stirred for 2 h at room temperature. Then the mixture was diluted with H 2 O (20 mL) and extracted with EtOAc (30 mL x 3) .
- Step 4 To a solution of N- [ (4-bromo-3-chlorophenyl) methyl] -5-fluoro-2-methoxybenzamide (0.8 g, 2.15 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (0.82 g, 3.22 mmol) in 1, 4-dioxane (20 mL) was added Pd (dppf) Cl 2 (0.16 g, 0.22 mmol) and KOAc (0.42 g, 4.29 mmol) . The resulting mixture was heated to 110°C for 12h under N 2 atmosphere.
- Step 1 A solution of 4-bromobenzoic acid (2.0 g, 10 mmol) in SOCl 2 (10 mL) was heated to 85°Cfor 2h under N 2 atmosphere. Then the reaction mixture was cooled down to room temperature, the solvent was removed under vacuo to give the crude product 4-bromobenzoyl chloride (2.2 g, yield: 100%) which was used to next step directly without purification.
- Step 2 To a solution of 4-bromo-N- (4- (trifluoromethyl) pyridin-2-yl) benzamide (2.2 g, 10 mmol) in pyridine (10 mL) was added 4- (trifluoromethyl) pyridin-2-amine (1.6 g, 10 mmol) . The resulting mixture was stirred at 65°C overnight under N 2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL x 3) .
- Step 3 To a stirred solution of 4-bromo-N- (4- (trifluoromethyl) pyridin-2-yl) benzamide (2.7 g, 7.85 mmol) and 4, 4, 4', 4', 5, 5, 5', 5'-octamethyl-2, 2'-bi (1, 3, 2-dioxaborolane) (3.0 g, 11.76 mmol) in dioxane (10 mL) was added KOAc (1.5 g, 15.7 mmol) and Pd (dppf) Cl 2 (0.6 g, 0.78 mmol) . The resulting mixture was heated to 110°C for 12h under N 2 atmosphere.
- Step 1 To a solution of N- (4-bromobenzyl) -5-fluoro-2-methoxybenzamide (2.7 g, 8.01 mmol) in DCM (30 mL) was added BBr 3 (16 mL, 16 mmol, 1M in DCM) under -50°C during 30 min.
- Step 2 To a solution of N- (4-bromobenzyl) -5-fluoro-2-hydroxybenzamide (2.5 g, 7.74 mmol) in MeCN (20 mL) was added K 2 CO 3 (1.6 g, 11.61 mmol) and CD 3 I (1.4 g, 9.30 mmol) . The resulting mixture was stirred at rt for 3 h under N 2 atmosphere.
- Step 3 To a stirred solution of N- (4-bromobenzyl) -5-fluoro-2- (methoxy-d3) benzamide (800 mg, 2.35mmol) and 4, 4, 4', 4', 5, 5, 5', 5'-octamethyl-2, 2'-bi (1, 3, 2-dioxaborolane) (716 mg, 2.82 mmol) in dioxane (10 mL) was added AcOK (461 mg, 4.70 mmol) and Pd (dppf) Cl 2 (172 mg, 0.24 mmol) . The resulting mixture was heated to 100°C for 12h under N 2 atmosphere.
- Step 1 To a solution of cyclopent-3-enol (7.1 g, 84.4 mmol) and imidazole (11.5 g, 168.8 mmol) in DMF (70 mL) was added TBDPSCl (25.4 g, 92.84 mmol) at 0°C, and the resulting mixture was stirred at 0 °C for 2 h.
- Step 3 To a stirred solution of tert-butyl (3, 4-dibromocyclopentyloxy) diphenylsilane (8 g, 17.16 mmol) in THF (100 mL) was added t-BuOK (9 g, 80.37 mmol) at 0°C slowly and the reaction mixture was stirred at 25°C for 18h.
- Step 4 To a stirred solution of (3-bromocyclopent-3-enyloxy) (tert-butyl) diphenylsilane (3 g, 7.5 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (1.8 g, 7.8 mmol) in 1, 4-dioxane (30 mL) was added Pd (dppf) Cl 2 (200 mg, 0.27 mmol) at 25°C slowly. The resulting mixture was heated to 100°C for 12h under N 2 atmosphere.
- Step 1 To a solution of 2-methyloxolan-3-one (3 g, 29.96 mmol) in THF (40 mL) was added LDA (18.0 mL, 36.0 mmol) dropwise at -78°C, the resulting mixture was stirred at -78°C for 1 h under nitrogen atmosphere, before 1, 1, 1-trifluoro-N-phenyl-N-trifluoromethanesulfonylmethanesulfonamide (10.70 g, 29.964 mmol in THF (10 mL) ) was added, the reaction mixture was stirred at -78°C for another 1 hr. The mixture was poured into ice aq.
- Step 2 To a solution of 2-methyl-4, 5-dihydrofuran-3-yl trifluoromethanesulfonate (700 mg, 3.0 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (766 mg, 3.0 mmol) in dioxane (10 mL) was added KOAc (591 mg, 6.0 mmol) and Pd (dppf) Cl2 (110 mg, 0.15 mmol) , the reaction mixture was stirred at 85°C for 3 h under nitrogen atmosphere.
- KOAc 591 mg, 6.0 mmol
- Pd (dppf) Cl2 110 mg, 0.15 mmol
- Step 1 To a stirred solution of 2-methylcyclopentane-1, 3-dione (0.93 mL, 8.92 mmol) and DIPEA (1.8 mL, 10.83 mmol) in Et 2 O (30 mL) was added Tf 2 O (1.6 mL, 10 mmol) at -78°C slowly and the reaction mixture was stirred at -78°C for 1.5h under nitrogen atmosphere.
- Step 2 To a stirred solution of 2-methyl-3-oxocyclopent-1-enyl trifluoromethanesulfonate (500 mg, 2.048 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (0.61 mL, 2.36 mmol) in 1, 4-dioxane (10 mL) was added Pd (dppf) Cl 2 (100 mg, 0.14 mmol) and KOAc (500 mg, 5.09 mmol) at 25°C slowly and the reaction mixture was stirred at 100°C for 2h under nitrogen atmosphere.
- 2-methyl-3-oxocyclopent-1-enyl trifluoromethanesulfonate 500 mg, 2.048 mmol
- Step 1 To a solution of methyl alaninate (14.0 g, 135.92 mmol) and ethyl acrylate (27.2 g, 271.84 mmol) in EtOH (200 mL) was added TEA (27.5 g, 271.84 mmol) under N 2 . The reaction mixture was heated to rt overnight. The reaction mixture was diluted with EtOAc (300 mL) . The mixture was washed with water and brine.
- Step 2 To a solution of ethyl 3- ( (1-methoxy-1-oxopropan-2-yl) amino) propanoate (11.0 g, 54.19 mmol) in DCM (200 mL) was added Boc 2 O (23.6 g, 108.38 mmol) and TEA (20.2 g, 200 mmol) under N 2 . The reaction mixture was stirred at rt overnight. The reaction mixture was diluted with DCM (100 mL) . The mixture was washed with water and brine.
- Step 3 To a solution of ethyl 3- ( (tert-butoxycarbonyl) (1-methoxy-1-oxopropan-2-yl) amino) propanoate (15.0 g, 49.50 mmol) in toluene (150 mL) was added t-BuOK (11.1 g, 99 mmol) under N 2 . The reaction mixture was stirred at rt for 2 hr. The reaction mixture was diluted with DCM (150 mL) . The mixture was washed with water and brine.
- Step 4 To a solution of 1- (tert-butyl) 3-ethyl 5-methyl-4-oxopyrrolidine-1, 3-dicarboxylate and 1- (tert-butyl) 2-methyl 2-methyl-3-oxopyrrolidine-1, 2-dicarboxylate (9.0 g, 35.02 mmol) in EtOH (20 mL) was added con. HCl (4 mL) . The mixture was stirred at 90 °C for 1h in a sealed tank. After cooled down to rt, was diluted with DCM (150 mL) . The mixture was washed with water and brine.
- Step 5 To a solution of 2-methylpyrrolidin-3-one (3.45 g, 34.85 mmol) in DCM (20 mL) was added Boc 2 O (15.2 g, 69.7 mmol) and DIPEA (7 g, 69.7 mmol) under N 2 . The reaction mixture was stirred at rt for 1h. The reaction mixture was diluted with DCM (100 mL) . The mixture was washed with water and brine.
- Step 6 To a solution of tert-butyl 2-methyl-3-oxopyrrolidine-1-carboxylate (3.0 g, 15.08 mmol) in THF (20 mL) was added LiHMDS (15.08 mL, 2.0 mmol/mL, 30.16 mmol) under N 2 . The reaction mixture was stirred at -78°C for 1h. Then Tf 2 O (5.10 g, 18.10 mmol) was added and stirred at -78°C for another 2 h. The reaction mixture was diluted with DCM (100 mL) . The mixture was washed with water and brine.
- Step 7 To a solution of tert-butyl 5-methyl-4- ( (trifluoromethyl) sulfonyl) oxy) -2, 3-dihydro-1H-pyrrole-1-carboxylate (1.9 g, 5.74 mmol) in dioxane (20 mL) was added Pd (dppf) Cl 2 (0.42 g, 0.57 mmol) , 4, 4, 4', 4', 5, 5, 5', 5'-octamethyl-2, 2'-bi (1, 3, 2-dioxaborolane) (2.2 g, 8.61 mmol) and AcOK (1.1g, 11.48 nnol) under N 2 . The reaction mixture was stirred at 90°C for 3h.
- Step 1 To a solution of 2- (trifluoromethyl) pyridin-4-amine (3 g, 18.51 mmol) in MeCN (50 mL) was added NBS (8.23 g, 46.27 mmol) portion wise at 0°C, the resulting mixture was warmed to room temperature and stirred overnight.
- Step 3 To a mixture of 3-bromo-2- (trifluoromethyl) pyridin-4-amine (400 mg, 1.66 mmol) and trimethyl-1, 3, 5, 2, 4, 6-trioxatriborinane (0.95 mL, 3.32 mmol, 3.5 M in THF) in 1, 4-dioxane (8 mL) and H 2 O (2 mL) was added K 2 CO 3 (459 mg, 3.32 mmol) and Pd (dppf) Cl 2 (121 mg, 0.17 mmol) . The resulting mixture was heated to 80°C for 12h under N 2 atmosphere.
- Step 4 To a mixture of 3-methyl-2- (trifluoromethyl) pyridin-4-amine (200 mg, 1.14 mmol) in MeCN (10 mL) was added tert-butyl nitrite (0.27 mL, 2.27 mmol) and CuBr 2 (363 mg, 2.27 mmol) . The resulting mixture was heated to 80°C for 12h under N 2 atmosphere.
- Step 5 To a mixture of 4-bromo-3-methyl-2- (trifluoromethyl) pyridine (80 mg, 0.33 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (127 mg, 0.50 mmol) in 1, 4-dioxane (10 mL) was added KOAc (65 mg, 0.67 mmol) and Pd (dppf) Cl 2 (24 mg, 0.03 mmol) . The resulting mixture was heated to 100°C and stirred overnight under N 2 atmosphere.
- Step 1 To a solution of 7-bromo-4, 6-dichloro-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine (2.2g, 5.7 mmol) , 2- (cyclopent-1-en-1-yl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (1.1 g, 5.7 mmol) and Na 2 CO 3 (1.2g, 11.4 mmol) in dioxane (20.0 mL) and H 2 O (4.0 mL) was added Pd (PPh 3 ) 4 (330mg, 0.3 mmol) , the mixture was stirred at 60 °C for 10 h under N 2 atmosphere.
- Step 2 To a solution of 7-bromo-6-chloro-4-cyclopentenyl-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine (0.3 g, 0.7mmol) in MeOH (5 mL) was added Pd (dppf) Cl 2 (52.4 mg, 0.1 mmol) and TEA (0.3 mL, 2.2 mmol) . The resulting mixture was stirred at 85 °C under CO (70 psi) in a sealed tank overnight.
- Step 3 To a solution of methyl 6-chloro-4- (cyclopent-1-en-1-yl) -1- [ (4-methoxyphenyl) -methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (240 mg, 0.6 mmol) in dioxane (8 mL) and H 2 O (2 mL) were added 2- (2-methoxyphenyl) -N- ⁇ [4- (4, 4, 5, 5-tetramethyl-1, 3-dioxolan-2-yl) phenyl] methyl ⁇ acetamide (231 mg, 0.6mmol) , Pd (dppf) Cl 2 (52 mg, 0.1 mmol) and K 2 CO 3 (250 mg, 1.8 mmol) .
- Step 4 To a solution of methyl 4- (cyclopent-1-en-1-yl) -6- (4- ⁇ [ (2-methoxyphenyl) -formamido] methyl ⁇ phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (260 mg, 0.4 mmol) in MeOH (5 mL) was added Pd/C (61 mg, 20%wet) and two drops of formic acid. The resulting mixture was stirred at 60 °C for 2 h under H 2 balloon.
- Step 5 To a solution of methyl 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (250 mg, 0.4 mmol) in DCM (5 mL) was added TFA (5 mL) . The resulting mixture was stirred at 40 °C for 1 h. After cooled down to rt, the reaction mixture was diluted with DCM (20 mL) , and adjust pH with sat. NaHCO 3 solution.
- Step 6 To a solution of methyl 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (100 mg, 0.2 mmol) in THF (5 mL) was added ammonia (28%in water) . The mixture was stirred at 100 °C for 6 h in a sealed tank.
- Step 1 To a solution of 7-bromo-4, 6-dichloro-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine (560 mg, 1.45 mmol) , 4, 4, 5, 5-tetramethyl-2- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1, 3, 2- dioxaborolane (365 mg, 1.37 mmol) and Na 2 CO 3 (460 mg, 4.34 mmol) in dioxane (10 mL) and H 2 O (2.0 mL) was added Pd (PPh 3 ) 4 (83 mg, 0.01 mmol) , the mixture was stirred at 60 °C for 10 h under N 2 atmosphere.
- Pd (PPh 3 ) 4 83 mg, 0.01 mmol
- Step 2 To a solution of 7-bromo-6-chloro-4- ⁇ 1, 4-dioxaspiro [4.5] dec-7-en-8-yl ⁇ -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine (500 mg, 1 mmol) in MeOH (10 mL) was added Pd(dppf) Cl 2 (74.5mg, 0.102mmol) and TEA (0.43mL, 3.056mmol) . The resulting mixture was stirred at 85 °C under CO (70 psi) in a sealed tank overnight.
- Step 3 To a stirred solution of methyl 6-chloro-1- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (75 mg, 0.16 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (74 mg, 0.19 mmol) in dioxane (4mL) and H 2 O (1 mL) was added K 2 CO 3 (44 mg, 0.32 mmol) and Pd(dppf) Cl 2 (14 mg, 0.02 mmol) slowly, the reaction mixture was heated to 100 °C for 18 h under N 2 atmosphere.
- Step 4 To a stirred solution of methyl 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -1- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylat e (80mg, 0.12 mmol) in MeOH (10 mL) was added Pd/C (8 mg, 10%) .
- Step 5 To a solution of methyl 4- ⁇ 1, 4-dioxaspiro [4.5] decan-8-yl ⁇ -6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (70 mg, 0.1 mmol) in MeOH (5 mL) and H 2 O (1 mL) was added NaOH (40 mg, 1.01 mmol) , the resulting mixture was stirred at 70°C for 5h.
- Step 6 To a stirred solution of 4- ⁇ 1, 4-dioxaspiro [4.5] decan-8-yl ⁇ -6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridi ne-7-carboxylic acid (60 mg, 0.09 mmol) and HATU (40 mg, 0.11 mmol) in DMF (5 mL) at 25 °C was added DIPEA (34 mg, 0.264 mmol) slowly, the reaction mixture was heated to rt for 10 min under NH 3 atmosphere.
- DIPEA 34 mg, 0.264 mmol
- Step 7 To a solution of 4- ⁇ 1, 4-dioxaspiro [4.5] decan-8-yl ⁇ -6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxami de (55 mg, 0.08 mmol) in DCM (5 mL) was added TFA (5 mL) under N 2 . The mixture was stirred for 3 h.
- Step 8 To a solution of 6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -4- (4-oxocyclohexyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (40 mg, 0.08 mmol) in MeOH (5 mL) was added NaBH 4 (13 mg, 0.39 mmol) under N 2 .
- Step 1 To a solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (766 mg, 1.71 mmol) and 4, 6-dichloro-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (600 mg, 1.71mmol) in dioxane (20 mL) and H 2 O (5 mL) was added Pd (dppf) Cl 2 (125 mg, 0.17 mmol) and K 2 CO 3 (708 mg, 5.13 mmol) . The resulting mixture was heated to 80°C and stirred for 12h under N 2 atmosphere.
- Step 2 To a solution of 4- (4- (tert-butyldiphenylsilyloxy) cyclopent-1-enyl) -6-chloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (870 mg, 1.37 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (631 mg, 1.69 mmol) in 1, 4-dioxane (20 mL) and H 2 O (5 mL) was added Pd (dppf) Cl 2 (100 mg, 0.14 mmol) and Cs 2 CO 3 (889 mg, 2.73 mmol) , the resulting mixture was heated to 110°C for 12h under N 2 atmosphere.
- 4-d (dppf) Cl 2 100 mg, 0.14 mmol
- Cs 2 CO 3 889 mg, 2.73
- Step 3 To a solution of 4- (4- (tert-butyldiphenylsilyloxy) cyclopent-1-enyl) -6- (4- ( (5-fluoro-2 -methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxami de (600 mg, 0.7 mmol) was added Pd/C (74 mg, 10%wet) . The resulting mixture was stirred at 50°C for 12h under H 2 atmosphere.
- Step 4 A solution of 4- (3- (tert-butyldiphenylsilyloxy) cyclopentyl) -6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamid e (500 mg, 0.58 mmol) in TFA (4 mL) was heated to 65°Cfor 4 h.
- Step 5 To a solution of 3- [7-carbamoyl-6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -1H-pyrazolo [4, 3-c] pyridin-4-yl] cyclopentyl 2, 2, 2-trifluoroacetate (400 mg, 0.67 mmol) in THF (10 mL) and H 2 O (5 mL) was added NaOH (133 mg, 3.34 mmol) . The resulting mixture was stirred for 2 h at room temperature.
- Example 6 &7 (cis isomers): Column: ChiralPak AD, 250 ⁇ 4.6mm I. D., 5um;
- Example 8 &9 (trans isomers) : Column: ChiralPak IA, 250 ⁇ 4.6mm I. D., 5um. The absolute configuration was not determined for all four compounds.
- Step 1 To a solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (630 mg, 1.80 mmol) and 4, 4, 5, 5-tetramethyl-2- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1, 3, 2-dioxaborolane (527 mg, 1.98 mmol) in dioxane (10 mL) and H 2 O (3 mL) was added Pd (dppf) Cl 2 (131 mg, 0.18 mmol) and K 2 CO 3 (497 mg, 3.60 mmol) . The resulting mixture was heated to 70°Cfor 12 h under N 2 atmosphere.
- Step 2 synthesis of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide
- Step 3 synthesis of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] decan-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide
- Step 4 synthesis of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (4-oxocyclohexyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide
- Step 5 To a solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (4-oxocyclohexyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (220 mg, 0.43 mmol) in MeOH (10 mL) was added NaBH 4 (33 mg, 0.86 mmol) . The resulting mixture was stirred at 0 °C for 10 min. The reaction mixture was diluted with EtOAc (20 mL) .
- Step 1 To a stirred solution of 4, 6-dichloro-2- [ (4-methoxyphenyl) methyl] -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (100 mg, 0.29 mmol) and (3-methylpyridin-4-yl) boronic acid (47 mg, 0.34 mmol) in dioxane (8 mL) and water (2 mL) at 25°C was added Pd (dppf) Cl 2 (20 mg, 0.028 mmol) and Na 2 CO 3 (60 mg, 0.57 mmol) slowly. he resulting mixture was heated to 80°C and stirred for 12h under N2 atmosphere.
- Step 2 To a stirred solution of 6-chloro-2- (4-methoxybenzyl) -4- (3-methylpyridin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (75 mg, 0.18 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (70 mg, 0.18mmol) in dioxane (8mL) and Water (2mL) at 25°C was added Pd (dppf) Cl 2 (14 mg, 0.02 mmol) and K 2 CO 3 (51 mg, 0.37 mmol) slowly.
- the resulting mixture was heated to 110°C for 12 h under N 2 atmosphere. Then the reaction mixture was cooled down to room temperature, the reaction mixture was diluted with H 2 O (20 mL) , extracted with EtOAc (20 mL x 3) .
- Step 3 A solution of 6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -2- [ (4-methoxyphenyl) methyl] -4- (3-methylpyridin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (60 mg, 0.1 mmol) in TFA (2 mL) was stirred at 65°C for 3 h. Then the reaction mixture was cooled down to room temperature, the resulting mixture was concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO 3 solution.
- Step 1 To a stirred solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (100 mg, 0.29 mmol) and 4- (tributylstannyl) pyrimidine (116 mg, 0.31 mmol) in dioxane (5 mL) at 25°C was added Pd (PPh 3 ) 4 (33 mg, 0.028 mmol) . The resulting mixture was heated to 80°C and stirred for 18h under N 2 atmosphere. Then the reaction mixture was cooled down to room temperature, the mixture was diluted with H 2 O (10 mL) , extracted with EtOAc (15 mL x 3) .
- Step 2 To a stirred solution of 6-chloro-2- (4-methoxybenzyl) -4- (pyrimidin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (100 mg, 0.25 mmol) and Intermediate A (106mg, 0.28mmol) in dioxane (8mL) and water (2mL) was added Pd (dppf) Cl 2 (15 mg, 0.025 mmol) and Cs 2 CO 3 (163 mg, 0.50 mmol) slowly, the resulting mixture was heated to 110°C for 12h under N 2 atmosphere.
- Step 3 A solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (pyrimidin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (90 mg, 0.15 mmol) in TFA (2 mL) was stirred at 65°C for 3 h. Then the reaction mixture was cooled down to room temperature, the resulting mixture was concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO 3 solution.
- Step 1 To a solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (200 mg, 0.57 mmol) and K 2 CO 3 (157 mg, 1.14 mmol) in MeCN (10 mL) was added (R) -pyrrolidin-3-ol (52 mg, 0.57 mmol) dropwised at 0°C, the resulting was stirred at room temperature for 12 h.
- Step 2 Synthesis of (R) -6- (4- ( (5-fluoro-2- (methoxy-d3) benzamido) methyl) phenyl) -4- (3-hydroxypyrrolidin-1-yl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide
- (R) -6-chloro-4- (3-hydroxypyrrolidin-1-yl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carbo xamide 75 mg, 0.19 mmol
- Intermediate G 87 mg, 0.22 mmol
- Pdppf Pd (dppf) Cl 2 (14 mg, 0.02 mmol)
- Cs 2 CO 3 122 mg, 0.37 mmol
- Step 3 A solution of (R) -6- (4- ( (5-fluoro-2- (methoxy-d3) benzamido) methyl) phenyl) -4- (3-hydroxypyrrolidin-1-yl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (70 mg, 0.11 mmol) in TFA (3 mL) was heated to 65°C for 2 h.
- Step 4 To a solution of (R) -1- (7-carbamoyl-6- (4- ( (5-fluoro-2- (methoxy-d 3 ) benzamido) -methyl) phenyl) -1H-pyrazolo- [4, 3-c] pyridin-4-yl) pyrrolidin-3-yl 2, 2, 2-trifluoroacetate (70 mg, 0.12 mmol) in THF (5 mL) and H 2 O (2 mL) was added NaOH (46 mg, 1.16 mmol) , the reaction mixture was heated to 65°Cfor 1 h.
- Step 1 To a solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (150 mg, 0.43 mmol) in MeCN (10mL) was added pyrrolidine (37 mg, 0.51 mmol) and K 2 CO 3 (118mg, 0.86mmol) at 0°C, the resulting mixture was stirred at room temperature for 12 h.
- Step 2 To a solution of 6-chloro-2- (4-methoxybenzyl) -4- (pyrrolidin-1-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (120, 0.31mmol) and Intermediate A (143 mg, 0.37 mmol) in dioxane (4 mL) and H 2 O (1 mL) was added Pd (dppf) Cl 2 (22 mg, 0.03 mmol) and Cs 2 CO 3 (202 mg, 0.62 mmol) . The resulting mixture was heated to 110°C for 12 h under N 2 atmosphere.
- Step 3 A solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (pyrrolidin-1-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (30 mg, 0.05 mmol) in TFA (3 mL) was heated to 65°C for 2 h. Then the reaction mixture was cooled down to room temperature, the resulting mixture was concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO 3 solution.
- Step 1 To a stirred solution of 1, 1, 1-trifluoropropan-2-ol (71 mg, 0.6 mmol) in DMF (5 mL) was added NaH (25 mg, 0.6 mmol, 60%) at 0°C under N2. The resulting mixture was stirred at 0°C for 0.5 h before 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (200 mg, 0.5 mmol) in DMF (2 mL) was added, the stirring was continued for another 2 h. The reaction mixture was quenched with aq.
- Step 2 To a stirred solution of 6-chloro-2- (4-methoxybenzyl) -4- ( (1, 1, 1-trifluoropropan-2-yl) oxy) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (226 mg, 0.5 mmol) and Intermediate A (245 mg, 0.6 mmol) in dioxane (10 mL) and H 2 O (2 mL) was added Cs 2 CO 3 (487 mg, 1.5 mmol) and Pd(dppf) Cl 2 (38 mg, 0.05 mmol) , the reaction mixture was stirred at 100 °C for 10 h under N 2 atmosphere.
- Step 3 A solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- ( (1, 1, 1-trifluoropropan-2-yl) oxy) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (90 mg, 0.14 mmol) in TFA (5 mL) was stirred at 65°Cfor 2 h. Then the reaction mixture was cooled down to room temperature and concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO 3 .
- Step 1 To a solution of 4-bromo-6-hydroxy-2- (4-methoxybenzyl) -2H-indazole-7-carbonitrile (890 mg, 2.48 mmol) and 2- ⁇ 1, 4-dioxaspiro [4.5] dec-7-en-8-yl ⁇ -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (727 mg, 2.73 mmol) in dioxane (10 mL) and H 2 O (2 mL) was added Pd (dppf) Cl 2 (181 mg, 0.24 mmol) and K 2 CO 3 (1.03 g, 7.45 mmol) under N 2 atmosphere. The reaction mixture was stirred at 100 °C for 3 h.
- Step 2 To a solution of 7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-indazol-6-yl trifluoromethanesulfonate (500 mg, 2.27 mmol) and TEA (0.63 mL, 4.55 mmol) in DCM (5 mL) were added Tf 2 O (0.56 mL, 3.41 mmol) in DCM (5 mL) at -50 °C under N 2 atmosphere. The reaction mixture was heated to -50 °C for 0.5 h. The reaction mixture was washed by sat. NaHCO 3 solution and brine.
- Step 3 To a solution of 7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-indazol-6-yl trifluoromethanesulfonate (500 mg, 0.91 mmol) and 5-fluoro-2-methoxy-N- ⁇ [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl ⁇ benzamide (420 mg, 1.09 mmol) in dioxane (5 mL) and water (1 mL) was added Na 2 CO 3 (192 mg, 1.82 mmol) and Pd(dppf) Cl 2 (66 mg, 0.091 mmol) .
- Step 4 To a solution of N- (4- (7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (500 mg, 0.75 mmol) in MeOH (15 mL) was added Pd/C 10% (50 mg, wt 10%) , the reaction mixture was stirred for 10 h at rt under H 2 (5 Psi) .
- Step 5 A solution of N- (4- (7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] decan-8-yl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (350 mg, 0.53 mmol) in TFA (2 mL) was stirred at 65 °C for 3 h. The reaction mixture was concentrated under reduced pressure, the residue was dissolved with DCM (15 mL) and washed with sat. NaHCO 3 solution (5 mL x 2) .
- Step 6 To a solution of N- ( ⁇ 4- [7-cyano-4- (4-oxocyclohexyl) -1H-indazol-6-yl] phenyl ⁇ methyl) -5-fluoro-2-methoxybenzamide (242 mg, 0.48 mmol) in MeOH (3 mL) was added NaBH 4 (36 mg, 0.97 mmol) at 0 °C , the reaction mixture was stirred at 20 °C for 0.5 h. The mixture was quenched with Sat. NH 4 Cl solution (5 mL) and extracted with DCM (15 mL x 2) .
- Step 7 To a solution of N- ( ⁇ 4- [7-cyano-4- (4-hydroxycyclohexyl) -1H-indazol-6-yl] phenyl ⁇ methyl) -5-fluoro-2-methoxybenzamide (162 mg, 0.32 mmol) in THF (5 mL) and EtOH (5 mL) was added NaOH (2 mL, 4 mmol) and H 2 O 2 (2 mL) at 20 °C , then the mixture was stirred at 20 °C for 16 h.
- Step 1 To a solution of 4-bromo-6-hydroxy-2- (4-methoxybenzyl) -2H-indazole-7-carbonitrile (300 mg, 0.84 mmol) and tert-butyldiphenyl ( (3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) cyclopent-3-en-1-yl) oxy) silane (452 mg, 1.01 mmol) in dioxane (4 mL) and H 2 O (1 mL) was added Pd (dppf) Cl 2 (101 mg, 0.12 mmol) and Na 2 CO 3 (178 mg, 1.68 mmol) , the resulting mixture was stirred at 110°C for 2 h under a nitrogen atmosphere.
- tert-butyldiphenyl ( (3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) cyclopent-3-en-1-yl) oxy) silane (452
- Step 2 To a solution of 4- (cyclopent-1-en-1-yl) -6-hydroxy-1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (380 mg, 0.63 mmol) in DCM (5 mL) was added DIPEA (0.22 mL, 1.26 mmol) and Tf 2 O (231 mg, 0.82 mmol) at -30°C, the reaction mixture was stirred at -30°C for 1h. The resulting mixture was diluted with water (5 mL) and extracted with DCM (10 mL x 3) .
- Step 3 To a solution of 4- (4- ( (tert-butyldiphenylsilyl) oxy) cyclopent-1-en-1-yl) -7-cyano-2- (4-methoxybenzyl) -2H-indazol-6-yl trifluoromethanesulfonate (310 mg, 0.42 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (194 mg, 0.50 mmol) in dioxine (4 mL) and H 2 O (1 mL) was added Pd (dppf) Cl 2 (45 mg, 0.05 mmol) and Na 2 CO 3 (89 mg, 0.84 mmol) , the resulting mixture was stirred at 110 °C for 2 h under N 2 atmosphere.
- Step 4 To a solution of N- (4- (4- (4- ( (tert-butyldiphenylsilyl) oxy) cyclopent-1-en-1-yl) -7-cyano-2- (4-methoxybenzyl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (260 mg, 0.31 mmol) in MeOH (5 mL) was added Pd/C (26 mg, wt10%) , the mixture was stirred at rt for 6 h under H 2 atmosphere.
- Step 5 To a solution of N- (4- (4- (3- ( (tert-butyldiphenylsilyl) oxy) cyclopentyl) -7-cyano-2-(4-methoxybenzyl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (200 mg, 0.24 mmol) in DCM (2 mL) was added TFA (2 mL) dropwised at 0°C, the mixture was stirred at 40°C for 5h. The reaction mixture was concentrated and diluted with sat.
- Step 6 To a solution of N- (4- (7-cyano-4- (2-hydroxycyclopentyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (100 mg, 0.21 mmol) in THF (2 mL) and MeOH (2 mL) was added H 2 O 2 (1 mL) and NaOH solution (0.04 mL, 0.08 mmol) dropwised at 0°C, the mixture was stirred at 60°C for 5 h.
- Step 1 To a solution of 4-bromo-6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (500 mg, 1.2 mmol) and 2- (cyclopent-1-en-1-yl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (289 mg, 1.49 mmol) in dioxane (4 mL) and H 2 O (1 mL) was added Pd (dppf) Cl 2 (101 mg, 0.12 mmol) and Na 2 CO 3 (263 mg, 2.5 mmol) , the reaction mixture was stirred at 110°C for 2 h under N 2 atmosphere.
- Step 2 To a solution of 4- (cyclopent-1-en-1-yl) -6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (360 mg, 0.92 mmol) in THF (2 mL) was added HCl (2 mL, 4 mmol) , the reaction mixture was stirred at 55°C for 2 h. The reaction mixture was diluted with H 2 O (10 mL) , extracted with EtOAc (10 mL x 2) .
- Step 3 To a solution of 4- (cyclopent-1-en-1-yl) -6-hydroxy-1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (280 mg, 0.81 mmol) in DCM (5 mL) was added DIPEA (0.27 mL, 1.62 mmol) then Tf 2 O (0.16 mL, 0.97 mmol) was added dropwised at -30°C. The reaction mixture was stirred at -30°C for 1h. The reaction mixture was diluted with water (5 mL) and extracted with DCM (10 mL x 3) .
- Step 4 To a solution of 7-cyano-4- (cyclopent-1-en-1-yl) -1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yl trifluoromethanesulfonate (260 mg, 0.55 mmol) and 2-methoxy-N- ⁇ [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl ⁇ benzamide (220 mg, 0.6 mmol) in dioxane (4 mL) and H 2 O (1 mL) was added Pd (dppf) Cl 2 (45 mg, 0.05 mmol) and Na 2 CO 3 (115 mg, 1.1 mmol) , the reaction mixture was stirred at 110 °C for 2 h under N 2 atmosphere.
- Step 5 To a solution of N- (4- (7-cyano-4- (cyclopent-1-en-1-yl) -1- (4-methoxybenzyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (250 mg, 0.44 mmol) in THF (5 mL) was added BH 3 .
- Step 6 To a solution of N- (4- (7-cyano-4- (2-hydroxycyclopentyl) -1- (4-methoxybenzyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (30 mg, 0.06 mmol) in DCM (2 mL) was added TFA (2 mL) dropwised at 0°C, the reaction mixture was stirred at 40°C for 5h. The reaction mixture was concentrated and diluted with sat.
- Step 7 To a solution of N- (4- (7-cyano-4- (2-hydroxycyclopentyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (25 mg, 0.04 mmol) in THF (2 mL) and MeOH (2 mL) was added H 2 O 2 (1 mL) and 2N NaOH (0.04 mL, 0.08 mmol) dropwise at 0°C, the reaction mixture was stirred at 60°C for 5 h.
- Step 1 To a stirred solution of methyl 4-bromo-7-methoxy-1H-indazole-6-carboxylate (3.0 g, 10.5mmol) and 2- (cyclopent-1-en-1-yl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (3.0 g, 15.4 mmol) in dioxane (50 mL) and H 2 O (10 mL) at 25°C was added K 2 CO 3 (800 mg, 5.7 mmol) and Pd(dppf) Cl 2 (50 mg, 0.7 mmol) slowly, the reaction mixture was heated to 100°C for 24h under N 2 atmosphere.
- K 2 CO 3 800 mg, 5.7 mmol
- Pd(dppf) Cl 2 50 mg, 0.7 mmol
- Step 2 To a stirred solution of methyl 4- (cyclopent-1-en-1-yl) -7-methoxy-1H-indazole-6-carboxylate (1.4 g, 5.1 mmol) in MeOH (15 mL) was added Pd/C (150 mg, 10%) . The resulting mixture was stirred for 24 h under H 2 atmosphere, filtered and concentrated to give the crude product methyl 4-cyclopentyl-7-methoxy-1H-indazole-6-carboxylate (1.2 g, yield: 85.1%) as a white solid which was used directly without further purification. LC/MS (ESI) m/z: 275 (M+H) + .
- Step 3 To a stirred solution of methyl 4-cyclopentyl-7-methoxy-1H-indazole-6-carboxylate (800 mg, 2.9 mmol) in DCM (20 mL) was added BBr 3 (5 mL, 1M in Tol. ) at -50°C, the mixture was stirred for 1 h at -50°C. The reaction mixture was quenched with MeOH and diluted with water (20 mL) , extracted with EtOAc (15 mL x 3) . The combined organic phase was washed with water and brine.
- Step 4 To a stirred solution of methyl 4-cyclopentyl-7-hydroxy-1H-indazole-6-carboxylate (500mg, 0.3mmol) and Tf 2 O (0.176 mL, 1.0 mmol) in DCM (5 mL) was added TEA (100 mg, 0.9 mmol) at 0 °C and stirred for 10min. The reaction mixture was diluted with water (20 mL) , extracted with EtOAc (15 mL x 3) .
- Step 5 To a stirred solution of methyl 4-cyclopentyl-7- (trifluoromethanesulfonyloxy) -1H-indazole-6-carboxylate (400 mg, 1.0 mmol) and Zn(CN) 2 (350 mg, 2.9 mmol) in DMF (5 mL) at 25°C was added Pd (dppf) Cl 2 (100 mg, 0.1 mmol) slowly, the reaction mixture was stirred at 130°C in microwave reactor for 2h under N 2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (100 mL x 3) .
- Step 6 To a solution of methyl 7-cyano-4-cyclopentyl-1H-indazole-6-carboxylate (230 mg, 0.8 mmol) in MeOH (10 mL) /H 2 O (2 mL) was added LiOH (160 mg, 4 mmol) , the resulting mixture was stirred at r.t. for 2h. Then the pH of mixture was adjusted to 5 with 1N HCl and extracted with EA (10 mL x 3) .
- Step 7 To a stirred solution of 7-cyano-4-cyclopentyl-1H-indazole-6-carboxylic acid (130 mg, 0.5mmol) and DPPA (150 mg, 0.5 mmol) in THF (5 mL) was added TEA (105 mg, 1 mmol) slowly at 25°C. The reaction mixture was stirred at 25°C for 2h under N 2 atmosphere. The mixture was added H 2 O (2 mL) and warmed to 65°C for another 3h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL x 3) .
- Step 8 To a stirred solution of 6-amino-4-cyclopentyl-1H-Indazole-7-carbonitrile (79 mg, 0.3 mmol) and CH 2 I 2 (187 mg, 0.7 mmol) in DCM (2.5 mL) and AcOH (0.4 mL, 7 mmol) at 0°C was added a solution of NaNO 2 (120 mg, 1.7mmol) in H 2 O (2.5 mL) slowly, the reaction mixture was stirred at 0 °C for 5 min. The reaction mixture was diluted with water (10 mL) and extracted with DCM (15 mL x 3) .
- Step 9 synthesis of 4-cyclopentyl-6- (4-phenoxyphenyl) -1H-indazole-7-carbonitrile
- 4-cyclopentyl-6-iodo-1H-indazole-7-carbonitrile (30 mg, 0.1 mmol) and (4-phenoxyphenyl) boronic acid (45 mg, 0.2 mmol) in dioxane (3 mL) and H 2 O (1 mL) at 25 °C were added NaHCO 3 (20 mg, 0.2 mmol) and Pd (dppf) Cl 2 (10 mg, 0.1mmol) slowly, the reaction mixture was heated to 60 °C for 18h under nitrogen atmosphere.
- Step 10 To a stirring solution of 4-cyclopentyl-6- (4-phenoxyphenyl) -1H-indazole-7-carbonitrile (14 mg, 0.1 mmol) and NaOH (40 mg, 1.0 mmol) in THF (2 mL) and MeOH (2 mL) at room temperature was added H 2 O 2 (2 mL) slowly and the reaction mixture was stirred at 65°C for 18h under N 2 atmosphere. The mixture was extracted with EtOAc (10 mL x 3) , the combined organic phase was washed with water and brine. The organic phase was dried over anhydrous Na 2 SO 4 , filtered and concentrated to give the crude product which was purified by prep.
- Step 1 To a solution of 4-bromo-1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile (250 mg, 0.61 mmol) and pyrrolidine (66mg, 0.92mmol) in dioxane (5 mL) was added Pd 2 (dba) 3 (114 mg, 0.14 mmol) , Xant-phos (72 mg, 0.14 mmol) and Cs 2 CO 3 (405 mg, 1.22 mmol) , the reaction mixture was stirred at 110°C for 10 h under a nitrogen atmosphere.
- Step 2 To a solution of 6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazole-7-carbonitrile (180 mg, 0.46 mmol) in THF (5 mL) was added 2N HCl (2 mL) , the reaction mixture was stirred at 55°C for 2 h.
- Step 3 To a solution of 6-hydroxy-1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazole-7-carbonitrile (140 mg, 0.40 mmol) in DCM (5 mL) was added DIPEA (51 mg, 0.40 mmol) , then Tf 2 O (112 mg, 0.402 mmol) was added dropwised at -30°C, the reaction mixture was stirred at -30°C for 1h.
- Step 4 To a solution of 7-cyano-1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazol-6-yl trifluoromethanesulfonate (110 mg, 0.23 mmol) and 5-fluoro-2-methoxy-N- ⁇ [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl ⁇ benzamide (132 mg, 0.34 mmol) in dioxane (4 mL) and H 2 O (1 mL) was added Pd (dppf) Cl 2 .
- Step 5 To a solution of methyl 6-chloro-4- ⁇ 1, 4-dioxaspiro [4.5] dec-7-en-8-yl ⁇ -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (65 mg, 0.14 mmol) in DCM (2 mL) was added TFA (2 mL) , the reaction mixture was stirred at 40 °C for 5 h.
- Step 6 A solution of N- ( ⁇ 4- [7-cyano-4- (pyrrolidin-1-yl) -1H-indazol-6-yl] phenyl ⁇ methyl) -5-fluoro-2-methoxybenzamide (60 mg, 0.13 mmol) in H 2 SO 4 (1 mL) was stirred at 55 °C for 3 h. The reaction mixture was poured into ice water, extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with H 2 O and brine, dried over anhydrous Na 2 SO 4 , concentrated.
- Step 1 To a solution of 4-bromo-1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile (300 mg, 0.75 mmol) and (3R) -pyrrolidin-3-ol (78 mg, 0.90 mmol) in dioxane (5 mL) were added Cs 2 CO 3 (486 mg, 1.49 mmol) , Xant-phos (86 mg, 0.15 mmol) and Pd 2 (dba) 3 (68 mg, 0.075 mmol) under N 2 . The resulting mixture was stirred for overnight at 110°C.
- Step 2 To a solution of (R) -4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile (120 mg, 0.29 mmol) in THF (2 mL) was added 2N HCl (2 mL) under N 2 . The mixture was stirred for 3 h at 65°C.
- Step 3 To a solution of (R) -6-hydroxy-4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -1H-indazole-7-carbonitrile (70 mg, 0.19 mmol) in DCM (5 mL) was added NEt 3 (77.6 mg, 0.77 mmol) and triflic anhydride (108 mg, 0.38 mmol) at -50°C. The mixture was stirred for 10 min.
- Step 4 To a solution of (R) -7-cyano-4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -1H-indazol-6-yl trifluoromethanesulfonate (60 mg, 0.12 mmol) and 5-fluoro-2-methoxy-N- ⁇ [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl ⁇ benzamide (51 mg, 0.13 mmol) in dioxane (4 mL) and H 2 O (1 mL) were added K 2 CO 3 (33 mg, 0.24 mmol) and Pd(dppf) Cl 2 (9 mg, 0.012 mmol) under N 2 .
- Step 5 To a stirred suspension of (R) -N- (4- (7-cyano-4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (40 mg, 0.066 mmol) in TFA (3 mL) . The mixture was stirred at 65 °C for 3 hr.
- Step 6 To a stirred suspension of (R) -N- (4- (7-cyano-4- (3-hydroxypyrrolidin-1-yl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (30 mg, 0.062 mmol) in con H 2 SO 4 (1 mL) . The mixture was stirred at 60 °C for 1h. After cooled down to rt, the reaction mixture was diluted with water (20 mL) , extracted with EtOAc (50 mL x 3) . The combined organic phase was washed by brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated.
- Step 1 To a solution of 4-bromo-1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile (250 mg, 0.61 mmol) and (R) -2-methylpyrrolidine (78 mg, 0.92 mmol) in dioxane (5 mL) was added Pd 2 (dba) 3 (114 mg, 0.14 mmol) , Xant-phos (72 mg, 0.14 mmol) and Cs 2 CO 3 (405 mg, 1.22 mmol) , the reaction mixture was stirred at 110°C for 10 h under a nitrogen atmosphere.
- Step 2 To a solution of (R) -1- (4-methoxybenzyl) -6- (methoxymethoxy) -4- (2-methylpyrrolidin-1-yl) -1H-indazole-7-carbonitrile (230 mg, 0.57 mmol) in THF (5 mL) was added 2N HCl (2 mL) , the reaction mixture was stirred at 55°C for 2 h.
- Step 3 To a solution of (R) -6-hydroxy-1- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -1H-indazole-7-carbonitrile (200 mg, 0.55 mmol) in DMF (5 mL) was added NCS (74 mg, 0.55 mmol) at -20°C, the mixture was stirred at rt for 8 h.
- Step 4 To a solution of (R) -5-chloro-6-hydroxy-2- (4-methoxybenzyl) -4-(2-methylpyrrolidin-1-yl) -2H-indazole-7-carbonitrile (120 mg, 0.30 mmol) in DCM (5 mL) was added DIPEA (78 mg, 0.60 mmol) , then Tf 2 O (0.06 mL, 0.36 mmol) was added dropwise at -30°C, the mixture was stirred at-30°C for 1h.
- Step 6 To a solution of (R) -N- (4- (5-chloro-7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (100 mg , 0.16 mmol) in DCM (2 mL) was added TFA (2 mL) , the reaction mixture was stirred at 40 °C for 5 h.
- Step 7 A solution of (R) -N- (4- (5-chloro-7-cyano-4- (2-methylpyrrolidin-1-yl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (65 mg, 0.13 mmol) in H 2 SO 4 (1 mL) was stirred at 55 °C for 3 h. The reaction mixture was poured into ice water, extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with H 2 O and brine, dried over anhydrous Na 2 SO 4 , concentrated.
- Step 1 To a solution of 4-bromo-6-hydroxy-2- (4-methoxybenzyl) -2H-indazole-7-carbonitrile (400 mg, 1.11 mmol) and (2R) -2-methylpyrrolidine (114 mg, 1.34 mmol) in dioxane (5 mL) were added Cs 2 CO 3 (727 mg, 2.23 mmol) , SPhos (45 mg, 0.11 mmol) and Pd 2 (dba) 3 (102 mg, 0.11 mmol) under N 2 . The resulting mixture was stirred for 16 h at 110°C.
- Step 2 To a solution of (R) -6-hydroxy-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazole-7-carbonitrile (437 mg, 1.20 mmol) in DCM (10 mL) was added DIPEA (0.4 mL, 2.41 mmol) and triflic anhydride (0.24 mL, 1.40 mmol) at -30°C. The mixture was stirred for 30 min at this temperature.
- Step 3 To a solution of (R) -7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl trifluoromethanesulfonate (596 mg, 1.20 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (510 mg, 1.32 mmol) in dioxane (10 mL) and H 2 O (2 mL) were added Cs 2 CO 3 (785 mg, 2.41 mmol) and Pd (dppf) Cl 2 (88 mg, 0.12 mmol) under N 2 .
- Step 4 A solution (R) -N- (4- (7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (342 mg, 0.56 mmol) in TFA (5 mL) was stirred at 65 °C for 3 h. Then the reaction mixture was cooled down to room temperature and concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO 3 .
- Step 5 A solution (R) -N- (4- (7-cyano-4- (2-methylpyrrolidin-1-yl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (150 mg, 0.31 mmol) in con H 2 SO 4 (3 mL) was stirred at 60 °C for 1h. After cooled down to rt, the reaction mixture was poured into ice-water (20 mL) , extracted with EtOAc (20 mL x 3) . The combined organic phase was washed by brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated.
- Step 1 To a solution of 2-fluoro-6-hydroxybenzonitrile (2 g, 14.6 mmol) in DCM (20 mL) were added MOMCl (1.41 g, 17.5 mmol) and DIPEA (2.8 g, 21.9 mmol) , the reaction mixture was stirred at room temperature for 2 h. The reaction was diluted with DCM (20 mL) and saturated Na 2 CO 3 solution. The organic layer was collected, washed with sat.
- Step 2 To a solution of 2-fluoro-6- (methoxymethoxy) benzonitrile (2.5 g, 13.8 mmol) in THF (20 mL) was added LDA (10.4 mL, 20.7 mmol) at -78 °C under N 2 . The reaction was stirred at the same temperature for 1 h before DMF (1.2 g, 16.7 mmol) was added, the resulting mixture was kept at -78 °C for about another 1 h. The reaction was quenched by sat. NH 4 Cl solution, extracted with EtOAc (20 mL x 3) .
- Step 3 To a solution of 2-fluoro-3-formyl-6- (methoxymethoxy) benzonitrile (400 mg, 1.9 mmol) in EtOH (10 mL) was added hydrazine (721 mg, 19.1 mmol) . The reaction mixture was stirred at 85°C for 12h. The resulting yellow solid was collected by filtration. The filter cake was washed with MeCN and then dried to give the crude product 6- (methoxymethoxy) -1H-indazole-7-carbonitrile (360 mg, yield: 92.7%) as a yellow solid which was used in next step directly without further purification.
- Step 4 To a solution of 6- (methoxymethoxy) -1H-indazole-7-carbonitrile (360 mg, 1.8 mmol) in DMF (10 mL) were added PMBCl (0.3 mL, 2.1 mmol) and Cs 2 CO 3 (808.0 mg, 2.5 mmol) , and the reaction was stirred at 60 °C for 1.5h. The reaction mixture was diluted with EtOAc (30 mL) . The mixture was washed with sat. LiCl solution, water and brine.
- Step 6 To a solution of 6-hydroxy-1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonit-rile (147 mg, 0.5 mmol) in DCM (10 mL) were added TEA (80 mg, 0.8 mmol) and Tf 2 O (178 mg, 0.6 mmol) , and the reaction mixture was stirred at room temperature for 1h.
- Step 7 To a solution of 7-cyano-1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yltrifluoromethanesulfonate (167 mg, 0.4 mmol) and 2-methoxy-N- ⁇ [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl ⁇ benzamide (164 mg, 0.45 mmol) in dioxane (10 mL) and H 2 O (2 mL) were added K 2 CO 3 (112 mg, 0.8 mmol) and Pd (dppf) Cl 2 (29 mg, 0.04 mmol) , the reaction mixture was stirred at 100 °C for 2h under N 2 atmosphere.
- Step 8 A solution of N- [ (4- ⁇ 7-cyano-1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yl ⁇ phenyl) methyl] -2-methoxybenzamide (120 mg, 0.24 mmol) in TFA (2 mL) was heated to 75°C for 1 h. The reaction was concentrated under reduced pressure, the residue was dissolved in EtOAc (15 mL) and washed by sat. NaHCO 3 solution (5 mL x 3) .
- Step 9 To a solution of N- ⁇ [4- (7-cyano-1H-indazol-6-yl) phenyl] methyl ⁇ -2-methoxybenzamide (98 mg, 0.26 mmol) in EtOH (2 mL) and THF (2 mL) were added NaOH (20 mg, 0.5 mmol) and H 2 O 2 (1 mL) , and the reaction mixture was stirred at 60°C for 2 h. The reaction was diluted with EtOAc (20 mL) .
- Step 1 To a stirred solution of 4, 6-dichloro-1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (80 mg, 0.23 mmol) and tert-butyl 4-aminobutanoate (50 mg, 0.31 mmol) in DMF (2 mL) was added TEA (40 mg, 0.40 mmol) at 25°C. The resulting mixture was stirred at rt for 18 h.
- Step 2 To a stirred solution of tert-butyl 4- ( ⁇ 7-carbamoyl-6-chloro-1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridin-4-yl ⁇ amino) butanoate (90 mg, 0.19 mmol) and 5-fluoro-2-methoxy-N- ⁇ [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl ⁇ benzamide (100 mg, 0.26 mmol) in 1, 4-dioxane (5 mL) and H 2 O (1mL) at 25°C was added Pd (dppf) Cl 2 (30 mg, 0.041 mmol) and K 2 CO 3 (100 mg, 0.724 mmol) , the reaction mixture was stirred at 110°C for 18h under N 2 atmosphere.
- Step 3 To a stirred solution of tert-butyl 4- ⁇ [7-carbamoyl-6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridin-4-yl] amino ⁇ butanoate (90 mg, 0.13 mmol) in DCM (5 mL) at 25°C was added TFA (3 mL) , the reaction mixture was stirred at 50°C for 18h.
- Step 4 To a stirred solution of4- ⁇ [7-carbamoyl-6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -1H-pyrazolo [4, 3-c] pyridin-4-yl] amino ⁇ butanoic acid (45 mg, 0.1 mmol) and HATU (50 mg, 0.13 mmol) in DMF (2 mL) was added DIPEA (25 mg, 0.19 mmol) at 25°C, the reaction mixture was heated to 50°C for 18h.
- DIPEA 25 mg, 0.19 mmol
- Step 2 To a solution of tert-butyl N- [ (tert-butoxy) carbonyl] -N- (2, 6-dichloropyridin-4-yl) carbamate (55.0 g, 151.4 mmol) in THF (300 mL) was added LDA (227 mL, 454.2 mmol) at -78°C under N 2 . The mixture was stirred for 30 min until the starting material was consumed completely. The reaction mixture was warmed to room temperature and quenched with sat. NH 4 Cl solution, extracted with EtOAc (100 mL x 3) .
- Step 3 To a solution of tert-butyl 4- (tert-butoxycarbonylamino) -2, 6-dichloronicotinate (2.0 g, 5.51 mmol) and 2-cyclopentenyl-4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan (0.96 g, 4.96 mmol) in dioxane (15 mL) and water (3 mL) were added K 2 CO 3 (1.52 g, 11.01 mmol) and Pd (dppf) Cl 2 (0.2 g, 0.28 mmol) under N 2 . The resulting mixture was stirred for 2 h at 60°C.
- Step 4 To a solution of tert-butyl 4- (tert-butoxycarbonylamino) -2-chloro-6-cyclopentenylnicotinate (1.1 g, 2.8 mmol) in EtOAc (20 mL) was added Pt/C (50 mg) . The mixture was stirred at rt for 4h under H 2 atmosphere.
- Step 5 To a solution of tert-butyl 4- ⁇ [ (tert-butoxy) carbonyl] amino ⁇ -2-chloro-6-cyclopentylpyridine-3-carboxylate (540 mg, 1.3 mmol) in DCM (5 mL) was added TFA (5 mL) under N 2 . The mixture was stirred for 3 h. The solvent was concentrated under reduced pressure to give the crude product 4-amino-2-chloro-6-cyclopentylpyridine-3-carboxylicacid (280 mg, yield: 89.7 %) as a yellow solid which was used directly without further purification. LC/MS (ESI) m/z: 241 (M+H) +
- Step 8 To a solution of methyl 4-amino-5-bromo-2-chloro-6-cyclopentylpyridine-3-carboxylate (200 mg, 0.6 mmol) and 2-methoxy-N- ⁇ [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl ⁇ benzamide (220 mg, 0.6 mmol) in dioxane (6 mL) and H 2 O (2 mL) were added K 2 CO 3 (249 mg, 1.8 mmol) and Pd (PPh 3 ) 4 (35 mg, 0.030 mmol) under N 2 . The reaction mixture was heated to 80°C for 10 h.
- Step 9 To a solution of methyl 4-amino-5-bromo-6-cyclopentyl-2- (4- ( (2-methoxybenzamido) methyl) phenyl) nicotinate (210 mg, 0.390 mmol) and 2- [2-ethoxyethenyl] -4, 4, 5, 5-tetramethyl-1, 3-dioxolane (78 mg, 0.4 mmol) in 1, 4-dioxane (8 mL) and H 2 O (2 mL) were added K 2 CO 3 (161 mg, 1.2 mmol) and Pd (PPh 3 ) 4 (45 mg, 0.04 mmol) under N 2 . The reaction mixture was heated to 60°C for 10 h.
- Step 10 A solution of methyl 4-amino-6-cyclopentyl-2- (4- ( (2-methoxybenzamido) methyl) phenyl) -5- (2-methoxyvinyl) nicotinate (140 mg, 0.3 mmol) in AcOH (5 mL) was heated to 100 °C in microwave reactor. Then the reaction mixture was concentrated, diluted with EtOAc (20 mL) , washed with water and brine.
- Step 11 To a solution of methyl 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxylate (100 mg, 0.206 mmol) in THF (5 mL) was added ammonia solution (5 mL, 28%in water) . The mixture was stirred at 100 °C for 12 h in a sealed tank.
- Step 1 To a solution of methyl 4-amino-5-bromo-2-chloro-6-cyclopentylnicotinate (500 mg, 1.51 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (583 mg, 1.51 mmol) in dioxane (15 mL) and H 2 O (3 mL) were added K 2 CO 3 (417 mg, 3.02 mmol) and Pd (PPh 3 ) 4 (173 mg, 0.15 mmol) under N 2 . The reaction mixture was heated to 80°C for 10 h. The reaction mixture was cooled to r.t.
- Step 2 To a solution of methyl 4-amino-5-bromo-6-cyclopentyl-2- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) nicotinate (500 mg, 0.90 mmol) and (E) -2- (2-ethoxyvinyl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (179 mg, 0.90 mmol) in 1, 4-dioxane (8 mL) and H 2 O (2 mL) were added K 2 CO 3 (248 mg, 1.80 mmol) and Pd (PPh 3 ) 4 (104 mg, 0.09 mmol) under N 2 .
- Step 3 A solution of 4-amino-6-cyclopentyl-5- (2-ethoxyvinyl) -2- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) nicotinate (430 mg, 0.79 mmol) in AcOH (5 mL) was heated to 100 °C in microwave reactor. Then the reaction mixture was concentrated, diluted with EtOAc (20 mL) , washed with water and brine.
- Step 4 To a stirred solution of methyl 4-cyclopentyl-6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxylate (230 mg, 0.46 mmol) in THF (2 mL) and MeOH (2 mL) was added NaOH (184 mg, 4.6 mmol) . The reaction mixture was stirred at 50°C for 18 h under N 2 atmosphere.
- Step 5 To a stirred solution of 4-cyclopentyl-6- (4- ⁇ [ (5-fluoro-2-methoxyphenyl) formamido] methyl ⁇ phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxylic acid (200 mg, 0.41 mmol) in DMF (5 mL) at 25°C was added TEA (124 mg, 1.23 mmol) and HATU (187 mg, 0.49 mmol) slowly, the reaction mixture was stirred at 25°C for 1 h under NH 3 atmosphere.
- Step 6 To a solution of 4-cyclopentyl-6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxamide (90 mg, 0.19 mmol) in 3 mL of AcOH and 3 mL of t-BuOH was added PyHBr3 (177 mg, 0.56 mmol) was stirred for overnight under N 2 . Then the Zn (121 mg, 1.85 mmol) , AcOH (3 ml) was added and stirred for 1 hour. The reaction mixture was concentrated in vacuum to remove most of solvent. The residue was poured into water (6 mL) and extracted with EtOAc (6 mL) .
- 0.1 ⁇ L diluted compounds were mixed with 5 ⁇ L enzyme working solution (Signalchem, Cat#B10-10H-10) by Echo (Labcyte, Cat#550) , and subsequently mixed with 5 ⁇ L substrate working solution (Sigma, Cat#P61-58) into 384-well assay plate (Perkin Elmer, Cat#6008280) to initiate the reaction. After incubation at 25°C for 60 min, 5 ⁇ L ADP Glo reagent (Promega, Cat#V9102) was added and incubated at 25°C for 60 min to terminate the reaction.
- kinase detection reagent Promega, Cat#V9102
- IC50 values were calculated by fitting %Inhibition values and log of compound concentrations to nonlinear regression (dose response –variable slope) with GraphPad Prism 6.0.
- Enzyme assay using recombinant form of wild type MEK1 was performed as follows using an ADP-Glo methodology.
- the compounds prepared in the above Examples were serially diluted 1: 3 in DMSO for 10-point dose IC50 mode in duplicate.
- 0.1 ⁇ L diluted compounds were mixed with 5 ⁇ L enzyme working solution (Signalchem, Cat#M02-10G) by Echo (Labcyte, Cat#550) , and subsequently mixed with 5 ⁇ L substrate working solution (Signalchem, Cat#M29-14G) into 384-well assay plate (Perkin Elmer, Cat#6008280) to initiate the reaction. After incubation at 25°C for 60 min, 5 ⁇ L ADP Glo reagent (Promega, Cat#V9102) was added and incubated at 25°C for 60 min to terminate the reaction.
- IC50 values were calculated by fitting %Inhibition values and log of compound concentrations to nonlinear regression (dose response –variable slope) with GraphPad Prism 6.0.
- Enzyme assay using recombinant form of wild type EGFR was performed as follows using a homogenous time-resolved fluorescence (HTRF) methodology.
- the compounds prepared in the above Examples were serially diluted 1: 3 in DMSO for 10-point dose IC50 mode in duplicate.
- EGFR kinase activity was tested in 1x kinase buffer (HTRF KinEASE-TK kit, Cisbio, Cat#62TK0PEC) , with 5 mM MgCl 2 , 1 mM MnCl 2 and 1 mM DTT.
- 0.1 ⁇ L diluted compounds were mixed with 5 ⁇ L 2x EGFR enzyme solution (Signalchem, Cat#E10-11G-10) by Echo (Labcyte, Cat#550) , and incubated at 25°C for 10 min. Subsequent 5 ⁇ L TK-substrate-biotin (Cisbio, 61TK0BLE) and ATP mixture substrate were added (Promega, Cat#V910B) into 384-well assay plate (Labcyte, P-05525-BC) to initiate the reaction.
- OCI-Ly10 human DLBCL (diffuse large B cell lymphoma) cell line (Cobioer Biosciences, CBP60558) which is dependent on NF ⁇ B signaling, was performed as follows using a Celltiter-Glo methodology.
- the compounds prepared in the above Examples were serially diluted 1: 4 in DMSO for 10-point dose IC50 mode in duplicate.
- OCI-Ly10 cells were cultured using IMDM medium (Gibco, Cat#12440-053) supplemented with 10%FBS (Invitrogen, Cat#10099141) and 1%Penicillin-streptomycin (Gibco, Cat#15140-122) in suspension in T75 flasks (Corning, Cat#430641) .
- OCI-Ly10 cells were seeded at a density of 8,000 cells/well into 96-well plates (Corning, Cat#3603) . 5 ⁇ L diluted compounds were then added into the cell plate and incubated for 72h at 37°C in a CO 2 incubator (ThermoFisher, Cat#371) . After 72h of compound treatment, 100 ⁇ L cell supernatant was removed and 70 ⁇ LCelltiter-Glo buffer (Promega, Cat#G7573) was added into the cell plate. After incubation at 25°Cfor 20 min, luminescence signal was measured on Envision (Perkin Elmer, Envision 2104) . IC50 values were calculated by fitting %Inhibition values and log of compound concentrations to nonlinear regression (dose response –variable slope) with GraphPad Prism 6.0.
- SIPPR Planned Parenthood Research
- the animals were housed in a room with a temperature maintained at around 20-26 °C and with a relative humidity of 40% ⁇ 70%under a 12: 12 h light–dark cycle, with free access to food and water. All procedures involving animals complied with the Laboratory Animal Management Principles of China. Animal study procedures were reviewed and approved by the Institutional Animal Care and Use Committee.
- the ICR mice received intravenous (IV; 1 mg/kg) or oral gavage (PO; 10 mg/kg) of test compounds after overnight fasting. Food was given 4 h post dose.
- IV intravenous
- PO oral gavage
- the OCI-LY10 tumor cell line will be maintained in vitro as suspension culture in IMDM medium modified supplemented with 20%heat inactivated fetal bovine serum at 37°C in an atmosphere of 5%CO 2 in air.
- the tumor cells will be routinely sub-cultured, not to exceed 4-5 passages.
- the cells growing in an exponential growth phase will be harvested and counted for tumor inoculation.
- Each mouse will be inoculated subcutaneously on the right flank with OCI-LY10 tumor cells (1 x 10 7 ) in 0.1 ml of IMDM Medium and High Concentration Matrigel mixture (1: 1 ratio) for tumor development.
- mice Based on the tumor volume and body weight, mice will be randomly assigned to respective groups such that the average starting tumor size and body weight is the same for each treatment group. and treatments will start when the mean tumor volume reaches about 120-180 mm 3 .
- the measurement of tumor size will be conducted twice a week with a caliper and recorded.
- the TVs are used for calculation of the tumor growth inhibition and tumor growth delay.
- TGI tumor growth inhibition
- %TGI [1- (TreatedTVfinal-TreatedVTinitial) / (VehicleTVfinal-VehicleTVinitial) ] *100
- the “TVfinal” and “TVinitial” are the mean tumor volumes on the final day and initial day.
Abstract
The present disclosure relates to a compound of formula I, wherein the variables are as defined in the specification; pharmaceutical compositions containing them, methods for preparing them, and their use.
Description
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the priority benefit of the International Application No. PCT/CN2021/089684, filed April 25, 2021; the content of which is herein incorporated by reference in its entirety.
The present disclosure provides heteroaromatic carboxamide compounds that inhibit Bruton’s Tyrosine kinase, BTK. The disclosure also provides processes for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of using these compounds to treat BTK-associated disease or disorder.
Bruton’s tyrosine kinase (BTK) , a non-receptor tyrosine kinase belonging to the Tec family of kinases, is broadly expressed in hematopoietic cells, with the exception of T cells. BTK plays a crucial role in signaling through the B-cell antigen receptor (BCR) and the Fcγ receptor (FcγR) in B cells and myeloid cells, respectively, and is involved in all aspects of B-cell development, including proliferation, maturation, differentiation, apoptosis and cell migration. Aberrant BTK expression and/or activity have been demonstrated in different cancers and in autoimmune disorders.
Significant advances have been made in developing BTK inhibitors as therapeutics towards hematologic malignancies as well as chronic inflammatory diseases. In fact, first generation BTK inhibitor ibrutinib (PCI-32765, Imbruvica) has been successful in treating B-cell malignancies and is approved for chronic lymphocytic leukemia (CLL) , relapsed or refractory mantle-cell lymphoma (MCL) and
macroglobulinemia (WM) . However, therapy-discontinuation occurred in up to 30%of patients with ibrutinib, which leads to a poor clinical outcome. Although second-generation BTK inibhitors such as acalabrutinib, zanubrutinib, and tirabrutinib which offer greater BTK selectivity may limit off-target toxicity, all of them are irreversible BTK inhibitors. The compounds react covalent and irreversibly with cysteine-481 in the ATP binding site of BTK, and therefore do not overcome common mechanisms of ibrutinib resistance that occurred in 30%of patient after treatment last more than 12 month. Notably, reversible BTK inhibitors including vecabrutinib, ARQ-531and LOXO-305, that do not rely on cysteine-481 for interactions with BTK, inhibit BTK activities in the presence of C481S mutation, and clinical evidence is starting to emerge to show that they can overcome resistance toward irreversible BTK inhibitors. Additionally, currently there is no approved BTK-targeted therapy for chronic autoimmune indications. This slow progress in the autoimmune/inflammatory arena may, at least in part, be due to the stringent safety requirements these indications indication such as RA and SLE demand. Therefore, the efforts continue in the search of reversible BTK inhibitors with better efficacy and less toxicities.
SUMMARY OF THE INVENTION
The compounds above as well as the active compounds disclosed in the context of the present disclosure (including the compounds of formula I, and the specific compounds) or their stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof are collectively called “the compound of the present invention” or “the compound of the present disclosure” .
The present disclosure provides a compound of formula I:
or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
X
1, X
2 and X
3 are each independently CR’ or N; R’ is selected from a group consisting of H, C
1-6alkyl, halo and oxo;
R
1 is selected from a group consisting of H, deuterium, 3-10 membered heterocyclyl, 5-12 membered heteroaryl, C
3-10cycloalkyl, C
3-10cycloalkyl-O-, C
3-10cycloalkenyl, 3-10 membered heterocyclyl-O-, C
6-10aryl, C
1-6alkyl, C
2-6 alkenyl, C
2-6 alkynyl, C
1-6alkoxyl, -C
1-6alkyl-O-C
1-6alkyl, -NH
2, -NH (C
1-6alkyl) and N (C
1-6alkyl)
2, wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of deuterium, halo, -OH, -CN, -NH
2, -NH (C
1-6alkyl) and -NH (C
1-6alkyl)
2; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -SH, -NH
2, oxo, halo, -CN, C
1-6alkyl, C
2-6alkenyl, C
2-6alkynyl, C
1-6haloalkyl, C
1-6alkoxyl, C
1-6haloalkoxyl, -C
1-6alkyl-O-C
1-6alkyl, -NH (C
1-6alkyl) , -N (C
1-6alkyl)
2, C
1-6alkyl-S-, -C
1-6alkyl-OH, C
3-6cycloalkyl, C
3-6halocycloalkyl, -C (O) C
1-6alkyl, -S (O)
nC
1-6alkyl, -C (O) OH, -C (O) OC
1-6alkyl, -C (O) NH
2, -C (O) NH (C
1-6alkyl) , -C (O) N (C
1-6alkyl)
2, -NHC (O) C
1-6alkyl, and 3-6 membered heterocyclyl optionally substituted with oxo;
Ar is -C
6-10aryl-Y-R
2, or -5-6 membered heteroaryl-Y-R
2, wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from a group consisting of halo, C
1-6alkoxyl and C
1-6alkyl;
Y is selected from a group consisting of O, S, - (CH
2)
m-NH-C (O) -, - (CH
2)
m-NH-S (O)
n-, - (CH
2)
m-N (C
1-6alkyl) -C (O) -, - (CH
2)
m-N (C
1-6alkyl) -S (O)
n-, - (CH
2)
m-C (O) -NH-, - (CH
2)
m-S (O)
n-NH-, - (CH
2)
m-C (O) -N (C
1-6alkyl) -and - (CH
2)
m-S (O)
n-N (C
1-6alkyl) -;
R
2 is C
6-10aryl or 5-10 membered heteroaryl, optionally substituted with one or more substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl, -OH, -SH, -CN, -NH
2, -NH (C
1-6alkyl) , -NH (C
1-6alkyl)
2, C
1-6alkyl-S-, -C
1-6alkyl-O-C
1-6alkyl, -C (O) C
1-6alkyl, -C (O) OH, -C (O) OC
1-6alkyl, -C (O) NH
2, -C (O) NH (C
1-6alkyl) , -C (O) N (C
1-6alkyl)
2, and -NHC (O) C
1-6alkyl;
m is 0 or 1; and
n is 1 or 2.
The compounds or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof above as well as the active compounds disclosed in the context of the present invention and covered by the scope of the compounds above are collectively called “the compound of the present invention” or “a compound of the present invention” .
The present disclosure also provides the compound of the present invention for use as a medicament.
The present disclosure also provides the compound of the present invention for use in the treatment or prevention of a BTK-associated disease or disorder.
The present disclosure also provides a pharmaceutical composition, comprising the compound of the present invention, and optionally a pharmaceutically acceptable carrier.
The present disclosure also provides a kit for treating or preventing a BTK-associated disease or disorder, comprising a pharmaceutical composition of the present disclosure and an instruction for use.
The present disclosure also provides the use of the compound of the present invention for treatment or prevention of a BTK-associated disease or disorder.
The present disclosure also provides the use of the compound of the present invention in the manufacture of a medicament for treatment or prevention of a BTK-associated disease or disorder.
The present disclosure also provides a method of in vivo or in vitro inhibiting the activity of BTK, comprising contacting an effective amount of the compound of the present invention with BTK.
The present disclosure also provides a method of treating or preventing a BTK-associated disease or disorder, comprising administering to the subject in need thereof an effective amount of the compound of the present invention.
The present disclosure also provides a combination, comprising the compound of the present invention and at least one additional therapeutic agent.
The present disclosure also provides a process for the preparation of the compound of the present invention, and itermediates for preparing the compound of the present invention.
Embodiments of the Disclosure
Embodiment 1. A compound of formula I:
or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
X
1, X
2 and X
3 are each independently CR’ or N; R’ is selected from a group consisting of H, C
1-6alkyl, halo and oxo;
R
1 is selected from a group consisting of H, deuterium, 3-10 membered heterocyclyl, 5-12 membered heteroaryl, C
3-10cycloalkyl, C
3-10cycloalkyl-O-, C
3-10cycloalkenyl, 3-10 membered heterocyclyl-O-, C
6-10aryl, C
1-6alkyl, C
2-6 alkenyl, C
2-6 alkynyl, C
1-6alkoxyl, -C
1-6alkyl-O-C
1-6alkyl, -NH
2, -NH (C
1-6alkyl) and N (C
1-6alkyl)
2, wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of deuterium, halo, -OH, -CN, -NH
2, -NH (C
1-6alkyl) and -NH (C
1-6alkyl)
2; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -SH, -NH
2, oxo, halo, -CN, C
1-6alkyl, C
2-6alkenyl, C
2-6alkynyl, C
1-6haloalkyl, C
1-6alkoxyl, C
1-6haloalkoxyl, -C
1-6alkyl-O-C
1-6alkyl, -NH (C
1-6alkyl) , -N (C
1-6alkyl)
2, C
1-6alkyl-S-, -C
1-6alkyl-OH, C
3-6cycloalkyl, C
3-6halocycloalkyl, -C (O) C
1-6alkyl, -S (O)
nC
1-6alkyl, -C (O) OH, -C (O) OC
1-6alkyl, -C (O) NH
2, -C (O) NH (C
1-6alkyl) , -C (O) N (C
1-6alkyl)
2, -NHC (O) C
1-6alkyl, and 3-6 membered heterocyclyl optionally substituted with oxo;
Ar is -C
6-10aryl-Y-R
2, or -5-6 membered heteroaryl-Y-R
2, wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from a group consisting of halo, C
1-6alkoxyl and C
1-6alkyl;
Y is selected from a group consisting of O, S, - (CH
2)
m-NH-C (O) -, - (CH
2)
m-NH-S (O)
n-, - (CH
2)
m-N (C
1-6alkyl) -C (O) -, - (CH
2)
m-N (C
1-6alkyl) -S (O)
n-, - (CH
2)
m-C (O) -NH-, - (CH
2)
m-S (O)
n-NH-, - (CH
2)
m-C (O) -N (C
1-6alkyl) -and - (CH
2)
m-S (O)
n-N (C
1-6alkyl) -;
R
2 is C
6-10aryl or 5-10 membered heteroaryl, optionally substituted with one or more substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl, -OH, -SH, -CN, -NH
2, -NH (C
1-6alkyl) , -NH (C
1-6alkyl)
2, C
1-6alkyl-S-, -C
1-6alkyl-O-C
1-6alkyl, -C (O) C
1-6alkyl, -C (O) OH, -C (O) OC
1-6alkyl, -C (O) NH
2, -C (O) NH (C
1-6alkyl) , -C (O) N (C
1-6alkyl)
2, and -NHC (O) C
1-6alkyl;
m is 0 or 1; and
n is 1 or 2.
Embodiment 2. The compound of embodiment 1 or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X
1 and X
3 are each independently CR’ or N; R’ is selected from a group consisting of H, C
1-6alkyl, halo and oxo.
Embodiment 3. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X
2 is CH.
Embodiment 4. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Y is selected from a group consisting of O, S, - (CH
2)
m-NH-C (O) -or - (CH
2)
m-C (O) -NH-.
Embodiment 5. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
2 is C
6-10aryl or 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl, -OH, -CN and -NH
2.
Embodiment 6. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
X
1 and X
3 are each independently CR’ or N; R’ is selected from a group consisting of H, C
1-6alkyl, halo and oxo;
X
2 is CH;
R
1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, C
3-8cycloalkyl, C
3-8cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C
6-10aryl, C
1-6alkyl, C
1-6alkoxyl, -NH
2, -NH (C
1-6alkyl) and N (C
1-6alkyl)
2, wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo, -OH, -CN and -NH
2; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -NH
2, oxo, halo, -CN, C
1-6alkyl, C
1-6haloalkyl, C
1-6alkoxyl, C
1-6haloalkoxyl, -NH (C
1-6alkyl) , -N (C
1-6alkyl)
2, C
1-6alkyl-S-, -C
1-6alkyl-OH, C
3-6cycloalkyl and C
3-6halocycloalkyl;
Ar is -C
6-10aryl-Y-R
2 or -5-6 membered heteroaryl-Y-R
2, wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from a group consisting of halo, C
1-6alkoxyl and C
1-6alkyl;
Y is selected from a group consisting of O, S, - (CH
2)
m-NH-C (O) -and - (CH
2)
m-C (O) -NH-;
R
2 is C
6-10aryl or 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl, -OH, -CN and -NH
2;
m is 0 or 1.
Embodiment 7. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X
1 is CR’ or N; R’ is H or halo.
Embodiment 8. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X
3 is selected from a group consisting of CH, C (=O) and N.
Embodiment 9. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
X
1 is CR’ or N; R’ is H or halo;
X
2 is CH;
X
3 is selected from a group consisting of CH, C (=O) or N;
R
1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, C
3-8cycloalkyl, C
3-8cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C
6-10aryl, C
1-6alkyl, C
1-6alkoxyl -NH
2, -NH (C
1-6alkyl) and N (C
1-6alkyl)
2, wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo, -OH, -CN and -NH
2; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -NH
2, oxo, halo, -CN, C
1-6alkyl, C
1-6haloalkyl, C
1-6alkoxyl, C
1-6haloalkoxyl, -NH (C
1-6alkyl) , -N (C
1-6alkyl)
2, C
1-6alkyl-S-and -C
1-6alkyl-OH;
Ar is -C
6-10aryl-Y-R
2, or -5-6 membered heteroaryl-Y-R
2, wherein each aryl or heteroaryl is optionally substituted with one or more halo;
Y is selected from a group consisting of O, S, - (CH
2)
m-NH-C (O) -and - (CH
2)
m-C (O) -NH-;
R
2 is C
6-10aryl or 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl, -OH, -CN and -NH
2; and
m is 0 or 1.
Embodiment 10. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, C
3-8cycloalkyl, C
3-8cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C
6-10aryl, C
1-6alkyl, C
1-6alkoxyl and N (C
1-6alkyl)
2, wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo, -OH and -CN; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -NH
2, oxo, halo, -CN, C
1-6alkyl, C
1-6haloalkyl, C
1-6alkoxyl, C
1-6haloalkoxyl and -C
1-6alkyl-OH;
Preferably, R
1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-10 membered heteroaryl, C
3-8cycloalkyl, C
3-8cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C
6-10aryl, C
1-6alkyl, C
1-6alkoxyl and N (C
1-6alkyl)
2, wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, oxo, halo, -CN, C
1-6alkyl, C
1-6haloalkyl, C
1-6alkoxyl, C
1-6haloalkoxyl and -C
1-6alkyl-OH.
Embodiment 11. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is -C
6-10aryl-Y-R
2, wherein said aryl is optionally substituted with one or more halo.
Embodiment 12. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is -5-6 membered heteroaryl-Y-R
2, wherein said heteroaryl is optionally substituted with one or more halo.
Embodiment 13. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
2 is C
6-10aryl or 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl and -OH.
Embodiment 14. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
2 is 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl and -OH.
Embodiment 15. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
2 is phenyl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl and -OH.
Embodiment 16. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
2 is phenyl or 6-membered heteroaryl, optionally substituted with 1 or 2 substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl and -OH.
Embodiment 17. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
2 is phenyl, optionally substituted with 1 or 2 substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl, halo, C
1-6haloalkyl and -OH.
Embodiment 18. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
2 is phenyl, optionally substituted with 1 or 2 substituents selected from a group consisting of C
1-6alkoxyl and halo.
Embodiment 19. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Y is selected from a group consisting of O, -CH
2-NH-C (O) -, -CH
2-C (O) -NH-and -C (O) -NH-.
Embodiment 20. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Y is O.
Embodiment 21. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Y is -CH
2-NH-C (O) -.
Embodiment 22. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X
3 is N.
Embodiment 23. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
X
1 is CR’ or N; R’ is H or halo;
X
2 is CH;
X
3 is N;
R
1 is selected from a group consisting of 3-8 membered heterocyclyl, 5-10 membered heteroaryl, C
3-8cycloalkyl, C
3-8cycloalkyl-O-, C
6-10aryl and N (C
1-6alkyl)
2, wherein alkyl is optionally substituted with one or more halo, -OH and -CN; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C
1-6alkyl, C
1-6haloalkyl and C
1-6alkoxyl;
Ar is -C
6-10aryl-Y-R
2, wherein each said C
6-10aryl is optionally substituted with one halo;
Y is -CH
2-NH-C (O) -; and
R
2 is C
6-10aryl substituted with 1, 2 or 3 substituents selected from a group consisting of C
1-6alkoxyl, deuterated C
1-6alkoxyl and halo.
Embodiment 24. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X
1 is CH.
Embodiment 25. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X
3 is N.
Embodiment 26. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is phenyl-Y-R
2, wherein said phenyl is optionally substituted with one halo.
Embodiment 27. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein: Ar is
wherein R
3 is H or halo.
Embodiment 28. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is
wherein R
3 is H or halo.
Embodiment 29. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein Ar is phenyl-Y-R
2.
Embodiment 30. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
2 is 2-methoxyl-phenyl or 2-methoxyl-5-fluoro-phenyl.
Embodiment 31. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is selected from a group consisting of 4-6 membered heterocyclyl, 5-10 membered heteroaryl, C
5-6cycloalkyl, C
3-6cycloalkyl-O-and phenyl, which are each optionally substituted with one or more with one or more substituents selected from a group consisting of -OH, halo, CN, C
1-6alkyl, C
1-6haloalkyl and C
1-6alkoxyl.
Embodiment 32. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is selected from a group consisting of 5-10 membered heteroaryl optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C
1-6alkyl, C
1-6haloalkyl and C
1-6alkoxyl.
Embodiment 33. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is N (C
1-6alkyl)
2 optionally substituted with one or more halo; preferably, R
1 is N (C
1-6alkyl)
2 substituted with one or more halo; more preferably, R
1 is
Embodiment 34. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is selected from a group consisting of 5-6 membered heteroaryl optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C
1-6alkyl, C
1-6haloalkyl and C
1-6alkoxyl.
Embodiment 35. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is selected from a group consisting of 5 membered heteroaryl optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C
1-6alkyl, C
1-6haloalkyl and C
1-6alkoxyl.
Embodiment 36. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is selected from a group consisting of 6 membered heteroaryl optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C
1-6alkyl, C
1-6haloalkyl and C
1-6alkoxyl.
Embodiment 37. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is pyridyl, optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C
1-6alkyl, C
1-6haloalkyl and C
1-6alkoxyl.
Embodiment 38. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein halo is F or Cl, preferably is F.
Embodiment 39. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein C
1-6haloalkyl is CF
3.
Embodiment 40. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is pyridyl optionally substituted with one or two substituents selected from a group consisting of -OH, methyl, F, OMe, and CF
3.
Embodiment 41. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R
1 is pyridin-4-yl substituted with C
1-6alkyl at 2-position and optionally further substituted at 3-position with a substituent selected from a group consisting of -OH, halo, CN, C
1-6alkyl, C
1-6haloalkyl and C
1-6alkoxyl.
Embodiment 42. The compound of any one of previous embodiments, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:
R
1 is selected from a group consisting of:
Further preferably, R
1 is selected from a group consisting of:
Embodiment 43. The compound of embodiment 1 which is selected from a group consisting of:
or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof.
Embodiment 44. The compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, for use as a medicament.
Embodiment 45. The compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a BTK-associated disease or disorder;
Preferably, the disease or disorder is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders, preferably hematological malignancies, more preferably B-cell malignancies, further more preferably, leukemias, lymphomas, Hodgkin's disease and myeloma;
More preferably, the disease or disorder is selected from acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV) , essential thrombocytopenia (ET) and idiopathic primary myelofibrosis (IMF/IPF/PMF) ) , diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, precursor B-lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, anaplastic large cell lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma (MM) ; rheumatoid arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, and spondylitis; asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) , silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia, bronchiectasis, pulmonary oxygen toxicity, and chronic lung inflammatory disease; systemic lupus erythematosus (SLE) , autoimmune thyroiditis, multiple sclerosis, chronic obstructive pulmonary disease (COPD) , myasthenia gravis, psoriasis, inflammatory bowel disease (IBD) , and idiopathic thrombocytopenic purpura; graft-versus-host disease (GVHD) and allograft rejection.
Embodiment 46. A pharmaceutical composition, comprising the compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.
Embodiment 47. Use of the compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment or prevention of a BTK-associated disease or disorder;
Preferably, the disease or disorder is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders, preferably hematological malignancies, more preferably B-cell malignancies, further more preferably, leukemias, lymphomas, Hodgkin's disease and myeloma;
More preferably, the disease or disorder is selected from acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV) , essential thrombocytopenia (ET) and idiopathic primary myelofibrosis (IMF/IPF/PMF) ) , diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, precursor B-lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, anaplastic large cell lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma (MM) ; rheumatoid arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, and spondylitis; asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) , silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia, bronchiectasis, pulmonary oxygen toxicity, and chronic lung inflammatory disease; systemic lupus erythematosus (SLE) , autoimmune thyroiditis, multiple sclerosis, chronic obstructive pulmonary disease (COPD) , myasthenia gravis, psoriasis, inflammatory bowel disease (IBD) , and idiopathic thrombocytopenic purpura; graft-versus-host disease (GVHD) and allograft rejection.
Embodiment 48. A method of in vivo or in vitro inhibiting the activity of BTK, comprising contacting an effective amount of the compound of any one of embodiments 1-43 or a pharmaceutically acceptable salt thereof with BTK.
Embodiment 49. A method of treating or preventing a BTK-associated disease or disorder, comprising administering to the subject in need thereof an effective amount of the compound of any one of embodiments 1-43 or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof;
Preferably, the disease or disorder is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders, preferably hematological malignancies, more preferably B-cell malignancies, further more preferably, leukemias, lymphomas, Hodgkin's disease and myeloma;
More preferably, the disease or disorder is selected from acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV) , essential thrombocytopenia (ET) and idiopathic primary myelofibrosis (IMF/IPF/PMF) ) , diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, precursor B-lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, anaplastic large cell lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma (MM) ; rheumatoid arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, and spondylitis; asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) , silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia, bronchiectasis, pulmonary oxygen toxicity, and chronic lung inflammatory disease; systemic lupus erythematosus (SLE) , autoimmune thyroiditis, multiple sclerosis, chronic obstructive pulmonary disease (COPD) , myasthenia gravis, psoriasis, inflammatory bowel disease (IBD) , and idiopathic thrombocytopenic purpura; graft-versus-host disease (GVHD) and allograft rejection.
Embodiment 50. A combination, comprising the compound of any one of embodiments 1-43, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent, wherein said additional therapeutic agent preferably is an anti-neoplastic agent, e.g., a radiotherapeutic agent, a chemotherapeutic agent, an immunotherapeutic agent, or a targeted therapeutic agent.
Embodiment 51. A compound selected from:
wherein P
1 is an amino-protecting group, preferably p-methoxybenzyl, and P
2 is a hydroxy-protecting group, preferably methoxymethyl.
Embodiment 52. A compound selected from:
wherein the PMB is p-methoxybenzyl, and the MOM is methoxymethyl.
Definitions
As used in the present disclosure, the following words, phrases and symbols have the meanings as set forth below, unless specified otherwise in the context.
As used herein, the singular forms “a” , “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
A dash ( “-” ) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, C
3-8cycloalkyl-O-is attached to the rest of the molecule through the oxygen.
The term “alkyl” as used herein refers to a straight or branched saturated hydrocarbon radical having 1-18 carbon atoms (C
1-18) , preferably 1-10 carbon atoms (C
1-10) , preferably 1-6 carbon atoms (C
1-6) , and more preferably 1-4 carbon atoms (C
1-4) or 1-3 carbon atoms (C
1-3) . For example, “C
1-6 alkyl” refers to the alkyl having 1-6 (1, 2, 3, 4, 5 or 6) carbon atoms. Examples of the alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl.
The term “alkenyl” as used herein refers to a straight or branched unsaturated hydrocarbon radical containing one or more, for example 1, 2, or 3 carbon-carbon double bonds (C=C) and having 2-10 carbon atoms (C
2-10) , preferably 2-6 carbon atoms (C
2-6) , more preferably 2-4 carbon atoms (C
2-4) . For example, “C
2-6 alkenyl” refers to the alkenyl having 2-6 (2, 3, 4, 5 or 6) carbon atoms, which preferably contains 1 or 2 carbon-carbon double bonds; “C
2-4 alkenyl” refers to the alkenyl having 2-4 carbon atoms, which preferably contains 1 carbon-carbon double bond. Examples of the alkenyl include, but are not limited to, vinyl, 2-propenyl, and 2-butenyl. The point of attachment for the alkenyl may or may not be on the double bond.
The term “alkynyl” as used herein refers to a straight or branched unsaturated hydrocarbon radical containing one or more, for example 1, 2, or 3, carbon-carbon triple bonds (C≡C) and having 2-10 carbon atoms (C
2-10) , preferably 2-6 carbon atoms (C
2-6) , more preferably 2-4 carbon atoms (C
2-4) . For example, “C
2-6 alkynyl” refers to the alkynyl having 2-6 (2, 3, 4, 5 or 6) carbon atoms, which preferably contains 1 or 2 carbon-carbon triple bonds; “C
2-4 alkynyl” refers to the alkynyl having 2-4 carbon atoms, which preferably contains 1 carbon-carbon triple bond. Examples of the alkynyl include, but are not limited to, ethynyl, 2-propynyl, and 2-butynyl. The point of attachment for the alkynyl may or may not be on the triple bond.
The term “halogen” or “halo” as used herein refers to fluoro, chloro, bromo, and iodo, preferably fluoro, chloro and bromo, more preferably fluoro and chloro, most preferably fluoro.
The term “haloalkyl” or alkyl substituted with halo as used interchangeably herein refers to the alkyl as defined herein, in which one or more, for example 1, 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atom, and when more than one hydrogen atoms are replaced with halogen atoms, the halogen atoms may be the same or different from each other. In one embodiment, the term “haloalkyl” as used herein refers to the alkyl as defined herein, in which two or more, such as 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atoms, wherein the halogen atoms are the same as each other. In another embodiment, the term “haloalkyl” as used herein refers to the alkyl as defined herein, in which two or more, for example 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atoms, wherein the halogen atoms may be different from each other. Examples of the haloalkyl include, but are not limited to, -CF
3, -CHF
2, -CH
2F, -CH
2CF
3, -CF
2CF
3, -CF
2CH
3, and the like. Preferably haloalkyl is C
1-6trifluoroalkyl, more preferably-CF
3.
The term “alkoxyl” as used herein refers to the group -O-alkyl, wherein the alkyl is as defined above. Examples of the alkoxyl include, but are not limited to, C
1-6 alkoxyl, such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, t-butoxy, pentoxy, and hexyloxy, including their isomers. Preferably alkoxyl is methoxy.
The term “haloalkoxyl” or alkoxyl substituted with halo as used interchangeably herein refers to the alkoxyl as defined herein, in which one or more, for example 1, 2, 3, 4, or 5 hydrogen atoms are replaced with halogen atom, and when more than one hydrogen atoms are replaced with halogen atoms, the halogen atoms may be the same or different from each other. Examples of the haloalkoxyl include, but are not limited to, trifluoroalkoxyl, preferably C
1-6trifluoroalkoxyl, more preferably
The term “cycloalkyl” as used herein refers to saturated cyclic hydrocarbon radical having 3-10 ring carbon atoms (C
3-10) , such as 3-8 ring carbon atoms (C
3-8) , 3-7 ring carbon atoms (C
3-7) , 3-6 ring carbon atoms (C
3-6) or 5-6 ring carbon atoms (C
5-6) , which may have one or more rings, e.g., 1 or 2 rings. “Cycloalkyl” may include a fused ring, a bridged ring, or a spirocyclic ring. For example, said cycloalkyl is monocyclic cycloalkyl, preferably monocyclic C
3-8cycloalkyl, preferably monocyclic C
3-6 cycloalkyl, and more preferably monocyclic C
5-6cycloalkyl. Examples of the monocyclic cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl. For example, said cycloalkyl is bicyclic cycloalkyl, preferably bicyclic C
5-C
10cycloalkyl. Examples of the bicyclic cycloalkyl include, but are not limited to, bicyclo [4.1.0] heptyl, bicyclo [3.1.1] heptyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, bicyclo [3.2.2] nonyl, spiro [3.3] heptyl, spiro [2.2] pentyl, spiro [2.3] hexyl, spiro [2.4] heptyl, spiro [2.5] octyl, and spiro [4.5] decyl. Preferably, the cycloalkyl is monocyclic C
3-6 cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
The term “cycloalkenyl” as used herein refers to non-aromatic, unsaturated cyclic hydrocarbon radical with at least one carbon-carbon double bond, having 3-10 ring carbon atoms (C
3-10) , such as 3-8 ring carbon atoms (C
3-8) , 3-7 ring carbon atoms (C
3-7) , 3-6 ring carbon atoms (C
3-6) or 5-6 ring carbon atoms (C
5-6) , which may have one or more rings, e.g., 1 or 2 rings. For example, said cycloalkenyl is monocyclic cycloalkenyl. Examples of the monocyclic cycloalkenyl include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl.
The term “heterocyclyl” as used herein refers to a saturated or partially unsaturated ring having 3-10 ring atoms (3-10 membered) , such as 3-8 ring atoms (3-8 membered) , 5-7 ring atoms (5-7 membered) , 3-6 ring atoms (3-6 membered) , 4-6 ring atoms (4-6 membered) or 5-6 ring atoms (5-6 membered) , with one or more of, such as 1, 2 or 3, preferably 1 or 2 of the ring atoms being heteroatoms independently selected from N, O and S, and the remaining ring atoms being carbon, and having one or more, for example 1, 2 or 3, preferably 1 or 2 rings, wherein the N or S heteroatom is optionally oxidized to various oxidation states. The point of attachment of heterocyclyl may be on N heteroatom or carbon atom. The ring (s) of the heterocyclyl also include (s) a fused ring, a bridged ring, or a spirocyclic ring. The ring (s) of the heterocyclyl may be saturated or contain (s) one or more, for example, one or two double bonds (i.e. partially unsaturated) , but is (are) not fully conjugated, and not the heteroaryl as defined herein. For example, “3-8 membered heterocyclyl” refers to the heterocyclyl having 3-8 ring atoms and containing 1, 2 or 3, preferably 1 or 2 ring heteroatoms independently selected from N, O and S preferably is saturated monocyclic 3-8 membered heterocyclyl. For example, “4-6 membered heterocyclyl” refers to the heterocyclyl having 4-6 ring atoms and containing 1 or 2 ring heteroatoms independently selected from N, O and S, preferably is saturated monocyclic 4-6 membered heterocyclyl, such as saturated monocyclic 4, 5, or 6 membered heterocyclyl. Examples of the heterocyclyl include, but are not limited to, oxiranyl, aziridinyl, thiiranyl, oxetanyl, azetidinyl (e.g., azetidin-1-yl, azetidin-2-yl, azetidin-3-yl) , thietanyl, pyrrolidinyl (e.g., pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl) , oxopyrrolidinyl (e.g., 2-oxopyrrolidin-1-yl) , tetrahydrofuryl (e.g., tetrahydrofuran-2-yl, tetrahydrofuran-3-yl) , dioxolaneyl, imidazolidinyl, morpholinyl (e.g., morpholino (i.e., morpholin-1-yl) , morpholin-2-yl, morpholin-3-yl) , thiomorpholinyl, piperidinyl (e.g., piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl) , piperazinyl (e.g., piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, piperazin-4-yl) , dihydropyranyl, tetrahydropyranyl (e.g., tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl) , hexahydrothiopyranyl, hexahydropyrimidyl, and oxazitanyl. Preferably, the heterocyclyl is azetidinyl, pyrrolidinyl, tetrahydrofuryl, piperidyl, piperazinyl, morpholino or tetrahydropyranyl, such as azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, piperid-1-yl, piperazin-1-yl or morpholino.
The term “aryl” as used herein refers to carbocyclic hydrocarbon radical having 6-14 carbon atoms (C
6-14) , preferably 6-10 carbon atoms (C
6-10) and consisting of one ring or more fused rings, wherein at least one ring is aromatic. Examples of the aryl include, but are not limited to, phenyl, naphthalenyl, 1, 2, 3, 4-tetrahydronaphthalenyl, phenanthryl, indenyl, indanyl, azulenyl, preferably phenyl and naphthalenyl, more preferably phenyl.
The term “heteroaryl” as used herein refers to a monocyclic, bicyclic or tricyclic ring system having 5-12 ring atoms (5-12 membered) , such as 5-10 ring atoms (5-10 membered) , 8-12 ring atoms (8-12 membered) , 5-8 ring atoms (5-8 membered) , 5-7 ring atoms (5-7 membered) , 5-6 ring atoms (5-6 membered) , 5 ring atoms (5 membered) or 6 ring atoms (6 membered) , wherein at least one ring is an 5 or 6 membered aromatic ring with one or more of, such as 1, 2 or 3, preferably 1 or 2 of the ring atoms being heteroatoms independently selected from N, O and S, and the remaining ring atoms being carbon, and wherein the N or S heteroatom is optionally oxidized to various oxidation states. For example, the heteroaryl is:
- 5-6 membered monocyclic heteroaryl, i.e. monocyclic aromatic hydrocarbon radical having 5 or 6 ring atoms (5 or 6 membered) , with one or more of, for example 1, 2 or 3, preferably 1 or 2 of the ring atoms being ring heteroatoms independently selected from N, O, and S (preferably N) , and the remaining ring atoms being carbon; preferably, monocyclic aromatic hydrocarbon radical having 6 ring atoms (6 membered) , with 1, 2 or 3, preferably 1 or 2 of the ring atoms being heteroatoms independently selected from N, O, and S, preferably N;
or
- 8-12 bicyclic heteroaryl, i.e. bicyclic aromatic hydrocarbon radical having 8, 9, 10, 11 or 12 ring atoms (8, 9, 10, 11 or 12 membered) , with one or more, for example, 1, 2, 3 or 4, preferably 1, 2 or 3 of the ring atoms are ring heteroatoms independently selected from N, O, and S (preferably N) , and the remaining ring atoms being carbon, wherein at least one of the rings is aromatic.
Examples of the heteroaryl include, but are not limited to, pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridin-5-yl, pyridin-6-yl) , pyridyl N-oxide, pyrazinyl (e.g., pyrazin-2-yl, pyrazin-3-yl) , pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl) , pyridazinyl (e.g., pyridazin-3-yl, pyridazin-4-yl) , pyrazolyl (e.g., pyrazol-1-yl, pyrazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl) , imidazolyl (e.g., imidazol-1-yl, imidazol-5-yl, imidazol-3-yl, imidazol-4-yl, imidazol-5-yl) , oxazolyl, isoxazolyl (e.g., isoxazol-4-yl) , oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, triazolyl, triazinyl, thienyl, furyl, pyranyl, pyrrolyl (e.g., pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl) , benzodioxolyl, benzooxazolyl, benzoisoxazolyl, benzothienyl, benzothiazolyl, benzoisothiazolyl, imidazopyridyl, imidazopyrrolyl, triazolopyridyl, indazolyl, pyrrolopyridyl, pyrrolopyrimidinyl, pyrazolopyridyl, pyrazolopyrimidinyl, tetrazolopyridyl, tetrahydropyrazolopyridyl, benzofuryl, benzoimidazolinyl, or indolyl. Preferably, the heteroaryl is pyrazolyl, pyridyl, pyridazinyl or pyrazinyl, more preferably pyrazol-1-yl, pyrazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridazin-3-yl, pyridazin-4-yl, pyrazin-2-yl or pyrazin-3-yl.
The term “oxo” as used herein refers to the group =O.
When a structure herein contains “ (R) ” and/or “ (S) ” , it means that the chiral center of the compound marked by “ (R) ” or “ (S) ” is a single configuration in either R-configuration or S-configuration. For example, the compounds of the present disclosure have an enantiomeric purity of at least 60%ee (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%ee (enantiomeric excess) , or any values between those enumerated values) , or have a diastereomeric purity of at least 60%de (diastereomeric excess) (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%de, or any values between those enumerated values) .
When a structure of a compound herein is marked by “isomer” , it means that the compound is an individual stereoisomer, but absolute configuration or relative configuration of the compound is (are) assigned arbitrarily or not assigned.
When a structure of a compound herein is marked by “cis or trans” , it means that the compound is an individual stereoisomer, but the configuration of the compound are assigned arbitrarily as cis or trans.
When a structure of a compound herein is marked by either “cis” or “trans” , it means that the compound is an individual stereoisomer, the relative configuration of the compound is either cis or trans as indicated, but the absolute configuration are not determined.
When a structure of a compound herein contains a bond represented by a wavy line
it means a mixture of isomers in any ratio of the compound.
When a group carries a wavy line
on a bond, the wavy line indicates the point of attachment of the group to the rest of the molecule.
The term “optional” or “optionally” as used herein means that the subsequently described event or circumstance may or may not occur, and the description includes instances wherein the event or circumstance occur and instances in which it does not occur. For example, “optionally substituted with one or more …” encompasses both “unsubstituted” and “substituted with 1, 2, 3 or more” substituents as defined. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups do not include any substitution or substitution patterns that are sterically impractical, chemically incorrect, synthetically non-feasible and/or inherently unstable.
The term “substituted” or “substituted with …” as used herein, means that one or more hydrogens on the designated atom or group are replaced with one or more substituents independently selected from the indicated group of substituents, provided that the designated atom's normal valence is not exceeded. The term “substituted with one or more …” means that one or more (e.g. 1, 2, 3 or 4, preferably 1 or 2) hydrogens on the designated atom or group are replaced with one or more (e.g. 1, 2, 3 or 4, preferably 1 or 2) substituents independently selected from the indicated group of substituents, provided that the designated atom's normal valence is not exceeded. When a substituent is oxo (i.e., =O) , then 2 hydrogens on a single atom are replaced by the oxo. Combinations of substituents and/or variables are permissible only if such combinations result in a chemically correct and stable compound. A chemically correct and stable compound is meant to imply a compound that is sufficiently robust to survive sufficient isolation from a reaction mixture.
It will be appreciated by a person skilled in the art that some of the compounds disclosed herein may contain one or more chiral centers or ring and therefore exist in two or more stereoisomers. The racemates of these isomers, the individual isomers and mixtures enriched in one enantiomer, as well as diastereomers and mixtures partially enriched with specific diastereomers when there are two chiral centers are within the scope of the present disclosure. It will be further appreciated by a person skilled in the art that the present disclosure includes all the individual stereoisomers (e.g. enantiomers, diastereoisomers, or cis-or trans-isomers) , racemic mixtures or partially resolved mixtures of the compounds disclosed herein and, where appropriate, the individual tautomeric forms thereof.
The racemate or other mixtures of isomers can be used as such or can be resolved into their individual isomers. The resolution can afford stereochemically pure compounds or mixtures enriched in one or more isomers. Methods for separation of isomers are well known (e.g., cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry" , Vol. 6, Wiley Interscience, 1971) .
The term “pharmaceutically acceptable salt” includes, but is not limited to, acid addition salts formed by the compounds disclosed herein with an inorganic acid, such as hydrochloride, hydrobromide, carbonate, bicarbonate, phosphate, sulfate, sulfite, nitrate and the like; as well as with an organic acid, such as formate, acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and salts with alkane-dicarboxylic acid of formula HOOC- (CH
2)
n-COOH wherein n is 0-4, and the like. Also, “pharmaceutically acceptable salt” includes base addition salts formed by the compound of the present invention carrying an acidic moiety with pharmaceutically acceptable cations, for example, sodium, potassium, calcium, aluminum, lithium, and ammonium.
In addition, if the compound described herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product is a free base, an acid addition salt, particularly a pharmaceutically acceptable acid addition salt, may be produced from a base compound by dissolving the free base in a suitable solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts. A person skilled in the art will recognize various synthetic methodologies that may be used without undue experimentation to prepare non-toxic pharmaceutically acceptable acid addition salts or base addition salts.
The term “solvate” means a solvent addition form that contains either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the solid state, thus forming a solvate. If the solvent is water, the solvate formed is a hydrate, when the solvent is ethanol, the solvate formed is an alcoholate.
The term “deuterated” group means a group, in which one or more, for example 1, 2 or 3 hydrogen atoms are replaced with its isotope deuterium (D) .
The term “protecting group” refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound. For example, an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include p-methoxybenzyl (PMB) , benzyl (Bn) , trityl (Trt) , acetyl, trifluoroacetyl, phthalimido, t-butoxycarbonyl (BOC) , benzyloxycarbonyl (CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc) . Similarly, a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable hydroxy-protecting groups include methoxymethyl, benzyl, benzyloxymethyl, methyl, triarylmethyl, acetyl, trialkylsilyl, dialkylphenylsilyl, benzoyl, and tetrahydropyranyl. For a general description of protecting groups and their use, see T.W. Greene and P.G.M. Wuts, “Protective Groups in Organic Synthesis” , 5
th Edition, Wiley, New York, 2014.
The term “pharmaceutical combination” as used herein means a product that results from the mixing or combining of more than one active agent and includes both fixed and non-fixed combinations of the active agents, e.g., kit or pharmaceutical composition. The term “fixed combination” means that the active agents, e.g. disclosure and an additional active agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term “non-fixed combination” means that the active agents, e.g. disclosure and an additional active agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the compounds in the body of the patient.
The term “treating” , “treat” or “treatment” in connection with a disease refers to administering one or more pharmaceutical substances, especially the compound of the present invention or a pharmaceutically acceptable salt thereof described herein to a subject that has the disease or disorder, or has a symptom of a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disease or disorder, the symptoms of the disease or disorder. In some embodiments, the disease is BTK-associated disease or disorder, such as a disease or disorder responsive to inhibition of BTK, preferably cancer.
The term “prevent” or “preventing” in connection with a disease refer to administering one or more pharmaceutical substances, especially the compound of the present invention or a pharmaceutically acceptable salt thereof described herein to a subject that has a predisposition toward a disease or disorder, or has a risk of suffering from a disease or disorder, with the purpose to prevent or slow down the occurrence of the disease or disorder in the subject. In some embodiments, the disease is BTK-associated disease or disorder, such as a disease or disorder responsive to inhibition of BTK, preferably cancer.
The term “effective amount” as used herein refers to an amount of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein effective to “treat” or “prevent” , as defined above, BTK-associated disease or disorder, such as a disease or disorder responsive to inhibition of BTK in a subject. The effective amount may cause any changes observable or measurable in a subject as described in the definition of “treating” , “treat” , “treatment” , “preventing” , or “prevent” above. For example, in the case of cancer, the effective amount can reduce the number of cancer or tumor cells; reduce the tumor size; inhibit or stop tumor cell infiltration into peripheral organs including, for example, the spread of tumor into soft tissue and bone; inhibit and stop tumor metastasis; inhibit and stop tumor growth; relieve to some extent one or more of the symptoms associated with the cancer; reduce morbidity and mortality; improve quality of life; or a combination of such effects. An effective amount may be an amount sufficient to reduce the symptoms of a BTK-associated disease or disorder. The term “effective amount” may also refer to an amount of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein effective to inhibit the activity of BTK in a subject.
The term “inhibition” or “inhibiting” indicates a decrease in the baseline activity of a biological activity or process. “Inhibition of BTK” refers to a decrease in the activity of BTK as a direct or indirect response to the presence of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein, relative to the activity of BTK in the absence of the compound of the present invention or a pharmaceutically acceptable salt thereof. The decrease in activity may be due to the direct interaction of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein with BTK, or due to the interaction of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein with one or more other factors that in turn affect the BTK activity. For example, the presence of the compound of the present invention or a pharmaceutically acceptable salt thereof described herein may decrease the BTK activity by directly binding to the BTK, by directly or indirectly causing another factor to decrease the BTK activity, or by directly or indirectly decreasing the amount of BTK present in the cell or organism.
The term “subject” as used herein means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like. The term “subject” does not denote a particular age or sex. In some embodiments, the subject is a human. In some embodiments of any of the methods or uses described herein, the subject is BTK-inhibitor naive. In other embodiments of any of the methods or uses described herein, the subject is not BTK-inhibitor naive.
The term “pharmaceutically acceptable” means that the substance following this term is useful in preparing a pharmaceutical composition and is generally safe, non-toxic, and neither biologically nor otherwise undesirable, especially for human pharmaceutical use.
The term “about” is used herein to mean approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above or below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above or below the stated value by a variance of 20%.
The term “tumors” herein refers to a cellular disorder characterized by uncontrolled or disregulated cell proliferation, decreased cellular differentiation, inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at other sites. The term “tumor” includes, but is not limited to, hematological malignancies and solid tumors, preferably is B-cell malignancies. The term “tumor” includes, but is not limited to, leukemias, lymphomas (non-Hodgkin's lymphoma) , Hodgkin's disease (also called Hodgkin's lymphoma) and myeloma. Non-limiting examples of tumor are acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV) , essential thrombocytopenia (ET) and idiopathic primary myelofibrosis) , diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, precursor B-lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, anaplastic large cell lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma (MM) . The term “tumor” encompasses cancer of skin, tissues, organs, bone, cartilage, blood, and vessels. The term “tumor” further encompasses primary tumors, metastatic tumors, recurrent tumors, and refractory tumors.
The term “autoimmune diseases” herein refers to a disease or condition arising from damage to an individual's own tissues or organs caused by the body's immune response to self-antigens. Examples of autoimmune diseases include, but are not limited to, chronic obstructive pulmonary disease (COPD) , allergic rhinitis, systemic lupus erythematosus, myasthenia gravis, multiple sclerosis (MS) , rheumatoid arthritis (RA) , psoriasis, inflammatory bowel disease (IBD) , asthma, idiopathic thrombocytopenic purpura, and myeloproliferative disease, such as myelofibrosis, post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET myelofibrosis) .
The term “inflammatory diseases” or “inflammatory disorders” refers to a pathological state that leads to inflammation, especially due to chemotaxis of neutrophils. Non-limiting examples of inflammatory diseases include chronic inflammation, autoimmune diabetes, rheumatoid arthritis (RA) , spondylitis, gouty arthritis and other joint disorders, multiple sclerosis (MS) , asthma, systemic lupus erythematosus, adult respiratory distress syndrome, Behcet disease, psoriasis, chronic lung inflammatory disease, allograft rejection, Crohn's disease, ulcerative colitis, inflammatory bowel disease (IBD) .
All numerical ranges herein should be understood as disclosing each and every value within the range and each and every subset of values within the range, regardless of whether they are specifically disclosed otherwise. For example, when referring to any numerical range, it should be regarded as referring to each and every numerical value in the numerical range, for example, each and every integer in the numerical range. The present disclosure includes all values falling within these ranges, all smaller ranges, and the upper or lower limit of the range.
Technical and scientific terms used herein and not specifically defined have the meaning commonly understood by a person skilled in the art, to which the present disclosure pertains.
Pharmaceutical Composition and Administration
The compounds of the present invention (such as any of the compounds of the Examples herein) alone or in combination with one or more additional active agents can be formulated into a pharmaceutical composition. The pharmaceutical composition includes: (a) an effective amount of invention; (b) a pharmaceutically acceptable excipient (for example, one or more pharmaceutically acceptable carriers) ; and optionally (c) at least one additional active agent.
A pharmaceutically acceptable excipient refers to an excipient that is compatible with the active ingredient (s) in the composition (in some embodiments, can stabilize the active ingredient) and is not harmful to the subject being treated. Suitable pharmaceutically acceptable excipients are disclosed in standard reference books in the art (e.g., Remington's Pharmaceutical Sciences, Remington: The Science and Practice of Pharmacy. ) , including one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., the compounds of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament) .
The compound of the invention can be administered in various known manners, such as orally, parenterally, by inhalation, or by implantation. The term “parenteral” as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion.
The compound of the present invention may be administered in any convenient formulation, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and an addtional active agent.
In one example, the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01 to 100 mg/kg, alternatively about 0.1 to 20 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day. In another embodiment, oral unit dosage forms, such as tablets and capsules, contain from about 0.1 to about 1000 mg of the compound of the invention.
Indications and Methods of Treatment
The disclosure relates to a method of treating or preventing a BTK-associated disease or disorder, comprising administering to the subject in need thereof an effective amount of the compound of the present invention.
In one embodiment, the compound of the present invention is used for the treatment or prevention of a BTK-associated disease or disorder.
Preferably, the BTK-associated disease or disorder as used herein is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders.
The tumors are hematological malignancies or solid tumors. More preferably the tumors are B-cell malignancies.
Non-limiting examples of BTK-associated disease or disorder include:
1.
Tumor (BTK-associated tumors) : hematological malignancies, solid tumors, preferably
B-cell malignancies
1.1.
Hematological malignancies (e.g., hematological malignancies that are BTK-associated tumors) is selected from the group consisting of leukemias, lymphomas (non-Hodgkin's lymphoma) , Hodgkin's disease (also called Hodgkin's lymphoma) , and myeloma, for instance, acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV) , essential thrombocytopenia (ET) and idiopathic primary myelofibrosis (IMF/IPF/PMF) ) , diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, precursor B-lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, anaplastic large cell lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma (MM) .
The tumors used herein also include transformation in hematological malignancies. Non-limiting examples of transformation in hematological malignancies include Richter's transformation, prolymphocytic transformation (e.g., prolymphocytic transformation of CLL) , transformed non-Hodgkins lymphoma, and blastoid lymphoma (e.g., blastoid variant mantle cell lymphoma) .
1.2.
Solid tumors (e.g., solid tumors that are BTK-associated tumors) . Examples of solid tumors include, for example, bone cancer, bone metastasis, breast cancer, gastro-esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer, prostate cancer, lung cancer, colon cancer, uterine cancer, hepatocellular cancer, head and neck cancer, gastric cancer, esophageal cancer, bladder cancer, colorectal cancer, renal cancer, skin cancer, brain tumors, thyroid cancer, and glioma. See, for example, Campbell, et al., Journal of Clinical Medicine, 2018, 7 (4) : 62 and Zucha et al., Oncotarget. 6 (15) : 13255-68, 2015, each of which is incorporated by reference in its entirety herein.
1.3.
B-cell malignancies include a B-cell non-Hodgkin lymphoma, Hodgkin lymphoma, or B-cell leukemia. Examples of the B-cell malignancies also include a Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia (ALL) , B-cell prolymphocytic leukemia, precursor B-lymphoblastic leukemia, or hairy cell leukemia.
2.
Other BTK-associated diseases (including inflammatory diseases and autoimmune
diseases) :
2.1. Arthritic diseases, such as rheumatoid arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis;
2.2. Infectious diseases, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome;
2.3. Multiple organ injury syndrome secondary to septicemia, trauma, or hemorrhage; ophthalmic disorders such as allergic conjunctivitis, vernal conjunctivitis, uveitis, and thyroid-associated ophthalmopathy; eosinophilic granuloma;
2.4. Pulmonary or respiratory disorders such as asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) , chronic pulmonary inflammatory disease (e.g., chronic obstructive pulmonary disease) , silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia, bronchiectasis, pulmonary oxygen toxicity, and chronic lung inflammatory disease;
2.5. Reperfusion injury of the myocardium, brain, or extremities;
2.6. Fibrosis such as cystic fibrosis; keloid formation or scar tissue formation; atherosclerosis;
2.7. Autoimmune diseases, including, but are not limited to, systemic lupus erythematosus (SLE) , autoimmune thyroiditis, multiple sclerosis, chronic obstructive pulmonary disease (COPD) , allergic rhinitis, lupus erythematosus, myasthenia gravis, rheumatoid arthritis (RA) , psoriasis, inflammatory bowel disease (IBD) , asthma, idiopathic thrombocytopenic purpura, and myeloproliferative disease, such as myelofibrosis, post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET myelofibrosis) ;
2.8. Some forms of diabetes, and Reynaud's syndrome;
2.9. Transplant rejection disorders such as graft-versus-host disease (GVHD) and allograft rejection;
2.10. Chronic glomerulonephritis; inflammatory bowel diseases such as inflammatory bowel disease (CIBD) , Crohn's disease, ulcerative colitis, and necrotizing enterocolitis;
2.11. Inflammatory dermatoses such as contact dermatitis, atopic dermatitis, psoriasis, or urticaria; fever and myalgias due to infection;
2.12. Central or peripheral nervous system inflammatory disorders such as meningitis, encephalitis, and brain or spinal cord injury due to minor trauma;
2.13. Sjogren's syndrome;
2.14. Diseases involving leukocyte diapedesis;
2.15. Alcoholic hepatitis;
2.16. Bacterial pneumonia; antigen-antibody complex mediated diseases; hypovolemic shock; Type I diabetes mellitus; acute and delayed hypersensitivity; disease states due to leukocyte;
2.17. Dyscrasia and metastasis; thermal injury; granulocyte transfusion-associated syndromes; and cytokine-induced toxicity;
2.18. Behcet disease.
3.
Disease of resistance to other BTK related treatment:
Disease of resistance to other BTK related treatment includes tumors with BTK inhibitor resistance mutations (e.g., that result in an increased resistance to a first BTK inhibitor, e.g., a substitution at amino acid position 481, e.g., C481S, C481T, C481R, C481G, and/or one or more BTK inhibitor resistance mutations) .
The compound of the present invention is used for treating or preventing a disease of resistance to other BTK related treatment by either dosing in combination or as a subsequent or additional (e.g., follow-up) therapy to existing drug treatments (e.g., said other BTK kinase inhibitors; e.g., first and/or second BTK kinase inhibitors) . In some embodiments, a first or second BTK kinase inhibitor can be selected from the group consisting of: ibrutinib, PRN1008, PRN473, ABBV-105, AC0058, acalabrutinib, zanubrutinib, spebrutinib, poseltinib, evobrutinib, M7583, tirabrutinib, CG'806, ARQ 531, BIIB068, vecabrutinib, AS871, CB 1763, CB988, GDC-0853, RN486, dasatinib, GNE-504, GNE-309, BCB-311, BTK Max, CT-1530, CGI-1746, CGI-560, LFM Al3, TP-0158, dtrmwxhs-12, CNX-774, and LOU064. In some embodiments, the first or second BTK kinase inhibitor is a covalent inhibitor. Exemplary covalent inhibitors of a BTK kinase include, but are not limited to, ibrutinib, PRN1008, PRN473, ABBV-105, AC0058, acalabrutinib, zanubrutinib, spebrutinib, poseltinib, evobrutinib, M7583, and tirabrutinib. In some embodiments, the first or second BTK kinase inhibitor is a non-covalent inhibitor. Exemplary non-covalent inhibitors of a BTK kinase include, but are not limited to, CG'806, ARQ 531, BIIB068, vecabrutinib, AS871, CB 1763, CB988, GDC-0853, RN486, and dasatinib.
Pharmaceutical Combination
The compound of the present invention may be used in combination with an additional active agent in the treatment of a BTK-associated disease or disorder. The additional active agent may be administered separately with the compound of the present invention or may be included with the compound of the present invention in a pharmaceutical composition according to the disclosure, such as a fixed combination product. In some embodiments, the additional active agent are those that are known or discovered to be effective in the treatment of BTK-associated disease or disorder, such as another BTK inhibitor or a compound that antagonizes another target associated with said particular disease. The combination may serve to increase efficacy, decrease one or more side effects, or decrease the required dose of the compound of the present invention.
In some embodiments, the compound of the present invention is administered in combination with an anti-neoplastic agent. The anti-neoplastic agents include, but are not limited to: radiotherapeutic agents, chemotherapeutic agents, immunotherapeutic agents, targeted therapeutic agents.
General Synthetic Methods
General synthetic method for preparation of 1H-pyrazolo [4, 3-c] pyridine-7-carboxamide analogs with
the general structure represented A-1 and A-2 (Scheme 1)
A-1-1 was synthesized from commercially available starting material 2, 4, 6-trichloropyridine based on literature synthesis of similar compounds (WO 2017042100) , and subsequent bromination followed deprotection afforded intermediate A-1-2. Treatment of A-1-2 with hydrazine afforded the corresponding cyclized compound A-1-3, which was transformed into the key intermediate compound A-1-4a after separation from its regioisomer A-1-4b. Selective and sequential Suzuki reactions at the two chlorine group on the 4, 6-dichloro-1H-pyrazolo [4, 3-c] pyridine-7-carboxamide of key intermediate A-1-4a, followed by multiple steps of functional group transformation, led to target compounds with the general structure of A-1. Alternatively, compound A-1-1 can be turned into intermediate A-2-2 following carboxylation, amide formation and deprotection. A-2-2 was then turned into key intermediate A-2-4a after ring closure and protection. 4-Nitrogen analogs with the general structure represented by A-2 can be obtained after treating A-2-4a with corresponding amines followed by Suzuki reactions.
Scheme 1
Wherein Ra is R
1 which is attached to the ring by C, and Rb is R
1 which is attached to the ring by N or O; P
1 or P
2 is protecting group; R
1 and Ar are as defined for formula I herein.
General synthetic method for preparation of 1H-pyrazolo [4, 3-c] pyridine-7-carboxamide analogs with
the general structure represented B-1 and B-2 (Scheme 2)
Scheme 2
Wherein Ra is R
1 which is attached to the ring by C, and Rb is R
1 which is attached to the ring by N or O; P
1 or P
2 is protecting group; R
1 and Ar are as defined for formula I herein.
As depicted in Route 1, intermediate B-1-1 can be obtained from commercially available 4-bromo-2, 6-difluorobenzonitrile following a two-steps procedure disclosed in WO2010059658 with modifications. Protection followed by formylation afforded compound B-1-2, which then was transformed to compound B-1-3a after separation from its regioisomer B-1-3b. B-1-3a and its deprotected version, B-1-3c, as key intermediates, can be used as starting points to prepare target compounds represented as B-1 or B-2 following multiple-step sequences, respectively.
Alternatively, Route 2 was also used in some cases. Following by modified procedures disclosed in US20180127370 and WO2004065367, commercially available methyl 5-bromo-2-hydroxy-4-methylbenzoate was transformed to methyl 5-bromo-2-methoxy-4-methyl-3-nitrobenzoate, which was subsequently turn into compound methyl 3-amino-5-bromo-2-methoxy-4-methylbenzoate following a reduction step. The subsequent ring closure afforded key intermediate B-1-6, which was transformed into key intermediate B-1-9 after a number of bond-forming and functional-group-transformation steps. With key intermediate B-1-9, target compounds represented by B-1 were prepared.
Each embodiment described in the present disclosure and the features in each embodiment should be understood as being capable of combining with each other in any manner, and those technical solutions obtained by such combination (s) are all included in the scope of the present disclosure the same as if each and every technical solution obtained by such combination (s) were specifically and individually listed, unless the context clearly shows otherwise.
All patents, patent applications, publications, and other references cited or referred to herein are in their entirety incorporated herein by reference to the extent allowed by law. The discussion of those references is intended merely to summarize the assertions made therein. No admission is made that any such patents, patent applications, publications or references, or any portion thereof, are relevant material or prior art. The right to challenge the accuracy and pertinence of any assertion of such patents, patent applications, publications, and other references as relevant material or prior art is specifically reserved.
EXAMPLES
The examples below are intended to illustrate the inventiononly, and should not be contorted to be limiting in any way.
Unless indicated otherwise, temperature is in degrees Centigrade, and pressure is at or near atmospheric. All MS (mass spectrometry) data were measured by Agilent 6120B; Shimadzu LCMS2010.
1H-NMR spectra were recorded on a nuclear magic resonance spectrometer operating at Bruker AVANCE NEO 400 MHz. When peak multiplicities are reported, the following abbreviations are used: s (singlet) , d (doublet) , t (triplet) , m (multiplet) , q (quarter) , br (broadened) , dd (doublet of doublets) dt (doublet of triplets) . Coupling constants, when given, are reported in Herz (Hz) .
All reagents and starting materials, except intermediates, used in this invention are commercially available or prepared according to the prior art.
All compound names except the reagents were generated by Chemdraw. If there’s any inconsistency between the structure and the name of a compound given in this invention, the structure prevails, unless the context shows that the structure is incorrect and the name is right.
If there’s any empty valence in any atom disclosed herein, the empty valence is the hydrogen atom which is omitted for convenience.
Isomers, if isolated from the same chromatagraphy separation condition in the following Examples, are named in the same sequence as they are eluted, unless specified otherwise.
In the following examples, the abbreviations below are used:
List of Abbreviation
Abbreviation | Full Name |
THF | tetrahydrofuran |
LDA | lithium diisopropylamide |
EtOAc | ethyl acetate |
Na 2SO 4 | sodium sulfate |
NMR | nuclear magnetic resonance |
s | singlet |
d | doublet |
m | multiplet |
CDCl 3 | deuterated chloroform |
PE | petroleum ether |
DMSO | dimethyl sulfoxide |
sat. | saturated |
p-TSA | p-Toluenesulfonic acid |
LC/MS | liquid chromatography-mass spectrometer |
TMEDA | N, N, N', N'-Tetramethylethylenediamine |
n-BuLi | n-butyllithium |
h | hour |
HCl | hydrochloride |
mL | milliliter |
mmol | millimole |
DCM | dichloromethane |
PPh 3 | triphenylphosphine |
DIAD | diisopropyl azodicarboxylate |
pH | potential of hydrogen |
DMF | N, N-dimethylformamide |
AcOH | acetic acid |
br | broad |
PMBCl | 4-methoxybenzylchloride |
BBr 3 | boron tribromide |
DIPEA | N, N-diisopropylethylamine |
MOMCl | chlormethyl methyl ether |
MeCN | acetonitrile |
HATU | O- (7-Azabenzotriazol-1-yl) -N, N, N', N'-tetramethyluronium hexafluorophosphate |
Pd (dppf) Cl 2 | 1, 1'-Bis (diphenylphosphino) ferrocene palladium (II) dichloride |
KOAc | potassium acetate |
prep-TLC | preparation thin layer chromatography |
Pd (PPh 3) 4 | tetrakis (triphenylphosphine) palladium |
MeOD | deuterated methanol |
TFA | trifluoroacetic acid |
K 2CO 3 | potassium carbonate |
NaBH 4 | sodium borohydride |
Cs 2CO 3 | cesium carbonate |
NaOH | sodium hydroxide |
NaHCO 3 | sodium bicarbonate |
SFC | supercritical fluid chromatography |
NaH | sodium hydride |
Zn (CN) 2 | zinc cyanide |
prep-HPLC | Preparation high performance liquid chromatography |
DPPA | diphenyl phosphoryl azide |
TEA | triethylamine |
r.t., | room temperature |
Xant-phos | 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene |
TBDPSCl | tert-butyl (chloro) diphenylsilane |
ESI | electrospray ionization |
Synthesis of key intermediate A-1-4a
Synthesis of 2, 4, 6-trichloro-3- (1, 3-dioxan-2-yl) pyridine (A-1-1)
Step 1: To a stirred suspension of 2, 4, 6-trichloropyridine (9.1 g, 49.8 mmol) in THF (100 mL) was added LDA (27.4 mL, 54.8 mmol) at -65℃, and the resulting mixture was stirred for 1 h under N
2 before piperidine-1-carbaldehyde (5.6 mL, 49.8 mmol) was added at this temperature. The mixture was stirred at -65℃ for 3h. Then the reaction mixture was quenched with sat. NH
4Cl, extracted with EtOAc (60 mL x 3) , the combined organic phase was washed by brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%) to obtain 2, 4, 6-trichloropyridine-3-carbaldehyde (4.1 g, yield: 39.1%) as a white solid. LC/MS (ESI) m/z: 211 (M+H)
+,
1H-NMR (400 MHz, DMSO) δ 10.27 (s, 1H) , 8.09 (s, 1H) .
Step 2: To a stirred suspension of 2, 4, 6-trichloropyridine-3-carbaldehyde (4.1 g, 19.5 mmol) and propane-1, 3-diol (2.1 mL, 29.2 mmol) in toluene (40 mL) was added p-TSA (0.7 g, 3.9 mmol) at 120℃ and the resulting mixture was stirred for 3h under N
2. After cooled down to rt, the reaction mixture was diluted with water (20 mL) , extracted with EtOAc (30 mL x 3) . The combined organic phase was washed by brine, dried over anhydrous Na
2SO
4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (EtOAc in PE= 0 ~ 10%) to obtain 2, 4, 6-trichloro-3- (1, 3-dioxan-2-yl) pyridine
(A-1-1) (4.2 g, yield: 80.3%) as a white solid. LC/MS (ESI) m/z: 268 (M+H)
+.
Synthesis of 5-bromo-2, 4, 6-trichloronicotinaldehyde (A-1-2)
Step 1 To a stirred suspension of 2, 4, 6-trichloro-3- (1, 3-dioxan-2-yl) pyridine
(A-1-1) (4.2 g, 15.6 mmol) and TMEDA (5.5 mL, 54.7 mmol) in THF (40 mL) was added n-BuLi (31.4 mL, 78.5 mmol) at -65℃, and the resulting mixture was stirred for 1h under N
2 before 1, 2-dibromotetrafluoroethane (4.1 mL, 31.3 mmol) was added. The mixture was stirred at the same temperature for 3h. After warmed to rt, the reaction mixture was quenched with sat. NH
4Cl and extracted with EtOAc (50 mL x 3) . The combined organic phase was washed by brine, driedover anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by flash chromatography on silica gel (EtOAc in PE= 0 ~ 10%) to obtain 3-bromo-2, 4, 6-trichloro-5- (1, 3-dioxan-2-yl) pyridine (4 g, yield: 73.6%) as a white solid. LC/MS (ESI) m/z: 348/350 (M+H)
+.
Step 2: To a stirred suspension of 3-bromo-2, 4, 6-trichloro-5- (1, 3-dioxan-2-yl) pyridine (4.0 g, 11.5 mmol) in THF (10 mL) was added 3N HCl (20 mL, 60 mmol) , the mixture was stirred at 80 ℃ overnight. After cooled down to rt, the reaction mixture was diluted with water (20 mL) , extracted with EtOAc (50 mL x 3) . The combined organic phase was washed by brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 10%) to obtain 5-bromo-2, 4, 6-trichloronicotinaldehyde
(A-1-2) (2.4 g, yield: 72%) as a white solid. LC/MS (ESI) m/z: 288 (M+H)
+.
Synthesis of 7-bromo-4, 6-dichloro-1H-pyrazolo [4, 3-c] pyridine (A-1-3)
To a stirred suspension of 5-bromo-2, 4, 6-trichloronicotinaldehyde (2.4 g, 8.3 mmol) in EtOH (20 mL) was added hydrazine hydrate (10 mL) dropwise at 0 ℃ and stirred for another 3h at rt. The solvent was concentrated under reduced pressure to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 10%, with 10%DCM) to obtain 7-bromo-4, 6-dichloro-1H-pyrazolo [4, 3-c] pyridine (1.0 g, yield: 45.2%) as a white solid.
1H NMR (400 MHz, DMSO) δ 14.51 (s, 1H) , 8.53 (s, 1H) .
Synthesis of 7-bromo-4, 6-dichloro-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine (A-1-4a)
To a stirred solution of 7-bromo-4, 6-dichloro-1H-pyrazolo [4, 3-c] pyridine (1.0 g, 3.8 mmol) , (4-methoxyphenyl) methanol (0.8 g, 5.7 mmol) and PPh
3 (1.5 g, 5.6 mmol) in THF (20 mL) was added DIAD (1.1 mL, 5.6 mmol) dropwise at 0℃ under N
2 atmosphere, the mixture was stirred overnight at rt. Then the mixture was concentrated under reduced pressure get the crude product which was purified by column chromatography on silica gel (EtOAc in PE= 0 ~ 10%, with 10%DCM) to obtain 7-bromo-4, 6-dichloro-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine (
A-1-4a) (0.6 g, yield: 41.4%) as a white solid, LC/MS (ESI) m/z: 386/388/390 (M+H)
+ and 7-bromo-4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine (
A-1-4b) (0.3 g, yield: 13%) as a white solid, LC/MS (ESI) m/z: 386/388/390 (M+H)
+.
Synthesis of key intermediate A-2-4a
Step 1: To a solution of 2, 4, 6-trichloro-3- (1, 3-dioxan-2-yl) pyridine (A-1-1) (79 g, 294 mmol) in THF (1 L) was added LDA (220 mL, 440 mmol) dropwise at -80℃ and stirred for 1 h, then the solution was bubbled with CO
2 for 1 h (maintain the inner temperature below -70℃) . After warmed to room temperature, the mixture was quenched with 1N HCl to pH=5, extracted with EtOAc (500 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product 2, 4, 6-trichloro-5- (1, 3-dioxan-2-yl) nicotinic acid (A-2-1) (96 g, quant. ) as a yellow solid which was used directly without further purification. LC/MS (ESI) m/z: 312/314 (M+H)
+.
Step 2: To a solution of 2, 4, 6-trichloro-5- (1, 3-dioxan-2-yl) nicotinic acid (A-2-1) (39 g, 124.78 mmol) and DMF (0.5 mL, 6.24 mmol) in THF (400 mL) was added oxalic dichloride (13 mL, 149.8 mmol) dropwise at -5℃ and the resulting mixture was stirred for 1 h, then bubbled with NH
3 for 1 h (maintain the inner temperature < 0℃) . Then the reaction mixture was warmed to room temperature, the mixture was diluted with EtOAc (400 mL) , filtered and the filtrate was concentrated in vacuo to give the crude product which was purified by flash chromatography on silica gel (EtOAc in DCM =0%~ 10%) to obtain the desired product 2, 4, 6-trichloro-5- (1, 3-dioxan-2-yl) nicotinamide (30 g, yield: 77.2%) as a light yellow solid. LC/MS (ESI) m/z: 311/313 (M+H)
+,
1H NMR (400 MHz, DMSO-d
6) δ 8.21 (br, 1H) , 8.06 (br, 1H) , 6.12 (s, 1H) , 4.19-4.16 (m, 2H) , 3.97-3.94 (m, 2H) , 2.12-2.08 (m, 1H) , 1.48-1.47 (m, 1H) .
Step 3: To a solution of 2, 4, 6-trichloro-5- (1, 3-dioxan-2-yl) nicotinamide (30 g, 96.3 mmol) in AcOH (400 mL) was added HCl (200 mL, 2.4 mol) at 5℃, the reaction mixture was heated to 50℃ for 2 h. the reaction mixture was cooled down to room temperature, the mixture was extracted with EtOAc (400 mL x 3) , the combined the organic phase was washed with sat. NaHCO
3, water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in DCM = 0%~ 5%) to obtain 2, 4, 6-trichloro-5-formylnicotinamide (A-2-2, 20 g, yield: 81.9 %) as a white solid. LC/MS (ESI) m/z: 253/255 (M+H)
+.
Step 4: To a solution of NaHCO
3 (13.3 g, 157.81mmol) and 2, 4, 6-trichloro-5-formylnicotinamide (A-2-2, 20 g, 78.91 mmol, 80%) in THF (600 mL) was added hydrazine hydrate (7.2 mL, 118.39 mmol) dropwised at 10℃, the reaction mixture was stirred for another 4 h at the same temperature. Then the mixture was quenched with sat. NH
4Cl, extracted with EtOAc (100 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in DCM = 0%~ 50%) to obtain the desired product 4, 6-dichloro-1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (A-2-3) (12 g, yield: 65.8%) as a yellow solid. LC/MS (ESI) m/z: 231/233 (M+H) +.
1H NMR (400 MHz, DMSO) δ 14.28 (s, 1H) , 8.44 (s, 1H) , 8.27 (br, 1H) , 8.09 (br, 1H) .
Step 5: To a solution of 4, 6-dichloro-1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (6.0 g, 25.97 mmol) and Na
2CO
3 (8.3 g, 77.91 mmol) in DMF (50 mL) was added PMBCl (5.3 mL, 38.95 mmol) dropwised at room temperature, the reaction mixture was heated to 50℃ for 2 h. Then the reaction mixture was cooled to room temperature, diluted with H
2O (100 mL) , extracted with EtOAc (100 ml x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in DCM = 0%~ 50%) to obtain the desired product 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (A-2-4a, 4.2 g, yield: 46.1%) as a yellow solid. LC/MS (ESI) m/z: 351/353 (M+H)
+.
1H NMR (400 MHz, DMSO) δ 9.06 (s, 1H) , 8.08 (br, 1H) , 7.85 (br, 1H) , 7.39 (d, J = 8.7 Hz, 2H) , 6.93 (d, J = 8.7 Hz, 2H) , 5.63 (s, 2H) , 3.74 (s, 3H) .
Synthesis of key intermediate B-1-3a
Step 1: To a solution of phenyl methanol (99.7 g, 922 mmol) in THF (1 L) was added NaH (44.3 g, 1.1 mol) at 0℃, the reaction mixture was stirred at 0 ℃ for 30 min under a nitrogen atmosphere, then 4-bromo-2, 6-difluorobenzonitrile (200 g, 922 mmol) in THF (1 L) was added dropwised to the solution and stirred for another 2 h. The reaction mixture was quenched by aq. NH
4Cl, extracted with EtOAc (1 L x 2) , the combined organic phase was washed with water and brine dried over Na
2SO
4, concentrated in vacuum to give the crude product 2- (benzyloxy) -4-bromo-6-fluorobenzonitrile (220 g, Yield: 78.2%) as a white solid.
1H NMR (400 MHz, DMSO) δ 7.55 –7.38 (m, 7H) , 5.35 (s, 2H) .
Step 2: To a solution of 2- (benzyloxy) -4-bromo-6-fluorobenzonitrile (220 g, 721.31 mmol) in DCM (2 L) was added BBr
3 (1057 mL, 865.57 mmol) dropwise at -78℃, the reaction mixture was stirred at 0 ℃ for 2 h under a nitrogen atmosphere. The reaction mixture was quenched by MeOH, concentrated in vacuum to give the crude product was purified by column chromatography on silica gel (EtOAc in PE=1%~ 5%) to obtain 4-bromo-2-fluoro-6-hydroxybenzonitrile (B-1-1, 145 g, yield: 93.5%) as a yellow solid. LC/MS (ESI) m/z: 215 (M-H)
+.
Step 3: To a solution of 4-bromo-2-fluoro-6-hydroxybenzonitrile (B-1-1, 145 g, 674.41 mmol) in DCM (1.5 L) was added DIPEA (232 mL, 1.35 mmol) , then MOMCl (59.1 g, 741.85 mmol) was added dropwiseat 0℃. The reaction mixture was stirred at 0 ℃ for 2 h under a nitrogen atmosphere. The reaction mixture was extracted with DCM (500 mL x 2) , the combined organic phase was washed by H
2O and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuum to obtain 4-bromo-2-fluoro-6- (methoxymethoxy) benzonitrile (160 g, yield: 91.6%) as a yellow solid which was used to next step without further purified. LC/MS (ESI) m/z: 477 (M-H)
+,
1H NMR (400 MHz, DMSO) δ 7.55 (dd, J = 8.8, 1.5 Hz, 1H) , 7.45 –7.43 (m, 1H) , 5.45 (s, 2H) , 3.44 (s, 3H)
Step 4: To a solution of 4-bromo-2-fluoro-6- (methoxymethoxy) benzonitrile (160 g, 617.76 mmol) in THF (1.6 L) was added LDA (401.5 mL, 803.09 mmol, 2M in THF) dropwise at -78℃, the mixture was stirred at -78 ℃ for 2 h under a nitrogen atmosphere, then DMF (117.3 g, 1606.18 mmol) was added to the mixture and keep the inner temperature under -70 ℃, the reaction mixture was stirred for another 1h at -78 ℃. The reaction mixture was quenched by aq. NH
4Cl, extracted with EtOAc (2 L x 2) , washed by H
2O and brine, dried over Na
2SO
4, concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=1%~ 10%) to obtain the desired product 4-bromo-2-fluoro-3-formyl-6- (methoxymethoxy) benzonitrile (B-1-1, 115 g, yield: 65%) as a yellow solid. LC/MS (ESI) m/z: 289 (M-H)
+.
Step 5: To a solution of 4-bromo-2-fluoro-3-formyl-6- (methoxymethoxy) benzonitrile (115 g, 400.70 mmol) in MeCN (1.5 L) was added N
2H
4. H
2O (26 g, 400.70 mmol, 80%in H
2O) dropwised at 0℃,the mixture was stirred at 0℃ for 1h, then the reaction mixture heated to 90℃ for 12 h. The reaction mixture was extracted with EtOAc (2 L x 2) , the combined organic phase was washed with water and brine, dried over Na
2SO
4, concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM=1%~ 5%) to obtain the desired product 4-bromo-6- (methoxymethoxy) -1H-indazole-7-carbonitrile (65 g, yield: 57.7%) as a white solid. LC/MS (ESI) m/z: 281 (M+1) +/283 (M+2) +,
1H NMR (400 MHz, DMSO) δ 14.13 (s, 1H) , 8.15 (d, J = 1.2 Hz, 1H) , 7.47 (s, 1H) , 5.48 (s, 2H) , 3.47 (s, 3H) .
Step 6: To a solution of 4-bromo-6- (methoxymethoxy) -1H-indazole-7-carbonitrile (27 g, 96.09 mmol) in DMF (300 mL) was added K
2CO
3 (26.5 g, 192.17 mmol) , and PMBCl (17.9 g, 115.3 mmol) , the mixture was stirred at 60℃ for 2 h. The reaction mixture was extracted with EtOAc (500 mL x 2) , washed with water and brine, dried over Na
2SO
4, the crude product was purified by column chromatography on silica gel (EtOAc in PE=1%to 10%) to obtain 4-bromo-1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile B-1-3a (12 g, yield: 30%) and 4-bromo-2- (4-methoxybenzyl) -6- (methoxymethoxy) -2H-indazole-7-carbonitrile B-1-3b (21.6 g, yield: 64%) as a yellow solid. LC/MS (ESI) m/z: 241 (M+H)
+
Synthesis of key intermediate 4-bromo-6-hydroxy-2- (4-methoxybenzyl) -2H-indazole-7-carbonitrile
(B-1-3d)
To a solution of 4-bromo-2- (4-methoxybenzyl) -6- (methoxymethoxy) -2H-indazole-7-carbonitrile (400 mg, 0.99 mmol) in THF (2 mL) was added HCl (2 mL, 2 mmol/mL) , the reaction mixture was stirred at 55℃ for 2 h. The mixture was diluted with H
2O (10 mL) , extracted with EtOAc (10 mL x 2) , The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product 4-bromo-6-hydroxy-2- (4-methoxybenzyl) -2H-indazole-7-carbonitrile (300 mg, 84.9%) as a white solid, which was used to next step directly without further purified. LC/MS (ESI) m/z: 358 [M+1]
+
Synthesis of key intermediate B-1-6
Step 1: To a stirred solution of methyl 5-bromo-2-hydroxy-4-methylbenzoate (5.0 g, 20.4 mmol) and K2CO3 (4.0 g, 28.9 mmol) in DMF (30 mL) was added MeI (3.6 g, 25.352 mmol) at room temperature slowly, the reaction mixture was stirred at 60℃ for 18h. The reaction mixture was diluted with water (200 mL) and extracted with EtOAc (100 mL x 3) . The combined organic phases were washed with water and brine. The organic phase was dried over anhydrous Na2SO4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=1%to 10%) to obtain methyl 5-bromo-2-methoxy-4-methylbenzoate (5.0 g, yield: 94.59%) as a white solid. LC/MS (ESI) m/z: 260 (M+H) +.
1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H) , 6.84 (s, 1H) , 3.88 (s, 3H) , 3.87 (s, 3H) , 2.42 (s, 3H) .
Step 2: To a stirred H
2SO
4 (30 mL) at 0℃ was added methyl 5-bromo-2-methoxy-4-methylbenzoate (5.0 g, 19.2 mmol) in portions. After the solution was clear, HNO
3 (1.25 mL, 19.2 mmol) was added dropwised over 30min, the mixture was stirred at 0℃ for extra 1h. The reaction mixture was diluted with sat. NaHCO
3 (200 mL) , extracted with EtOAc (100 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=0 to 10%) to obtain methyl 5-bromo-2-methoxy-4-methyl-3-nitrobenzoate (5.2 g , yield: 88.6%) as a pale oil. LC/MS (ESI) m/z: 305 (M+H)
+.
1H NMR (400 MHz, CDCl
3) δ 8.16 (s, 1H) , 3.93 (s, 3H) , 3.91 (s, 3H) , 2.35 (s, 3H) .
Step 3: To a stirred solution of methyl 5-bromo-2-methoxy-4-methyl-3-nitrobenzoate (2g, 6.5 mmol) and Fe powder (2g, 35.7 mmol) in EtOH (20mL) at 25 ℃ was added HCl (0.2 mL, 2.400 mmol) and then heated to 80℃ stirred for 18 h. The reaction mixture was cooled down to r.t. and filtered, The filtrate was diluted with water (20 mL) , the mixture was extracted with EtOAc (30 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE= 2%~ 50%) to obtain methyl 3-amino-5-bromo-2-methoxy-4-methylbenzoate (560 mg, yield: 31.0%) as a yellow solid. LC/MS (ESI) m/z: 275 (M+H)
+.
1H NMR (400 MHz, CDCl
3) δ 7.48 (s, 1H) , 4.05 (s, 2H) , 3.90 (s, 3H) , 3.83 (s, 3H) , 2.30 (s, 3H) .
Step 4: To a stirred solution of methyl 3-amino-5-bromo-2-methoxy-4-methylbenzoate (300 mg, 1.0 mmol) in HBF
4 (2 mL, 31.4 mmol) was added NaNO
2 (75 mg, 1.0 mmol, in 1mLwater) dropwised. The reaction mixture was stirred at 10℃ for 30 min and precipitate formed. The cooled reaction mixture was filtered and the solid product washed with small amounts of H
2O, MeOH and Et
2O subsequently and dried under high vacuum to obtain yellow solid 400mg of diazonium salt. In another dry flask, 18-crowm-6 (289 mg, 1.0 mmol) and AcOK (200 mg, 2.0 mmol) were pre-dried under high vacuum for 1 h and CHCl
3 (50mL) was added. The suspension was stirred at room temperature for 10 min. Then the diazonium salt was added to the mixture in small portions under N
2 atmosphere. The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with water (20 mL) , extracted with EtOAc (15 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE= 2%~ 25%) to obtain methyl4-bromo-7-methoxy-1H-indazole-6-carboxylate ( (B-1-6, 180 mg, yield: 57.7%) as a yellow solid. LC/MS (ESI) m/z: 285 (M+H)
+ 287 (M+H+2)
+.
1H NMR (400 MHz, CDCl
3) δ 8.10 (s, 1H) , 7.76 (s, 1H) , 4.08 (s, 3H) , 3.97 (s, 3H) .
Preparation of boronic acid intermediates
N- { [3-chloro-4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl} -5-fluoro-2-methoxybenzamide (intermediate A)
Step 1: To a solution of Sodium hydride (417 mg, 10.44mmol) in dry DMF (10 mL) was added tert-butyl N- [ (tert-butoxy) carbonyl] carbamate (756 mg, 3.48 mmol) portion wise at 0℃, the resulting mixture was stirred for 1 h at 0℃ followed by the addition of 1-bromo-4- (bromomethyl) -2-chlorobenzene (900 mg, 3.17 mmol) , the reaction mixture was stirred for another 2 h at the same temperature. Then the mixture was quenched with cold sat. NH
4Cl, extracted with EtOAc (40 mL x 3) , washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to obtain tert-butyl N- [ (4-bromo-3-chlorophenyl) methyl] -N- [ (tert-butoxy) carbonyl] carbamate (1.6 g, 100%) as a white solid which was used directly without further purification. LC/MS (ESI) m/z: 420/422 (M+H)
+.
Step 2: To a solution of tert-butyl N- [ (4-bromo-3-chlorophenyl) methyl] -N- [ (tert-butoxy) carbonyl] carbamate (1.6 g, 3.8 mmol) in EtOAc (10 mL) was added HCl (10 mL, 4 mol/L in 1, 4-dioxane) at 0℃, the reaction mixture was stirred for 2 h at room temperature. Then concentrated under reduced pressure to obtain crude product (4-bromo-3-chlorophenyl) methanamine hydrochloride (0.7 g, yield: 83.3%) as a yellow solid, which was used to next step directly without further purification. LC/MS (ESI) m/z: 220/222 (M+H)
+.
Step 3: To a solution of (4-bromo-3-chlorophenyl) methanamine hydrochloride (0.7 g, 3.18 mmol) , 5-fluoro-2-methoxybenzoic acid (0.65g, 3.81 mmol) and HATU (1.69 g, 4.44 mmol) in DMF (5 mL) was added TEA (1.32 mL, 9.52 mmol) , the mixture was stirred for 2 h at room temperature. Then the mixture was diluted with H
2O (20 mL) and extracted with EtOAc (30 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to get the residue which was purified by column chromatography on silica gel (EtOAc in PE = 0%~ 20%) to obtain the desired product N- [ (4-bromo-3-chlorophenyl) methyl] -5-fluoro-2-methoxybenzamide (0.8 g, yield: 67.63%) as a white solid. LC/MS (ESI) m/z: 372/374 (M+H)
+.
Step 4: To a solution of N- [ (4-bromo-3-chlorophenyl) methyl] -5-fluoro-2-methoxybenzamide (0.8 g, 2.15 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (0.82 g, 3.22 mmol) in 1, 4-dioxane (20 mL) was added Pd (dppf) Cl
2 (0.16 g, 0.22 mmol) and KOAc (0.42 g, 4.29 mmol) . The resulting mixture was heated to 110℃ for 12h under N
2 atmosphere. After cooled down to room temperature, the mixture was diluted with H
2O (10 mL) , extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0%~ 20%) to obtain the desired product N- { [3-chloro-4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl} -5-fluoro-2-methoxybenzamide (720 mg, yield: 79.91%) as a light-yellow solid.
Intermediate B:
5-Fluoro-2- (methoxy-d3) -N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide
Step 1: A solution of 4-bromobenzoic acid (2.0 g, 10 mmol) in SOCl
2 (10 mL) was heated to 85℃for 2h under N
2 atmosphere. Then the reaction mixture was cooled down to room temperature, the solvent was removed under vacuo to give the crude product 4-bromobenzoyl chloride (2.2 g, yield: 100%) which was used to next step directly without purification.
Step 2: To a solution of 4-bromo-N- (4- (trifluoromethyl) pyridin-2-yl) benzamide (2.2 g, 10 mmol) in pyridine (10 mL) was added 4- (trifluoromethyl) pyridin-2-amine (1.6 g, 10 mmol) . The resulting mixture was stirred at 65℃ overnight under N
2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0%~ 3%) to obtain the desired product 4-bromo-N- (4- (trifluoromethyl) pyridin-2-yl) benzamide (2.7 g, yield: 78.5%) as a white solid. LC/MS (ESI) m/z: 345 (M+H)
+.
Step 3: To a stirred solution of 4-bromo-N- (4- (trifluoromethyl) pyridin-2-yl) benzamide (2.7 g, 7.85 mmol) and 4, 4, 4', 4', 5, 5, 5', 5'-octamethyl-2, 2'-bi (1, 3, 2-dioxaborolane) (3.0 g, 11.76 mmol) in dioxane (10 mL) was added KOAc (1.5 g, 15.7 mmol) and Pd (dppf) Cl
2 (0.6 g, 0.78 mmol) . The resulting mixture was heated to 110℃ for 12h under N
2 atmosphere. After cooled down to room temperature, the mixture was diluted with H
2O (10 mL) , extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 30%) to obtain 4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -N- (4- (trifluoromethyl) pyridin-2-yl) benzamide (2.8 g, yield: 91%) as a white solid. LC/MS (ESI) m/z: 393 (M+H)
+.
Intermediate C:
5-Fluoro-2- (methoxy-d3) -N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide
Step 1: To a solution of N- (4-bromobenzyl) -5-fluoro-2-methoxybenzamide (2.7 g, 8.01 mmol) in DCM (30 mL) was added BBr
3 (16 mL, 16 mmol, 1M in DCM) under -50℃ during 30 min. Then the reaction mixture was stirred for 2h at this temperature, the mixture was quenched with NH4Cl (30 mL) , extracted with DCM (30 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0%~ 3%) to obtain the desired product N- (4-bromobenzyl) -5-fluoro-2-hydroxybenzamide (2.5 g, yield: 96.6%) as a white solid. LC/MS (ESI) m/z: 324 (M+H)
+.
Step 2: To a solution of N- (4-bromobenzyl) -5-fluoro-2-hydroxybenzamide (2.5 g, 7.74 mmol) in MeCN (20 mL) was added K
2CO
3 (1.6 g, 11.61 mmol) and CD
3I (1.4 g, 9.30 mmol) . The resulting mixture was stirred at rt for 3 h under N
2 atmosphere. The mixture was diluted with H
2O (20 mL) , extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0%~ 3%) to obtain the desired product N- (4-bromobenzyl) -5-fluoro-2- (methoxy-d3) benzamide (0.8 g, yield: 30.4 %) as a white solid. LC/MS (ESI) m/z: 341 (M+H)
+.
Step 3: To a stirred solution of N- (4-bromobenzyl) -5-fluoro-2- (methoxy-d3) benzamide (800 mg, 2.35mmol) and 4, 4, 4', 4', 5, 5, 5', 5'-octamethyl-2, 2'-bi (1, 3, 2-dioxaborolane) (716 mg, 2.82 mmol) in dioxane (10 mL) was added AcOK (461 mg, 4.70 mmol) and Pd (dppf) Cl
2 (172 mg, 0.24 mmol) . The resulting mixture was heated to 100℃ for 12h under N
2 atmosphere. After cooled down to room temperature, the mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 100%) to obtain 5-fluoro-2- (methoxy-d3) -N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (900 mg, yield: 98.8%) as a white solid. LC/MS (ESI) m/z: 389 (M+H)
+.
Intermediate H:
tert-Butyldiphenyl (3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) cyclopent-3-enyloxy) silane
Step 1: To a solution of cyclopent-3-enol (7.1 g, 84.4 mmol) and imidazole (11.5 g, 168.8 mmol) in DMF (70 mL) was added TBDPSCl (25.4 g, 92.84 mmol) at 0℃, and the resulting mixture was stirred at 0 ℃ for 2 h. The mixture was diluted with H
2O (300 mL) , extracted with EtOAc (100 mL x 3) , then the organic layer was washed by water and brine, the collected organic layer was dried over Na
2SO
4 and concentrated to give a crude product which purified by column chromatography on silica gel (PE =100%) to afford tert-butyl (cyclopent-3-enyloxy) diphenylsilane (27.2 g, yield: 99.9%) as a colorless oil.
Step 2: To a solution of tert-butyl (cyclopent-3-enyloxy) diphenylsilane (27.2 g, 84.33 mmol) in CCl
4 (270 mL) was added Br
2 (4.3 mL, 84.33 mmol) at rt under N
2. The mixture was stirred for 3 h until the starting material was consumed completely. The mixture was concentrate to give a crude product which was purified by column chromatography on silica gel (PE = 100%) to give tert-butyl (3, 4-dibromocyclopentyloxy) diphenylsilane (33 g, yield: 80.9%) as a colorless oil.
Step 3: To a stirred solution of tert-butyl (3, 4-dibromocyclopentyloxy) diphenylsilane (8 g, 17.16 mmol) in THF (100 mL) was added t-BuOK (9 g, 80.37 mmol) at 0℃ slowly and the reaction mixture was stirred at 25℃ for 18h. The reaction mixture was diluted with water (200 mL) at 0℃, the mixture was extracted with EtOAc (200 mL x 3) , the combined organic phase was washed by water and brine, the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=5%) to obtain (3-bromocyclopent-3-enyloxy) (tert-butyl) diphenylsilane (3 g, yield: 45.4%) as a colorless oil.
Step 4: To a stirred solution of (3-bromocyclopent-3-enyloxy) (tert-butyl) diphenylsilane (3 g, 7.5 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (1.8 g, 7.8 mmol) in 1, 4-dioxane (30 mL) was added Pd (dppf) Cl
2 (200 mg, 0.27 mmol) at 25℃ slowly. The resulting mixture was heated to 100℃ for 12h under N
2 atmosphere. After cooled down to room temperature, the mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0%~ 30%) to obtain tert-butyldiphenyl (3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) cyclopent-3-enyloxy) silane (2 g, yield: 59.7%) as a colorless oil.
1H NMR (400 MHz, CDCl
3) δ 7.66 (dt, J = 8.0, 1.8 Hz, 4H) , 7.38 (ddd, J = 18.0, 9.8, 4.7 Hz, 6H) , 6.45 –6.37 (m, 1H) , 4.56 (dq, J = 6.4, 4.8 Hz, 1H) , 2.70 –2.44 (m, 4H) , 1.26 (s, 12H) , 1.04 (s, 9H) .
Intermediate I:
Synthesis of 4, 4, 5, 5-tetramethyl-2- (2-methyl-4, 5-dihydrofuran-3-yl) -1, 3, 2-dioxaborolane
Step 1: To a solution of 2-methyloxolan-3-one (3 g, 29.96 mmol) in THF (40 mL) was added LDA (18.0 mL, 36.0 mmol) dropwise at -78℃, the resulting mixture was stirred at -78℃ for 1 h under nitrogen atmosphere, before 1, 1, 1-trifluoro-N-phenyl-N-trifluoromethanesulfonylmethanesulfonamide (10.70 g, 29.964 mmol in THF (10 mL) ) was added, the reaction mixture was stirred at -78℃ for another 1 hr. The mixture was poured into ice aq. NH
4Cl (20 mL) , extracted with EtOAc (30 mL x 3) . The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in petroleum = 1%to 5%) to obtain the desired product 2-methyl-4, 5-dihydrofuran-3-yl trifluoromethanesulfonate (700 mg, yield: 10 %) as an yellow oil, which can be used to next step directly without further purification.
LC/MS (ESI) m/z: 233 [M+1]
+
Step 2: To a solution of 2-methyl-4, 5-dihydrofuran-3-yl trifluoromethanesulfonate (700 mg, 3.0 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (766 mg, 3.0 mmol) in dioxane (10 mL) was added KOAc (591 mg, 6.0 mmol) and Pd (dppf) Cl2 (110 mg, 0.15 mmol) , the reaction mixture was stirred at 85℃ for 3 h under nitrogen atmosphere. The reaction mixture was concentrated in vacuum to get the crude product which was purified by column chromatography on silica gel (EtOAc in petroleum = 1%to 5%) to obtain the desired product 4, 4, 5, 5-tetramethyl-2- (2-methyl-4, 5-dihydrofuran-3-yl) -1, 3, 2-dioxaborolane (400 mg, yield: 63.1%) as an colorless oil. LC/MS (ESI) m/z: 211 [M+1]
+
Intermediate K:
Synthesis of 2-methyl-3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) cyclopent-2-enone
Step 1: To a stirred solution of 2-methylcyclopentane-1, 3-dione (0.93 mL, 8.92 mmol) and DIPEA (1.8 mL, 10.83 mmol) in Et
2O (30 mL) was added Tf
2O (1.6 mL, 10 mmol) at -78℃ slowly and the reaction mixture was stirred at -78℃ for 1.5h under nitrogen atmosphere. The reaction mixture was diluted with water (40 mL) , the mixture was extracted with EtOAc (60 mL x 3) , the combined organic phase was washed by water and brine, the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (PE in DCM=0 %to 10%) to obtain 2-methyl-3-oxocyclopent-1-enyl trifluoromethanesulfonate (1.5 g, yield: 69%) as a colorless oil. LC/MS (ESI) m/z: 245 [M+1] +, 1H NMR (400 MHz, CDCl
3) δ 2.92 (m, 2H) , 2.71 –2.60 (m, 2H) , 1.79 (m, 3H) .
.
Step 2: To a stirred solution of 2-methyl-3-oxocyclopent-1-enyl trifluoromethanesulfonate (500 mg, 2.048 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (0.61 mL, 2.36 mmol) in 1, 4-dioxane (10 mL) was added Pd (dppf) Cl
2 (100 mg, 0.14 mmol) and KOAc (500 mg, 5.09 mmol) at 25℃ slowly and the reaction mixture was stirred at 100℃ for 2h under nitrogen atmosphere. The reaction mixture was diluted with water (40 mL) , the mixture was extracted with EtOAc (60 mL x 3) , the combined organic phase was washed by water and brine, the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (PE in DCM=0%to 50%) to obtain 2-methyl-3- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) cyclopent-2-en-1-one (300 mg, yield: 66%) as a colorless oil. LC/MS (ESI) m/z: 223 [M+1]
+,
1H NMR (400 MHz, CDCl
3) δ 2.65 –2.58 (m, 2H) , 2.33 (dd, J = 8.6, 4.1 Hz, 2H) , 1.97 –1.91 (m, 3H) , 1.31 (d, J = 3.3 Hz, 12H) .
Intermediate L:
Synthesis of tert-butyl 5-methyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2, 3-dihydro-1H-pyrrole-1-carboxylate
Step 1: To a solution of methyl alaninate (14.0 g, 135.92 mmol) and ethyl acrylate (27.2 g, 271.84 mmol) in EtOH (200 mL) was added TEA (27.5 g, 271.84 mmol) under N
2. The reaction mixture was heated to rt overnight. The reaction mixture was diluted with EtOAc (300 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 10%~ 20%) to obtain the desired product ethyl 3- ( (1-methoxy-1-oxopropan-2-yl) amino) propanoate (11.0 g, yield: 39.87 %) as an off-white oil. LC/MS (ESI) m/z: 204 (M+H)
+
Step 2: To a solution of ethyl 3- ( (1-methoxy-1-oxopropan-2-yl) amino) propanoate (11.0 g, 54.19 mmol) in DCM (200 mL) was added Boc
2O (23.6 g, 108.38 mmol) and TEA (20.2 g, 200 mmol) under N
2. The reaction mixture was stirred at rt overnight. The reaction mixture was diluted with DCM (100 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 10%~ 20%) to obtain the desired product ethyl 3- ( (tert-butoxycarbonyl) (1-methoxy-1-oxopropan-2-yl) amino) propanoate (15.0 g, yield: 91.5%) as an off-white oil. LC/MS (ESI) m/z: 304 (M+H)
+
Step 3: To a solution of ethyl 3- ( (tert-butoxycarbonyl) (1-methoxy-1-oxopropan-2-yl) amino) propanoate (15.0 g, 49.50 mmol) in toluene (150 mL) was added t-BuOK (11.1 g, 99 mmol) under N
2. The reaction mixture was stirred at rt for 2 hr. The reaction mixture was diluted with DCM (150 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 10%~ 40%) to obtain the desired mixture product 1- (tert-butyl) 3-ethyl 5-methyl-4-oxopyrrolidine-1, 3-dicarboxylate and 1- (tert-butyl) 2-methyl 2-methyl-3-oxopyrrolidine-1, 2-dicarboxylate (9.0 g, yield: 70.75%) as an off-white oil. LC/MS (ESI) m/z: 258 and 272 (M+H)
+
Step 4: To a solution of 1- (tert-butyl) 3-ethyl 5-methyl-4-oxopyrrolidine-1, 3-dicarboxylate and 1- (tert-butyl) 2-methyl 2-methyl-3-oxopyrrolidine-1, 2-dicarboxylate (9.0 g, 35.02 mmol) in EtOH (20 mL) was added con. HCl (4 mL) . The mixture was stirred at 90 ℃ for 1h in a sealed tank. After cooled down to rt, was diluted with DCM (150 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was used without purification to obtain the desired 2-methylpyrrolidin-3-one (3.45 g, yield: 100%) as an off-white oil. LC/MS (ESI) m/z: 100 (M+H)
+
Step 5: To a solution of 2-methylpyrrolidin-3-one (3.45 g, 34.85 mmol) in DCM (20 mL) was added Boc
2O (15.2 g, 69.7 mmol) and DIPEA (7 g, 69.7 mmol) under N
2. The reaction mixture was stirred at rt for 1h. The reaction mixture was diluted with DCM (100 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 5%~ 30%) to obtain the desired product tert-butyl 2-methyl-3-oxopyrrolidine-1-carboxylate (6.5 g, yield: 93.26%) as an off-white oil. LC/MS (ESI) m/z: 200 (M+H)
+
Step 6: To a solution of tert-butyl 2-methyl-3-oxopyrrolidine-1-carboxylate (3.0 g, 15.08 mmol) in THF (20 mL) was added LiHMDS (15.08 mL, 2.0 mmol/mL, 30.16 mmol) under N
2. The reaction mixture was stirred at -78℃ for 1h. Then Tf
2O (5.10 g, 18.10 mmol) was added and stirred at -78℃ for another 2 h. The reaction mixture was diluted with DCM (100 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 5%~ 30%) to obtain the desired product tert-butyl 5-methyl-4- ( ( (trifluoromethyl) sulfonyl) oxy) -2, 3-dihydro-1H-pyrrole-1-carboxylate (1.9 g, yield: 38.06%) as an off-white oil. LC/MS (ESI) m/z: 332 (M+H)
+
Step 7: To a solution of tert-butyl 5-methyl-4- ( ( (trifluoromethyl) sulfonyl) oxy) -2, 3-dihydro-1H-pyrrole-1-carboxylate (1.9 g, 5.74 mmol) in dioxane (20 mL) was added Pd (dppf) Cl
2 (0.42 g, 0.57 mmol) , 4, 4, 4', 4', 5, 5, 5', 5'-octamethyl-2, 2'-bi (1, 3, 2-dioxaborolane) (2.2 g, 8.61 mmol) and AcOK (1.1g, 11.48 nnol) under N
2. The reaction mixture was stirred at 90℃ for 3h. The reaction mixture was diluted with DCM (100 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 5%~ 30%) to obtain the desired product tert-butyl 5-methyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2, 3-dihydro-1H-pyrrole-1-carboxylate (1.3 g, yield: 73.30%) as an off-white oil. LC/MS (ESI) m/z: 310 (M+H)
+
Intermediate M:
3-methyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2- (trifluoromethyl) pyridine
Step 1: To a solution of 2- (trifluoromethyl) pyridin-4-amine (3 g, 18.51 mmol) in MeCN (50 mL) was added NBS (8.23 g, 46.27 mmol) portion wise at 0℃, the resulting mixture was warmed to room temperature and stirred overnight. Then the mixture was mixture was diluted with H
2O (50 mL) , extracted with EtOAc (50 mL x 3) , washed by water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 10%) to obtain 3, 5-dibromo-2- (trifluoromethyl) pyridin-4-amine (3 g, yield: 50.7%) as a yellow oil. LC/MS: m/z: 319/321/323 (M+H)
+.
1H NMR (400 MHz, CDCl
3) δ 8.37 (s, 1H) , 5.46 (s, 2H) .
Step 2: To a solution of 3, 5-dibromo-2- (trifluoromethyl) pyridin-4-amine (800 mg, 2.50 mmol) in EtOH (20 mL) was added Pd/C (10%, 133 mg, 0.13 mmol) . The mixture was stirred for 3 h at room temperature. Then the mixture was filtered through a pad of cite and the filtrate was concentrated in vacuo to give the crude product which was purified by flash chromatography on silica gel (EtOAc in PE = 0 ~ 50%) to obtain 3-bromo-2- (trifluoromethyl) pyridin-4-amine (400 mg, yield: 66.4%) as a yellow solid. LC/MS: m/z: 241/243 (M+H)
+.
1H NMR (400 MHz, DMSO-d
6) δ8.07 (d, J = 5.6 Hz, 1H) , 6.94 (d, J = 5.6 Hz, 1H) , 5.75 (br, 2H) .
Step 3: To a mixture of 3-bromo-2- (trifluoromethyl) pyridin-4-amine (400 mg, 1.66 mmol) and trimethyl-1, 3, 5, 2, 4, 6-trioxatriborinane (0.95 mL, 3.32 mmol, 3.5 M in THF) in 1, 4-dioxane (8 mL) and H
2O (2 mL) was added K
2CO
3 (459 mg, 3.32 mmol) and Pd (dppf) Cl
2 (121 mg, 0.17 mmol) . The resulting mixture was heated to 80℃ for 12h under N
2 atmosphere. After cooled down to room temperature, the mixture was diluted with H
2O (10 mL) , extracted with EtOAc (10 mL x 3) , washed by water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 50%) to obtain 3-methyl-2- (trifluoromethyl) pyridin-4-amine (200 mg, yield: 68.4%) as a yellow solid. LC/MS: m/z: 177 (M+H)
+.
Step 4: To a mixture of 3-methyl-2- (trifluoromethyl) pyridin-4-amine (200 mg, 1.14 mmol) in MeCN (10 mL) was added tert-butyl nitrite (0.27 mL, 2.27 mmol) and CuBr
2 (363 mg, 2.27 mmol) . The resulting mixture was heated to 80℃ for 12h under N
2 atmosphere. After cooled down to room temperature, the mixture was diluted with H
2O (10 mL) , extracted with EtOAc (10 mL x 3) , washed by water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 5%) to obtain 4-bromo-3-methyl-2- (trifluoromethyl) pyridine (80 mg, yield: 29.4%) as a yellow oil. LC/MS: m/z: 240/242 (M+H)
+.
Step 5: To a mixture of 4-bromo-3-methyl-2- (trifluoromethyl) pyridine (80 mg, 0.33 mmol) and 4, 4, 5, 5-tetramethyl-2- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 3, 2-dioxaborolane (127 mg, 0.50 mmol) in 1, 4-dioxane (10 mL) was added KOAc (65 mg, 0.67 mmol) and Pd (dppf) Cl
2 (24 mg, 0.03 mmol) . The resulting mixture was heated to 100℃ and stirred overnight under N
2 atmosphere. After cooled down to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo to obtain [3-methyl-2- (trifluoromethyl) pyridin-4-yl] boronic acid (80 mg, yield: 117.2%) as a brown oil, which can be used to next step directly without further purification. LC/MS: m/z: 206 (M+H)
+.
Intermediate N: 4, 6-dimethylpyrimidin-5-ylboronic acid
To a solution of 5-bromo-4, 6-dimethylpyrimidine (500 mg, 2.67 mmol) in THF (10 mL) was added n-BuLi (1.6 mL, 1.6 mmol/mL) dropwise at -78℃ and stirred at -78℃ for 1 h under nitrogen atmosphere before B (OMe)
3 (780 mg, 5.34 mmol in 5 ml THF) was added, the reaction mixture was stirred at -78℃ for another 1 hr. The mixture was poured into ice aq. NH
4Cl (20 mL) , extracted with EtOAc (20 mL x 3) . The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM = 2%-5%) to obtain (4, 6-dimethylpyrimidin-5-yl) boronic acid (8 mg , yield: 1.97%) as a yellow solid. LC/MS (ESI) m/z: 153 [M+1] +
Table 1. Preparation of boronic ester intermediate. Boroic esters D –G were prepared by procedures similar to that of Intermediate A, B, C; Intermediate J was prepared by procedures similar to that of Intermediate I, Intermediates O-U were prepared by procedures similar to that of Intermediates K-N with modification from commercially available starting material
Example 1:
4-Cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxam ide (BNB-1049-01)
Step 1: To a solution of 7-bromo-4, 6-dichloro-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine (2.2g, 5.7 mmol) , 2- (cyclopent-1-en-1-yl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (1.1 g, 5.7 mmol) and Na
2CO
3 (1.2g, 11.4 mmol) in dioxane (20.0 mL) and H
2O (4.0 mL) was added Pd (PPh
3)
4 (330mg, 0.3 mmol) , the mixture was stirred at 60 ℃ for 10 h under N
2 atmosphere. The reaction mixture was concentrated in vacuum and the crude product was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 10%) to obtain the desired product 7-bromo-6-chloro-4- (cyclopent-1-en-1-yl) -1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine (1.1 g, yield: 46.2%) as a white solid. LC/MS (ESI) m/z: 418/420 [M+H] +,
1H NMR (400 MHz, CDCl
3) δ8.27 (s, 1H) , 7.13 (d, J = 8.7 Hz, 2H) , 6.85 –6.79 (m, 3H) , 5.94 (d, J = 5.7 Hz, 2H) , 3.77 (s, 3H) , 3.06 –2.87 (m, 2H) , 2.64 (m, 2H) , 2.13 –2.03 (m, 2H) .
Step 2: To a solution of 7-bromo-6-chloro-4-cyclopentenyl-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine (0.3 g, 0.7mmol) in MeOH (5 mL) was added Pd (dppf) Cl
2 (52.4 mg, 0.1 mmol) and TEA (0.3 mL, 2.2 mmol) . The resulting mixture was stirred at 85 ℃ under CO (70 psi) in a sealed tank overnight. After cooled down to rt, the solvent was concentrated under reduced pressure to give the crude product which was purified by column chromatography on silica gel (EtOAc in DCM = 0 ~ 50%) to obtain methyl 6-chloro-4- (cyclopent-1-en-1-yl) -1- [ (4-methoxy-phenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carbo xylate (240 mg, yield: 84.2%) as a yellow solid. LC/MS (ESI) m/z: 398 (M+H)
+.
Step 3: To a solution of methyl 6-chloro-4- (cyclopent-1-en-1-yl) -1- [ (4-methoxyphenyl) -methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (240 mg, 0.6 mmol) in dioxane (8 mL) and H
2O (2 mL) were added 2- (2-methoxyphenyl) -N- { [4- (4, 4, 5, 5-tetramethyl-1, 3-dioxolan-2-yl) phenyl] methyl} acetamide (231 mg, 0.6mmol) , Pd (dppf) Cl
2 (52 mg, 0.1 mmol) and K
2CO
3 (250 mg, 1.8 mmol) . Then the resulting mixture was stirred for 2 h at 100 ℃ under N
2 atmosphere. After cooled down to rt, water (5 mL) was added and extract with EtOAc (10 x 3 mL) . The combined organic layer was washed with water and brine, dried over Na
2SO
4, filtered and concentrated give the crude product which was purified by column chromatography on silica gel (EtOAc in DCM= 0 ~ 15%) to obtain methyl 4- (cyclopent-1-en-1-yl) -6- (4- { [ (2-methoxyphenyl) formamido] methyl} phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (260 mg, yield: 71.5%) as a yellow solid. LC/MS (ESI) m/z: 603 (M+H)
+.
Step 4: To a solution of methyl 4- (cyclopent-1-en-1-yl) -6- (4- { [ (2-methoxyphenyl) -formamido] methyl} phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (260 mg, 0.4 mmol) in MeOH (5 mL) was added Pd/C (61 mg, 20%wet) and two drops of formic acid. The resulting mixture was stirred at 60 ℃ for 2 h under H
2 balloon. After cooled down to room temperature, the mixture was filtered, the filtrate was concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in DCM= 0 ~ 20%) to obtain desired product methyl 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (200 mg, yield: 76.7%) as a yellow solid. LC/MS (ESI) m/z: 605 (M+H)
+.
Step 5: To a solution of methyl 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (250 mg, 0.4 mmol) in DCM (5 mL) was added TFA (5 mL) . The resulting mixture was stirred at 40 ℃ for 1 h. After cooled down to rt, the reaction mixture was diluted with DCM (20 mL) , and adjust pH with sat. NaHCO
3 solution. The organic phase was dried over anhydrous Na
2SO
4 and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in DCM= 0 ~ 50%) to obtain methyl 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (100 mg, yield: 49.9%) as a yellow solid. LC/MS (ESI) m/z: 485 (M+H)
+.
Step 6: To a solution of methyl 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (100 mg, 0.2 mmol) in THF (5 mL) was added ammonia (28%in water) . The mixture was stirred at 100 ℃ for 6 h in a sealed tank. After cooled down to rt, the reaction mixture was concentrated to give the crude product which was purified by prep-TLC (DCM: MeOH=15: 1) to obtain the desired product 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (3 mg, yield: 3.1%) as a light yellow solid.
1H NMR (400 MHz, MeOD) δ 8.34 (s, 1H) , 7.91 (dd, J = 7.7, 1.8 Hz, 1H) , 7.76 (d, J = 8.3 Hz, 2H) , 7.50 (ddd, J = 16.0, 8.9, 5.1 Hz, 3H) , 7.16 (d, J = 8.3 Hz, 1H) , 7.10 –7.04 (m, 1H) , 4.69 (s, 2H) , 4.58 (s, 2H) , 3.97 (s, 3H) , 3.76 –3.70 (m, 1H) , 2.20 –2.05 (m, 4H) , 1.98 –1.89 (m, 2H) , 1.81 (m, 2H) ; LC/MS (ESI) m/z: 470 (M+H)
+.
Example 2:
6- (4- ( (5-Fluoro-2-methoxybenzamido) methyl) phenyl) -4- (4-hydroxycyclohexyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (BNB-1055-01)
Step 1: To a solution of 7-bromo-4, 6-dichloro-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine (560 mg, 1.45 mmol) , 4, 4, 5, 5-tetramethyl-2- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1, 3, 2- dioxaborolane (365 mg, 1.37 mmol) and Na
2CO
3 (460 mg, 4.34 mmol) in dioxane (10 mL) and H
2O (2.0 mL) was added Pd (PPh
3)
4 (83 mg, 0.01 mmol) , the mixture was stirred at 60 ℃ for 10 h under N
2 atmosphere. The reaction mixture was concentrated in vacuum and the crude product was purified by column chromatography on silica gel (EtOAc in PE= 2%~ 10%) to obtain the desired product 7-bromo-6-chloro-1- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1H-pyrazolo [4, 3-c] pyr idine (510 mg, yield: 72%) as a white solid.
1H NMR (400 MHz, DMSO) δ 9.24 (s, 1H) , 7.37 (d, J =8.7 Hz, 2H) , 6.93 (d, J = 8.7 Hz, 2H) , 6.73 (t, J = 3.9 Hz, 1H) , 5.62 (s, 2H) , 3.95 (m, 4H) , 3.73 (s, 3H) , 2.79 –2.68 (m, 2H) , 2.51 (m, 2H) , 1.84 (t, J = 6.5 Hz, 2H) .
Step 2: To a solution of 7-bromo-6-chloro-4- {1, 4-dioxaspiro [4.5] dec-7-en-8-yl} -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine (500 mg, 1 mmol) in MeOH (10 mL) was added Pd(dppf) Cl
2 (74.5mg, 0.102mmol) and TEA (0.43mL, 3.056mmol) . The resulting mixture was stirred at 85 ℃ under CO (70 psi) in a sealed tank overnight. After cooled down to rt, the solvent was concentrated under reduced pressure to give the crude product which was purified by column chromatography on silica gel (EtOAc in DCM = 0 ~ 50%) to obtain methyl 6-chloro-4- {1, 4-dioxaspiro [4.5] dec-7-en-8-yl} -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyr idine-7-carboxylate (248 mg, yield: 52%) as a yellow solid. LC/MS (ESI) m/z: 470 (M+H)
+.
Step 3: To a stirred solution of methyl 6-chloro-1- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (75 mg, 0.16 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (74 mg, 0.19 mmol) in dioxane (4mL) and H
2O (1 mL) was added K
2CO
3 (44 mg, 0.32 mmol) and Pd(dppf) Cl
2 (14 mg, 0.02 mmol) slowly, the reaction mixture was heated to 100 ℃ for 18 h under N
2 atmosphere. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 100%) to obtain methyl 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -1- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] de c-7-en-8-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (80 mg, Yield: 72.2%) as a white solid. LC/MS (ESI) m/z: 693 (M+H)
+.
Step 4: To a stirred solution of methyl 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -1- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylat e (80mg, 0.12 mmol) in MeOH (10 mL) was added Pd/C (8 mg, 10%) . The resulting mixture was stirred for 24 h under H
2 atmosphere, filtered and concentrated to give the crude product methyl 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -1- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] de can-8-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (70mg, yield: 87.6%) as a white solid, which was used directly without further purification. LC/MS (ESI) m/z: 695 (M+H)
+.
Step 5: To a solution of methyl 4- {1, 4-dioxaspiro [4.5] decan-8-yl} -6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (70 mg, 0.1 mmol) in MeOH (5 mL) and H
2O (1 mL) was added NaOH (40 mg, 1.01 mmol) , the resulting mixture was stirred at 70℃ for 5h. Then the pH of mixture was adjusted to 5 with 1N HCl, filtered, the filtered cake was purified directly by prep-HPLC to afford the desired product 4- {1, 4-dioxaspiro [4.5] decan-8-yl} -6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} ph enyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylic acid (60 mg, yield: 87.5 %) as a white solid. LC/MS (ESI) m/z: 681 (M+H)
+.
Step 6: To a stirred solution of 4- {1, 4-dioxaspiro [4.5] decan-8-yl} -6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridi ne-7-carboxylic acid (60 mg, 0.09 mmol) and HATU (40 mg, 0.11 mmol) in DMF (5 mL) at 25 ℃ was added DIPEA (34 mg, 0.264 mmol) slowly, the reaction mixture was heated to rt for 10 min under NH
3 atmosphere. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (PE: EtOAc = 50: 1 to 3: 1) to obtain 4- {1, 4-dioxaspiro [4.5] decan-8-yl} -6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (55 mg, Yield: 91.8%) as a white solid. LC/MS (ESI) m/z: 680 (M+H)
+.
Step 7: To a solution of 4- {1, 4-dioxaspiro [4.5] decan-8-yl} -6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxami de (55 mg, 0.08 mmol) in DCM (5 mL) was added TFA (5 mL) under N
2. The mixture was stirred for 3 h. The solvent was concentrated under reduced pressure to give the crude product 6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -4- (4-oxocyclohexyl) -1H-pyr azolo [4, 3-c] pyridine-7-carboxamide (40 mg, yield: 96 %) as a yellow solid which was used directly without further purification. LC/MS (ESI) m/z: 516 (M+H)
+
Step 8: To a solution of 6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -4- (4-oxocyclohexyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (40 mg, 0.08 mmol) in MeOH (5 mL) was added NaBH
4 (13 mg, 0.39 mmol) under N
2. After stirred for 3 h, the reaction mixture was concentrated to give the crude product which was purified by prep-TLC (DCM : MeOH=15: 1) to obtain the desired product 6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -4- (4-hydroxycyclohexyl) -1H -pyrazolo [4, 3-c] pyridine-7-carboxamide (8 mg, yield: 20%) as a white solid.
1H NMR (400 MHz, MeOD) δ 8.40 (s, 1H) , 7.75 (d, J = 8.2 Hz, 2H) , 7.63 (dd, J = 9.3, 3.2 Hz, 1H) , 7.47 (d, J = 8.3 Hz, 2H) , 7.25 (ddd, J = 9.1, 7.6, 3.3 Hz, 1H) , 7.16 (dd, J = 9.1, 4.2 Hz, 1H) , 4.68 (s, 2H) , 3.96 (s, 3H) , 3.74 –3.62 (m, 1H) , 3.22 (dd, J = 12.9, 8.2 Hz, 1H) , 2.11 (d, J = 11.8 Hz, 2H) , 2.06 –1.95 (m, 4H) , 1.51 (dt, J = 17.0, 11.6 Hz, 2H) , LC/MS (ESI) m/z: 518 (M+H)
+.
Table 2: Compounds of the general structures of A-1: The compounds in the following table were prepared from key intermediate
A-1-4a according to using the general method for synthesis of Example 1 and Example 2 with modifications
Example 6-9:
6- (4- ( (5-Fluoro-2-methoxybenzamido) methyl) phenyl) -4- (3-hydroxycyclopentyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide
Step 1: To a solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (766 mg, 1.71 mmol) and 4, 6-dichloro-1- (4-methoxybenzyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (600 mg, 1.71mmol) in dioxane (20 mL) and H
2O (5 mL) was added Pd (dppf) Cl
2 (125 mg, 0.17 mmol) and K
2CO
3 (708 mg, 5.13 mmol) . The resulting mixture was heated to 80℃ and stirred for 12h under N
2 atmosphere. Then the reaction mixture was cooled down to room temperature, the mixture was diluted with H
2O (20 mL) , extracted with EtOAc (20 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0%~ 70%) to obtain the desired product 4- (4- (tert-butyldiphenylsilyloxy) cyclopent-1-enyl) -6-chloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (870 mg, yield: 79.91%) as a yellow solid. LC/MS (ESI) m/z: 637 (M+H)
+.
Step 2: To a solution of 4- (4- (tert-butyldiphenylsilyloxy) cyclopent-1-enyl) -6-chloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (870 mg, 1.37 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (631 mg, 1.69 mmol) in 1, 4-dioxane (20 mL) and H
2O (5 mL) was added Pd (dppf) Cl
2 (100 mg, 0.14 mmol) and Cs
2CO
3 (889 mg, 2.73 mmol) , the resulting mixture was heated to 110℃ for 12h under N
2 atmosphere. The reaction mixture was cooled down to room temperature, diluted with H
2O (20 mL) , extracted with EtOAc (20 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0%~ 100%) to obtain the desired product 4- (4- (tert-butyldiphenylsilyloxy) cyclopent-1-enyl) -6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phe nyl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (600 mg, yield: 51.1%) as a yellow solid. LC/MS (ESI) m/z: 860 (M+H)
+.
Step 3: To a solution of 4- (4- (tert-butyldiphenylsilyloxy) cyclopent-1-enyl) -6- (4- ( (5-fluoro-2 -methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxami de (600 mg, 0.7 mmol) was added Pd/C (74 mg, 10%wet) . The resulting mixture was stirred at 50℃ for 12h under H
2 atmosphere. The reaction mixture was cooled down to room temperature, filtered and the filtrate was concentrated in vacuo to give the crude product which was purified by flash chromatography on silica gel (EtOAc in PE = 0%~ 50%) to obtain the desired product 4- (3- (tert-butyldiphenylsilyloxy) cyclopentyl) -6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) - 2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (500 mg, yield: 83.1%) as a yellow solid. LC/MS (ESI) m/z: 862 (M+H)
+.
Step 4: A solution of 4- (3- (tert-butyldiphenylsilyloxy) cyclopentyl) -6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamid e (500 mg, 0.58 mmol) in TFA (4 mL) was heated to 65℃for 4 h. the reaction mixture was cooled down to room temperature, the reaction mixture was concentrated under reduced pressure to obtain the crude product 3- [7-carbamoyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1H-pyrazolo [4, 3-c] p yridin-4-yl] cyclopentyl 2, 2, 2-trifluoroacetate (300 mg, yield: 86.3%) as a yellow solid which was used to next step directly without further purification. LC/MS (ESI) m/z: 600 (M+H)
+.
Step 5: To a solution of 3- [7-carbamoyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1H-pyrazolo [4, 3-c] pyridin-4-yl] cyclopentyl 2, 2, 2-trifluoroacetate (400 mg, 0.67 mmol) in THF (10 mL) and H
2O (5 mL) was added NaOH (133 mg, 3.34 mmol) . The resulting mixture was stirred for 2 h at room temperature. The reaction mixture was adjusted the pH to 6 with 1N HCl, extracted with EtOAc (10 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM = 0%~ 3%) to get two pairs of enantiomers, which were further separated by SFC to obtain four absolutely configuration desired product (Waters UPC2 analytical, Mobile phase: A for CO2 and B for methanol (0.05%DEA) , Gradient: 10 min @40%B in A, Flow rate: 2.0 mL/min, Back pressure: 100 bar, Column temperature: 35℃) . For Example 6 &7 (cis isomers) : Column: ChiralPak AD, 250×4.6mm I. D., 5um; For Example 8 &9 (trans isomers) : Column: ChiralPak IA, 250×4.6mm I. D., 5um. The absolute configuration was not determined for all four compounds.
Example 6 (obtained from the first eluent, cis, isomer 1) : (BNB-1098-01) (15 mg, yield: 4.47%) as a white solid, LC/MS (ESI) m/z: 504 (M+H)
+,
1H NMR (400 MHz, DMSO-d
6) δ 13.57 (s, 1H) , 8.86 (t, J = 6.1 Hz, 1H) , 8.47 (s, 1H) , 7.83 (s, 1H) , 7.72 (d, J = 8.2 Hz, 2H) , 7.62 (s, 1H) , 7.53 (dd, J = 9.2, 3.3 Hz, 1H) , 7.41 –7.31 (m, 3H) , 7.19 (dd, J = 9.1, 4.3 Hz, 1H) , 5.11 (d, J = 5.9 Hz, 1H) , 4.56 (d, J =6.1 Hz, 2H) , 4.32 –4.22 (m, 1H) , 3.91 (s, 3H) , 3.83 –3.71 (m, 1H) , 2.32 (ddd, J = 14.5, 8.9, 5.9 Hz, 1H) , 2.14 –2.03 (m, 2H) , 1.96 (ddd, J = 12.4, 7.4, 4.8 Hz, 1H) , 1.85 (ddd, J = 17.1, 11.5, 7.2 Hz, 1H) , 1.73 (td, J = 11.8, 6.9 Hz, 1H) .
Example 7 (obtained from the second eluent, cis, isomer 2) : (BNB-1099-01) (25 mg, yield: 7.44%) as a white solid, LC/MS (ESI) m/z: 504 (M+H)
+,
1H NMR (400 MHz, DMSO-d
6) δ 13.57 (s, 1H) , 8.86 (t, J = 6.1 Hz, 1H) , 8.47 (s, 1H) , 7.84 (s, 1H) , 7.72 (d, J = 8.2 Hz, 2H) , 7.62 (s, 1H) , 7.53 (dd, J = 9.2, 3.3 Hz, 1H) , 7.40 –7.32 (m, 3H) , 7.19 (dd, J = 9.1, 4.3 Hz, 1H) , 5.12 (d, J = 5.9 Hz, 1H) , 4.56 (d, J = 6.1 Hz, 2H) , 4.27 (dd, J = 9.8, 4.9 Hz, 1H) , 3.91 (s, 3H) , 3.81 –3.72 (m, 1H) , 2.32 (ddd, J = 14.6, 8.9, 5.9 Hz, 1H) , 2.08 (ddd, J = 16.4, 8.0, 4.2 Hz, 2H) , 1.99 –1.92 (m, 1H) , 1.89 –1.80 (m, 1H) , 1.77 –1.69 (m, 1H) .
Example 8 (obtained from the first eluent, trans, isomer 3) : (BNB-1107-01) (13 mg, yield: 3.87%) as a white solid, LC/MS (ESI) m/z: 504 (M+H)
+,
1H NMR (400 MHz, CD
3OD) δ 8.35 (s, 1H) , 7.76 (d, J = 8.1 Hz, 2H) , 7.62 (dd, J = 9.2, 3.2 Hz, 1H) , 7.44 (dd, J = 20.2, 7.9 Hz, 3H) , 7.32 –7.22 (m, 2H) , 7.16 (dd, J = 9.1, 4.2 Hz, 1H) , 4.68 (s, 2H) , 4.55 –4.51 (m, 1H) , 4.09 –4.03 (m, 1H) , 3.96 (s, 3H) , 2.38 –2.30 (m, 2H) , 2.13 (ddd, J = 18.6, 12.7, 7.0 Hz, 3H) , 1.82 –1.74 (m, 1H) .
Example 9 (obtained from the second eluent, trans, isomer 4) : (BNB-1108-01) (12 mg, yield: 3.57%) as a white solid, LC/MS (ESI) m/z: 504 (M+H)
+,
1H NMR (400 MHz, CD
3OD) δ 8.25 (s, 1H) , 7.67 (d, J = 8.3 Hz, 2H) , 7.53 (dd, J = 9.2, 3.2 Hz, 1H) , 7.36 (d, J = 8.3 Hz, 2H) , 7.15 (ddd, J = 9.1, 7.6, 3.3 Hz, 1H) , 7.06 (dd, J = 9.1, 4.2 Hz, 1H) , 4.58 (s, 2H) , 4.43 (ddd, J = 8.2, 5.5, 2.9 Hz, 1H) , 4.01 –3.92 (m, 1H) , 3.86 (s, 3H) , 2.29 –2.20 (m, 2H) , 2.10 –1.95 (m, 3H) , 1.72 –1.65 (m, 1H) .
Example 10 &11:
6- (4- ( (5-Fluoro-2-methoxybenzamido) methyl) phenyl) -4- (4-hydroxycyclohexyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (stereochemistry not assigned)
Step 1: To a solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (630 mg, 1.80 mmol) and 4, 4, 5, 5-tetramethyl-2- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -1, 3, 2-dioxaborolane (527 mg, 1.98 mmol) in dioxane (10 mL) and H
2O (3 mL) was added Pd (dppf) Cl
2 (131 mg, 0.18 mmol) and K
2CO
3 (497 mg, 3.60 mmol) . The resulting mixture was heated to 70℃for 12 h under N
2 atmosphere. Then the reaction mixture was cooled down to room temperature, the mixture was diluted with H
2O (20 mL) , extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0%~ 3%) to obtain the desired product 6-chloro-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-c arboxamide (450 mg, yield: 55.1%) as a white solid. LC/MS (ESI) m/z: 455 (M+H)
+.
Step 2: synthesis of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide To a solution of 6-chloro-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-c arboxamide (450 mg, 1.0 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (424 mg, 1.10 mmol) in dioxane (10 mL) and H
2O (3 mL) was added Pd (dppf) Cl
2 (73 mg, 0.10 mmol) and Cs
2CO
3 (652 mg, 2.0 mmol) . The resulting mixture was heated to 110℃ for 12 h under N
2 atmosphere. Then the reaction mixture was cooled down to room temperature, the mixture was diluted with H
2O (20 mL) , extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0%~ 3%) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] de c-7-en-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (450 mg, yield: 66.5%) as a white solid. LC/MS (ESI) m/z: 678 (M+H)
+.
Step 3: synthesis of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] decan-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide To a stirred solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] de c-7-en-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (450 mg, 0.66 mmol) in MeOH (10 mL) was added Pd/C (45 mg, 10%wet) , then the resulting mixture was stirred at 50℃ for 24 h under H
2 atmosphere. The reaction mixture was filtered and concentrated to give the crude product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] de can-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (300 mg, yield: 71.1%) as a white solid, which was used in next step directly without further purification. LC/MS (ESI) m/z: 680 (M+H)
+.
Step 4: synthesis of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (4-oxocyclohexyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide A solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] decan-8-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (320 mg, 0.47 mmol) in TFA (3 mL) was stirred at 65 ℃ for 1 h. After cool down to rt, the reaction mixture was diluted with DCM (20 mL) , and adjust pH with sat. NaHCO
3 solution, collected the organic phase, dried over anhydrous Na
2SO
4 and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in DCM= 0 ~ 50%) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (4-oxocyclohexyl) -1H-pyrazolo [4, 3-c] pyridi ne-7-carboxamide (220 mg, yield: 90.9%) as a white solid. LC/MS (ESI) m/z: 516 (M+H)
+.
Step 5: To a solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (4-oxocyclohexyl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (220 mg, 0.43 mmol) in MeOH (10 mL) was added NaBH
4 (33 mg, 0.86 mmol) . The resulting mixture was stirred at 0 ℃ for 10 min. The reaction mixture was diluted with EtOAc (20 mL) . The organic phase was dried over anhydrous Na
2SO
4 and concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0 ~ 5%) to give the product which was separated by SFC (Instrument: Waters UPC2 analytical SFC, Column: ChiralCel OD, 250×4.6mm I. D., 5um, Mobile phase: A for CO
2 and B for methanol (0.05%DEA) , Gradient: 10 min @40%B in A, Flow rate: 2.0 mL/min, Back pressure: 100 bar, Column temperature: 35℃) to obtain the cis and trans product. LC/MS (ESI) m/z: 518 (M+H)
+.
Example 10 (obtained from the first eluent, isomer 1, BNB-1082-01) 10 mg (yield: 4.5%) as a white solidand
1H NMR (400 MHz, DMSO) δ 13.53 (s, 1H) , 8.86 (s, 1H) , 8.40 (s, 1H) , 7.87 (s, 1H) , 7.75 (d, J = 7.8 Hz, 2H) , 7.62 (s, 1H) , 7.53 (d, J = 9.4 Hz, 1H) , 7.44 –7.30 (m, 3H) , 7.20 (s, 1H) , 4.56 (d, J = 5.0 Hz, 2H) , 4.41 (s, 1H) , 3.91 (s, 4H) , 3.24 (m, 1H) , 2.21 –2.19 (m, 2H) , 1.81 –1.78 (m, 2H) , 1.65 –1.62 (d, J = 10.7 Hz, 4H) .
Exampe 11 (obtained from the second eluent, isomer 2, BNB-1083-01) 61 mg (yield: 27.4%) as a white solid.
1H NMR (400 MHz, DMSO) δ 13.53 (s, 1H) , 8.86 (t, J = 6.1 Hz, 1H) , 8.45 (s, 1H) , 7.85 (s, 1H) , 7.72 (d, J = 8.2 Hz, 2H) , 7.62 (s, 1H) , 7.53 (dd, J = 9.2, 3.3 Hz, 1H) , 7.45 –7.29 (m, 2H) , 7.19 (dd, J = 9.1, 4.3 Hz, 1H) , 4.63 (d, J = 4.3 Hz, 1H) , 4.55 (d, J = 6.0 Hz, 2H) , 3.91 (s, 3H) , 3.18 –3.13 (m, 1H) , 3.22 –3.11 (m, 1H) , 2.05 –1.73 (m, 6H) , 1.55 –1.31 (m, 2H) .
Table 3: The following compounds were prepared from A-2-4a and appropriate intermediates according to procedures similar to that of Example 6 to 9 and 10 &11 with modifications:
Example 40:
6- (4- ( (5-Fluoro-2-methoxybenzamido) methyl) phenyl) -4- (3-methylpyridin-4-yl) -1H-pyrazolo [4, 3-c] p yridine-7-carboxamide (BNB-1170-01)
Step 1: To a stirred solution of 4, 6-dichloro-2- [ (4-methoxyphenyl) methyl] -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (100 mg, 0.29 mmol) and (3-methylpyridin-4-yl) boronic acid (47 mg, 0.34 mmol) in dioxane (8 mL) and water (2 mL) at 25℃ was added Pd (dppf) Cl
2 (20 mg, 0.028 mmol) and Na
2CO
3 (60 mg, 0.57 mmol) slowly. he resulting mixture was heated to 80℃ and stirred for 12h under N2 atmosphere. Then the reaction mixture was cooled down to room temperature, the mixture was diluted with H
2O (10 mL) , extracted with EtOAc (15 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0%~ 70%) to obtain the desired product 6-chloro-2- (4-methoxybenzyl) -4- (3-methylpyridin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (75 mg, 0.26 mmol) as a yellow solid. LC/MS (ESI) m/z: 408 (M+H) +.
Step 2: To a stirred solution of 6-chloro-2- (4-methoxybenzyl) -4- (3-methylpyridin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (75 mg, 0.18 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (70 mg, 0.18mmol) in dioxane (8mL) and Water (2mL) at 25℃ was added Pd (dppf) Cl
2 (14 mg, 0.02 mmol) and K
2CO
3 (51 mg, 0.37 mmol) slowly. The resulting mixture was heated to 110℃ for 12 h under N
2 atmosphere. Then the reaction mixture was cooled down to room temperature, the reaction mixture was diluted with H
2O (20 mL) , extracted with EtOAc (20 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM = 0 ~ 3%) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (3-methylpyridin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (60 mg, 0.1 mmol) as a yellow solid. LC/MS (ESI) m/z: 631 (M+H) +.
Step 3: A solution of 6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -2- [ (4-methoxyphenyl) methyl] -4- (3-methylpyridin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (60 mg, 0.1 mmol) in TFA (2 mL) was stirred at 65℃ for 3 h. Then the reaction mixture was cooled down to room temperature, the resulting mixture was concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO
3 solution. The organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by Prep-TLC (MeOH in DCM=5 %) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (3-methylpyridin-4-yl) -1H-pyrazolo [4, 3-c] p yridine-7-carboxamide (15 mg, Yield: 30%) as a white solid. LC/MS (ESI) m/z: 511 [M+1]
+,
1H NMR (400 MHz, DMSO) δ 8.85 (s, 1H) , 8.64 –8.57 (m, 2H) , 8.17 (s, 2H) , 7.76 (d, J = 8.2 Hz, 3H) , 7.56 –7.51 (m, 2H) , 7.41 –7.32 (m, 3H) , 7.19 (dd, J = 9.2, 4.3 Hz, 1H) , 4.56 (d, J = 6.1 Hz, 2H) , 3.90 (s, 3H) , 2.37 (s, 3H) .
Example 41:
6- (4- ( (5-Fluoro-2-methoxybenzamido) methyl) phenyl) -4- (pyrimidin-4-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (BNB-1186-01)
Step 1: To a stirred solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (100 mg, 0.29 mmol) and 4- (tributylstannyl) pyrimidine (116 mg, 0.31 mmol) in dioxane (5 mL) at 25℃ was added Pd (PPh
3)
4 (33 mg, 0.028 mmol) . The resulting mixture was heated to 80℃ and stirred for 18h under N
2 atmosphere. Then the reaction mixture was cooled down to room temperature, the mixture was diluted with H
2O (10 mL) , extracted with EtOAc (15 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0%~ 70%) to obtain the desired product 6-chloro-2- (4-methoxybenzyl) -4- (pyrimidin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (100 mg, Yield: 86%) as a yellow solid. LC/MS (ESI) m/z: 395 (M+H) +.
.
Step 2: To a stirred solution of 6-chloro-2- (4-methoxybenzyl) -4- (pyrimidin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (100 mg, 0.25 mmol) and Intermediate A (106mg, 0.28mmol) in dioxane (8mL) and water (2mL) was added Pd (dppf) Cl
2 (15 mg, 0.025 mmol) and Cs
2CO
3 (163 mg, 0.50 mmol) slowly, the resulting mixture was heated to 110℃ for 12h under N
2 atmosphere. Then the reaction mixture was cooled down to room temperature, the reaction mixture was diluted with H
2O (20 mL) , extracted with EtOAc (20 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM = 0 ~ 3%) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (pyrimidin-4-yl) -2H-p yrazolo [4, 3-c] pyridine-7-carboxamide (90 mg, yield: 60%) as a yellow solid. LC/MS (ESI) m/z: 618 (M+H) +.
Step 3: A solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (pyrimidin-4-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (90 mg, 0.15 mmol) in TFA (2 mL) was stirred at 65℃ for 3 h. Then the reaction mixture was cooled down to room temperature, the resulting mixture was concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO
3 solution. The organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by Prep-TLC (MeOH in DCM= 5 %) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (pyrimidin-4-yl) -1H-pyrazolo [4, 3-c] pyridine -7-carboxamide (25 mg, Yield: 34%) as a white solid. LC/MS (ESI) m/z: 498 [M+1]
+,
1H NMR (400 MHz, DMSO) δ 13.91 (s, 1H) , 9.47 (d, J = 1.3 Hz, 1H) , 9.16 –8.94 (m, 2H) , 8.89 (t, J = 6.1 Hz, 1H) , 8.57 (dd, J = 5.2, 1.4 Hz, 1H) , 8.10 (s, 1H) , 7.88 (d, J = 8.3 Hz, 2H) , 7.83 (s, 1H) , 7.54 (dd, J = 9.2, 3.3 Hz, 1H) , 7.46 (d, J = 8.3 Hz, 2H) , 7.35 (ddd, J = 9.0, 7.9, 3.3 Hz, 1H) , 7.20 (dd, J = 9.1, 4.3 Hz, 1H) , 4.59 (d, J = 6.1 Hz, 2H) , 3.92 (s, 3H) .
Table 4: The following compounds were prepared from A-2-4a and appropriate intermediate A according to procedures similar to that of Example 40 or 41 with modifications
Example 74:
(R) -6- (4- ( (5-fluoro-2- (methoxy-d3) benzamido) methyl) phenyl) -4- (3-hydroxypyrrolidin-1-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (BNB-1091-01)
Step 1: To a solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (200 mg, 0.57 mmol) and K
2CO
3 (157 mg, 1.14 mmol) in MeCN (10 mL) was added (R) -pyrrolidin-3-ol (52 mg, 0.57 mmol) dropwised at 0℃, the resulting was stirred at room temperature for 12 h. Then the reaction mixture was concentrated under reduced pressure to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM = 0%~ 2%) to obtain the desired product (R) -6-chloro-4- (3-hydroxypyrrolidin-1-yl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carbo xamide (150 mg, yield: 65.5%) as a yellow solid. LC/MS (ESI) m/z: 402 (M+H)
+.
Step 2: Synthesis of (R) -6- (4- ( (5-fluoro-2- (methoxy-d3) benzamido) methyl) phenyl) -4- (3-hydroxypyrrolidin-1-yl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide To a solution of (R) -6-chloro-4- (3-hydroxypyrrolidin-1-yl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carbo xamide (75 mg, 0.19 mmol) and Intermediate G (87 mg, 0.22 mmol) in dioxane (5 mL) and H
2O (1 mL) was added Pd (dppf) Cl
2 (14 mg, 0.02 mmol) and Cs
2CO
3 (122 mg, 0.37 mmol) . The resulting mixture was heated to 110℃ for 12 h under N
2 atmosphere. Then the reaction mixture was cooled down to room temperature, the mixture was diluted with H
2O (20 mL) , extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0%~ 3%) to obtain the desired product (R) -6- (4- ( (5-fluoro-2- (methoxy-d3) benzamido) methyl) phenyl) -4- (3-hydroxypyrrolidin-1-yl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (70 mg, yield: 59.7%) as a yellow solid. LC/MS (ESI) m/z: 628 (M+H)
+.
Step 3: A solution of (R) -6- (4- ( (5-fluoro-2- (methoxy-d3) benzamido) methyl) phenyl) -4- (3-hydroxypyrrolidin-1-yl) -2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (70 mg, 0.11 mmol) in TFA (3 mL) was heated to 65℃ for 2 h. Then the reaction mixture was cooled down to room temperature, the resulting mixture was concentrated in vacuo to obtain the crude product (R) -1- (7-carbamoyl-6- (4- ( (5-fluoro-2- (methoxy-d
3) benzamido) methyl) phenyl) -1H-pyrazolo [4, 3-c] pyridin-4-yl) pyrrolidin-3-yl2, 2, 2-trifluoroacetate (70 mg, quant. ) as a yellow solid which was used directly without further purification. LC/MS (ESI) m/z: 604 (M+H)
+.
Step 4: To a solution of (R) -1- (7-carbamoyl-6- (4- ( (5-fluoro-2- (methoxy-d
3) benzamido) -methyl) phenyl) -1H-pyrazolo- [4, 3-c] pyridin-4-yl) pyrrolidin-3-yl 2, 2, 2-trifluoroacetate (70 mg, 0.12 mmol) in THF (5 mL) and H
2O (2 mL) was added NaOH (46 mg, 1.16 mmol) , the reaction mixture was heated to 65℃for 1 h. The resulting mixture was cooled down to room temperature, and adjusted the pH to 7 with 1N HCl, extracted with EtOAc (10 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0%~ 3%) to get the crude product which was purified by prep-TLC (MeOH in DCM= 5%) to obtain the desired product (R) -6- (4- ( (5-fluoro-2- (methoxy-d
3) benzamido) methyl) phenyl) -4- (3-hydroxypyrrolidin-1-yl) -1H-pyra zolo [4, 3-c] pyridine-7-carboxamide (15 mg, yield: 25.5%) as a white solid. LC/MS (ESI) m/z: 508 (M+H)
+.
1H NMR (400 MHz, DMSO-d
6) δ 12.99 (s, 1H) , 8.85 (t, J = 6.1 Hz, 1H) , 8.20 (s, 1H) , 7.64 (d, J = 8.1 Hz, 2H) , 7.53 (dd, J = 9.2, 3.3 Hz, 1H) , 7.37 –7.31 (m, 3H) , 7.28 –7.13 (m, 2H) , 6.92 (s, 1H) , 5.04 (d, J = 2.9 Hz, 1H) , 4.55 (d, J = 6.2 Hz, 2H) , 4.44 –4.41 (m, 1H) , 3.84 –3.82 (m, 3H) , 2.06 –1.97 (m, 2H) .
Example 75:
6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (pyrrolidin-1-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (BNB-1075-01)
Step 1: To a solution of 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (150 mg, 0.43 mmol) in MeCN (10mL) was added pyrrolidine (37 mg, 0.51 mmol) and K
2CO
3 (118mg, 0.86mmol) at 0℃, the resulting mixture was stirred at room temperature for 12 h. Then the reaction mixture was concentrated under reduced pressure to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM = 0%~ 2%) to obtain the desired product 6-chloro-2- (4-methoxybenzyl) -4- (pyrrolidin-1-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (120 mg, yield: 72.5%) as a yellow solid. LC/MS (ESI) m/z: 386 (M+H)
+.
Step 2: To a solution of 6-chloro-2- (4-methoxybenzyl) -4- (pyrrolidin-1-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (120, 0.31mmol) and Intermediate A (143 mg, 0.37 mmol) in dioxane (4 mL) and H
2O (1 mL) was added Pd (dppf) Cl
2 (22 mg, 0.03 mmol) and Cs
2CO
3 (202 mg, 0.62 mmol) . The resulting mixture was heated to 110℃ for 12 h under N
2 atmosphere. Then the reaction mixture was cooled down to room temperature, the reaction mixture was diluted with H
2O (20 mL) , extracted with EtOAc (20 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0%~ 3%) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (pyrrolidin-1-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (30 mg, yield: 15.9%) as a white solid. LC/MS (ESI) m/z: 609 (M+H)
+.
Step 3: A solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- (pyrrolidin-1-yl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (30 mg, 0.05 mmol) in TFA (3 mL) was heated to 65℃ for 2 h. Then the reaction mixture was cooled down to room temperature, the resulting mixture was concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO
3 solution. The organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by Prep-TLC (MeOH in DCM= 5%) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (pyrrolidin-1-yl) -1H-pyrazolo [4, 3-c] pyridin e-7-carboxamide (11 mg, yield: 45 %) as a white solid:
1H NMR (400 MHz, DMSO) δ 12.98 (s, 1H) , 8.84 (t, J = 6.1 Hz, 1H) , 8.20 (s, 1H) , 7.64 (d, J = 8.2 Hz, 2H) , 7.53 (dd, J = 9.2, 3.3 Hz, 1H) , 7.33 (dd, J = 12.5, 5.7 Hz, 3H) , 7.28 –7.14 (m, 2H) , 6.90 (s, 1H) , 4.54 (d, J = 6.1 Hz, 2H) , 3.90 (s, 3H) , 3.75 (s, 4H) , 1.99 (s, 4H) ; LC/MS (ESI) m/z: 489 (M+H)
+.
Example 76:
6- (4- ( (5-Fluoro-2-methoxybenzamido) methyl) phenyl) -4- ( (1, 1, 1-trifluoropropan-2-yl) oxy) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (BNB-1130-01)
Step 1: To a stirred solution of 1, 1, 1-trifluoropropan-2-ol (71 mg, 0.6 mmol) in DMF (5 mL) was added NaH (25 mg, 0.6 mmol, 60%) at 0℃ under N2. The resulting mixture was stirred at 0℃ for 0.5 h before 4, 6-dichloro-2- (4-methoxybenzyl) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (200 mg, 0.5 mmol) in DMF (2 mL) was added, the stirring was continued for another 2 h. The reaction mixture was quenched with aq. NH4Cl, extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na2SO4, concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE =10%~ 40%) to obtain the desired product 6-chloro-2- (4-methoxybenzyl) -4- ( (1, 1, 1-trifluoropropan-2-yl) oxy) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (226 mg, yield: 92.5%) as a grey solid. LC/MS (ESI) m/z: 429 (M+H)
+
Step 2: To a stirred solution of 6-chloro-2- (4-methoxybenzyl) -4- ( (1, 1, 1-trifluoropropan-2-yl) oxy) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (226 mg, 0.5 mmol) and Intermediate A (245 mg, 0.6 mmol) in dioxane (10 mL) and H
2O (2 mL) was added Cs
2CO
3 (487 mg, 1.5 mmol) and Pd(dppf) Cl
2 (38 mg, 0.05 mmol) , the reaction mixture was stirred at 100 ℃ for 10 h under N
2 atmosphere. The reaction mixture was concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 30%~ 50%) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- ( (1, 1, 1-trifluor opropan-2-yl) oxy) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (90 mg, yield: 26.2%) as a white solid. LC/MS (ESI) m/z: 652 (M+1)
+.
Step 3: A solution of 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2- (4-methoxybenzyl) -4- ( (1, 1, 1-trifluoropropan-2-yl) oxy) -2H-pyrazolo [4, 3-c] pyridine-7-carboxamide (90 mg, 0.14 mmol) in TFA (5 mL) was stirred at 65℃for 2 h. Then the reaction mixture was cooled down to room temperature and concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO
3. The organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM= 0%~ 3%) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- ( (1, 1, 1-trifluoropropan-2-yl) oxy) -1H-pyrazo lo[4, 3-c] pyridine-7-carboxamide (65 mg, yield: 88.5%) as a white solid. LC/MS (ESI) m/z: 532 (M+H) + ,
1H NMR (400 MHz, DMSO) δ 13.65 (s, 1H) , 8.90 (t, J = 6.1 Hz, 1H) , 8.21 (s, 1H) , 7.84 (s, 1H) , 7.74 (d, J = 8.2 Hz, 2H) , 7.62 (s, 1H) , 7.53 (dd, J = 9.2, 3.3 Hz, 1H) , 7.45 –7.27 (m, 3H) , 7.19 (dd, J = 9.1, 4.3 Hz, 1H) , 6.27 –6.12 (m, 1H) , 4.56 (d, J = 6.0 Hz, 2H) , 3.90 (s, 3H) , 1.55 (d, J = 6.5 Hz, 3H) .
Table 5: The following compounds were prepared from the A-2-4a and appropriate intermediates according to Example 74, 75 &76
Example 112 &113:
6- (4- { [ (5-Fuoro-2-methoxyphenyl) formamido] methyl} phenyl) -4- [4-hydroxycyclohexyl] -1H-indazol e-7-carboxamide (BNB-1100-01, 112) and 6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -4- [4-hydroxycyclohexyl] -1H-indazol e-7-carboxamide (BNB-1101-01, 113)
Step 1: To a solution of 4-bromo-6-hydroxy-2- (4-methoxybenzyl) -2H-indazole-7-carbonitrile (890 mg, 2.48 mmol) and 2- {1, 4-dioxaspiro [4.5] dec-7-en-8-yl} -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (727 mg, 2.73 mmol) in dioxane (10 mL) and H
2O (2 mL) was added Pd (dppf) Cl
2 (181 mg, 0.24 mmol) and K
2CO
3 (1.03 g, 7.45 mmol) under N
2 atmosphere. The reaction mixture was stirred at 100 ℃ for 3 h. The reaction mixture was cooled to r.t. and diluted with EtOAc (10 mL) . The mixture was washed with water and brine. The organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 30%~ 50%) to obtain the desired product 6-hydroxy-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-indazole-7-carbonitrile (950 mg, yield: 91.5%) as a yellow solid. LC/MS (ESI) m/z: 418 (M+H) +.
Step 2: To a solution of 7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-indazol-6-yl trifluoromethanesulfonate (500 mg, 2.27 mmol) and TEA (0.63 mL, 4.55 mmol) in DCM (5 mL) were added Tf
2O (0.56 mL, 3.41 mmol) in DCM (5 mL) at -50 ℃ under N
2 atmosphere. The reaction mixture was heated to -50 ℃ for 0.5 h. The reaction mixture was washed by sat. NaHCO
3 solution and brine. And the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product 7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-indazol-6-yl trifluoromethanesulfonate (500 mg, yield: 75.9%) as a white solid. LC/MS (ESI) m/z: 572 (M+Na)
+
Step 3: To a solution of 7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-indazol-6-yl trifluoromethanesulfonate (500 mg, 0.91 mmol) and 5-fluoro-2-methoxy-N- { [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl} benzamide (420 mg, 1.09 mmol) in dioxane (5 mL) and water (1 mL) was added Na
2CO
3 (192 mg, 1.82 mmol) and Pd(dppf) Cl
2 (66 mg, 0.091 mmol) . The reaction mixture was added heated at 100 ℃ for 4 h. The reaction mixture was cooled to r.t. and diluted with EtOAc (30 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 30%~ 50%) to obtain the desired product N- (4- (7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-indazol-6-yl) benzyl) -5 -fluoro-2-methoxybenzamide (599 mg, yield: 99%) as a white solid. LC/MS (ESI) m/z: 681 (M+Na)
+
Step 4: To a solution of N- (4- (7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] dec-7-en-8-yl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (500 mg, 0.75 mmol) in MeOH (15 mL) was added Pd/C 10% (50 mg, wt 10%) , the reaction mixture was stirred for 10 h at rt under H
2 (5 Psi) . The reaction was filtered and concentrated to give the crude product N- (4- (7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] decan-8-yl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (350 mg , yield: 69.7%) as a grey solid which was used in next step directly without further purification. LC/MS (ESI) m/z: 661 (M+H)
+.
Step 5: A solution of N- (4- (7-cyano-2- (4-methoxybenzyl) -4- (1, 4-dioxaspiro [4.5] decan-8-yl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (350 mg, 0.53 mmol) in TFA (2 mL) was stirred at 65 ℃ for 3 h. The reaction mixture was concentrated under reduced pressure, the residue was dissolved with DCM (15 mL) and washed with sat. NaHCO
3 solution (5 mL x 2) . The organic layer was dried over Na
2SO
4, filtered and concentrated to give the crude product N- ({4- [7-cyano-4- (4-oxocyclohexyl) -1H-indazol-6-yl] phenyl} methyl) -5-fluoro-2-methoxybenzamide (242 mg, 0.48 mmol, 92%) as a red solid which was used in next step directly without further purification. LC/MS (ESI) m/z: 497 (M+H)
+.
Step 6: To a solution of N- ( {4- [7-cyano-4- (4-oxocyclohexyl) -1H-indazol-6-yl] phenyl} methyl) -5-fluoro-2-methoxybenzamide (242 mg, 0.48 mmol) in MeOH (3 mL) was added NaBH
4 (36 mg, 0.97 mmol) at 0 ℃ , the reaction mixture was stirred at 20 ℃ for 0.5 h. The mixture was quenched with Sat. NH
4Cl solution (5 mL) and extracted with DCM (15 mL x 2) . The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM = 1%~ 5%) to obtain the desired product N- ({4- [7-cyano-4- (4-hydroxycyclohexyl) -1H-indazol-6-yl] phenyl} methyl) -5-fluoro-2-methoxybenz amide (162 mg, yield: 66.6%) . LC/MS (ESI) m/z: 499 (M+H)
+
Step 7: To a solution of N- ( {4- [7-cyano-4- (4-hydroxycyclohexyl) -1H-indazol-6-yl] phenyl} methyl) -5-fluoro-2-methoxybenzamide (162 mg, 0.32 mmol) in THF (5 mL) and EtOH (5 mL) was added NaOH (2 mL, 4 mmol) and H
2O
2 (2 mL) at 20 ℃ , then the mixture was stirred at 20 ℃ for 16 h. The mixture was diluted with H
2O (2 mL) and extracted with EtOAc (10 mL x 3) , the combined organic layer was dried over Na
2SO
4, filtered and concentrated to give crude product which was purified by Prep-TLC (EtOAc in PE = 100%) the obtain pure product which was separated with Waters UPC2 analytical SFC (Column: ChiralCel OJ, 250×4.6mm I. D., 5um; Mobile phase: A for CO2 and B for methanol (0.05%DEA) ; Gradient: 8 min @40%B in A, Flow rate: 2.0 mL/min, Back pressure: 100 bar, Column temperature: 35℃)
Example 112 was obtained from the first eluent (Peak 1) : 25 mg (Yield: 14.9%) LC/MS (ESI) m/z: 517 (M+H) +,
1H NMR (400 MHz, DMSO) δ 13.08 (s, 1H) , 8.85 (t, J = 6.0 Hz, 1H) , 8.22 (s, 1H) , 7.53 (dd, J = 9.3, 3.4 Hz, 2H) , 7.46 (d, J = 8.2 Hz, 2H) , 7.42 (s, 1H) , 7.39 (s, 1H) , 7.37 (s, 1H) , 7.33 (dd, J = 7.9, 3.4 Hz, 1H) , 7.19 (dd, J = 9.1, 4.2 Hz, 1H) , 6.91 (s, 1H) , 4.55 (d, J = 6.1 Hz, 2H) , 4.43 (d, J = 3.5 Hz, 1H) , 3.96-3.94 (m, 1H) , 3.91 (s, 3H) , 3.03-3.01 (m, 1H) , 2.06 –1.99 (m, 2H) , 1.79-1.77 (m, 2H) , 1.67-1.60 (m, 4H) ; LC/MS (ESI) m/z: 517 (M+H)
+.
Example 113 was obtained from the second eluent (Peak 2) : 0.8 mg (Yield: 0.48%) 1H NMR (400 MHz, DMSO) δ 13.14 (s, 1H) , 8.91 (t, J = 6.0 Hz, 1H) , 8.32 (s, 1H) , 7.59 (dd, J = 9.2, 3.3 Hz, 2H) , 7.50 (t, J = 9.2 Hz, 3H) , 7.45 –7.37 (m, 3H) , 7.26 (dd, J = 9.2, 4.3 Hz, 1H) , 6.96 (s, 1H) , 4.66 (d, J =4.3 Hz, 1H) , 4.61 (d, J = 6.1 Hz, 2H) , 3.97 (s, 3H) , 3.61-3.59 (m, 1H) , 3.05-2.96 (m, 1H) , 2.02-1.93 (m, 4H) , 1.80-1.71 (m, 2H) , 1.50-1.41 (m, 2H) . LC/MS (ESI) m/z: 517 (M+H)
+.
Example 114:
6- (4- ( (5-Fluoro-2-methoxybenzamido) methyl) phenyl) -4- (3-hydroxycyclopentyl) -1H-indazole-7-carb oxamide (BNB-1080-01)
Step 1: To a solution of 4-bromo-6-hydroxy-2- (4-methoxybenzyl) -2H-indazole-7-carbonitrile (300 mg, 0.84 mmol) and tert-butyldiphenyl ( (3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) cyclopent-3-en-1-yl) oxy) silane (452 mg, 1.01 mmol) in dioxane (4 mL) and H
2O (1 mL) was added Pd (dppf) Cl
2 (101 mg, 0.12 mmol) and Na
2CO
3 (178 mg, 1.68 mmol) , the resulting mixture was stirred at 110℃ for 2 h under a nitrogen atmosphere. The reaction mixture was concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 1%~ 5%) to obtain the desired product 4- (4- ( (tert-butyldiphenylsilyl) oxy) cyclopent-1-en-1-yl) -6-hydroxy-2- (4-methoxybenzyl) -2H-indazole -7-carbonitrile (380 mg, yield: 75.5%) as a white solid. LC/MS (ESI) m/z: 600 [M+1]
+.
Step 2: To a solution of 4- (cyclopent-1-en-1-yl) -6-hydroxy-1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (380 mg, 0.63 mmol) in DCM (5 mL) was added DIPEA (0.22 mL, 1.26 mmol) and Tf
2O (231 mg, 0.82 mmol) at -30℃, the reaction mixture was stirred at -30℃ for 1h. The resulting mixture was diluted with water (5 mL) and extracted with DCM (10 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give 4- (4- ( (tert-butyldiphenylsilyl) oxy) cyclopent-1-en-1-yl) -7-cyano-2- (4-methoxybenzyl) -2H-indazol-6-yl trifluoromethanesulfonate (310 mg, yield: 67.3%) as a brow solid without further purified. LC/MS (ESI) m/z: 732 [M+1]
+
Step 3: To a solution of 4- (4- ( (tert-butyldiphenylsilyl) oxy) cyclopent-1-en-1-yl) -7-cyano-2- (4-methoxybenzyl) -2H-indazol-6-yl trifluoromethanesulfonate (310 mg, 0.42 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (194 mg, 0.50 mmol) in dioxine (4 mL) and H
2O (1 mL) was added Pd (dppf) Cl
2 (45 mg, 0.05 mmol) and Na
2CO
3 (89 mg, 0.84 mmol) , the resulting mixture was stirred at 110 ℃ for 2 h under N
2 atmosphere. The reaction mixture was concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 1%~ 10%) to obtain N- (4- (4- (4- ( (tert-butyldiphenylsilyl) oxy) cyclopent-1-en-1-yl) -7-cyano-2- (4-methoxybenzyl) -2 H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (260 mg, yield: 73.7%) as a gray solid. LC/MS (ESI) m/z: 841 [M+1]
+
Step 4: To a solution of N- (4- (4- (4- ( (tert-butyldiphenylsilyl) oxy) cyclopent-1-en-1-yl) -7-cyano-2- (4-methoxybenzyl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (260 mg, 0.31 mmol) in MeOH (5 mL) was added Pd/C (26 mg, wt10%) , the mixture was stirred at rt for 6 h under H
2 atmosphere. The reaction mixture was filtered and concentrated to give the crude product N- (4- (4- (3- ( (tert-butyldiphenylsilyl) oxy) cyclopentyl) -7-cyano-2- (4-methoxybenzyl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (200 mg, yield: 76.6%) as a yellow solid, which was used to next step directly without further purification. LC/MS (ESI) m/z: 843 [M+1]
+
Step 5: To a solution of N- (4- (4- (3- ( (tert-butyldiphenylsilyl) oxy) cyclopentyl) -7-cyano-2-(4-methoxybenzyl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (200 mg, 0.24 mmol) in DCM (2 mL) was added TFA (2 mL) dropwised at 0℃, the mixture was stirred at 40℃ for 5h. The reaction mixture was concentrated and diluted with sat. NaHCO
3 (5 mL) , the mixture was extracted with DCM (10 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give N- (4- (7-cyano-4- (2-hydroxycyclopentyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (100 mg, 0. 21 mmol, 85.9%) as a brown solid, which was used to next step directly without further purification. LC/MS (ESI) m/z: 485 [M+1]
+
Step 6: To a solution of N- (4- (7-cyano-4- (2-hydroxycyclopentyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (100 mg, 0.21 mmol) in THF (2 mL) and MeOH (2 mL) was added H
2O
2 (1 mL) and NaOH solution (0.04 mL, 0.08 mmol) dropwised at 0℃, the mixture was stirred at 60℃ for 5 h. The reaction mixture was diluted with H
2O (5 mL) and extracted with EtOAc (10 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by Prep-TLC (MeOH in DCM = 5%) to obtain the desired product 6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (3-hydroxycyclopentyl) -1H-indazole-7-carb oxamide (35 mg, yield: 33.3%) as a white solid. LC/MS (ESI) m/z: 503 [M+1]
+
1H NMR (400 MHz, DMSO) δ 13.09 (s, 1H) , 8.86 (m, 1H) , 8.33 (s, 1H) , 7.53 (m, 2H) , 7.45 (m, 3H) , 7.39 –7.32 (m, 3H) , 7.19 (dd, J = 9.1, 4.3 Hz, 1H) , 6.99 (s, 1H) , 4.72 (d, J = 3.9 Hz, 1H) , 4.55 (d, J = 6.1 Hz, 2H) , 4.30 (d, J = 4.2 Hz, 1H) , 3.91 (s, 3H) , 3.49 –3.37 (m, 1H) , 2.42 –2.41 (m, 1H) , 2.02 –1.99 (m, 2H) , 1.85 –1.65 (m, 3H) .
Example 115:
4- (2-Hydroxycyclopentyl) -6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-indazole-7-carboxamide (BNB-1058-01)
Step 1: To a solution of 4-bromo-6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (500 mg, 1.2 mmol) and 2- (cyclopent-1-en-1-yl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (289 mg, 1.49 mmol) in dioxane (4 mL) and H
2O (1 mL) was added Pd (dppf) Cl
2 (101 mg, 0.12 mmol) and Na
2CO
3 (263 mg, 2.5 mmol) , the reaction mixture was stirred at 110℃ for 2 h under N
2 atmosphere. The reaction mixture was concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 1%~ 5%) to obtain the desired product 4- (cyclopent-1-en-1-yl) -6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitr ile (360 mg, yield: 74.4%) as a white solid. LC/MS (ESI) m/z: 390 [M+1]
+.
Step 2: To a solution of 4- (cyclopent-1-en-1-yl) -6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (360 mg, 0.92 mmol) in THF (2 mL) was added HCl (2 mL, 4 mmol) , the reaction mixture was stirred at 55℃ for 2 h. The reaction mixture was diluted with H
2O (10 mL) , extracted with EtOAc (10 mL x 2) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product 4- (cyclopent-1-en-1-yl) -6-hydroxy-1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (280 mg, yield: 87.7%) as a white solid which was used in next step directly without further purification. LC/MS (ESI) m/z: 346 [M+1]
+
Step 3: To a solution of 4- (cyclopent-1-en-1-yl) -6-hydroxy-1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (280 mg, 0.81 mmol) in DCM (5 mL) was added DIPEA (0.27 mL, 1.62 mmol) then Tf
2O (0.16 mL, 0.97 mmol) was added dropwised at -30℃. The reaction mixture was stirred at -30℃ for 1h. The reaction mixture was diluted with water (5 mL) and extracted with DCM (10 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give 7-cyano-4- (cyclopent-1-en-1-yl) -1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yl trifluoromethanesulfonate (260 mg, 67.2%) as a brown solid which was used in next step directly without further purification. LC/MS (ESI) m/z: 478 [M+1]
+
Step 4: To a solution of 7-cyano-4- (cyclopent-1-en-1-yl) -1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yl trifluoromethanesulfonate (260 mg, 0.55 mmol) and 2-methoxy-N- { [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl} benzamide (220 mg, 0.6 mmol) in dioxane (4 mL) and H
2O (1 mL) was added Pd (dppf) Cl
2 (45 mg, 0.05 mmol) and Na
2CO
3 (115 mg, 1.1 mmol) , the reaction mixture was stirred at 110 ℃ for 2 h under N
2 atmosphere. The reaction mixture was concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 1%~ 20%) to obtain the desired product N- (4- (7-cyano-4- (cyclopent-1-en-1-yl) -1- (4-methoxybenzyl) -1H-indazol-6-yl) benzyl) -2-methoxyben zamide as a gray solid. LC/MS (ESI) m/z: 569 [M+1]
+
Step 5: To a solution of N- (4- (7-cyano-4- (cyclopent-1-en-1-yl) -1- (4-methoxybenzyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (250 mg, 0.44 mmol) in THF (5 mL) was added BH
3. Me
2S (0.09 mL, 1mmol/mL) dropwised at 0℃, the reaction mixture was stirred at this temperature for 1 h, before EtOH (1 mL) was added dropwised at 0℃, then H
2O
2 (1 mL) and NaOH (0.44 mL, 2 mmol/mL) was added to the solution in turn, the mixture was stirred at rt for 3 h. The reaction mixture was diluted with H
2O (10 mL) and extracted with EtOAc (10 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM = 1%~ 3%) to obtain the desired product N- (4- (7-cyano-4- (2-hydroxycyclopentyl) -1- (4-methoxybenzyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (30 mg, yield: 11.5%) as a yellow solid. LC/MS (ESI) m/z: 587 [M+1]
+
Step 6: To a solution of N- (4- (7-cyano-4- (2-hydroxycyclopentyl) -1- (4-methoxybenzyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (30 mg, 0.06 mmol) in DCM (2 mL) was added TFA (2 mL) dropwised at 0℃, the reaction mixture was stirred at 40℃ for 5h. The reaction mixture was concentrated and diluted with sat. NaHCO
3 (5 mL) , the mixture was extracted with DCM (10 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product N- (4- (7-cyano-4- (2-hydroxycyclopentyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (25 mg, yield: 83.3%) as a brow solid, which was used to next step directly without further purification. LC/MS (ESI) m/z: 467 [M+1]
+
Step 7: To a solution of N- (4- (7-cyano-4- (2-hydroxycyclopentyl) -1H-indazol-6-yl) benzyl) -2-methoxybenzamide (25 mg, 0.04 mmol) in THF (2 mL) and MeOH (2 mL) was added H
2O
2 (1 mL) and 2N NaOH (0.04 mL, 0.08 mmol) dropwise at 0℃, the reaction mixture was stirred at 60℃ for 5 h. The reaction mixture was diluted with H
2O (5 mL) and extracted with EtOAc (10 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by Prep-TLC (MeOH in DCM = 5%) to obtain the desired product 4- (2-hydroxycyclopentyl) -6- (4- { [ (2-methoxyphenyl) formamido] methyl} phenyl) -1H-indazole-7-carb oxamide (6 mg, yield: 30 %) as a white solid. LC/MS (ESI) m/z: 485 [M+1]
+;
1H NMR (400 MHz, DMSO) δ 13.06 (s, 1H) , 8.76 (t, J = 6.1 Hz, 1H) , 8.21 (s, 1H) , 7.84 –7.72 (m, 1H) , 7.52 –7.36 (m, 7H) , 7.17 (d, J = 8.4 Hz, 1H) , 7.05 (t, J = 7.5 Hz, 1H) , 6.92 (s, 1H) , 4.82 (d, J = 5.4 Hz, 1H) , 4.56 (d, J = 6.0 Hz, 2H) , 4.24 (m, 1H) , 3.92 (s, 3H) , 3.27 (m, 1H) , 2.22 –2.14 (m, 1H) , 2.0 –1.98 (m, 1H) , 1.82 –1.79 (m, 3H) , 1.66 –1.58 (m, 1H) .
Table 6: The following compounds were prepared from the appropriate intermediates B-1-3a or B-1-3d and appropriate boronic acid/ester according to similar procures used Example 112, 113, 114 &115 (B-1, Route 1) with modifications:
Example 129 4-Cyclopentyl-6- (4-phenoxyphenyl) -1H-indazole-7-carboxamide (BNB-1042-01) :
Step 1: To a stirred solution of methyl 4-bromo-7-methoxy-1H-indazole-6-carboxylate (3.0 g, 10.5mmol) and 2- (cyclopent-1-en-1-yl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (3.0 g, 15.4 mmol) in dioxane (50 mL) and H
2O (10 mL) at 25℃ was added K
2CO
3 (800 mg, 5.7 mmol) and Pd(dppf) Cl
2 (50 mg, 0.7 mmol) slowly, the reaction mixture was heated to 100℃ for 24h under N
2 atmosphere. The reaction mixture was diluted with water (20 mL) , extracted with EtOAc (100 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 25%) to obtain methyl 4- (cyclopent-1-en-1-yl) -7-methoxy-1H-indazole-6-carboxylate (1.5 g, yield: 52.4%) as a white solid. LC/MS (ESI) m/z: 273 (M+H)
+.
Step 2: To a stirred solution of methyl 4- (cyclopent-1-en-1-yl) -7-methoxy-1H-indazole-6-carboxylate (1.4 g, 5.1 mmol) in MeOH (15 mL) was added Pd/C (150 mg, 10%) . The resulting mixture was stirred for 24 h under H
2 atmosphere, filtered and concentrated to give the crude product methyl 4-cyclopentyl-7-methoxy-1H-indazole-6-carboxylate (1.2 g, yield: 85.1%) as a white solid which was used directly without further purification. LC/MS (ESI) m/z: 275 (M+H)
+.
1H NMR (400 MHz, CDCl
3) δ 8.18 (s, 1H) , 7.42 (s, 1H) , 4.05 (s, 3H) , 3.97 (s, 3H) , 3.45 –3.33 (m, 1H) , 2.23 –2.11 (m, 2H) , 1.97 –1.67 (m, 6H) .
Step 3: To a stirred solution of methyl 4-cyclopentyl-7-methoxy-1H-indazole-6-carboxylate (800 mg, 2.9 mmol) in DCM (20 mL) was added BBr
3 (5 mL, 1M in Tol. ) at -50℃, the mixture was stirred for 1 h at -50℃. The reaction mixture was quenched with MeOH and diluted with water (20 mL) , extracted with EtOAc (15 mL x 3) . The combined organic phase was washed with water and brine. The organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 25%) to obtain methyl 4-cyclopentyl-7-hydroxy-1H-indazole-6-carboxylate (500 mg, yield: 60%) as a white solid. LC/MS (ESI) m/z: 275 (M+H)
+.
1H NMR (400 MHz, CDCl
3) δ 8.18 (s, 1H) , 7.42 (s, 1H) , 4.05 (s, 3H) , 3.97 (s, 3H) , 3.45 –3.33 (m, 1H) , 2.23 –2.11 (m, 2H) , 1.97 –1.67 (m, 6H) .
Step 4: To a stirred solution of methyl 4-cyclopentyl-7-hydroxy-1H-indazole-6-carboxylate (500mg, 0.3mmol) and Tf
2O (0.176 mL, 1.0 mmol) in DCM (5 mL) was added TEA (100 mg, 0.9 mmol) at 0 ℃ and stirred for 10min. The reaction mixture was diluted with water (20 mL) , extracted with EtOAc (15 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 25%) to obtain methyl 4-cyclopentyl-7- (trifluoromethanesulfonyloxy) -1H-indazole-6-carboxylate (600 mg, Yield: 51%) as a white solid. LC/MS (ESI) m/z: 393 (M+H)
+.
1H NMR (400 MHz, CDCl
3) δ 10.54 (d, J = 50.9 Hz, 1H) , 8.24 (d, J = 1.5 Hz, 1H) , 7.26 (t, J = 1.8 Hz, 1H) , 3.99 (s, 3H) , 3.47 (dd, J = 16.3, 7.8 Hz, 1H) , 2.21 (d, J = 3.9 Hz, 2H) , 1.93-1.80 (m, 6H) .
Step 5: To a stirred solution of methyl 4-cyclopentyl-7- (trifluoromethanesulfonyloxy) -1H-indazole-6-carboxylate (400 mg, 1.0 mmol) and Zn(CN)
2 (350 mg, 2.9 mmol) in DMF (5 mL) at 25℃ was added Pd (dppf) Cl
2 (100 mg, 0.1 mmol) slowly, the reaction mixture was stirred at 130℃ in microwave reactor for 2h under N
2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (100 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 25%) to obtain methyl 7-cyano-4-cyclopentyl-1H-indazole-6-carboxylate (230 mg, yield: 83.8%) as a white solid. LC/MS (ESI) m/z: 270 (M+H)
+.
1H NMR (400 MHz, CDCl
3) δ 11.07 (d, J = 55.9 Hz, 1H) , 8.26 (d, J = 5.4 Hz, 1H) , 7.73 (s, 1H) , 3.99 (s, 3H) , 3.54 –3.39 (m, 1H) , 2.22 –2.12 (m, 2H) , 1.91 –1.69 (m, 6H) .
Step 6: To a solution of methyl 7-cyano-4-cyclopentyl-1H-indazole-6-carboxylate (230 mg, 0.8 mmol) in MeOH (10 mL) /H
2O (2 mL) was added LiOH (160 mg, 4 mmol) , the resulting mixture was stirred at r.t. for 2h. Then the pH of mixture was adjusted to 5 with 1N HCl and extracted with EA (10 mL x 3) . The combined organic layers were dried over Na
2SO
4, concentrated and purified by prep-HPLC to afford the desiredproduct7-cyano-4-cyclopentyl-1H-indazole-6-carboxylic acid (170 mg, 74.0 %yield) as light-yellow solid. LC/MS (ESI) m/z: 256 (M+H)
+.
Step 7: To a stirred solution of 7-cyano-4-cyclopentyl-1H-indazole-6-carboxylic acid (130 mg, 0.5mmol) and DPPA (150 mg, 0.5 mmol) in THF (5 mL) was added TEA (105 mg, 1 mmol) slowly at 25℃. The reaction mixture was stirred at 25℃ for 2h under N
2 atmosphere. The mixture was added H
2O (2 mL) and warmed to 65℃ for another 3h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL x 3) . The combined organic phase was washed with water and brine, the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~25%) to obtain the desired product 6-amino-4-cyclopentyl-1H-indazole-7-carbonitrile (79 mg, yield: 68.6%) as a white solid. LC/MS (ESI) m/z: 227 (M+H)
+;
1H NMR (400 MHz, CDCl
3) δ 8.01 (s, 1H) , 6.43 (s, 1H) , 4.66 (s, 2H) , 3.38 –3.19 (m, 1H) , 2.14 (dd, J = 14.1, 8.7 Hz, 2H) , 1.89 –1.70 (m, 6H) .
Step 8: To a stirred solution of 6-amino-4-cyclopentyl-1H-Indazole-7-carbonitrile (79 mg, 0.3 mmol) and CH
2I
2 (187 mg, 0.7 mmol) in DCM (2.5 mL) and AcOH (0.4 mL, 7 mmol) at 0℃ was added a solution of NaNO
2 (120 mg, 1.7mmol) in H
2O (2.5 mL) slowly, the reaction mixture was stirred at 0 ℃ for 5 min. The reaction mixture was diluted with water (10 mL) and extracted with DCM (15 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 25%) to obtain methyl 4- (cyclopent-1-en-1-yl) -7-methoxy-1H-indazole-6-carboxylate (75 mg, Yield: 74%) as a white solid. LC/MS (ESI) m/z: 338 (M+H)
+.
1H NMR (400 MHz, CDCl3) δ 10.55 (s, 1H) , 8.20 (s, 1H) , 7.51 (s, 1H) , 3.43 (dd, J = 16.9, 8.9 Hz, 1H) , 2.19 (dd, J = 11.4, 6.6 Hz, 2H) , 1.95 –1.74 (m, 6H) .
Step 9: synthesis of 4-cyclopentyl-6- (4-phenoxyphenyl) -1H-indazole-7-carbonitrile To a stirred solution of 4-cyclopentyl-6-iodo-1H-indazole-7-carbonitrile (30 mg, 0.1 mmol) and (4-phenoxyphenyl) boronic acid (45 mg, 0.2 mmol) in dioxane (3 mL) and H
2O (1 mL) at 25 ℃ were added NaHCO
3 (20 mg, 0.2 mmol) and Pd (dppf) Cl
2 (10 mg, 0.1mmol) slowly, the reaction mixture was heated to 60 ℃ for 18h under nitrogen atmosphere. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL x 3) . The combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 25%) to obtain 4-cyclopentyl-6- (4-phenoxyphenyl) -1H-indazole-7-carbonitrile (14 mg, Yield: 41.4%) as a white solid. LC/MS (ESI) m/z: 380 (M+H)
+.
1H NMR (400 MHz, CDCl3) δ 10.78 (s, 1H) , 8.28 (s, 1H) , 7.64 –7.57 (m, 2H) , 7.44 –7.35 (m, 2H) , 7.20 –7.15 (m, 2H) , 7.15 –7.08 (m, 4H) , 3.57 –3.46 (m, 1H) , 2.34 –2.14 (m, 2H) , 1.87 (dddd, J = 14.4, 9.1, 6.8, 4.7 Hz, 6H) .
Step 10: To a stirring solution of 4-cyclopentyl-6- (4-phenoxyphenyl) -1H-indazole-7-carbonitrile (14 mg, 0.1 mmol) and NaOH (40 mg, 1.0 mmol) in THF (2 mL) and MeOH (2 mL) at room temperature was added H
2O
2 (2 mL) slowly and the reaction mixture was stirred at 65℃ for 18h under N
2 atmosphere. The mixture was extracted with EtOAc (10 mL x 3) , the combined organic phase was washed with water and brine. The organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by prep. TLC (EtOAc in PE = 30%) to obtain 4-cyclopentyl-6- (4-phenoxyphenyl) -1H-indazole-7-carboxamide (3 mg, yield: 23.9 %) as a white solid. LC/MS (ESI) m/z: 398 (M+H)
+.
1H NMR (400 MHz, CD
3OD) δ 8.20 (s, 1H) , 7.52 –7.47 (m, 2H) , 7.42 –7.34 (m, 2H) , 7.14 (t, J = 7.4 Hz, 1H) , 7.07 –7.02 (m, 5H) , 3.53 (dd, J = 16.0, 8.1 Hz, 1H) , 2.25 –2.18 (m, 2H) , 1.94 –1.79 (m, 6H) .
Table 7: The following compounds were prepared from from B-1-6 and appropriate boronic acid/ester intermediates according to similar procures used for Example 129 (B-1, Route 2) with modifications:
Example 133:
6- (4- ( (5-Fluoro-2-methoxybenzamido) methyl) phenyl) -4- (pyrrolidin-1-yl) -1H-indazole-7-carboxamid e (BNB-1063-01)
Step 1: To a solution of 4-bromo-1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile (250 mg, 0.61 mmol) and pyrrolidine (66mg, 0.92mmol) in dioxane (5 mL) was added Pd
2 (dba)
3 (114 mg, 0.14 mmol) , Xant-phos (72 mg, 0.14 mmol) and Cs
2CO
3 (405 mg, 1.22 mmol) , the reaction mixture was stirred at 110℃ for 10 h under a nitrogen atmosphere. The reaction mixture was concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM=1%~ 3%) to obtain to 6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazole-7-carbonitrile (180 mg, yield: 73.8%) as a gray solid, LC/MS (ESI) m/z: 393 [M+1]
+
Step 2: To a solution of 6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazole-7-carbonitrile (180 mg, 0.46 mmol) in THF (5 mL) was added 2N HCl (2 mL) , the reaction mixture was stirred at 55℃ for 2 h. The reaction mixture was extracted with EtOAc (20 mL x 2) , the combined organic phase was washed with water and brine, dried over Na
2SO
4, concentrated to give the crude product 6-hydroxy-1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazole-7-carbonitrile (140 mg, yield: 87.4%) as a yellow solid which was used to next step without further purified. LC/MS (ESI) m/z: 349 [M+1]
+
Step 3: To a solution of 6-hydroxy-1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazole-7-carbonitrile (140 mg, 0.40 mmol) in DCM (5 mL) was added DIPEA (51 mg, 0.40 mmol) , then Tf
2O (112 mg, 0.402 mmol) was added dropwised at -30℃, the reaction mixture was stirred at -30℃ for 1h. The reaction mixture was extracted with DCM (10 mL x 3) , the combined organic phase was washed with water and brine, dried over Na
2SO
4, concentrated to give the crude product 7-cyano-1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazol-6-yltrifluoromethanesulfonate (110 mg, yield: 57.5%) as a brown solid, which was used to next step without further purified. LC/MS (ESI) m/z: 481 [M+1]
+
Step 4: To a solution of 7-cyano-1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazol-6-yl trifluoromethanesulfonate (110 mg, 0.23 mmol) and 5-fluoro-2-methoxy-N- { [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl} benzamide (132 mg, 0.34 mmol) in dioxane (4 mL) and H
2O (1 mL) was added Pd (dppf) Cl
2. CH
2Cl
2 (51 mg, 0.06 mmol) and Na
2CO
3 (66 mg, 0.62 mmol) , the reaction mixture was stirred at 100 ℃ for 10 h under N
2 atmosphere. The reaction mixture was concentrated in vacuum to give the crude product was purified by column chromatography on silica gel (EtOAc in PE=5%~ 20%) to obtain the desired product N- [ (4- {7-cyano-1- [ (4-methoxyphenyl) methyl] -4- (pyrrolidin-1-yl) -1H-indazol-6-yl} phenyl) methyl] -5 -fluoro-2-methoxybenzamide (120 mg, yield: 66.7%) as a white solid. LC/MS (ESI) m/z: 590 [M+1]
+
Step 5: To a solution of methyl 6-chloro-4- {1, 4-dioxaspiro [4.5] dec-7-en-8-yl} -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxylate (65 mg, 0.14 mmol) in DCM (2 mL) was added TFA (2 mL) , the reaction mixture was stirred at 40 ℃ for 5 h. The reaction mixture was concentrated in vacuum to give the crude product N- ({4- [7-cyano-4- (pyrrolidin-1-yl) -1H-indazol-6-yl] phenyl} methyl) -5-fluoro-2-methoxybenzamide (60 mg, yield: 62.8%) as a brown oil which was used in next step without further purification. LC/MS (ESI) m/z: 470 [M+1]
+.
Step 6: A solution of N- ( {4- [7-cyano-4- (pyrrolidin-1-yl) -1H-indazol-6-yl] phenyl} methyl) -5-fluoro-2-methoxybenzamide (60 mg, 0.13 mmol) in H
2SO
4 (1 mL) was stirred at 55 ℃ for 3 h. The reaction mixture was poured into ice water, extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with H
2O and brine, dried over anhydrous Na
2SO
4, concentrated. The crude product which was purified by Prep-TLC (MeOH in DCM=5%) to obtain the desired product 6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -4- (pyrrolidin-1-yl) -1H-indazole-7-carboxamide (6 mg, yield: 9.6%) as a white solid LC/MS (ESI) m/z: 488[M+1] +, 1H NMR (400 MHz, CD
3OD) δ 8.26 (s, 1H) , 7.63 (dd, J = 9.3, 3.2 Hz, 1H) , 7.52 –7.43 (m, 5H) , 7.30 –7.23 (m, 1H) , 7.17 (dd, J = 9.0, 4.1 Hz, 1H) , 5.93 (s, 1H) , 4.68 (s, 2H) , 3.97 (s, 3H) , 3.73 –3.64 (m, 4H) , 2.15 –2.07 (m, 4H) .
Example134:
(R) -6- (4- ( (5-Fluoro-2-methoxybenzamido) methyl) phenyl) -4- (3-hydroxypyrrolidin-1-yl) -1H-indazole -7-carboxamide (BNB-1072-01)
Step 1: To a solution of 4-bromo-1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile (300 mg, 0.75 mmol) and (3R) -pyrrolidin-3-ol (78 mg, 0.90 mmol) in dioxane (5 mL) were added Cs
2CO
3 (486 mg, 1.49 mmol) , Xant-phos (86 mg, 0.15 mmol) and Pd
2 (dba)
3 (68 mg, 0.075 mmol) under N
2 . The resulting mixture was stirred for overnight at 110℃. The reaction mixture was cooled to room temperature and concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 100%) to obtain the desired product (R) -4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile (120 mg, yield 39.4%) as an oil. LC/MS (ESI) m/z: 409 (M+H)
+.
Step 2: To a solution of (R) -4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile (120 mg, 0.29 mmol) in THF (2 mL) was added 2N HCl (2 mL) under N
2. The mixture was stirred for 3 h at 65℃. The solvent was concentrated under reduced pressure to give the crude product (R) -6-hydroxy-4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -1H-indazole-7-carbonitrile (70 mg, yield: 65.4 %) as a yellow solid which was used directly without further purification. LC/MS (ESI) m/z: 365 (M+H)
+.
Step 3: To a solution of (R) -6-hydroxy-4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -1H-indazole-7-carbonitrile (70 mg, 0.19 mmol) in DCM (5 mL) was added NEt
3 (77.6 mg, 0.77 mmol) and triflic anhydride (108 mg, 0.38 mmol) at -50℃. The mixture was stirred for 10 min. The solvent was concentrated under reduced pressure to give the crude product (R) -7-cyano-4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -1H-indazol-6-yl trifluoromethanesulfonate (60 mg, yield: 62.9 %) as yellow solid which was used directly without further purification. LC/MS (ESI) m/z: 497 (M+H)
+.
Step 4: To a solution of (R) -7-cyano-4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -1H-indazol-6-yl trifluoromethanesulfonate (60 mg, 0.12 mmol) and 5-fluoro-2-methoxy-N- { [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl} benzamide (51 mg, 0.13 mmol) in dioxane (4 mL) and H
2O (1 mL) were added K
2CO
3 (33 mg, 0.24 mmol) and Pd(dppf) Cl
2 (9 mg, 0.012 mmol) under N
2. The reaction mixture was heated to 90℃ for 3 h. The reaction mixture was cooled to rt and diluted with EtOAc (30 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 10%~ 100%) to obtain the desired product N- [ (4- {7-cyano-4- [ (3R) -3-hydroxypyrrolidin-1-yl] -1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yl} p henyl) methyl] -5-fluoro-2-methoxybenzamide (40 mg, yield: 54.7%) as a white solid. LC/MS (ESI) m/z: 606 (M+H)
+.
Step 5: To a stirred suspension of (R) -N- (4- (7-cyano-4- (3-hydroxypyrrolidin-1-yl) -1- (4-methoxybenzyl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (40 mg, 0.066 mmol) in TFA (3 mL) . The mixture was stirred at 65 ℃ for 3 hr. After cooled down to rt, the reaction mixture was diluted with water (20 mL) , extracted with EtOAc (50 mL x 3) , the combined organic phase was washed by brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the residue which was purified by column chromatography on silica gel (PE: EtOAc=100 to 10: 1) to obtain (R) -N- (4- (7-cyano-4- (3-hydroxypyrrolidin-1-yl) -1H-indazol-6-yl) benzyl) -5-fluoro-2 methoxybenzamide (30 mg, yield: 93.6%) as a white solid. LC/MS (ESI) m/z: 486 (M+H)
+.
Step 6: To a stirred suspension of (R) -N- (4- (7-cyano-4- (3-hydroxypyrrolidin-1-yl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (30 mg, 0.062 mmol) in con H
2SO
4 (1 mL) . The mixture was stirred at 60 ℃ for 1h. After cooled down to rt, the reaction mixture was diluted with water (20 mL) , extracted with EtOAc (50 mL x 3) . The combined organic phase was washed by brine, dried over anhydrous Na
2SO
4, filtered and concentrated. The crude product was purified by column chromatography on silica gel (PE: EtOAc=100 to 1: 10) to obtain (R) -6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (3-hydroxypyrrolidin-1-yl) -1H-indazole -7-carboxamide (4.4 mg, yield: 14%) as a white solid. LC/MS (ESI) m/z: 504 (M+H)
+.
1H NMR (400 MHz, DMSO) δ 12.60 (s, 1H) , 8.86 (s, 1H) , 8.21 (s, 1H) , 7.53 (d, J = 6.6 Hz, 1H) , 7.40-7.35 (m, 5H) , 7.22-7.21 (m, 1H) , 7.07 (s, 1H) , 6.08 (s, 1H) , 5.80 (s, 1H) , 5.04 (s, 1H) , 4.56 (d, J = 5.3 Hz, 2H) , 4.44 (s, 1H) , 3.91 (s, 3H) , 3.79-3.63 (m, 3H) , 3.46-3.44 (m, 1H) , 2.05-1.97 (m, 2H) .
Table 8: The following compounds were prepared from B-1-3a and appropriate boronic acid/ester intermediates according to procedures used for preparation of Example 133 &Example 134 (B-2, route 1) with modifications
Example 146:
(R) -5-Chloro-6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (2-methylpyrrolidin-1-yl) -1H-indazole-7-carboxamide (BNB-1119-01)
Step 1: To a solution of 4-bromo-1- (4-methoxybenzyl) -6- (methoxymethoxy) -1H-indazole-7-carbonitrile (250 mg, 0.61 mmol) and (R) -2-methylpyrrolidine (78 mg, 0.92 mmol) in dioxane (5 mL) was added Pd
2 (dba)
3 (114 mg, 0.14 mmol) , Xant-phos (72 mg, 0.14 mmol) and Cs
2CO
3 (405 mg, 1.22 mmol) , the reaction mixture was stirred at 110℃ for 10 h under a nitrogen atmosphere. The reaction mixture was concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM=1%~ 3%) to obtain to (R) -1- (4-methoxybenzyl) -6- (methoxymethoxy) -4- (2-methylpyrrolidin-1-yl) -1H-indazole-7-carbonitr ile (230 mg, yield: 92.8%) as a gray solid, LC/MS (ESI) m/z: 407 [M+1]
+
Step 2: To a solution of (R) -1- (4-methoxybenzyl) -6- (methoxymethoxy) -4- (2-methylpyrrolidin-1-yl) -1H-indazole-7-carbonitrile (230 mg, 0.57 mmol) in THF (5 mL) was added 2N HCl (2 mL) , the reaction mixture was stirred at 55℃ for 2 h. The reaction mixture was extracted with EtOAc (20 mL x 2) , the combined organic phase was washed with water and brine, dried over Na
2SO
4, concentrated to give the crude product (R) -6-hydroxy-1- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -1H-indazole-7-carbonitrile (200 mg, yield: 96.9%) as a yellow solid which was used to next step without further purified. LC/MS (ESI) m/z: 363 [M+1]
+
Step 3: To a solution of (R) -6-hydroxy-1- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -1H-indazole-7-carbonitrile (200 mg, 0.55 mmol) in DMF (5 mL) was added NCS (74 mg, 0.55 mmol) at -20℃, the mixture was stirred at rt for 8 h. The mixture was diluted with H
2O (10 mL) , extracted with EtOAc (10 mL x 2) , The combined organic phase was washed by water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM=1%~ 5 %) to obtain the desired product
(R) -5-chloro-6-hydroxy-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazole-7-carbonitril e (120 mg, yield: 54%) as a white solid. LC/MS (ESI) m/z: 397 [M+1]
+
Step 4: To a solution of (R) -5-chloro-6-hydroxy-2- (4-methoxybenzyl) -4-(2-methylpyrrolidin-1-yl) -2H-indazole-7-carbonitrile (120 mg, 0.30 mmol) in DCM (5 mL) was added DIPEA (78 mg, 0.60 mmol) , then Tf
2O (0.06 mL, 0.36 mmol) was added dropwise at -30℃, the mixture was stirred at-30℃ for 1h. The reaction mixture was diluted with H
2O (10 mL) , extracted with DCM (10 mL x 2) , The combined organic phase was washed by water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to obtain (R) -5-chloro-7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl trifluoromethanesulfonate (110 mg, yield: 68.8%) as a brow solid, which can be used to next step directly without further purification. LC/MS (ESI) m/z: 530 (M+H)
+
Step 5: To a solution of (R) -5-chloro-7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl trifluoromethanesulfonate (110 mg, 0.21 mmol) , 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (80 mg, 0.21 mmol) and Na2CO3 (44 mg, 0.42 mmol) in dioxane (4 mL) and H2O (1 mL) was added Pd (dppf) Cl2 (15 mg, 0.02 mmol) , The reaction mixture was concentrated in vacuum to give the crude product was purified by column chromatography on silica gel (EtOAc in PE=5%~ 30%) to obtain the desired product (R) -N- (4- (5-chloro-7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6 -yl) benzyl) -5-fluoro-2-methoxybenzamide (100 mg, yield: 75.4%) as a white solid. LC/MS (ESI) m/z: 639 [M+1]
+
Step 6: To a solution of (R) -N- (4- (5-chloro-7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (100 mg , 0.16 mmol) in DCM (2 mL) was added TFA (2 mL) , the reaction mixture was stirred at 40 ℃ for 5 h. The reaction mixture was concentrated in vacuum to give the crude product (R) -N- (4- (5-chloro-7-cyano-4- (2-methylpyrrolidin-1-yl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methox ybenzamide (65 mg, yield: 63.12%) as a brow solid, which can be used to next step directly without further purification. LC/MS (ESI) m/z: 519 [M+1]
+
Step 7: A solution of (R) -N- (4- (5-chloro-7-cyano-4- (2-methylpyrrolidin-1-yl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (65 mg, 0.13 mmol) in H
2SO
4 (1 mL) was stirred at 55 ℃ for 3 h. The reaction mixture was poured into ice water, extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with H
2O and brine, dried over anhydrous Na
2SO
4, concentrated. The crude product which was purified by Prep-TLC (MeOH in DCM=5%) to obtain the desired product (R) -5-chloro-6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (2-methylpyrrolidin-1-yl) -1H-indazole-7-carboxamide (26 mg, yield: 41.9%) as a white solid:
1H NMR (400 MHz, DMSO) δ 13.16 (s, 1H) , 8.88 (t, J = 6.2 Hz, 1H) , 8.30 (s, 1H) , 7.55 (dd, J = 9.2, 3.3 Hz, 1H) , 7.39 –7.31 (m, 3H) , 7.23 (ddd, J = 13.5, 11.7, 5.6 Hz, 5H) , 4.58 (d, J = 6.1 Hz, 2H) , 4.37 (dd, J = 13.7, 6.3 Hz, 1H) , 3.99 (dd, J = 15.6, 8.5 Hz, 1H) , 3.91 (s, 3H) , 3.19 (t, J = 6.7 Hz, 1H) , 2.24 (s, 1H) , 1.90 (dd, J = 31.7, 21.6 Hz, 2H) , 1.61 –1.48 (m, 1H) , 1.01 (d, J = 6.0 Hz, 3H) ; LC/MS (ESI) m/z: 537 [M+1]
+.
Example 147
(R) -6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -4- (2-methylpyrrolidin-1-yl) -1H-indazole-7 -carboxamide (BNB-1109-01)
Step 1: To a solution of 4-bromo-6-hydroxy-2- (4-methoxybenzyl) -2H-indazole-7-carbonitrile (400 mg, 1.11 mmol) and (2R) -2-methylpyrrolidine (114 mg, 1.34 mmol) in dioxane (5 mL) were added Cs
2CO
3 (727 mg, 2.23 mmol) , SPhos (45 mg, 0.11 mmol) and Pd
2 (dba)
3 (102 mg, 0.11 mmol) under N
2.The resulting mixture was stirred for 16 h at 110℃. The reaction mixture was cooled to room temperature and concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 50%to 70%) to obtain the desired product (R) -6-hydroxy-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazole-7-carbonitrile (437 mg, yield: 107%) as a yellow solid. LC/MS (ESI) m/z: 363 (M+H)
+.
Step 2: To a solution of (R) -6-hydroxy-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazole-7-carbonitrile (437 mg, 1.20 mmol) in DCM (10 mL) was added DIPEA (0.4 mL, 2.41 mmol) and triflic anhydride (0.24 mL, 1.40 mmol) at -30℃. The mixture was stirred for 30 min at this temperature. The solvent was concentrated under reduced pressure to give the crude product (R) -7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl trifluoromethanesulfonate (596 mg, yield: 99.96%) as yellow solid which was used directly to next step without further purification. LC/MS (ESI) m/z: 495 (M+H)
+.
Step 3: To a solution of (R) -7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl trifluoromethanesulfonate (596 mg, 1.20 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (510 mg, 1.32 mmol) in dioxane (10 mL) and H
2O (2 mL) were added Cs
2CO
3 (785 mg, 2.41 mmol) and Pd (dppf) Cl
2 (88 mg, 0.12 mmol) under N
2. The reaction mixture was heated to 90℃ for 3 h. The reaction mixture was cooled to rt and diluted with EtOAc (30 mL) , the mixture was washed with water and brine, the organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 30%to 50%) to obtain the desired product (R) -N- (4- (7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl) benzy l) -5-fluoro-2-methoxybenzamide (342 mg, yield: 47%) as a white solid. LC/MS (ESI) m/z: 604 (M+H)
+.
Step 4: A solution (R) -N- (4- (7-cyano-2- (4-methoxybenzyl) -4- (2-methylpyrrolidin-1-yl) -2H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (342 mg, 0.56 mmol) in TFA (5 mL) was stirred at 65 ℃ for 3 h. Then the reaction mixture was cooled down to room temperature and concentrated in vacuo to obtain the crude product which was dissolved in EtOAc (15 mL) and adjusted the pH to 8 with sat. NaHCO
3. The organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0%to 10%) to obtain (R) -N- (4- (7-cyano-4- (2-methylpyrrolidin-1-yl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (150 mg, yield: 54%) as a red solid. LC/MS (ESI) m/z: 484 (M+H)
+.
Step 5: A solution (R) -N- (4- (7-cyano-4- (2-methylpyrrolidin-1-yl) -1H-indazol-6-yl) benzyl) -5-fluoro-2-methoxybenzamide (150 mg, 0.31 mmol) in con H
2SO
4 (3 mL) was stirred at 60 ℃ for 1h. After cooled down to rt, the reaction mixture was poured into ice-water (20 mL) , extracted with EtOAc (20 mL x 3) . The combined organic phase was washed by brine, dried over anhydrous Na
2SO
4, filtered and concentrated. The crude product was purified by column chromatography on silica gel (EtOAc in PE = 100%) to obtain Example 147 (10.5 mg, yield: 6.75%) as a white solid:
1H NMR (400 MHz, DMSO) δ 12.59 (s, 1H) , 8.86 (t, J = 6.1 Hz, 1H) , 8.17 (s, 1H) , 7.53 (dd, J = 9.2, 3.3 Hz, 1H) , 7.45 –7.30 (m, 5H) , 7.19 (dd, J = 9.2, 4.3 Hz, 1H) , 7.07 (s, 1H) , 6.13 (s, 1H) , 5.85 (s, 1H) , 4.56 (d, J = 6.1 Hz, 2H) , 4.28 (s, 1H) , 3.91 (s, 3H) , 3.76 (s, 1H) , 3.54 (d, J = 8.7 Hz, 1H) , 2.06 (dd, J = 28.8, 21.4 Hz, 3H) , 1.72 (s, 1H) , 1.19 (d, J = 6.1 Hz, 3H) ; LC/MS (ESI) m/z: 502 (M+H)
+.
Example 148: 6- (4- ( (2-Methoxybenzamido) methyl) phenyl) -1H-indazole-7-carboxamide (BNB-1059-01)
Step 1: To a solution of 2-fluoro-6-hydroxybenzonitrile (2 g, 14.6 mmol) in DCM (20 mL) were added MOMCl (1.41 g, 17.5 mmol) and DIPEA (2.8 g, 21.9 mmol) , the reaction mixture was stirred at room temperature for 2 h. The reaction was diluted with DCM (20 mL) and saturated Na
2CO
3 solution. The organic layer was collected, washed with sat. NaCl solution and concentrated in vacuo to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=10%~ 50%) to afford the desired product 2-fluoro-6- (methoxymethoxy) benzonitrile (2.5 g , yield: 94.6%) as a white solid.
Step 2: To a solution of 2-fluoro-6- (methoxymethoxy) benzonitrile (2.5 g, 13.8 mmol) in THF (20 mL) was added LDA (10.4 mL, 20.7 mmol) at -78 ℃ under N
2. The reaction was stirred at the same temperature for 1 h before DMF (1.2 g, 16.7 mmol) was added, the resulting mixture was kept at -78 ℃ for about another 1 h. The reaction was quenched by sat. NH
4Cl solution, extracted with EtOAc (20 mL x 3) . The combined organic phase was dried with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=10%~ 30%) to obtain the desired product 2-fluoro-3-formyl-6- (methoxymethoxy) benzonitrile (1.2 g, yield: 40.9%) as a brown oil.
1H NMR (400 MHz, CDCl
3) δ 10.23 (s, 1H) , 8.12 –7.98 (m, 1H) , 7.17 (d, J = 9.0 Hz, 1H) , 5.40 (s, 2H) , 3.54 (s, 3H) .
Step 3: To a solution of 2-fluoro-3-formyl-6- (methoxymethoxy) benzonitrile (400 mg, 1.9 mmol) in EtOH (10 mL) was added hydrazine (721 mg, 19.1 mmol) . The reaction mixture was stirred at 85℃ for 12h. The resulting yellow solid was collected by filtration. The filter cake was washed with MeCN and then dried to give the crude product 6- (methoxymethoxy) -1H-indazole-7-carbonitrile (360 mg, yield: 92.7%) as a yellow solid which was used in next step directly without further purification. LCMS: ESI m/z 204 [M+H]
+.
Step 4: To a solution of 6- (methoxymethoxy) -1H-indazole-7-carbonitrile (360 mg, 1.8 mmol) in DMF (10 mL) were added PMBCl (0.3 mL, 2.1 mmol) and Cs
2CO
3 (808.0 mg, 2.5 mmol) , and the reaction was stirred at 60 ℃ for 1.5h. The reaction mixture was diluted with EtOAc (30 mL) . The mixture was washed with sat. LiCl solution, water and brine. The organic phase was dried, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=10%~ 30%) to obtain the desired product 6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (380 mg, yield: 66.3%) as a yellow oil. LCMS: ESI m/z 324 [M+H]
+.
Step 5: To a solution of 6- (methoxymethoxy) -1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (380 mg, 1.2 mmol) in MeOH (5 mL) was added HCl (1 mL, 2 mmol) , the resulting mixture was heated to 65℃ for 1h. The reaction mixture was concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=5%~ 30%) to obtain the desired product 6-hydroxy-1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonitrile (280 mg , yield: 85.3%) as a yellow oil. LCMS: ESI m/z 280 [M+H]
+.
Step 6: To a solution of 6-hydroxy-1- [ (4-methoxyphenyl) methyl] -1H-indazole-7-carbonit-rile (147 mg, 0.5 mmol) in DCM (10 mL) were added TEA (80 mg, 0.8 mmol) and Tf
2O (178 mg, 0.6 mmol) , and the reaction mixture was stirred at room temperature for 1h. The reaction mixture was diluted with DCM (20 mL) , the organic phase was washed with water and brine, The collected organic layer was dried, filtered and concentrated to give the crude product 7-cyano-1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yl trifluoromethanesulfonate (167 mg, yield: 77.1%) as a yellow oil which was used to next step directly without further purification. LCMS: ESI m/z 412 [M+H]
+.
Step 7: To a solution of 7-cyano-1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yltrifluoromethanesulfonate (167 mg, 0.4 mmol) and 2-methoxy-N- { [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl} benzamide (164 mg, 0.45 mmol) in dioxane (10 mL) and H
2O (2 mL) were added K
2CO
3 (112 mg, 0.8 mmol) and Pd (dppf) Cl
2 (29 mg, 0.04 mmol) , the reaction mixture was stirred at 100 ℃ for 2h under N
2 atmosphere. The reaction was cooled and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=10%~ 50%) to obtain the desired product N- [ (4- {7-cyano-1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yl} phenyl) methyl] -2-methoxybenzamide (182 mg, yield: 89.2%) as a yellow oil. LCMS: ESI m/z 503 [M+H]
+.
Step 8: A solution of N- [ (4- {7-cyano-1- [ (4-methoxyphenyl) methyl] -1H-indazol-6-yl} phenyl) methyl] -2-methoxybenzamide (120 mg, 0.24 mmol) in TFA (2 mL) was heated to 75℃ for 1 h.The reaction was concentrated under reduced pressure, the residue was dissolved in EtOAc (15 mL) and washed by sat. NaHCO
3 solution (5 mL x 3) . The organic layer was collected, dried and concentrated to give the crude product N- { [4- (7-cyano-1H-indazol-6-yl) phenyl] methyl} -2-methoxybenzamide (103 mg, yield: 86.8%) as a brown solid which was used in next step directly without further purification. LCMS: ESI m/z 383 [M+H]
+.
Step 9: To a solution of N- { [4- (7-cyano-1H-indazol-6-yl) phenyl] methyl} -2-methoxybenzamide (98 mg, 0.26 mmol) in EtOH (2 mL) and THF (2 mL) were added NaOH (20 mg, 0.5 mmol) and H
2O
2 (1 mL) , and the reaction mixture was stirred at 60℃ for 2 h. The reaction was diluted with EtOAc (20 mL) . The resulting mixture was washed with water and brine, the collected organic phase was dried, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM=10%~ 50%) to afford the desired product 6- (4- { [ (2-methoxyphenyl) formamido] methyl} phenyl) -1H-indazole-7-carboxamide (17 mg, yield: 34.2 %) as a white solid. LCMS: ESI m/z 401 [M+H]
+. 1H NMR (400 MHz, DMSO) δ 13.16 (s, 1H) , 8.77 (t, J = 6.1 Hz, 1H) , 8.13 (s, 1H) , 7.89 –7.74 (m, 2H) , 7.65 (s, 1H) , 7.50 (dd, J = 13.1, 4.9 Hz, 4H) , 7.39 (d, J = 8.1 Hz, 2H) , 7.20 –7.01 (m, 3H) , 4.56 (d, J = 6.1 Hz, 2H) , 3.92 (s, 3H)
Example 149:
6- (4- { [ (5-Fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -4- (2-oxopyrrolidin-1-yl) -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (BNB-1088-01)
Step 1: To a stirred solution of 4, 6-dichloro-1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridine-7-carboxamide (80 mg, 0.23 mmol) and tert-butyl 4-aminobutanoate (50 mg, 0.31 mmol) in DMF (2 mL) was added TEA (40 mg, 0.40 mmol) at 25℃. The resulting mixture was stirred at rt for 18 h. The reaction mixture was poured into water (5 mL) , the mixture was extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=10%~ 50%) to obtain the desired product tert-butyl 4- ( {7-carbamoyl-6-chloro-1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridin-4-yl} amino) but anoate (90 mg , yield: 83%) as a pale oil. LC/MS (ESI) m/z: 474 (M+H)
+.
Step 2: To a stirred solution of tert-butyl 4- ( {7-carbamoyl-6-chloro-1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridin-4-yl} amino) butanoate (90 mg, 0.19 mmol) and 5-fluoro-2-methoxy-N- { [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl} benzamide (100 mg, 0.26 mmol) in 1, 4-dioxane (5 mL) and H
2O (1mL) at 25℃ was added Pd (dppf) Cl
2 (30 mg, 0.041 mmol) and K
2CO
3 (100 mg, 0.724 mmol) , the reaction mixture was stirred at 110℃ for 18h under N
2 atmosphere. The reaction mixture was diluted with water (10 mL) , the mixture was extracted with EtOAc (15 mL x 3) , the combined organic phase was washed with water and brine, the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=10%~ 50%) to obtain the desired product tert-butyl 4- { [7-carbamoyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridin-4-yl] amino} butanoate (90 mg, yield: 68%) as a pale oil. LC/MS (ESI) m/z: 697 (M+H)
+.
Step 3: To a stirred solution of tert-butyl 4- { [7-carbamoyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1- [ (4-methoxyphenyl) methyl] -1H-pyrazolo [4, 3-c] pyridin-4-yl] amino} butanoate (90 mg, 0.13 mmol) in DCM (5 mL) at 25℃ was added TFA (3 mL) , the reaction mixture was stirred at 50℃ for 18h. The reaction mixture was poured into water (5 mL) , extracted with EtOAc (60 mL x 3) , the combined organic phase was washed with sat. NaHCO
3, water and brine, the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM=1%~ 5%) to obtain desired product 4- { [7-carbamoyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1H-pyrazolo [4, 3-c] pyridin-4-yl] amino} butanoic acid (40 mg, yield: 59.6 %) as a pale solid. LC/MS (ESI) m/z: 521 (M+H)
+.
Step 4: To a stirred solution of4- { [7-carbamoyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1H-pyrazolo [4, 3-c] pyridin-4-yl] amino} butanoic acid (45 mg, 0.1 mmol) and HATU (50 mg, 0.13 mmol) in DMF (2 mL) was added DIPEA (25 mg, 0.19 mmol) at 25℃, the reaction mixture was heated to 50℃ for 18h. The reaction mixture was poured into water (10 mL) , the mixture was extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (MeOH in DCM=1%~5%) to obtain the desired product 6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -4- (2-oxopyrrolidin-1-yl) -1H-pyrazolo [4, 3c] pyridine-7-carboxamide (10 mg, yield: 23%) as a white solid. LC/MS (ESI) m/z: 503 (M+H)
+.
1H NMR (400 MHz, DMSO) δ 8.86 (t, J = 5.6 Hz, 1H) , 8.34 (s, 1H) , 7.84 (s, 1H) , 7.75 (d, J = 8.2 Hz, 2H) , 7.64 (s, 1H) , 7.52 (dd, J = 9.3, 3.3 Hz, 1H) , 7.43 –7.30 (m, 3H) , 7.19 (dd, J = 9.2, 4.3 Hz, 1H) , 4.55 (d, J = 6.3 Hz, 2H) , 4.12 (t, J = 7.1 Hz, 2H) , 3.90 (s, 3H) , 2.67 (dd, J = 4.9, 3.0 Hz, 2H) , 2.19 –2.09 (m, 2H) .
Example 150:
4-Cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxamide (BNB-1050-01)
Step 1: To a solution of 2, 6-dichloropyridin-4-amine (25.0 g, 153.37 mmol) and Boc
2O (100.3g, 460.1 mmol) in DCM (300 mL) was added DMAP (1.87 g, 15.3 mmol) under N
2 with stirred. The mixture was stirred for 3 h until the starting material was consumed completely. The reaction mixture was concentrated in vacuum to remove excess DCM. The residue was poured into water (100 mL) and extracted with EtOAc (100 mL x 3) . The organic layer was dried over MgSO4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 2%) . The title tert-butyl N- [ (tert-butoxy) carbonyl] -N- (2, 6-dichloropyridin-4-yl) carbamate (55 g, yield 99%) as white solid. LC/MS (ESI) m/z: 364 (M+H) +.
Step 2: To a solution of tert-butyl N- [ (tert-butoxy) carbonyl] -N- (2, 6-dichloropyridin-4-yl) carbamate (55.0 g, 151.4 mmol) in THF (300 mL) was added LDA (227 mL, 454.2 mmol) at -78℃ under N
2. The mixture was stirred for 30 min until the starting material was consumed completely. The reaction mixture was warmed to room temperature and quenched with sat. NH
4Cl solution, extracted with EtOAc (100 mL x 3) . The organic layer was dried over MgSO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 2%) to obtain the desired product tert-butyl 4- (tert-butoxycarbonylamino) -2, 6-dichloronicotinate (53g, yield 96%) as a white solid. LC/MS (ESI) m/z: 364 (M+H)
+.
1H NMR (400 MHz, DMSO) δ 9.84 (s, 1H) , 7.63 (s, 1H) , 1.60 (s, 9H) , 1.52 (s, 9H) .
Step 3: To a solution of tert-butyl 4- (tert-butoxycarbonylamino) -2, 6-dichloronicotinate (2.0 g, 5.51 mmol) and 2-cyclopentenyl-4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan (0.96 g, 4.96 mmol) in dioxane (15 mL) and water (3 mL) were added K
2CO
3 (1.52 g, 11.01 mmol) and Pd (dppf) Cl
2 (0.2 g, 0.28 mmol) under N
2 . The resulting mixture was stirred for 2 h at 60℃. The reaction mixture was cooled to room temperature and concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 2%) to obtain the desired product tert-butyl 4- (tert-butoxycarbonylamino) -2-chloro-6-cyclopentenylnicotinate (1.1 g, yield 51%) as white solid. LC/MS (ESI) m/z: 395 (M+H)
+.
1H NMR (400 MHz, DMSO) δ 9.46 (s, 1H) , 7.52 (s, 1H) , 6.67 (s, 1H) , 2.69 –2.60 (m, 2H) , 2.55 (m, 2H) , 2.02 –1.97 (m, 2H) , 1.54 (s, 9H) , 1.46 (d, J = 1.7 Hz, 9H) .
Step 4: To a solution of tert-butyl 4- (tert-butoxycarbonylamino) -2-chloro-6-cyclopentenylnicotinate (1.1 g, 2.8 mmol) in EtOAc (20 mL) was added Pt/C (50 mg) . The mixture was stirred at rt for 4h under H
2 atmosphere. The resulting reaction mixture was filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 1%~ 4%) to obtain the desired product tert-butyl 4- (tert-butoxycarbonylamino) -2-chloro-6-cyclopentylnicotinate (540 mg, yield: 49 %) as a white solid. LC/MS (ESI) m/z: 397 (M+H)
+.
1H NMR (400 MHz, DMSO) δ 9.40 (s, 1H) , 7.38 (s, 1H) , 3.08 (m, 1H) , 2.06 –1.89 (m, 2H) , 1.75 (m, 2H) , 1.64 (m, 4H) , 1.53 (s, 9H) , 1.46 (s, 9H) .
Step 5: To a solution of tert-butyl 4- { [ (tert-butoxy) carbonyl] amino} -2-chloro-6-cyclopentylpyridine-3-carboxylate (540 mg, 1.3 mmol) in DCM (5 mL) was added TFA (5 mL) under N
2. The mixture was stirred for 3 h. The solvent was concentrated under reduced pressure to give the crude product 4-amino-2-chloro-6-cyclopentylpyridine-3-carboxylicacid (280 mg, yield: 89.7 %) as a yellow solid which was used directly without further purification. LC/MS (ESI) m/z: 241 (M+H)
+
Step 6: To a solution of 4-amino-2-chloro-6-cyclopentylpyridine-3-carboxylicacid (280 mg, 1.1 mmol) in DCM (5 mL) was added TMSCHN
2 (501 mg, 4.4 mmol) under N
2 atmosphere. The mixture was stirred for 1h. The reaction mixture was quenched with AcOH (1 mL) under ice-bath. The mixture was concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 2%~ 10%) to obtain the desired product methyl 4-amino-2-chloro-6-cyclopentylpyridine-3-carboxylate (190 mg, yield: 68 %) as a white solid. LC/MS (ESI) m/z: 255 (M+H)
+.
1H NMR (400 MHz, CDCl
3) δ 6.35 (s, 1H) , 5.70 (br, 2H) , 3.08 –2.88 (m, 1H) , 2.00 (m, 2H) , 1.84 –1.74 (m, 2H) , 1.73 –1.63 (m, 4H) .
Step 7: To a solution of methyl 4-amino-2-chloro-6-cyclopentylpyridine-3-carboxylate (190 mg, 0.74 mmol) in MeCN (5 mL) was added NBS (145 mg, 0.8 mmol) at 0℃, the resulting mixture was stirred for 2h at 0℃. Solvent was removed under reduced pressure to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 0 ~ 5 %) to obtain the desired product methyl 4-amino-5-bromo-2-chloro-6-cyclopentylpyridine-3-carboxylate (230 mg, yield: 93.3 %) as white solid. LC/MS (ESI) m/z: 333/335 (M+H)
+
Step 8: To a solution of methyl 4-amino-5-bromo-2-chloro-6-cyclopentylpyridine-3-carboxylate (200 mg, 0.6 mmol) and 2-methoxy-N- { [4- (tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl] methyl} benzamide (220 mg, 0.6 mmol) in dioxane (6 mL) and H
2O (2 mL) were added K
2CO
3 (249 mg, 1.8 mmol) and Pd (PPh
3)
4 (35 mg, 0.030 mmol) under N
2. The reaction mixture was heated to 80℃ for 10 h. The reaction mixture was cooled to r.t. and diluted with EtOAc (30 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 10%~ 20%) to obtain the desired product methyl 4-amino-5-bromo-6-cyclopentyl-2- (4- ( (2-methoxybenzamido) methyl) phenyl) nicotinate (140 mg, yield: 43.4%) as a white solid. LC/MS (ESI) m/z: 538/540 (M+H)
+
Step 9: To a solution of methyl 4-amino-5-bromo-6-cyclopentyl-2- (4- ( (2-methoxybenzamido) methyl) phenyl) nicotinate (210 mg, 0.390 mmol) and 2- [2-ethoxyethenyl] -4, 4, 5, 5-tetramethyl-1, 3-dioxolane (78 mg, 0.4 mmol) in 1, 4-dioxane (8 mL) and H
2O (2 mL) were added K
2CO
3 (161 mg, 1.2 mmol) and Pd (PPh
3)
4 (45 mg, 0.04 mmol) under N
2. The reaction mixture was heated to 60℃ for 10 h. The reaction mixture was cooled to r.t. and diluted with EtOAc (30 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 10%~ 20%) to obtain the desired product methyl 4-amino-6-cyclopentyl-2- (4- ( (2-methoxybenzamido) methyl) phenyl) -5- (2-methoxyvinyl) nicotinate (140 mg, yield: 67.8%) as white solid. LC/MS (ESI) m/z: 516 (M+H)
+
Step 10: A solution of methyl 4-amino-6-cyclopentyl-2- (4- ( (2-methoxybenzamido) methyl) phenyl) -5- (2-methoxyvinyl) nicotinate (140 mg, 0.3 mmol) in AcOH (5 mL) was heated to 100 ℃ in microwave reactor. Then the reaction mixture was concentrated, diluted with EtOAc (20 mL) , washed with water and brine. The organic layer was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (DCM: MeOH=100: 1 to 30: 1) to obtain methyl 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxylate (100 mg, yield: 78.2%) as a white solid. LC/MS (ESI) m/z: 484 (M+H)
+
Step 11: To a solution of methyl 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxylate (100 mg, 0.206 mmol) in THF (5 mL) was added ammonia solution (5 mL, 28%in water) . The mixture was stirred at 100 ℃ for 12 h in a sealed tank. After cooled down to rt, the reaction mixture was concentrated to give the crude product which was purified by prep-TLC (DCM : MeOH=15: 1) to obtain the desired product 4-cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxamid e (5.5 mg, yield: 5.69%) as a white solid. LC/MS (ESI) m/z: 469 (M+H)
+.
1H NMR (400 MHz, MeOD) δ 7.91 (dd, J = 7.8, 1.8 Hz, 1H) , 7.70 (d, J = 8.2 Hz, 2H) , 7.55 –7.44 (m, 4H) , 7.41 (d, J =3.3 Hz, 1H) , 7.16 (d, J = 8.3 Hz, 1H) , 7.07 (t, J = 7.5 Hz, 1H) , 6.77 (d, J = 3.2 Hz, 1H) , 4.68 (s, 2H) , 3.97 (s, 3H) , 3.69 –3.61 (m, 1H) , 2.17 –2.04 (m, 4H) , 1.94 (m, 2H) , 1.86 –1.70 (m, 2H)
Example 151:
4-Cyclopentyl-6- (4- ( (2-methoxybenzamido) methyl) phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxamide (BNB-1065-01)
Step 1: To a solution of methyl 4-amino-5-bromo-2-chloro-6-cyclopentylnicotinate (500 mg, 1.51 mmol) and 5-fluoro-2-methoxy-N- (4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzyl) benzamide (583 mg, 1.51 mmol) in dioxane (15 mL) and H
2O (3 mL) were added K
2CO
3 (417 mg, 3.02 mmol) and Pd (PPh
3)
4 (173 mg, 0.15 mmol) under N
2. The reaction mixture was heated to 80℃ for 10 h. The reaction mixture was cooled to r.t. and diluted with EtOAc (30 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 10%~ 20%) to obtain the desired product methyl 4-amino-5-bromo-6-cyclopentyl-2- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) nicotinate (500 mg, yield: 59.9%) as a white solid. LC/MS (ESI) m/z: 557/559 (M+H)
+
Step 2: To a solution of methyl 4-amino-5-bromo-6-cyclopentyl-2- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) nicotinate (500 mg, 0.90 mmol) and (E) -2- (2-ethoxyvinyl) -4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (179 mg, 0.90 mmol) in 1, 4-dioxane (8 mL) and H
2O (2 mL) were added K
2CO
3 (248 mg, 1.80 mmol) and Pd (PPh
3)
4 (104 mg, 0.09 mmol) under N
2. The reaction mixture was heated to 60℃ for 10 h. The reaction mixture was cooled to r.t. and diluted with EtOAc (30 mL) . The mixture was washed with water and brine. The organic phase was dried over with anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE = 10%~ 20%) to obtain the desired product 4-amino-6-cyclopentyl-5- (2-ethoxyvinyl) -2- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) nicot inate (430 mg, yield: 87.3%) as white solid. LC/MS (ESI) m/z: 548 (M+H)
+
Step 3: A solution of 4-amino-6-cyclopentyl-5- (2-ethoxyvinyl) -2- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) nicotinate (430 mg, 0.79 mmol) in AcOH (5 mL) was heated to 100 ℃ in microwave reactor. Then the reaction mixture was concentrated, diluted with EtOAc (20 mL) , washed with water and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (DCM: MeOH=100: 1 to 30: 1) to obtain methyl 4-cyclopentyl-6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-car boxylate (220 mg, yield: 55.8%) as a white solid. LC/MS (ESI) m/z: 502 (M+H)
+
Step 4: To a stirred solution of methyl 4-cyclopentyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxylate (230 mg, 0.46 mmol) in THF (2 mL) and MeOH (2 mL) was added NaOH (184 mg, 4.6 mmol) . The reaction mixture was stirred at 50℃ for 18 h under N
2 atmosphere. The mixture was extracted with EtOAc (10 mL x 3) , the combined organic phase was washed with water and brine, the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product was used without purification to obtain 4-cyclopentyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxylic acid (200 mg, yield: 89.5%) as a white solid. LC/MS (ESI) m/z: 488 (M+H)
+.
Step 5: To a stirred solution of 4-cyclopentyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxylic acid (200 mg, 0.41 mmol) in DMF (5 mL) at 25℃ was added TEA (124 mg, 1.23 mmol) and HATU (187 mg, 0.49 mmol) slowly, the reaction mixture was stirred at 25℃ for 1 h under NH
3 atmosphere. The reaction mixture was diluted with water (20 mL) , the mixture was extracted with EtOAc (20 mL x 3) , the combined organic phase was washed with water and brine, the organic phase was dried over anhydrous Na
2SO
4, filtered and concentrated to give the crude product which was purified by column chromatography on silica gel (EtOAc in PE=50: 1 to 1: 1) to obtain 4-cyclopentyl-6- (4- { [ (5-fluoro-2-methoxyphenyl) formamido] methyl} phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxamide (170 mg, Yield: 85.2%) as a white solid. LC/MS (ESI) m/z: 487 (M+H)
+.
Step 6: To a solution of 4-cyclopentyl-6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -1H-pyrrolo [3, 2-c] pyridine-7-carboxamide (90 mg, 0.19 mmol) in 3 mL of AcOH and 3 mL of t-BuOH was added PyHBr3 (177 mg, 0.56 mmol) was stirred for overnight under N
2. Then the Zn (121 mg, 1.85 mmol) , AcOH (3 ml) was added and stirred for 1 hour. The reaction mixture was concentrated in vacuum to remove most of solvent. The residue was poured into water (6 mL) and extracted with EtOAc (6 mL) . The organic layer was dried over MgSO
4, filtered and concentrated. The title 4-cyclopentyl-6- (4- ( (5-fluoro-2-methoxybenzamido) methyl) phenyl) -2-oxo-2, 3-dihydro-1H-pyrrolo [3, 2-c] pyridine-7-carboxamide was obtained by column chromatography on silica gel eluting with EtOAc in PE= 50%as a white solid (20 mg, yield 21.5%) . LC/MS (ESI) m/z: 503 (M+H)
+.
1H NMR (400 MHz, DMSO) δ 10.70 (s, 1H) , 8.84 (t, J = 6.1 Hz, 1H) , 7.75 (s, 1H) , 7.64 (d, J = 8.2 Hz, 2H) , 7.53 (dd, J = 9.2, 3.3 Hz, 1H) , 7.41 (s, 1H) , 7.34 (dd, J = 13.5, 5.7 Hz, 3H) , 7.19 (dd, J =9.1, 4.3 Hz, 1H) , 4.54 (d, J = 6.1 Hz, 2H) , 3.90 (s, 3H) , 3.61 (s, 2H) , 3.19 –3.08 (m, 1H) , 1.93 (d, J =8.0 Hz, 2H) , 1.87 –1.71 (m, 4H) , 1.63 (dd, J = 7.1, 4.6 Hz, 2H) .
Biological Testing
1. BTK kinase biochemical activity
The effectiveness of the compounds prepared in the above Examples as BTK inhibitors was determined using an ADP-Glo methodology. Enzyme assay using recombinant form of wild type BTK (Signalchem, Cat#B10-10H-10) and recombinant form of BTK-C481S (Signalchem, Cat#B10-12CH-10) were performed as follows. Compounds were serially diluted 1: 3 in DMSO for 10-point dose IC50 mode in duplicate. BTK kinase activity was tested in assay buffer containing 50 mM HEPES, 1 mM EGTA, 10 mM Mg
2+, 0.01%BRIJ35 and 2 mM DTT (pH=7.4) . 0.1 μL diluted compounds were mixed with 5 μL enzyme working solution (Signalchem, Cat#B10-10H-10) by Echo (Labcyte, Cat#550) , and subsequently mixed with 5 μL substrate working solution (Sigma, Cat#P61-58) into 384-well assay plate (Perkin Elmer, Cat#6008280) to initiate the reaction. After incubation at 25℃ for 60 min, 5 μL ADP Glo reagent (Promega, Cat#V9102) was added and incubated at 25℃ for 60 min to terminate the reaction. After addition of 10 μL kinase detection reagent (Promega, Cat#V9102) and incubation at 25℃ for 60 min, plates were read on Envision (Perkin Elmer, Envision 2104) for US LUM as RLU. IC50 values were calculated by fitting %Inhibition values and log of compound concentrations to nonlinear regression (dose response –variable slope) with GraphPad Prism 6.0.
2. MEK1 Kinase Activity Assay
Enzyme assay using recombinant form of wild type MEK1 (Signalchem, Cat#M02-10G) was performed as follows using an ADP-Glo methodology. The compounds prepared in the above Examples were serially diluted 1: 3 in DMSO for 10-point dose IC50 mode in duplicate. MEK1 kinase activity was tested in assay buffer containing 50 mM HEPES, 1 mM EGTA, 10 mM Mg
2+, 0.01%BRIJ35 and 2 mM DTT (pH=7.4) . 0.1 μL diluted compounds were mixed with 5 μL enzyme working solution (Signalchem, Cat#M02-10G) by Echo (Labcyte, Cat#550) , and subsequently mixed with 5 μL substrate working solution (Signalchem, Cat#M29-14G) into 384-well assay plate (Perkin Elmer, Cat#6008280) to initiate the reaction. After incubation at 25℃ for 60 min, 5 μL ADP Glo reagent (Promega, Cat#V9102) was added and incubated at 25℃ for 60 min to terminate the reaction. After addition of 10 μL kinase detection reagent and incubation at 25℃ for 60 min, plates were read on Envision (Perkin Elmer, Envision 2104) for US LUM as RLU. IC50 values were calculated by fitting %Inhibition values and log of compound concentrations to nonlinear regression (dose response –variable slope) with GraphPad Prism 6.0.
3. EGFR Kinase Activity Assay
Enzyme assay using recombinant form of wild type EGFR (Signalchem, Cat#E10-11G-10) was performed as follows using a homogenous time-resolved fluorescence (HTRF) methodology. The compounds prepared in the above Examples were serially diluted 1: 3 in DMSO for 10-point dose IC50 mode in duplicate. EGFR kinase activity was tested in 1x kinase buffer (HTRF KinEASE-TK kit, Cisbio, Cat#62TK0PEC) , with 5 mM MgCl
2, 1 mM MnCl
2 and 1 mM DTT. 0.1 μL diluted compounds were mixed with 5 μL 2x EGFR enzyme solution (Signalchem, Cat#E10-11G-10) by Echo (Labcyte, Cat#550) , and incubated at 25℃ for 10 min. Subsequent 5 μL TK-substrate-biotin (Cisbio, 61TK0BLE) and ATP mixture substrate were added (Promega, Cat#V910B) into 384-well assay plate (Labcyte, P-05525-BC) to initiate the reaction. After incubation at 25℃ for 40 min, 10 μL 2X Sa-XL 665 and TK-antibody-Cryptate (Cisbio, 06A) was added into each well of the assay plate and incubated at 25℃ for 60 min. Fluorescence signal was read at 615 nm (Cryptate) and 665 nm (XL665) on Envision (Perkin Elmer, Envision 2104) . IC50 values were calculated by fitting %Inhibition values and log of compound concentrations to nonlinear regression (dose response –variable slope) with GraphPad Prism 6.0.
4. OCI-Ly10 Cell Proliferation Assay
Cell proliferation assay using OCI-Ly10 human DLBCL (diffuse large B cell lymphoma) cell line (Cobioer Biosciences, CBP60558) which is dependent on NFκB signaling, was performed as follows using a Celltiter-Glo methodology. The compounds prepared in the above Examples were serially diluted 1: 4 in DMSO for 10-point dose IC50 mode in duplicate. OCI-Ly10 cells were cultured using IMDM medium (Gibco, Cat#12440-053) supplemented with 10%FBS (Invitrogen, Cat#10099141) and 1%Penicillin-streptomycin (Gibco, Cat#15140-122) in suspension in T75 flasks (Corning, Cat#430641) . After centrifugation and resuspension with culturing media, OCI-Ly10 cells were seeded at a density of 8,000 cells/well into 96-well plates (Corning, Cat#3603) . 5 μL diluted compounds were then added into the cell plate and incubated for 72h at 37℃ in a CO
2 incubator (ThermoFisher, Cat#371) . After 72h of compound treatment, 100 μL cell supernatant was removed and 70 μLCelltiter-Glo buffer (Promega, Cat#G7573) was added into the cell plate. After incubation at 25℃for 20 min, luminescence signal was measured on Envision (Perkin Elmer, Envision 2104) . IC50 values were calculated by fitting %Inhibition values and log of compound concentrations to nonlinear regression (dose response –variable slope) with GraphPad Prism 6.0.
PK protocol
ICR mice (male, 6–8 weeks old, 26–30 g, n=9 for each route of administration) were purchased from Shanghai Institute of Planned Parenthood Research (SIPPR) (Shanghai, China) . The animals were housed in a room with a temperature maintained at around 20-26 ℃ and with a relative humidity of 40%~ 70%under a 12: 12 h light–dark cycle, with free access to food and water. All procedures involving animals complied with the Laboratory Animal Management Principles of China. Animal study procedures were reviewed and approved by the Institutional Animal Care and Use Committee. The ICR mice received intravenous (IV; 1 mg/kg) or oral gavage (PO; 10 mg/kg) of test compounds after overnight fasting. Food was given 4 h post dose. Compounds were formulated in DMA, Solutol HS-15 and Saline (10: 10: 80, v/v/v) to yield a nominal concentration of 0.2 mg/mL (i.v. route) and 1mg/mL (p.o. route) for administration. Blood samples (110 μL) were collected via jugular vein sinus at appropriate time points (n=3 for each time points) . Blood samples were placed into tubes containing K2EDTA and centrifuged under refrigerated conditions at 5,500 rpm for 10 min to separate plasma. Plasma samples were stored at -20 ℃ before analysis. Plasma (20 μL) was mixed with 100 μL ACN containing internal standard in a 96-well plate to precipitate the protein. After vortexing for 10 second, the plate was centrifuged at 3, 760 rpm at 4 ℃ for 10 min, and 60 μL of supernatant was diluted with 60 μL H2O before LC/MS/MS analysis. Pharmacokinetic parameters were determined using non-compartmental WinNonlin (Pharsight, Mountain View, CA, USA) analysis.
Efficacy studies
General procedures for animal care and housing are in accordance with the standard, Commission on Life Sciences, National Research Council, standard operating procedures. The OCI-LY10 tumor cell line will be maintained in vitro as suspension culture in IMDM medium modified supplemented with 20%heat inactivated fetal bovine serum at 37℃ in an atmosphere of 5%CO
2 in air. The tumor cells will be routinely sub-cultured, not to exceed 4-5 passages. The cells growing in an exponential growth phase will be harvested and counted for tumor inoculation. Each mouse will be inoculated subcutaneously on the right flank with OCI-LY10 tumor cells (1 x 10
7) in 0.1 ml of IMDM Medium and High Concentration Matrigel mixture (1: 1 ratio) for tumor development. Based on the tumor volume and body weight, mice will be randomly assigned to respective groups such that the average starting tumor size and body weight is the same for each treatment group. and treatments will start when the mean tumor volume reaches about 120-180 mm
3. The measurement of tumor size will be conducted twice a week with a caliper and recorded. The tumor volume (mm
3) is estimated using the formula: TV=a × b
2/2, where “a” and “b” are long and short diameters of a tumor, respectively.
The TVs are used for calculation of the tumor growth inhibition and tumor growth delay. For the tumor growth inhibition (TGI) , the value using the formula:
a. %T/C= (TreatedTVfinal-TreatedTVinitial) / (VehicleTVfina-VehicleTVinitial) *100
b. %TGI= [1- (TreatedTVfinal-TreatedVTinitial) / (VehicleTVfinal-VehicleTVinitial) ] *100
The “TVfinal” and “TVinitial” are the mean tumor volumes on the final day and initial day.
Table 9. Biological activities of selected example (A<50 nM; B: 50 to 100 nM; C: 100 nM to 1000 nM; D>1000 nM)
Claims (18)
- A compound of formula I:or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:X 1, X 2 and X 3 are each independently CR’ or N; R’ is selected from a group consisting of H, C 1-6alkyl, halo and oxo;R 1 is selected from a group consisting of H, deuterium, 3-10 membered heterocyclyl, 5-12 membered heteroaryl, C 3-10cycloalkyl, C 3-10cycloalkyl-O-, C 3-10cycloalkenyl, 3-10 membered heterocyclyl-O-, C 6-10aryl, C 1-6alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6alkoxyl, -C 1-6alkyl-O-C 1-6alkyl, -NH 2, -NH (C 1-6alkyl) and N (C 1-6alkyl) 2, wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of deuterium, halo, -OH, -CN, -NH 2, -NH (C 1-6alkyl) and -NH (C 1-6alkyl) 2; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -SH, -NH 2, oxo, halo, -CN, C 1-6alkyl, C 2-6alkenyl, C 2-6alkynyl, C 1-6haloalkyl, C 1-6alkoxyl, C 1-6haloalkoxyl, -C 1-6alkyl-O-C 1-6alkyl, -NH (C 1-6alkyl) , -N (C 1-6alkyl) 2, C 1-6alkyl-S-, -C 1-6alkyl-OH, C 3-6cycloalkyl, C 3-6halocycloalkyl, -C (O) C 1-6alkyl, -S (O) nC 1-6alkyl, -C (O) OH, -C (O) OC 1-6alkyl, -C (O) NH 2, -C (O) NH (C 1-6alkyl) , -C (O) N (C 1-6alkyl) 2, -NHC (O) C 1-6alkyl, and 3-6 membered heterocyclyl optionally substituted with oxo;Ar is -C 6-10aryl-Y-R 2, or -5-6 membered heteroaryl-Y-R 2, wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from a group consisting of halo, C 1-6alkoxyl and C 1-6alkyl;Y is selected from a group consisting of O, S, - (CH 2) m-NH-C (O) -, - (CH 2) m-NH-S (O) n-, - (CH 2) m-N (C 1-6alkyl) -C (O) -, - (CH 2) m-N (C 1-6alkyl) -S (O) n-, - (CH 2) m-C (O) -NH-, - (CH 2) m-S (O) n-NH-, - (CH 2) m-C (O) -N (C 1-6alkyl) -and - (CH 2) m-S (O) n-N (C 1-6alkyl) -;R 2 is C 6-10aryl or 5-10 membered heteroaryl, optionally substituted with one or more substituents selected from a group consisting of C 1-6alkoxyl, deuterated C 1-6alkoxyl, halo, C 1-6haloalkyl, -OH, -SH, -CN, -NH 2, -NH (C 1-6alkyl) , -NH (C 1-6alkyl) 2, C 1-6alkyl-S-, -C 1-6alkyl-O-C 1-6alkyl, -C (O) C 1-6alkyl, -C (O) OH, -C (O) OC 1-6alkyl, -C (O) NH 2, -C (O) NH (C 1-6alkyl) , -C (O) N (C 1-6alkyl) 2, and -NHC (O) C 1-6alkyl;m is 0 or 1; andn is 1 or 2.
- The compound of claim 1 or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:X 1 and X 3 are each independently CR’ or N; R’ is selected from a group consisting of H, C 1-6alkyl, halo and oxo;X 2 is CH;R 1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, C 3-8cycloalkyl, C 3-8cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C 6-10aryl, C 1-6alkyl, C 1-6alkoxyl, -NH 2, -NH (C 1-6alkyl) and -N (C 1-6alkyl) 2, wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo, -OH, -CN and -NH 2; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -NH 2, oxo, halo, -CN, C 1-6alkyl, C 1-6haloalkyl, C 1-6alkoxyl, C 1-6haloalkoxyl, -NH (C 1-6alkyl) , -N (C 1-6alkyl) 2, C 1-6alkyl-S-, -C 1-6alkyl-OH, C 3-6cycloalkyland C 3-6halocycloalkyl;Ar is -C 6-10aryl-Y-R 2 or -5-6 membered heteroaryl-Y-R 2, wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from a group consisting of halo, C 1-6alkoxyl and C 1-6alkyl;Y is selected from a group consisting of O, S, - (CH 2) m-NH-C (O) -and - (CH 2) m-C (O) -NH-;R 2 is C 6-10arylor 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6alkoxyl, deuterated C 1-6alkoxyl, halo, C 1-6haloalkyl, -OH, -CN and -NH 2;m is 0 or 1.
- The compound of any one of claims 1-2, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein:X 1 is CR’ or N; R’ is H or halo;X 2 is CH;X 3 is selected from a group consisting of CH, C (=O) or N;R 1 is selected from a group consisting of H, 3-8 membered heterocyclyl, 5-12 membered heteroaryl, C 3-8cycloalkyl, C 3-8cycloalkyl-O-, 3-8 membered heterocyclyl-O-, C 6-10aryl, C 1-6alkyl, C 1-6alkoxyl -NH 2, -NH (C 1-6alkyl) and N (C 1-6alkyl) 2, wherein each alkyl or alkoxyl is optionally substituted with one or more substituents selected from a group consisting of halo, -OH, -CN and -NH 2; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, -NH 2, oxo, halo, -CN, C 1-6alkyl, C 1-6haloalkyl, C 1-6alkoxyl, C 1-6haloalkoxyl, -NH (C 1-6alkyl) , -N (C 1-6alkyl) 2, C 1-6alkyl-S-and -C 1-6alkyl-OH;Ar is -C 6-10aryl-Y-R 2, or -5-6 membered heteroaryl-Y-R 2, wherein each aryl or heteroaryl is optionally substituted with one or more halo;Y is selected from a group consisting of O, S, - (CH 2) m-NH-C (O) -and - (CH 2) m-C (O) -NH-;R 2 is C 6-10aryl or 5-6 membered heteroaryl, optionally substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6alkoxyl, deuterated C 1-6alkoxyl, halo, C 1-6haloalkyl, -OH, -CN and -NH 2; andm is 0 or 1.
- The compound of any one of claims 1-3, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein X 3 is N.
- The compound of any one of claims 1-4, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, whereinX 1 is CR’ or N; R’ is H or halo;X 2 is CH;X 3 is N;R 1 is selected from a group consisting of 3-8 membered heterocyclyl, 5-10 membered heteroaryl, C 3-8cycloalkyl, C 3-8cycloalkyl-O-, C 6-10aryl and N (C 1-6alkyl) 2, wherein alkyl is optionally substituted with one or more halo, -OH and -CN; and wherein each heterocyclyl, heteroaryl, cycloalkyl or aryl is optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6alkyl, C 1-6haloalkyl and C 1-6alkoxyl;Ar is -C 6-10aryl-Y-R 2, wherein each said C 6-10aryl is optionally substituted with one halo;Y is -CH 2-NH-C (O) -; andR 2 is C 6-10aryl substituted with 1, 2 or 3 substituents selected from a group consisting of C 1-6alkoxyl, deuterated C 1-6alkoxyl and halo.
- The compound of any one of claims 1-6, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 2 is 2-methoxyl-phenyl or 2-methoxyl-5-fluoro-phenyl.
- The compound of any one of claims 1-7, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, wherein R 1 is selected from a group consisting of 4-6 membered heterocyclyl, 5-10 membered heteroaryl, C 5-6cycloalkyl, C 3-6cycloalkyl-O-and phenyl, which are each optionally substituted with one or more with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6alkyl, C 1-6haloalkyl and C 1-6alkoxyl;Preferably, R 1 is selected from a group consisting of 5-6 membered heteroaryl optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6alkyl, C 1-6haloalkyl and C 1-6alkoxyl;Preferably, R 1 is pyridyl, optionally substituted with one or more substituents selected from a group consisting of -OH, halo, CN, C 1-6alkyl, C 1-6haloalkyl and C 1-6alkoxyl;More preferably, R 1 is pyridin-4-yl substituted with C 1-6alkyl at 2-position and optionally further substituted at 3-position with a substituent selected from a group consisting of -OH, halo, CN, C 1-6alkyl, C 1-6haloalkyl and C 1-6alkoxyl.
- The compound of any one of claims 1-10, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, for use as a medicament.
- The compound of any one of claims 1-10, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a BTK-associated disease or disorder;Preferably, the disease or disorder is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders, preferably hematological malignancies, more preferably B-cell malignancies, further more preferably, leukemias, lymphomas, Hodgkin's disease and myeloma;More preferably, the disease or disorder is selected from acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV) , essential thrombocytopenia (ET) and idiopathic primary myelofibrosis) , diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, precursor B-lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, anaplastic large cell lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma (MM) ; rheumatoid arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, and spondylitis; asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) , silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia, bronchiectasis, pulmonary oxygen toxicity, and chronic lung inflammatory disease; systemic lupus erythematosus (SLE) , autoimmune thyroiditis, multiple sclerosis, chronic obstructive pulmonary disease (COPD) , myasthenia gravis, psoriasis, inflammatory bowel disease (IBD) , and idiopathic thrombocytopenic purpura; graft-versus-host disease (GVHD) and allograft rejection.
- A pharmaceutical composition, comprising the compound of any one of claims 1-10, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.
- Use of the compound of any one of claims 1-10, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment or prevention of a BTK-associated disease or disorder, or use of the compound of any one of claims 1-10, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, for treatment or prevention of a BTK-associated disease or disorder;Preferably, the disease or disorder is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders, preferably hematological malignancies, more preferably B-cell malignancies, further more preferably, leukemias, lymphomas, Hodgkin's disease and myeloma;More preferably, the disease or disorder is selected from acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV) , essential thrombocytopenia (ET) and idiopathic primary myelofibrosis) , diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, precursor B-lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, anaplastic large cell lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma (MM) ; rheumatoid arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, and spondylitis; asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) , silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia, bronchiectasis, pulmonary oxygen toxicity, and chronic lung inflammatory disease; systemic lupus erythematosus (SLE) , autoimmune thyroiditis, multiple sclerosis, chronic obstructive pulmonary disease (COPD) , myasthenia gravis, psoriasis, inflammatory bowel disease (IBD) , and idiopathic thrombocytopenic purpura; graft-versus-host disease (GVHD) and allograft rejection.
- A method of in vivo or in vitro inhibiting the activity of BTK, comprising contacting an effective amount of the compound of any one of claims 1-10 or a pharmaceutically acceptable salt thereof with BTK.
- A method of treating or preventing a BTK-associated disease or disorder, comprising administering to the subject in need thereof an effective amount of the compound of any one of claims 1-10 or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof;Preferably, the disease or disorder is selected from tumors, autoimmune diseases, infectious diseases, inflammatory diseases and neurological disorders, preferably hematological malignancies, more preferably B-cell malignancies, further more preferably, leukemias, lymphomas, Hodgkin's disease and myeloma;More preferably, the disease or disorder is selected from acute lymphocytic leukemia (ALL) , acute myeloid leukemia (AML) , acute promyelocytic leukemia (APL) , chronic lymphocytic leukemia (CLL) , chronic myeloid leukemia (CML) , chronic myelomonocytic leukemia (CMML) , chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL) , anaplastic large-cell lymphoma (ALCL) , prolymphocytic leukemia (PML) , juvenile myelomonocyctic leukemia (JMML) , adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS) , mixed lineage leukemia (MLL) , myelodysplastic syndromes (MDSs) , myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV) , essential thrombocytopenia (ET) and idiopathic primary myelofibrosis) , diffuse large B cell lymphoma (DLBCL) (e.g., activated B cell-like DLBCL (ABC-DLBCL) ) , follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B cell lymphoma, splenic marginal zone lymphoma) , Burkitt lymphoma, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma (LPL) ) , primary central nervous system lymphoma, small lymphocytic lymphoma, precursor B-lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, anaplastic large cell lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma (MM) ; rheumatoid arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, and spondylitis; asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) , silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, vasculitis, emphysema, pneumonia, bronchiectasis, pulmonary oxygen toxicity, and chronic lung inflammatory disease; systemic lupus erythematosus (SLE) , autoimmune thyroiditis, multiple sclerosis, chronic obstructive pulmonary disease (COPD) , myasthenia gravis, psoriasis, inflammatory bowel disease (IBD) , and idiopathic thrombocytopenic purpura; graft-versus-host disease (GVHD) and allograft rejection.
- A combination, comprising the compound of any one of claims 1-10, or a stereoisomer, racemate, geometric isomer, tautomer, hydrate or solvate, or pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent, wherein said additional therapeutic agent preferably is an anti-neoplastic agent, e.g., a radiotherapeutic agent, a chemotherapeutic agent, an immunotherapeutic agent, or a targeted therapeutic agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280007132.XA CN116348453A (en) | 2021-04-25 | 2022-04-22 | Heteroaromatic carboxamide compounds and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2021/089684 | 2021-04-25 | ||
CN2021089684 | 2021-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022228302A1 true WO2022228302A1 (en) | 2022-11-03 |
Family
ID=83847811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/088440 WO2022228302A1 (en) | 2021-04-25 | 2022-04-22 | Heteroaromatic carboxamide compounds and its use |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116348453A (en) |
WO (1) | WO2022228302A1 (en) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014173289A1 (en) * | 2013-04-25 | 2014-10-30 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
WO2014210255A1 (en) * | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
US20150005277A1 (en) * | 2013-06-28 | 2015-01-01 | Beigene, Ltd. | Protein Kinase Inhibitors and Uses Thereof |
WO2015048662A2 (en) * | 2013-09-30 | 2015-04-02 | X-Rx Discovery, Inc. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
WO2016065226A1 (en) * | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhobitors |
WO2016161571A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
WO2017079519A1 (en) * | 2015-11-06 | 2017-05-11 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
WO2017103611A1 (en) * | 2015-12-16 | 2017-06-22 | Redx Pharma Plc | Compounds useful as kinase inhibitors |
WO2018092047A1 (en) * | 2016-11-18 | 2018-05-24 | Joint Stock Company "Biocad" | Inhibitors of bruton's tyrosine kinase |
WO2018175512A1 (en) * | 2017-03-22 | 2018-09-27 | Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. | Bruton's tyrosine kinase inhibitors |
CN111704611A (en) * | 2019-07-25 | 2020-09-25 | 上海凌达生物医药有限公司 | Aryl spiro SHP2 inhibitor compound, preparation method and application |
CN114085207A (en) * | 2020-10-16 | 2022-02-25 | 广州百霆医药科技有限公司 | Bruton tyrosine protein kinase inhibitor and application thereof |
-
2022
- 2022-04-22 WO PCT/CN2022/088440 patent/WO2022228302A1/en active Application Filing
- 2022-04-22 CN CN202280007132.XA patent/CN116348453A/en active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014173289A1 (en) * | 2013-04-25 | 2014-10-30 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
WO2014210255A1 (en) * | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
US20150005277A1 (en) * | 2013-06-28 | 2015-01-01 | Beigene, Ltd. | Protein Kinase Inhibitors and Uses Thereof |
WO2015048662A2 (en) * | 2013-09-30 | 2015-04-02 | X-Rx Discovery, Inc. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
WO2016065226A1 (en) * | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhobitors |
WO2016161571A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
WO2017079519A1 (en) * | 2015-11-06 | 2017-05-11 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
WO2017103611A1 (en) * | 2015-12-16 | 2017-06-22 | Redx Pharma Plc | Compounds useful as kinase inhibitors |
WO2018092047A1 (en) * | 2016-11-18 | 2018-05-24 | Joint Stock Company "Biocad" | Inhibitors of bruton's tyrosine kinase |
WO2018175512A1 (en) * | 2017-03-22 | 2018-09-27 | Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. | Bruton's tyrosine kinase inhibitors |
CN111704611A (en) * | 2019-07-25 | 2020-09-25 | 上海凌达生物医药有限公司 | Aryl spiro SHP2 inhibitor compound, preparation method and application |
CN114085207A (en) * | 2020-10-16 | 2022-02-25 | 广州百霆医药科技有限公司 | Bruton tyrosine protein kinase inhibitor and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN116348453A (en) | 2023-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI618698B (en) | Novel pyrimidine and pyridine compounds and their usage | |
CA2846652C (en) | Heterocyclylamines as pi3k inhibitors | |
TW202120488A (en) | Compound as shp2 inhibitor and use thereof | |
US10822348B2 (en) | Inhibitors of Bruton's tyrosine kinase and methods of their use | |
JP7222590B2 (en) | 3-Azabicyclo[3,1,1]heptane derivative and pharmaceutical composition containing the same | |
KR102111570B1 (en) | Novel Imidazopyridazine Compounds and their Use | |
JP7462951B2 (en) | JAK inhibitors | |
CN111171049A (en) | Tyrosine kinase inhibitors and uses thereof | |
JP2023522725A (en) | 3-Azabicycloalkyl derivative and pharmaceutical composition containing the same | |
WO2016119707A1 (en) | Novel heteroaryl and heterocycle compounds, compositions and methods | |
WO2022170043A1 (en) | Quinazoline derived compounds as egfr inhibitors and their uses thereof | |
WO2019085894A1 (en) | Nitrogen-containing fused ring compound, preparation method therefor, and use thereof | |
AU2021295413A1 (en) | Amidopyrimidone derivatives | |
JP2023522863A (en) | Tricyclic compounds as EGFR inhibitors | |
KR20200052321A (en) | Cycloolefin substituted heteroaromatic compounds and uses thereof | |
WO2022266458A1 (en) | 6-heterocycloalkyl-quinazoline derivatives and uses thereof | |
TW202346297A (en) | Compounds with activity of anti-kras-mutated tumors | |
WO2022228302A1 (en) | Heteroaromatic carboxamide compounds and its use | |
TWI749518B (en) | Piperazine amide derivative, its preparation method and its use in medicine | |
TW202237577A (en) | Compounds, compositions, and methods | |
CN117343056A (en) | Pyridopyrrole derivatives and their use in medicine | |
EP4284797A1 (en) | Pyrazoleamide derivatives | |
CN117800975A (en) | Compounds with anti-KRAS mutant tumor activity | |
EP4271676A1 (en) | Carbonyl substituted diazaspiro compounds and its use | |
WO2022037691A1 (en) | Aromatic ring-lactam compound, preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22794773 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22794773 Country of ref document: EP Kind code of ref document: A1 |